
<html lang="en"     class="pb-page"  data-request-id="3904eca3-cdd1-4b16-a552-3b173726e6ba"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01870;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases" /></meta><meta name="dc.Creator" content="Nello  Mainolfi" /></meta><meta name="dc.Creator" content="Takeru  Ehara" /></meta><meta name="dc.Creator" content="Rajeshri G.  Karki" /></meta><meta name="dc.Creator" content="Karen  Anderson" /></meta><meta name="dc.Creator" content="Aengus  Mac Sweeney" /></meta><meta name="dc.Creator" content="Sha-Mei  Liao" /></meta><meta name="dc.Creator" content="Upendra A.  Argikar" /></meta><meta name="dc.Creator" content="Keith  Jendza" /></meta><meta name="dc.Creator" content="Chun  Zhang" /></meta><meta name="dc.Creator" content="James  Powers" /></meta><meta name="dc.Creator" content="Daniel W.  Klosowski" /></meta><meta name="dc.Creator" content="Maura  Crowley" /></meta><meta name="dc.Creator" content="Toshio  Kawanami" /></meta><meta name="dc.Creator" content="Jian  Ding" /></meta><meta name="dc.Creator" content="Myriam  April" /></meta><meta name="dc.Creator" content="Cornelia  Forster" /></meta><meta name="dc.Creator" content="Michael  Serrano-Wu" /></meta><meta name="dc.Creator" content="Michael  Capparelli" /></meta><meta name="dc.Creator" content="Rrezarta  Ramqaj" /></meta><meta name="dc.Creator" content="Catherine  Solovay" /></meta><meta name="dc.Creator" content="Frederic  Cumin" /></meta><meta name="dc.Creator" content="Thomas M.  Smith" /></meta><meta name="dc.Creator" content="Luciana  Ferrara" /></meta><meta name="dc.Creator" content="Wendy  Lee" /></meta><meta name="dc.Creator" content="Debby  Long" /></meta><meta name="dc.Creator" content="Melissa  Prentiss" /></meta><meta name="dc.Creator" content="Andrea  De Erkenez" /></meta><meta name="dc.Creator" content="Louis  Yang" /></meta><meta name="dc.Creator" content="Fang  Liu" /></meta><meta name="dc.Creator" content="Holger  Sellner" /></meta><meta name="dc.Creator" content="Finton  Sirockin" /></meta><meta name="dc.Creator" content="Eric  Valeur" /></meta><meta name="dc.Creator" content="Paulus  Erbel" /></meta><meta name="dc.Creator" content="Daniela  Ostermeier" /></meta><meta name="dc.Creator" content="Paul  Ramage" /></meta><meta name="dc.Creator" content="Bernd  Gerhartz" /></meta><meta name="dc.Creator" content="Anna  Schubart" /></meta><meta name="dc.Creator" content="Stefanie  Flohr" /></meta><meta name="dc.Creator" content="Nathalie  Gradoux" /></meta><meta name="dc.Creator" content="Roland  Feifel" /></meta><meta name="dc.Creator" content="Barbara  Vogg" /></meta><meta name="dc.Creator" content="Christian  Wiesmann" /></meta><meta name="dc.Creator" content="Jürgen  Maibaum" /></meta><meta name="dc.Creator" content="Jörg  Eder" /></meta><meta name="dc.Creator" content="Richard  Sedrani" /></meta><meta name="dc.Creator" content="Richard A.  Harrison" /></meta><meta name="dc.Creator" content="Muneto  Mogi" /></meta><meta name="dc.Creator" content="Bruce D.  Jaffee" /></meta><meta name="dc.Creator" content="Christopher M.  Adams" /></meta><meta name="dc.Description" content="The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinu..." /></meta><meta name="Description" content="The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinu..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 19, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01870" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01870" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01870" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01870" /></link>
        
    
    

<title>Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01870" /></meta><meta property="og:title" content="Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0019.jpeg" /></meta><meta property="og:description" content="The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01870"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01870">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01870&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01870&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01870&amp;href=/doi/10.1021/acs.jmedchem.9b01870" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5697-5722</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01869" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.9b01806" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Nello Mainolfi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nello Mainolfi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nello++Mainolfi">Nello Mainolfi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takeru Ehara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takeru Ehara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takeru++Ehara">Takeru Ehara</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajeshri G. Karki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajeshri G. Karki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajeshri+G.++Karki">Rajeshri G. Karki</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2210-5789" title="Orcid link">http://orcid.org/0000-0003-2210-5789</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen Anderson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Anderson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Anderson">Karen Anderson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aengus Mac Sweeney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aengus Mac Sweeney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aengus++Mac+Sweeney">Aengus Mac Sweeney</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7250-9541" title="Orcid link">http://orcid.org/0000-0001-7250-9541</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sha-Mei Liao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sha-Mei Liao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sha-Mei++Liao">Sha-Mei Liao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Upendra A. Argikar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Upendra A. Argikar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Upendra+A.++Argikar">Upendra A. Argikar</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0939-0813" title="Orcid link">http://orcid.org/0000-0002-0939-0813</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keith Jendza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keith Jendza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keith++Jendza">Keith Jendza</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chun Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chun Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chun++Zhang">Chun Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Powers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Powers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Powers">James Powers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel W. Klosowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel W. Klosowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+W.++Klosowski">Daniel W. Klosowski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maura Crowley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maura Crowley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maura++Crowley">Maura Crowley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Toshio Kawanami</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Toshio Kawanami</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Toshio++Kawanami">Toshio Kawanami</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Ding">Jian Ding</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Myriam April</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Myriam April</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Myriam++April">Myriam April</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cornelia Forster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cornelia Forster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cornelia++Forster">Cornelia Forster</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Serrano-Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Serrano-Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Serrano-Wu">Michael Serrano-Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Capparelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Capparelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Capparelli">Michael Capparelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rrezarta Ramqaj</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rrezarta Ramqaj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rrezarta++Ramqaj">Rrezarta Ramqaj</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Catherine Solovay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Catherine Solovay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Catherine++Solovay">Catherine Solovay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frederic Cumin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frederic Cumin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frederic++Cumin">Frederic Cumin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas M. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas M. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+M.++Smith">Thomas M. Smith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luciana Ferrara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luciana Ferrara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luciana++Ferrara">Luciana Ferrara</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wendy Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wendy Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wendy++Lee">Wendy Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Debby Long</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Debby Long</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Debby++Long">Debby Long</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa Prentiss</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa Prentiss</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa++Prentiss">Melissa Prentiss</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea De Erkenez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea De Erkenez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++De+Erkenez">Andrea De Erkenez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Louis Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louis Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louis++Yang">Louis Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fang++Liu">Fang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Holger Sellner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holger Sellner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holger++Sellner">Holger Sellner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Finton Sirockin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Finton Sirockin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Finton++Sirockin">Finton Sirockin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2536-7485" title="Orcid link">http://orcid.org/0000-0003-2536-7485</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric Valeur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Valeur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Valeur">Eric Valeur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paulus Erbel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paulus Erbel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paulus++Erbel">Paulus Erbel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniela Ostermeier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniela Ostermeier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniela++Ostermeier">Daniela Ostermeier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Ramage</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Ramage</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Ramage">Paul Ramage</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bernd Gerhartz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernd Gerhartz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernd++Gerhartz">Bernd Gerhartz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Schubart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Schubart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Schubart">Anna Schubart</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefanie Flohr</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefanie Flohr</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefanie++Flohr">Stefanie Flohr</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nathalie Gradoux</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nathalie Gradoux</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nathalie++Gradoux">Nathalie Gradoux</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roland Feifel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roland Feifel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roland++Feifel">Roland Feifel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara Vogg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara Vogg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Vogg">Barbara Vogg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Wiesmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Wiesmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Wiesmann">Christian Wiesmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jürgen Maibaum</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jürgen Maibaum</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%BCrgen++Maibaum">Jürgen Maibaum</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jörg Eder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jörg Eder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%B6rg++Eder">Jörg Eder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Sedrani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Sedrani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Sedrani">Richard Sedrani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard A. Harrison</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard A. Harrison</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Harrison">Richard A. Harrison</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Muneto Mogi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Muneto Mogi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Muneto++Mogi">Muneto Mogi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bruce D. Jaffee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bruce D. Jaffee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+D.++Jaffee">Bruce D. Jaffee</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Christopher M. Adams</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher M. Adams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +1-617-871-7724. E-mail: <a href="/cdn-cgi/l/email-protection#dbb8b3a9b2a8afb4abb3bea996f5babfbab6a89bb5b4adbaa9afb2a8f5b8b4b6"><span class="__cf_email__" data-cfemail="7f1c170d160c0b100f171a0d32511e1b1e120c3f1110091e0d0b160c511c1012">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+M.++Adams">Christopher M. Adams</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5246-884X" title="Orcid link">http://orcid.org/0000-0002-5246-884X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01870&amp;href=/doi/10.1021%2Facs.jmedchem.9b01870" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5697–5722</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 19, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 November 2019</li><li><span class="item_label"><b>Published</b> online</span>19 February 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01870" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01870</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5697%26pageCount%3D26%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DNello%2BMainolfi%252C%2BTakeru%2BEhara%252C%2BRajeshri%2BG.%2BKarki%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D11%26contentID%3Dacs.jmedchem.9b01870%26title%3DDiscovery%2Bof%2B4-%2528%25282S%252C4S%2529-4-Ethoxy-1-%2528%25285-methoxy-7-methyl-1H-indol-4-yl%2529methyl%2529piperidin-2-yl%2529benzoic%2BAcid%2B%2528LNP023%2529%252C%2Ba%2BFactor%2BB%2BInhibitor%2BSpecifically%2BDesigned%2BTo%2BBe%2BApplicable%2Bto%2BTreating%2Ba%2BDiverse%2BArray%2Bof%2BComplement%2BMediated%2BDiseases%26numPages%3D26%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5722%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01870"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3336</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01870" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Nello&quot;,&quot;last_name&quot;:&quot;Mainolfi&quot;},{&quot;first_name&quot;:&quot;Takeru&quot;,&quot;last_name&quot;:&quot;Ehara&quot;},{&quot;first_name&quot;:&quot;Rajeshri&quot;,&quot;last_name&quot;:&quot;G. Karki&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Anderson&quot;},{&quot;first_name&quot;:&quot;Aengus&quot;,&quot;last_name&quot;:&quot;Mac Sweeney&quot;},{&quot;first_name&quot;:&quot;Sha-Mei&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Upendra&quot;,&quot;last_name&quot;:&quot;A. Argikar&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;Jendza&quot;},{&quot;first_name&quot;:&quot;Chun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Powers&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;W. Klosowski&quot;},{&quot;first_name&quot;:&quot;Maura&quot;,&quot;last_name&quot;:&quot;Crowley&quot;},{&quot;first_name&quot;:&quot;Toshio&quot;,&quot;last_name&quot;:&quot;Kawanami&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Myriam&quot;,&quot;last_name&quot;:&quot;April&quot;},{&quot;first_name&quot;:&quot;Cornelia&quot;,&quot;last_name&quot;:&quot;Forster&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Serrano-Wu&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Capparelli&quot;},{&quot;first_name&quot;:&quot;Rrezarta&quot;,&quot;last_name&quot;:&quot;Ramqaj&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;Solovay&quot;},{&quot;first_name&quot;:&quot;Frederic&quot;,&quot;last_name&quot;:&quot;Cumin&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;M. Smith&quot;},{&quot;first_name&quot;:&quot;Luciana&quot;,&quot;last_name&quot;:&quot;Ferrara&quot;},{&quot;first_name&quot;:&quot;Wendy&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Debby&quot;,&quot;last_name&quot;:&quot;Long&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;Prentiss&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;De Erkenez&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Fang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Holger&quot;,&quot;last_name&quot;:&quot;Sellner&quot;},{&quot;first_name&quot;:&quot;Finton&quot;,&quot;last_name&quot;:&quot;Sirockin&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Valeur&quot;},{&quot;first_name&quot;:&quot;Paulus&quot;,&quot;last_name&quot;:&quot;Erbel&quot;},{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;Ostermeier&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Ramage&quot;},{&quot;first_name&quot;:&quot;Bernd&quot;,&quot;last_name&quot;:&quot;Gerhartz&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Schubart&quot;},{&quot;first_name&quot;:&quot;Stefanie&quot;,&quot;last_name&quot;:&quot;Flohr&quot;},{&quot;first_name&quot;:&quot;Nathalie&quot;,&quot;last_name&quot;:&quot;Gradoux&quot;},{&quot;first_name&quot;:&quot;Roland&quot;,&quot;last_name&quot;:&quot;Feifel&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Vogg&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Wiesmann&quot;},{&quot;first_name&quot;:&quot;Jürgen&quot;,&quot;last_name&quot;:&quot;Maibaum&quot;},{&quot;first_name&quot;:&quot;Jörg&quot;,&quot;last_name&quot;:&quot;Eder&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Sedrani&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Harrison&quot;},{&quot;first_name&quot;:&quot;Muneto&quot;,&quot;last_name&quot;:&quot;Mogi&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;D. Jaffee&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;M. Adams&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5697-5722&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01870&quot;},&quot;abstract&quot;:&quot;The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01870&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01870" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01870&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01870" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01870&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01870" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01870&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01870&amp;href=/doi/10.1021/acs.jmedchem.9b01870" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01870" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01870" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01870%26sid%3Dliteratum%253Aachs%26pmid%3D32073845%26genre%3Darticle%26aulast%3DMainolfi%26date%3D2020%26atitle%3DDiscovery%2Bof%2B4-%2528%25282S%252C4S%2529-4-Ethoxy-1-%2528%25285-methoxy-7-methyl-1H-indol-4-yl%2529methyl%2529piperidin-2-yl%2529benzoic%2BAcid%2B%2528LNP023%2529%252C%2Ba%2BFactor%2BB%2BInhibitor%2BSpecifically%2BDesigned%2BTo%2BBe%2BApplicable%2Bto%2BTreating%2Ba%2BDiverse%2BArray%2Bof%2BComplement%2BMediated%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D11%26spage%3D5697%26epage%3D5722%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291862" title="Indoles">Indoles</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291870" title="Piperidines">Piperidines</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/jmcmar.2020.63.issue-11/20200611/jmcmar.2020.63.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (<b>41</b>), which is currently being evaluated clinically in several diverse AP mediated indications.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The complement system is a major means of eliminating foreign pathogens and is a critical component of the innate immune system. The role of complement in defending against foreign pathogens has been known for over 100 years.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Complement is now recognized as a contributing factor to a wide range of human diseases of noninfectious origin as well.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> There are three pathways that comprise the complement system, the classical, lectin, and alternative pathways, all of which converge on a key nodal protein, C3. In addition, the alternative pathway (AP) serves as an amplification loop of complement activation. The alternative pathway, in particular, has come to prominence as a contributor to various human diseases<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> including age-related macular degeneration (AMD),<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> paroxysmal nocturnal hemoglobinuria (PNH),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> atypical hemolytic uremic syndrome (aHUS),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and various glomerular diseases (e.g., C3 glomerulopathy (C3G)).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Components of the complement system that are limited to the AP include the proteases factor D (FD) and factor B (FB), as well as the γ globulin protein properdin (factor P). Due to strong association of the alternative pathway with many diseases of high unmet need, we began drug discovery programs against all three targets. Our efforts toward low molecular weight inhibitors of FD have been described previously,<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> as has our development of an antibody targeting factor P.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> We recently disclosed our efforts to target FB as well.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Herein we describe in more detail our efforts to develop low molecular weight inhibitors of FB culminating in the discovery of LNP023 which is currently being evaluated clinically in several different indications.</div><div class="NLM_p">FB is a trypsin-like serine protease (93 kDa) that circulates in human blood in a latent form at a relatively high concentration of approximately 3 μM.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> FB can bind to C3b or C3(H<sub>2</sub>O) to generate pro-C3 convertase (C3bB) causing a conformational change that enables the complex to become a substrate for FD. FD cleaves the Arg234–Lys235 bond of FB in this complex, liberating the N-terminal fragment (Ba), while the remaining FB subunit (Bb), which contains the serine protease domain, becomes a critical component of the now fully activated C3 convertase.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> Of note, C3 convertase can cleave additional C3 to produce more C3b, thereby further amplifying the local complement response. Binding of a second C3b molecule to the C3 convertase complex in the presence of excess C3b generates a C5 convertase complex, C3bBbC3b, thereby shifting substrate specificity from C3 to C5 and leading to membrane attack complex (MAC) formation, which results in cell lysis and release of C5a, a major chemotaxin (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the alternative complement pathway (AP) from initiation to cell lysis, as well as representing the breakdown of C3b via the actions of factor I and factor H.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At the outset of our program we strived for a compound profile that was suitable for oral dosing and would therefore enable treatment of an array of AP mediated diseases impacting a diverse set of target tissues, e.g., PNH (red blood cells), C3G (kidney), and AMD (eye). The desire to design inhibitors as an AMD therapy posed an additional hurdle. While FB is primarily synthesized by the liver, it is also known that FB can be locally produced in the eye by retinal pigment epithelial (RPE) cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> There are conflicting reports whether the fraction of FB present in the RPE layer of the eye is locally produced or systemically derived,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> so we aimed for a molecule that could inhibit FB mediated complement activation both in the blood and also locally in the posterior tissues of the eye. Targeting the posterior tissues of the eye (e.g., the retina and RPE/choroid) poses additional drug discovery challenges; for example, the neural retina, being part of the central nervous system, is protected by the blood–retinal barrier (BRB). The BRB serves a similar function as the blood–brain barrier and can be a formidable obstacle.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">Recognizing the aforementioned challenges, it was clear that the known covalent inhibitors of FB, including pan protease inhibitors nafamostat (FUT-175),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> sepimostat (FUT-187)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as well as various peptide aldehydes,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> lack the specificity and/or pharmacokinetic profiles suitable for our needs. In addition, it was recognized that some of the unique structural aspects of FB, in particular in the serine protease domain (SPD), may require a different targeting strategy than we have employed with success for other serine proteases.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26−28)</a> While FB can exhibit weak catalytic activity against small dipeptides and tripeptides in vitro,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> in an endogenous setting, full catalytic competency requires an activation event, as is typically the case with chymotrypsin-like serine proteases. In the case of FB this involves binding to C3b, followed by FD mediated release of Ba as described earlier. These rearrangements, and the dissociation of Ba, cause significant conformational movement in the SPD, enabling access to substrate (i.e., C3), even though the orientation of the catalytic triad does not appear to be significantly altered during these events.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> This mechanism is distinct from activation of more typical chymotrypsin-like serine protease zymogens. Generally, when the zymogen undergoes proteolytic activation, a free NH<sub>3</sub><sup>+</sup> terminus is formed to enable a salt bridge with a conserved Asp in the S1 substrate binding pocket. This event enables the catalytic site to create an “oxyanion hole” and adopt an active confirmation.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> FD mediated cleavage of C3bB does not liberate a free NH<sub>3</sub><sup>+</sup> terminus within the SP domain; thus the active site exhibits a different charge distribution than in other serine proteases.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Furthermore, FB differs from other trypsin-like serine proteases by having a neutral Asn at the bottom of the S1 pocket instead of the typically conserved negatively charged Asp (position 189; chymotrypsinogen numbering has been used throughout this paper) and a relatively larger Asp226 instead of a neutral glycine residue.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> From a drug discovery perspective, we hoped to capitalize on the unique features of FB and its activation. We rationalized that the distinct SPD of FB might make protease selectivity less of a concern but would also suggest that using other serine protease inhibitors as chemical starting points may not be viable. Furthermore, the dramatic conformational changes that accompany FB binding to C3b and the loss of Ba via FD might provide an opportunity for molecules that have a preferential affinity for the C3 convertase SPD over the latent FB SPD, which could be advantageous considering the high abundance of latent FB in serum.</div><div class="NLM_p">With these concepts in mind we undertook an aggressive integrated hit finding approach that included (1) a high throughput screen to evaluate activity of the full Novartis compound collection (∼1.1 million compounds at that time) in a MAC deposition assay in an ELISA format, (2) a more FB targeted high throughput assay of ∼250K compounds measuring inhibition of C3 cleavage by a form of FB activated by cobra venom factor (CVF-Bb),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and (3) a fragment based screen (FBS) guided by NMR and X-ray. While all three approaches afforded interesting chemical starting points, ultimately the CVF-Bb assay proved most fruitful affording a hit rate of ∼0.6% and identifying the aminoimidazoline <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Compound <b>1</b> afforded a mean IC<sub>50</sub> of 6.6 ± 3.5 μM (<i>n</i> = 22) in this assay format and was further validated biophysically by SPR (<i>K</i><sub>d</sub> = 10 μM) and via cocrystallization with the catalytic domain of human FB. Moreover, <b>1</b> afforded IC<sub>50</sub> values of >30 μM when assessed against an internal panel of 17 proteases. The crystal structure shows the imidazoline ring positioned in the S3 pocket formed by residues Glu97, Tyr99, Tyr172F, Pro172D and making a hydrogen bond with the backbone carbonyl of Gly216 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The naphthyl ring appears to establish a cation−π interaction with Arg192, perhaps stabilized in the crystal structure by the presence of a sulfate ion from crystallization buffer solution. The naphthyl resides at the opening of the S1 pocket. The bromine substituent at C-2 of the naphthyl occupied a groove formed by residues Pro172D and Val218.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of compound <b>1</b> bound to the catalytic domain of human FB at 1.64 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSW">6QSW</a>.pdb)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and in vitro potency against CVF-Bb, hERG, and adrenergic receptors α1a and α2c. The ligand binding pocket is shown in gray, and H-bonding interaction is shown as black dotted lines. Crystallographic water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While a cursory inspection of the cocrystal structure of <b>1</b> suggested many opportunities to enhance potency by expanding and/or filling regions of the protein (e.g., oxyanion hole and S1′ pocket), we initially chose to explore modifications of the imidazoline with an additional aim of improving the off-target selectivity profile of <b>1</b>. Profiling of <b>1</b> in an internal panel of over 25 enzymes, receptors, and ion channels highlighted undesirable activity against hERG (radioligand binding (RLB) assay IC<sub>50</sub> = 7.1 μM) and binding to the adrenergic α1a and α2c receptors, with IC<sub>50</sub> values of 0.3 and 0.18 μM, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We rationalized that basicity of the imidazoline was the source of the observed off-target activity.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Before we began our efforts to replace the imidazoline we first replaced the bromine at the 2-position of the naphthyl ring of <b>1</b> with the more chemically stable chloride to afford <b>2</b> with similar potency against FB (CVF-Bb IC<sub>50</sub> = 8.8 μM; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Turning to the imidazoline, replacement with less basic aminoimidazole derivative <b>3</b> led to a complete loss in activity. Reviewing the X-ray structure of <b>1</b> bound with FB, it appeared that the S3 pocket formed by residues Glu97, Tyr99, Tyr172F, and Pro172D would open up and accommodate larger ring systems, leading to the design of benzimidazole derivative <b>4</b>. However, trying to enhance potency by filling this pocket while reducing basicity also led to a complete loss in activity. More subtle modifications such as replacement of the imidazoline with the oxazoline isostere (<b>5</b>) or the slightly larger tetrahydropyrimidine (<b>6</b>) maintained some affinity for FB but were clearly inferior to the imidazoline.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration Related Replacement of the Imidazoline of Compound <b>2</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0014.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Half-maximal inhibition of cobra venom factor Bb complex (CVF-Bb) in an ELISA format; data represent mean values of at least duplicate measurements.</p></div></div><div></div></div><div class="NLM_p">With the initial relatively conservative efforts to replace the imidazoline not having proven productive, we hypothesized that alterations to the naphthyl core may provide the necessary enhancements in potency to warrant a re-evaluation of imidazoline replacements. To that end we returned to the X-ray of <b>1</b> bound to FB to guide these efforts. Direct elaboration of the naphthyl ring did not appear promising when considering what appeared to be a relatively tight fit of the 2-bromine and 4-methyl substituents. The naphthyl core also did not offer tractable trajectories to grow the molecule into the oxyanion hole, a common means of enhancing potency.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> In addition, the apolar nature of the naphthyl would potentially make it more challenging to create positive interactions with the relatively polar S1 pocket. However, the X-ray structure suggested that replacing the naphthyl core with an indole would be advantageous. We rationalized that the 2-position of the indole would offer the appropriate trajectory to vector toward the oxyanion hole, while the 3-position would offer an opportunity to fill the space near Tyr99. To explore these possibilities, we synthesized indole <b>7</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), which encouragingly maintained the potency observed for the direct naphthyl comparator <b>1</b>. To explore whether the C-3 position of the indole offered an opportunity to enhance potency, the 3-chloro indole <b>8</b> was prepared. While <b>8</b> afforded a modest drop in potency, it more importantly furnished a cocrystal structure with the catalytic domain of FB (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of indole <b>8</b> (yellow) with the catalytic domain of FB at 2.84 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8U">6T8U</a>.pdb) overlaid with naphthyl <b>1</b> (cyan). The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Initial SAR Exploration Related to Indole Derivative <b>7</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0015.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Half-maximal inhibition of cobra venom factor Bb complex (CVF-Bb) in an ELISA format; data represent mean values of at least duplicate measurements.</p></div></div><div></div></div><div class="NLM_p">Surprisingly, the crystal structure of <b>8</b> revealed that the indole core adopts a flipped binding orientation relative to what was hypothesized. Instead of pointing toward Tyr99, the 3-chloro group followed the trajectory of the bromine atom of <b>1</b>, while the indole nitrogen established a hydrogen bond with the backbone carbonyl of Thr190, as opposed to being oriented closer to Ser195. In addition, the indole was positioned deeper in the S1 pocket than the naphthyl, even though the imidazoline maintained the H-bonding with Gly216. This unexpected binding mode led us to reassess the importance of the C-5 bromo and C-7 methyl on the indole core (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Replacement of the C-5 bromide with a methyl (<b>9</b>) afforded similar activity against FB. However, substitution at C-5 was found to be critical as compounds <b>10</b> and <b>11</b> did not exhibit any inhibitory activity up to 100 μM. Substitution at C-7 also proved to be critical with compound <b>12</b> also being devoid of appreciable activity against FB.</div><div class="NLM_p">With the new indole core in hand, and a better understanding of the SAR at C-5 and C-7, we returned to our initial goal of replacing the aminoimidazoline, as indole <b>7</b> still exhibited binding to the α2c adrenergic receptor with an IC<sub>50</sub> of 0.15 μM. However, the indole core did improve selectivity over hERG and the α1a adrenergic receptor with <b>7</b> possessing a hERG RLB IC<sub>50</sub> of 24 μM, and an IC<sub>50</sub> of >30 μM for α1a. A conservative replacement with a carbon linked imidazoline afforded <b>13</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) that maintained FB activity but did not attenuate α2c activity (0.38 μM) and brought back hERG and α1a activity with IC<sub>50</sub> values of 7.2 μM and 0.49 μM, respectively. Nonetheless, we were encouraged by the fact that the 2-amino linker was not required for on-target affinity. However, replacing the imidazoline with the substantially less basic 1,2,4-triazole as in <b>14</b> led to a complete loss of FB activity. Recognizing that positioning of the indole core deeper in the S1 pocket might afford additional space in the S3 pocket, we reinvestigated the benzimidazole motif which was not suitable when combined with the naphthyl core. In the case of the indole core, the C-linked benzimidazole (<b>15</b>) proved much more fruitful. Compound <b>15</b> maintained FB activity relative to <b>13</b> but abolished α1a, α2c, and hERG activity (all >30 μM). This encouraging result led to a substantial SAR campaign aimed at optimizing the potency and ADME properties of this benzimidazole subseries, which is out of the scope of this manuscript and will be reported separately in due course. In addition to the benzimidazole we also explored simpler amines of varying basicity. Introduction of an ethylamine (<b>16</b>), aimed at mimicking one of the basic amines of the imidazoline, led to nearly complete loss in FB activity (∼15% inhibition at 100 μM), as did the morpholine <b>17</b> (∼21% inhibition at 100 μM). However, despite these results, the piperidine derivative <b>18</b> afforded a measurable IC<sub>50</sub> of 50 μM. The simplicity and small size (MW = 242.4 g/mol) of <b>18</b> combined with the ability to replace the concerning aminoimidazoline moiety with a piperidine that offered new vectors to grow from led us to further explore the SAR around this compound.</div><div class="NLM_p">Referring to the X-ray cocrystal structures of <b>1</b> and <b>8</b>, it appeared that the piperidine offered suitable vectors both to the S3 pocket and to a groove in FB between Pro172D and Val218 that is occupied by the Br of <b>1</b> and the Cl of <b>8</b>. In the probing of this groove, the 2-position of the piperidine was functionalized by phenyl (<b>19</b>) and −CH<sub>2</sub>OH (<b>20</b>) groups to explore the impact of lipophilic and polar functionalities (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Encouragingly, both modifications to the piperidine led to an improvement in FB potency with the stereochemistry playing a significant factor.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Related to the 2- and 4- Positions of the Piperidine Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0016.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Half-maximal inhibition of cobra venom factor Bb complex (CVF-Bb) in an ELISA format.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Half-maximal inhibition of human FB in TR-FRET based competition binding assay (FB-comp); data represent mean values of at least duplicate measurements.</p></div></div><div></div></div><div class="NLM_p">The more potent phenyl enantiomer yielded a cocrystal structure with FB (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which enabled the determination that the <i>S</i> absolute stereochemistry was preferred. The X-ray structure also revealed that indeed the phenyl ring situated nicely in the groove between Pro172D and Val218. The compound went deeper into the S1 pocket relative to <b>8</b> with the indole nitrogen now making a H-bond with the side chain of Thr190 instead of the backbone carbonyl in <b>8</b>. The protonated nitrogen of the piperidine appears to be making a H-bonding interaction with Gly216 similar to the imidazoline.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of indole (<i>S</i>)<b>-19</b> (green) with the catalytic domain of FB at 1.70 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8W">6T8W</a>.pdb). Of note the phenyl ring sits in the Pro172D and Val218 groove. The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic waters are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The X-ray also revealed that the 4-positon of the piperidine was well positioned to enable growing into the S3 pocket. Guided by the X-ray of (<i>S</i>)-<b>19</b>, we first decided to explore the S3 pocket with a small set of phenylpiperidines, before following up on the hydroxyl analog <b>20</b>. The selected disubstituted piperidines were prepared as racemic sets of diastereomers (<b>21</b>–<b>28</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), and the ascribed relative stereochemistry was elucidated by NOE interactions between C-2 and C-4 protons of the piperidines. Of note, at this stage in the program, we began to employ an alternative assay format for our primary FB biochemical screening assay, a more operationally efficient TR-FRET based competition binding assay (FB-comp). In this assay, compounds are evaluated for their ability to displace a Cy5-labeled small-molecule inhibitor probe from native FB.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Installation of an −OMe at the 4 position of the piperidine afforded a substantial improvement in potency when oriented in a trans configuration, and importantly (±)-<b>21</b> also exhibited a substantial reduction in α2c receptor binding affinity (IC<sub>50</sub> = 11 μM), although hERG activity remained (RLB IC<sub>50</sub> = 2.3 μM). Replacement of the ether with a hydroxyl ((±)-<b>23</b>) led to a ∼10-fold drop in potency. Interestingly, when the C-4 position was substituted with a methylamine, the stereochemical preference was reversed with the cis conformation proving more potent ((±)-<b>26</b>). Lastly, a −CH<sub>2</sub>OH moiety at C-4 reverted the preference to the trans configuration ((±)-<b>27</b>) and afforded only a slight reduction in potency relative to (±)-<b>21</b>. Considering the potency of (±)-<b>21</b> and the desire to avoid any potential ADME liabilities associated with the primary alcohol of (±)-<b>27</b>, we chose to assess the individual enantiomers of (±)-<b>21</b>. Compound (−)-<b>21</b> was determined to be the more active of the two enantiomers and for the first time in this subseries afforded a submicromolar IC<sub>50</sub> value of 0.72 μM. The SAR learnings from the C-2 phenyl substituted piperidines also applied to the C-2 alcohol <b>20</b>, as the C-4 methoxy substituted piperidine (2<i>S</i>,4<i>S</i>)-<b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which also afforded a ∼2× improvement in potency over the most active enantiomer of <b>20</b>.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro potency of (2<i>S</i>,4<i>S</i>)-<b>29</b> as assessed in the CVF-Bb assay, a cocrystal structure of (2<i>S</i>,4<i>S</i>)-<b>29</b> (yellow) bound to the catalytic domain of human FB at 1.77 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSX">6QSX</a>.pdb)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> highlighting an interaction with a sulfate ion from the crystallization buffer, and an overlay with (<i>S</i>)-<b>19</b> (green) from its cocrystal structure. The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the enhancement in FB potency, the binding affinity of <b>29</b> against the α1a and α2c receptors was reduced with IC<sub>50</sub> values of >30 μM and 16 μM, respectively. The hERG inhibitory activity (RLB IC<sub>50</sub> = 14 μM) was also attenuated relative to (±)-<b>21</b>. More intriguingly, a cocrystal of (2<i>S</i>,4<i>S</i>)-<b>29</b> with FB revealed an interaction between the hydroxyl group and a sulfate ion from the crystallization buffer, which in turn made a complex hydrogen bonding network with Arg192, Val218, and Asn220B (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). In an effort to capitalize on this observation, we tried to mimic this interaction by incorporating moieties at the C-2 position of the piperidine that had the potential to engage in a similar hydrogen bonding network as the sulfate ion (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Unfortunately, attempts to replicate these interactions with a sulfonamide (<b>30</b>), sulfone (<b>31</b>), or urea (<b>32</b>) were largely unproductive, with only the sulfone affording potency in the range of <b>29</b>. These results led us to reassess the X-ray crystal structures of <b>29</b> and (<i>S</i>)-<b>19</b> bound to FB. When overlaying these two molecules (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), it became evident that the <i>para</i> position of the phenyl ring in (<i>S</i>)-<b>19</b> was perfectly situated to place a substituent into the space occupied by the sulfate. Thus, a series of <i>para</i> substituted phenyl piperidines were prepared with the aim of mimicking some of the protein interactions made by the sulfate ion (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Related to Efforts To Mimic the Interactions of the Sulfate Ion Observed in the Cocrystal Structure of <b>29</b> with FB</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0017.gif" alt="" id="gr17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Half-maximal inhibition of human FB in TR-FRET based competition binding assay (FB-comp); data represent mean values of at least duplicate measurements.</p></div></div><div></div></div><div class="NLM_p">Sulfone ((±)-<b>33</b>) and amide ((±)-<b>34</b>) moieties both afforded a ∼4- to 8-fold improvement in FB potency as racemates relative to the unsubstituted enantiopure phenyl piperidine (<i>S</i>)-<b>19</b>. More strikingly, when a carboxylic acid was installed at the <i>para</i> position ((±)-<b>35</b>), a nearly 100-fold improvement in potency was observed, providing confidence that we were successfully mimicking at least to some extent the protein interactions seen with the sulfate ion. This was confirmed by X-ray crystallography as cocrystallization of (±)-<b>35</b> with FB yielded the structure shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. The structure revealed the acid to be engaged in several key hydrogen bonds to both Asn220B and the Asp218A-NH. Separation of the enantiomers of the carboxylic acid revealed (−)-<b>35</b> as the more potent enantiomer affording an IC<sub>50</sub> of 0.033 μM.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Furthermore, the addition of the acid abolished hERG and adrenergic receptor activity. With this exciting improvement in potency and a clean off-target profile, more advanced profiling of (−)-<b>35</b> was warranted. In a functional in vitro assay assessing AP-mediated MAC deposition of 50% human serum induced by zymosan-A, (−)-<b>35</b> afforded an IC<sub>50</sub> of 0.25 μM. The submicromolar IC<sub>50</sub> value was of particular note as this concentration is significantly below the endogenous FB protein levels of ∼1 to 2 μM in these diluted human samples. This result is indicative of (−)-<b>35</b> perhaps having an affinity preference for the FB SPD when part of C3 and/or C5 convertase complex (vide supra). Acid (−)-<b>35</b> also possessed excellent physicochemical and ADME properties, which translated to an attractive mouse pharmacokinetic profile (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal of (−)-<b>35</b> (yellow) bound to the catalytic domain of human FB at 2.29 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8V">6T8V</a>.pdb) in addition to in vitro potency, ADME, and mouse PK profile of (−)-<b>35</b>. <sup><i>a</i></sup>Determined for (±)-<b>35</b>. <sup><i>b</i></sup>Equilibrium high throughput solubility in aqueous buffer (pH 6.8). <sup><i>c</i></sup>Mouse (Ms) and human (H) liver microsomes (LM). <sup><i>d</i></sup>Plasma exposure was measured out to 7 h postdose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unfortunately, (−)-<b>35</b> proved to be substantially less efficacious when assessed for functional activity using a 50% mouse serum assay measuring C3b deposition (IC<sub>50</sub> = 2.28 μM), presumably due to species differences in the protein structure. From sequence analysis, we determined that the catalytic domain of mouse FB has a sequence identity of only 80% compared to human. In particular, three residues, Pro172B (Gln in mouse FB), Arg192 (Lys in mouse FB), and Asn220B (Asp in mouse FB) that form the ligand binding pocket are different in mouse FB. While potency against human FB was obviously most critical, the fact that the in vivo pharmacology of a selective FB inhibitor had never been reported led to the desire to identify compounds that were potent against both the human and mouse protein to enable evaluation of PK/PD and efficacy in various disease models. We reasoned that filling the S3 pocket should provide an enhancement in potency against the human enzyme as was the case with (−)-<b>21</b> and <b>29</b> and that this may also lead to a concomitant increase in mouse potency. Installing the −OMe at C-4 of the piperidine yielded <b>36</b> possessing the 2<i>S</i>,4<i>S</i> stereochemistry as the most potent stereoisomer affording an IC<sub>50</sub> of 0.024 μM in the human FB-comp assay (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> More importantly <b>36</b> afforded similar potency in both the 50% human serum MAC deposition assay and the 50% mouse serum C3b deposition assay with IC<sub>50</sub> values of 0.15 μM and 0.16 μM, respectively. In addition, <b>36</b> afforded a promising mouse PK profile demonstrating low clearance (8 mL min<sup>–1</sup> kg<sup>–1</sup>) and good oral bioavailability (41%).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro and in Vivo Profiles of Advanced FB Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0018.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are mean values for at least <i>n</i> = 2.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">For human, serum IC<sub>50</sub> values reflect inhibition of MAC deposition, and for mouse C3b deposition, all values are mean values of at least <i>n</i> = 2.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Assessments of the inhibition of C3d+iC3b formation in the mouse LPS-challenge model.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Mice were dosed at 1 mg/kg iv and 10 mg/kg po, and compound exposure was measured in plasma. CL is represented in mL min<sup>–1</sup> kg<sup>–1</sup>. Vd<sub>ss</sub> is expressed as L/kg. <i>T</i><sub>1/2</sub> and MRT are expressed in hours, and AUC<sub>0-last</sub> is derived from po dosing and represented in μM·h, with the last plasma measurement taken at 7 h postdose.</p></div></div><div></div></div><div class="NLM_p">The improvement in potency in mouse serum along with an acceptable PK offered the opportunity to evaluate <b>36</b> in a PD model of AP complement activation.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The model involved an intraperitoneal administration of lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria, which induces activation of the AP. Activation can be assessed by the measurement of an increase in AP breakdown products, in particular C3d and iC3b. Proteolysis of C3b, the product of C3 convertase activity, by factor I (FI) with factor H (FH) serving as a cofactor generates iC3b. iC3b can be further broken down by FI into C3c and C3d (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Thus, a reduction in C3d+iC3b levels of LPS treated mice upon FB inhibitor administration would afford an assessment of AP inhibition. Importantly, in mice treated with intraperitoneal LPS, AP activation is observed both in plasma and in ocular tissues, thus providing an opportunity to assess PD in both compartments. Encouragingly, compound <b>36</b> administered orally at a dose of 30 mg/kg provided an inhibition of C3d+iC3b levels at 8 h postdose of 43% and 35% in plasma and in ocular tissues (whole eye homogenate), respectively. The promising in vivo profile for <b>36</b> led us to evaluate subtle changes to the scaffold, in particular by expanding deeper into the S3 pocket via replacement of the C-4 piperidine methoxy with an ethoxy residue, as well as probing the small space occupied by the indole C-5 methyl in an effort to maximize van der Waals interactions with the protein (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These subtle changes had very little impact on the in vitro FB potency of the compounds as assessed in either the FB-comp biochemical assay or the functional serum assays. Furthermore, these subtle changes only led to modest changes in relevant PK parameters with no apparent SAR trends observed. However, despite the similar in vitro potency and PK profiles, the compounds did differentiate themselves in terms of in vivo PD, in particular in ocular tissues. Empirically it was observed that indoles substituted with a C-5 methoxy (e.g., <b>38</b> and <b>41</b>) afforded a greater degree of ocular AP suppression than methyl and cPr comparators. The methoxy substituted indoles also provided better suppression of in vivo plasma AP activation as well, although the differences compared to the corresponding cPr and methyl analogs were not as dramatic. Compound <b>41</b> demonstrated the best balance of plasma and ocular inhibition and was therefore selected for further profiling.</div><div class="NLM_p">From an in vitro perspective, <b>41</b> exhibited a <i>K</i><sub>d</sub> value of 7.9 nM with human FB as determined by SPR. The X-ray cocrystal of <b>41</b> with FB protein (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> revealed the acid hydrogen bonding with Asn220B side chain and the Asp218A-NH and the ethoxy group positioned in the S3 pocket, while the indole nitrogen maintained an interaction with Thr190 and the indole methoxy occupying a small pocket formed by His57 and Tyr99.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal of <b>41</b> within the catalytic domain of FB at 1.7 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RAV">6RAV</a>.pdb).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic waters are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, <b>41</b> exhibited excellent selectivity over other proteases affording IC<sub>50</sub> values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM). The selectivity was consistent with the unique nature of the FB SPD. Additionally, <b>41</b> furnished IC<sub>50</sub> values of >30 μM across an internal panel of ∼110 enzymes, receptors, and ion channels, including hERG and adrenergic receptors α1a and α2c.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">In vivo, <b>41</b> exhibited a dose responsive relationship for plasma and ocular inhibition of iC3b+C3d when employed in the C57BL/6 mouse LPS challenge mouse model at doses ranging from 3 to 30 mg/kg when assessed at 4 h (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A full time course of a single 30 mg/kg oral dose indicated near complete AP inhibition out to 8 h in both plasma and ocular tissues with partial suppression of iC3b+C3d in both tissues out to 12 h.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose–response relationship of <b>41</b> in the mouse LPS challenge model (% inhibition at 4 h ± SEM; all values have <i>p</i> values of <0.05) and time course of plasma<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and ocular AP inhibition ± SEM with a 30 mg/kg oral dose of <b>41</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The observed pharmacology in whole mouse eye homogenates was promising as it relates to the potential of developing a FB inhibitor as a therapy for AMD. In AMD it is thought that the disease may initiate at tissues of the posterior segment, in particular in the RPE, Bruch’s membrane (BM), and choroid region.<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> Unfortunately, the small size of the mouse eye hampers precise tissue dissection, making a direct assessment of PK/PD in RPE/BM/choroid tissues particularly challenging. Thus, to better understand the exposure of <b>41</b> in these tissues, we conducted ocular PK studies in pigmented brown Norway rats (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Upon an oral dose of 10 mg/kg, exposure was evaluated in the posterior eye cup (PEC), which consists of the target tissue, the RPE/BM/choroid, and the posterior sclera. Exposure in the retina and plasma was also evaluated. In brown Norway rats, <b>41</b> achieved exposure in the PEC well above the IC<sub>50</sub> value recorded in the 50% human serum MAC deposition assay, and while the <i>C</i><sub>max</sub> in this compartment was blunted relative to what was observed in plasma, there was an enhancement in AUC, potentially due to <b>41</b> exhibiting a moderate affinity for melanin.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Exposure in the retina was substantially lower presumably due to limited ability to cross the BRB.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Concentration versus time profile for <b>41</b> in PEC, retina, and plasma and PK parameters after a single dose (po 10 mg/kg) in brown Norway rats. <sup><i>a</i></sup>Plasma samples were taken only from two animals, and thus a standard deviation was not calculated. <sup><i>b</i></sup>AUC values were calculated as the mean of all the available concentration vs time data points for each ocular tissue. Standard deviations cannot be calculated because each time point is terminal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With a better understanding of the ocular PK profile of <b>41</b>, we then looked to further characterize the systemic PK profile in species beyond the mouse (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The iv/po dosing experiments with <b>41</b> in Wistar Han rats and beagle dogs demonstrated that low clearance and good oral bioavailability were not limited to mice. Plasma protein binding was also comparable across species with values ranging from 57% to 74% in mouse, rat, dog, and human plasma at a concentration of 5 μM of <b>41</b>. The robust PK profile in the dog also enabled evaluation of the pharmacodynamic effects of <b>41</b> in an ex vivo dog experiment. In this study, <b>41</b> was dosed orally at a relatively low dose of 3 mg/kg and blood was drawn at various time points over the course of 36 h. The collected blood samples were processed to provide serum which was treated with zymosan-A to induce AP activation. Under these conditions <b>41</b> afforded complete suppression of AP activation, as measured by MAC deposition, out to 6 h and afforded 55% inhibition out to 12 h.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Ex vivo pharmacodynamic effects of <b>41</b> in beagle dogs (<i>n</i> = 4, 3 mg/kg po), evaluating percent inhibition of MAC deposition in 50% serum ± SEM and PK/PD relationship, and pharmacokinetic parameters of <b>41</b> in Wistar Han rats (<i>n</i> = 2, at 1 mg/kg iv and 30 mg/kg po) and beagle dogs (<i>n</i> = 3, 0.1 mg/kg iv and 10 mg/kg po) and represented as mean values. d.n. denotes dose normalized. Standard deviations are reported wherever applicable.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>41</b> was also profiled in a series of experiments to assess efficacy of FB inhibition in various disease states including a mouse model of antibody-induced arthritis and a rat model of membranous nephropathy. In both cases <b>41</b> demonstrated both robust PD and efficacy as has been previously reported.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compound <b>41</b> also demonstrated the ability to block AP activation ex vivo using blood from patients with C3G and PNH as has been previously disclosed.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> C3G, a chronic kidney disease, is caused by C3 convertase dysregulation due to the presence of C3 convertase stabilizing autoantibodies (C3 nephritic factors) and/or mutations in complement proteins. PNH is characterized by the aberrant complement-mediated lysis of erythrocytes due to a somatic mutation in the PIG-A gene in hematopoietic stem cells leading to a lack of complement regulators on the cell surface. As previously reported, with C3G patient samples <b>41</b> could achieve statistically significant inhibition at a concentration of 1.1 μM, but concentrations of >3 μM were required for complete inhibition likely due to the high level of AP activity in patient sera.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In the case of PNH patient derived samples, <b>41</b> was effective in preventing erythrocyte lysis with an IC<sub>50</sub> value of 0.4 μM.</div><div class="NLM_p last">On the strength of these data, <b>41</b>, possessing the internal compound code LNP023, was selected for IND-enabling toxicology studies in rats and dogs, where <b>41</b> afforded a safety profile that supported continued clinical development. Completion of Ph1 studies in healthy volunteers has led to the initiation of a series of ongoing Ph2 studies in patients with C3G, PNH, and IgA nephropathy, the results of which will be reported in due course.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40704" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40704" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Initial efforts to develop SAR around the aminoimidazoline hit <b>1</b> relied heavily on the use of the reaction of chloro-1,3-dimethylimidazolinium chloride (DMC-Cl) with the appropriate thiourea intermediate as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a></div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Syntheses of Aniline-Linked Inhibitors <b>1</b>–<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For exploration around the imidazoline ring, substituted naphthylanilines of type <b>A</b> were converted to thiourea intermediates of type <b>B</b>, followed by DMC-Cl mediated condensation with the appropriate diamine or intramolecular cyclization with the pendant R<sub>2</sub> group to provide the final heterocyclic compounds (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a> and <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, for additional details). Indoleimidazolines <b>7</b>–<b>12</b> were generally prepared by similar sequences: tosyl-protected indoles <b>C</b> were converted to thioureas <b>D</b>, followed by condensation with ethylenediamine, deprotection, and optional C3-functionalization (see also <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a> and <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_p">Compounds that contain carbon-linked heteroaryls or nitrogen-containing aliphatic heterocycles at the indole 4-position were generally prepared as outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, taking advantage of the common aldehyde intermediate (<b>43</b>).</div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Routes for C-Linked Indoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaNO<sub>2</sub>, KI, HCl, H<sub>2</sub>O, EtOAc; then <i>n</i>-BuLi, DMF, CPME; (b) CBr<sub>4</sub>, PPh<sub>3</sub>, DCM; (c) ethylenediamine; (d) isoamylamine, NaOEt, EtOH; (e) 1,2-phenylenediamine, DABCO, NMP; (f) LAH, THF; (g) 1-SEM-1,2,4-triazole, <i>n</i>-BuLi, THF; (h) MsCl, Et<sub>3</sub>N, DCM; (i) TBAF, THF; (j) piperidine, NaBH(OAc)<sub>3</sub>, AcOH, DCM, MeOH; (k) NaBH<sub>4</sub>, MeOH, THF; (l) Vilsmeier reagent, DCM.</p></p></figure><div class="NLM_p">The common aldehyde intermediate was derived by employing a Sandmeyer reaction to convert amine <b>42</b> to the corresponding aryl iodide, which was then treated with <i>n</i>-butyllithium and DMF to provide <b>43</b>. To access imidazoline <b>13</b> and benzimidazole <b>15</b>, the aldehyde was converted to dibromoolefin <b>44</b> followed by condensation with the appropriate diamine. Alternatively, nucleophilic attack of <b>43</b> with the lithiate of SEM-protected 1,2,4-triazole gave alcohol <b>45</b>, which was reduced and deprotected to provide <b>14</b>. The aldehyde could also be used directly to make final compounds by reductive amination followed by deprotection, as was done for piperidine <b>18</b>. However, it was found to be more efficient to convert the aldehyde to chloride <b>46</b> and displace with the appropriate amines. Morpholine <b>17</b> and substituted piperidines <b>19</b>–<b>36</b> were all made using this strategy, in some cases requiring additional functionalization steps after the coupling to obtain the desired piperidine substitution patterns. The amine coupling partners were either commercially available (<b>17</b>, <b>19</b>, <b>20</b>), previously reported (<b>29</b>),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> or synthesized in a similar manner to the route shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a> for additional details). For 2,4-disubstituted piperidines, the diastereomers could be separated by flash chromatography at various stages of the syntheses and were then carried forward separately to the final compounds as racemates. For select compounds, chiral HPLC or SFC was used to resolve the single enantiomers, either on the final compounds or on a protected late-stage intermediate.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Representative Synthesis of 2,4-Disubstituted Piperidine Intermediates and Inhibitors <b>39</b>–<b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i><sup>i</sup></i>PrMgCl·LiCl, Cbz-Cl, THF; (b) Zn, AcOH; (c) LiBH<sub>4</sub>, THF; (d) TBDPS-Cl, imidazole, DMF; (e) separation of diastereomers by flash chromatography; (f) TBAF, THF; (g) NaH, EtI, DMF; (h) Ba(OH)<sub>2</sub>, <sup><i>i</i></sup>PrOH, H<sub>2</sub>O; (i) K<sub>2</sub>CO<sub>3</sub>, MeI, DMF; (j) H<sub>2</sub>, Pd/C, MeOH; (k) (±)-<b>50</b>, DIPEA, DMA; (l) K<sub>2</sub>CO<sub>3</sub>, MeOH; then TMS-diazomethane, toluene, MeOH; (m) chiral SFC; (n) LiOH, H<sub>2</sub>O, MeOH, THF; (o) (2<i>S</i>,4<i>S</i>)-<b>50</b>, NaBH(OAc)<sub>3</sub>, DCE.</p></p></figure><div class="NLM_p">A representative synthesis of the 2,4-disubstituted piperidine building block and its elaboration into final analogs <b>39</b>–<b>41</b> is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><div class="NLM_p last">Synthesis of the requisite piperidines began with turbo Grignard-mediated addition of 4-bromobenzonitrile to 4-methoxypyridine followed by trapping with Cbz-Cl to provide dihydropyridone <b>47</b>. Sequential reductions afforded the 4-hydroxypiperidine as a mixture of diastereomers, which proved difficult to separate. However, conversion to the TBPDS silyl ether allowed for easier separation of the diastereomers by flash chromatography, and the desired trans diastereomer <b>48</b> was then deprotected to give <b>49</b> as a racemic mixture. The required amine coupling partner <b>50</b> could then be accessed through standard functional group manipulations. <b>50</b> was reacted with indole chlorides <b>51</b> and <b>52</b> (prepared as described in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) to generate protected intermediates <b>53</b> and <b>54</b>. Boc deprotection using K<sub>2</sub>CO<sub>3</sub> in MeOH also caused partial hydrolysis of the methyl ester, which was fully re-esterified using TMS-diazomethane. We often found that the chiral separation of final compounds was quite challenging presumably due in part to their zwitterionic nature, so typically the separation was performed at the methyl ester stage followed by hydrolysis of each isomer, as was done for <b>39</b> and <b>40</b>. For <b>41</b>, we desired a route that would avoid such a late stage chiral separation, especially when working on larger scale. Therefore, intermediate <b>49</b> was resolved into its single enantiomers by chiral SFC, and the desired (2<i>S</i>,4<i>S</i>) enantiomer was converted to (2<i>S</i>,4<i>S</i>)-<b>50</b> in a similar manner as before. This was subjected to a reductive amination with aldehyde <b>57</b> (prepared as described in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>), followed by global deprotection with lithium hydroxide to complete an efficient synthesis of <b>41</b>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43177" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43177" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">An integrated hit finding approach identified <b>1</b>, containing a naphthyl core with an aminoimidazoline moiety, as a selective FB inhibitor. Knowledge gained from X-ray cocrystallography informed our efforts to enhance the potency and drug-like properties of <b>1</b>, resulting in replacement of the naphthyl core with an indole. X-ray cocrystallography further revealed that the indole scaffold bound to FB with a flipped binding orientation relative to <b>1</b> and offered new SAR opportunities in relation to exploring a groove in FB between Pro172D and Val218 and the S3 pocket leading to the piperidine <b>29</b>. Leveraging the serendipitous interaction of the hydroxyl of <b>29</b> with a fortuitous sulfate ion observed in a X-ray cocrystal with FB enabled a potency breakthrough by incorporating a phenylcarboxylic acid at the 2-position of the piperidine, which ultimately led to the discovery of <b>41</b> (LNP023), the first reported highly selective inhibitor of FB. Interestingly, <b>41</b> demonstrates an IC<sub>50</sub> value in 50% human serum AP activation assay that is well below the concentration of FB, suggestive that <b>41</b> has preferential affinity for the SPD of FB when engaged as part of the C3 convertase complex. Compound <b>41</b> is orally bioavailable exhibiting low clearance across three preclinical species and achieves robust exposure in the posterior eyecup of rats. The potency and PK profile of <b>41</b> have led to the establishment of PD modulation and/or efficacy in several diverse animal models as well as in blood samples from patients with AP-mediated diseases. Compound <b>41</b> is currently undergoing Ph2 clinical evaluation in patients with C3G, PNH, and IgA nephropathy.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">1.  Experimental Procedures and Compound Characterization for Novel Compounds. General Chemistry Information</h3><div class="NLM_p last">Unless otherwise specified, all solvents and reagents were obtained from commercial suppliers and used without further drying or purification. NMR spectra were recorded on a Bruker Avance II 400 MHz spectrometer. All chemical shifts are reported in parts per million (δ) relative to tetramethylsilane. The following abbreviations are used to denote signal patterns: s = singlet, d = doublet, t = triplet, m = multiplet, and br = broad. Unless otherwise noted, flash chromatography was conducted using grade 60 230–400 mesh silica gel from Fisher Chemical (S825-1) or by utilizing the CombiFlash Companion from Teledyne Isco, Inc. and RediSep Rf disposable normal phase silica gel columns (4–330 g). Thin layer chromatography was performed using 2.5 cm × 7.5 cm glass-backed TLC silica gel 60 F254 plates from EMD Chemicals, Inc. (15341-1) and visualized by UV light. HPLC purifications were performed on a Waters preparative HPLC system controlled by MassLynx. Systems were run with acetonitrile/water gradient with 0.1% TFA modifier on a Waters SunFire Prep C18 OBD 5 μm, 30 mm × 100 mm column (RP-HPLC-A) or 0.1% (28% aq NH<sub>4</sub>OH) modifier on a Gemini NX 5 μm C18 110 Å 100 mm × 30 mm column (RP-HPLC-B). Low resolution mass spectra were recorded using an Agilent 1100 series LC–MS spectrometer. The purity of all exemplified compounds was ≥95%, as determined by both <sup>1</sup>H NMR and HPLC–UV at a wavelength of 214 nm. Optical rotations were obtained with a PerkinElmer model 341 polarimeter. Unless otherwise stated, chiral starting materials were commercially available with ee ≥ 98%. Compound <b>10</b> (CAS no. 67830-86-8) has been previously reported.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Synthetic procedures for indole and piperidine intermediates not described below can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Procedure A: Aromatic Halogenation</h3><div class="NLM_p last">To a solution of the aromatic compound (1.0 equiv) in DMF (0.1 M) at −20 °C was added NCS or NBS (1.0 equiv), and this was warmed to 0 °C over 30 min. The reaction was diluted with saturated aqueous sodium bicarbonate and saturated aqueous sodium thiosulfate, extracted with EtOAc, dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified by FCC to provide the desired product.</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure B: Thiourea Formation</h3><div class="NLM_p last">To a solution of the aromatic amine (1.0 equiv) in DCM (0.1–0.25 M) at rt was added DIPEA or Et<sub>3</sub>N (2.0–4.0 equiv) followed by thiophosgene (1.0–1.5 equiv). This was stirred for 15–60 min, then the aliphatic amine (2.0–8.0 equiv) was added and the mixture was stirred for 30 min. The reaction was diluted with DCM, washed with saturated aqueous sodium bicarbonate and saturated aqueous brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was used without further purification or purified by FCC to provide the desired product.</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure C: Guanidine Formation/Cyclization with DMC-Cl</h3><div class="NLM_p last">To a solution of the thiourea (1.0 equiv) in ACN (0.05–0.2 M) at rt were added DIPEA or Et<sub>3</sub>N (2.0–4.0 equiv) and chloro-1,3-dimethylimidazolinium chloride (DMC-Cl) (1.2–1.5 equiv). This was stirred at rt for 30–60 min, then the amine or diamine (2.0–5.0 equiv) was added, and this was stirred at reflux for 4–16 h. At this point the reaction mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate and saturated aqueous brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated, or the reaction mixture was concentrated directly. The crude material was purified by FCC and/or RP-HPLC to provide the desired product.</div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure D: Nitro to Amine Reduction</h3><div class="NLM_p last">A suspension of the nitro compound (1.0 equiv) and 10% Pd/C or PtO<sub>2</sub> (0.1 equiv) in MeOH or 1:1 MeOH/EtOAc (0.12 M) was stirred under hydrogen atmosphere at rt for 3–6 h. The reaction was filtered through Celite and concentrated to give the crude material, which was either used without further purification or purified by FCC to provide the desired product.</div></div><div id="sec5_1_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure E: Tosyl Deprotection with LAH</h3><div class="NLM_p last">To a solution of the tosyl-protected indole (1.0 equiv) in THF (0.03 M) at 0 °C was added LAH (10 equiv), and this was stirred at rt for 20 h. The reaction was cooled to 0 °C and worked up by the Fieser method (for each gram of LAH were added water (1 mL), then 15% aqueous NaOH (1 mL), then water (3 mL)). This was warmed to rt and stirred for 15 min, then filtered through Celite, rinsing with THF, concentrated, and purified by RP-HPLC and/or FCC to provide the desired product.</div></div><div id="sec5_1_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure F: Tosyl Deprotection with Potassium Hydroxide</h3><div class="NLM_p last">A mixture of the tosyl-protected indole (1.0 equiv), KOH (10 equiv), and either isoamylamine (5 equiv) or 28% aqueous ammonium hydroxide (20–30 equiv) in MeOH or EtOH (0.08 M) was heated via microwave irradiation at 100–110 °C for 1–2 h. The reactions were worked up and purified by different methods as outlined in the individual examples to provide the desired products.</div></div><div id="sec5_1_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure G: Boc Deprotection with TFA</h3><div class="NLM_p last">To a solution of the Boc-protected indole (1.0 equiv) in DCM (0.1 M) at 0 °C was added TFA (30 equiv), and the reaction was stirred at rt for 30 min to 2 h, then concentrated to provide the desired product which was used without further purification.</div></div><div id="sec5_1_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure H: Boc Deprotection with K<sub>2</sub>CO<sub>3</sub></h3><div class="NLM_p last">To a solution of the Boc-protected indole (1.0 equiv) in MeOH (0.04 M) was added K<sub>2</sub>CO<sub>3</sub> (5–10 equiv), and this was heated at 70–80 °C (reflux) for 1.5–4 h. The reactions were worked up and purified by different methods as outlined in the individual examples to provide the desired products.</div></div><div id="sec5_1_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure I: One-Pot Chloro Displacement and Tosyl Deprotection</h3><div class="NLM_p last">To a solution of tosyl-protected chloroindole (1.0 equiv) in EtOH (0.07 M) were added DIPEA (3.0–6.0 equiv) and the desired amine (1.5–2.0 equiv), and this was heated via microwave irradiation at 50–120 °C for 15–60 min. The reaction was cooled to rt, KOH (10 equiv) and 28% aqueous ammonium hydroxide (50 equiv) were added, and this was heated again via microwave irradiation at 80–100 °C for 1–2 h. The reaction was diluted with saturated aqueous brine, extracted 3× with DCM, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by FCC or RP-HPLC to provide the desired product.</div></div><div id="sec5_1_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure J: Chloro Displacement Using K<sub>2</sub>CO<sub>3</sub>/DMSO</h3><div class="NLM_p last">To a solution of the amine (1.0–2.0 equiv) in DMSO (0.15–0.4 M) was added K<sub>2</sub>CO<sub>3</sub> (2.0–8.0 equiv), and this was stirred at rt for 5 min. The chloride (1.0 equiv) was added, and this was stirred at 80–90 °C for 1–15 h. The reaction was cooled to rt, diluted with water, extracted with EtOAc. The organic extract was washed with water and saturated aqueous brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude material, which was either used without further purification or purified by FCC to provide the desired product.</div></div><div id="sec5_1_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure K: Chloro Displacement Using DIPEA/DMA/EtOH</h3><div class="NLM_p last">To a solution of the amine (1.0–1.5 equiv) in dimethylacetamide and/or EtOH (0.1–0.3 M) was added DIPEA (2.5–5.0 equiv) followed by the chloride (1.0 equiv), and this was stirred at 80–100 °C for 1–3 h. The reaction was cooled to rt, concentrated, and purified by FCC to provide the desired product.</div></div><div id="sec5_1_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure L: Nitrile Hydrolysis and Tosyl Deprotection</h3><div class="NLM_p last">To a solution of the nitrile-containing tosyl-protected indole (1.0 equiv) in EtOH (0.14 M) was added KOH (8.0 equiv), and this was stirred and heated at 130 °C via microwave irradiation for 2.5 h. The reaction was cooled to rt, acidified with saturated aqueous citric acid, extracted 2× with 9:1 DCM/TFE, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to provide the desired product which was used without further purification.</div></div><div id="sec5_1_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure M: Esterification with TMS-diazomethane</h3><div class="NLM_p last">To a solution of the carboxylic acid (1.0 equiv) in 3:1 toluene/MeOH (0.02–0.1 M) was added dropwise TMS-diazomethane (2 M in Et<sub>2</sub>O, 2.5–9.0 equiv), and this was stirred at rt for 0.5–2 h. Acetic acid was added until gas stopped evolving, then the mixture was extracted with EtOAc, and the organic extract was washed successively with 5% aqueous sodium bicarbonate (twice), water, and saturated aqueous brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by FCC to provide the desired product.</div></div><div id="sec5_1_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure N: Ester Hydrolysis</h3><div class="NLM_p last">To a solution of the ester (1.0 equiv) in MeOH and/or THF (0.05–0.15 M) was added 1 M aqueous LiOH (3.0–9.0 equiv), and this was stirred either at rt for 16 h or at 70 °C for 1–8 h, as denoted in the individual examples. The reaction was concentrated and purified by RP-HPLC to provide the desired product.</div></div><div id="sec5_1_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure O: Reductive Amination</h3><div class="NLM_p last">To a solution of the amine (1.0 equiv) and aldehyde (1.0–1.5 equiv) in DCE (0.2 M) was added NaBH(OAc)<sub>3</sub> (3.0–5.0 equiv), and this was stirred at rt for 16–40 h. The reaction was diluted with EtOAc, washed successively with 5% aqueous sodium bicarbonate, water, and saturated aqueous brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude material, which was either used without further purification or purified by FCC to provide the desired product.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(2-Bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1<i>H</i>-imidazol-2-amine (<b>1</b>)</h3><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Step 1: <i>N</i>-(4-Methylnaphthalen-1-yl)-4,5-dihydro-1<i>H</i>-imidazol-2-amine (<b>59</b>)</h4><div class="NLM_p last">To a solution of 4-methylnaphthalen-1-amine (CAS no. 4523-45-9, 150 mg, 0.954 mmol) in isobutyl alcohol (5 mL) was added 2-imidazolinesulfonic acid (300 mg, 2 mmol). The reaction was stirred at reflux for 4 h, then cooled to rt, concentrated, and purified by RP-HPLC-A. Fractions containing product were diluted with DCM and saturated aqueous NaHCO<sub>3</sub>. The layers were separated and the organic layer was dried, filtered and concentrated to provide the title compound (50 mg, 23%). MS (ESI+) <i>m</i>/<i>z</i> 226.0 (M + H).</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Step 2: <i>N</i>-(2-Bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1<i>H</i>-imidazol-2-amine (<b>1</b>)</h4><div class="NLM_p last">To a solution of <b>59</b> (45 mg, 0.200 mmol) in DCM (2 mL) at 0 °C was added a solution of Br<sub>2</sub> (2 M in DCM, 10.3 μL, 0.200 mmol) in DCM (1 mL) dropwise. The reaction was stirred for 2 h and then diluted with 1 M aqueous NaOH, extracted with DCM, dried, filtered, concentrated, and purified by RP-HPLC-A. Fractions containing product were diluted with DCM and saturated aqueous NaHCO<sub>3</sub>. The resulting layers were separated and the organic layer was dried, filtered, and concentrated to provide the title compound (21 mg, 35%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.08–7.52 (m, 5H), 3.60 (br s, 4H), 2.68 (s, 3H). HRMS calcd for C<sub>14</sub>H<sub>15</sub>BrN<sub>3</sub> (M + H)<sup>+</sup> 304.0449 and 306.0429, found 304.0457 and 306.0438.</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-4,5-dihydro-1<i>H</i>-imidazol-2-amine (<b>2</b>)</h3><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 1: 2-Chloro-4-methylnaphthalen-1-amine (<b>60</b>)</h4><div class="NLM_p last">General procedure A with 4-methylnaphthalen-1-amine (CAS no. 4523-45-9, 2.8 g, 17.8 mmol) and NCS, followed by FCC purification (0–20% EtOAc/heptanes), provided the title compound (1.56 g, 46%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.87 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.50 (m, 2H), 7.19 (s, 1H), 5.68 (s, 2H), 2.48 (s, 3H). MS (ESI+) <i>m</i>/<i>z</i> 192.1 (M + H).</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 2: 1-(2-Chloro-4-methylnaphthalen-1-yl)-3-methylthiourea (<b>61</b>)</h4><div class="NLM_p last">General procedure B with <b>60</b> (1.2 g, 6.26 mmol) and methylamine (33% in ethanol, 3 mL, 24.1 mmol) provided the title compound (1.42 g, 86%) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 265.1 (M + H).</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 3: <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-4,5-dihydro-1<i>H</i>-imidazol-2-amine (<b>2</b>)</h4><div class="NLM_p last">General procedure C with <b>61</b> (50 mg, 0.201 mmol) and ethylenediamine (0.027 mL, 0.402 mmol), followed by RP-HPLC-A, provided the title compound (15 mg, 20%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.49 (s, 1H), 8.34 (s, 1H), 8.13 (dd, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.91 (dd, <i>J</i> = 7.4, 2.1 Hz, 1H), 7.78–7.65 (m, 2H), 7.62 (s, 1H), 3.66 (s, 4H), 2.71 (s, 3H). HRMS calcd for C<sub>14</sub>H<sub>15</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> 260.0954, found 260.0958.</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-1<i>H</i>-imidazol-2-amine (<b>3</b>)</h3><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 1: 1-(2-Chloro-4-methylnaphthalen-1-yl)-3-(2,4,6-trimethoxybenzyl)thiourea (<b>62</b>)</h4><div class="NLM_p last">General procedure B with <b>60</b> (263 mg, 1.37 mmol) and 2,4,6-trimethoxybenzylamine (641 mg, 2.74 mmol) provided the title compound (0.509 g, 86%) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 430.9 (M + H).</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step 2: (<i>E</i>)-1-(2-Chloro-4-methylnaphthalen-1-yl)-1-(2,2-diethoxyethyl)-3-(2,4,6-trimethoxybenzyl)guanidine (<b>63</b>)</h4><div class="NLM_p last">General procedure C with <b>62</b> (509 mg, 1.18 mmol) and aminoacetalaldehyde diethyl acetal (472 mg, 3.54 mmol) provided the title compound (626 mg, quant) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 530.3 (M + H).</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 3: <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-1<i>H</i>-imidazol-2-amine (<b>3</b>)</h4><div class="NLM_p last">To a solution of <b>63</b> (626 mg, 1.18 mmol) in isopropanol (5.04 mL) was added 1.2 N aqueous HCl (15.52 mL), and the reaction was stirred at 80 °C overnight. The reaction was diluted with saturated aqueous sodium bicarbonate and extracted with DCM. The organic layers were combined and passed through an Isolute phase separator, concentrated, and purified by RP-HPLC-A. Fractions containing product were lyophilized and triturated with acetonitrile. The solid was filtered and dried to provide the title compound (4.5 mg, 1.4% for two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.16–8.09 (m, 1H), 7.70–7.58 (m, 3H), 7.25–7.18 (m, 1H), 6.69–6.63 (m, 2H), 5.16 (s, 2H), 2.72 (d, <i>J</i> = 1.0 Hz, 3H). HRMS calcd for C<sub>14</sub>H<sub>13</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> 258.0798, found 258.0858.</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-amine (<b>4</b>)</h3><div class="NLM_p last">General procedure C with <b>61</b> (150 mg, 0.567 mmol) and benzene-1,2-diamine (245 mg, 2.27 mmol) was followed except that the cyclization step was performed in DMF at 130 °C. FCC purification (0–10% MeOH/DCM), followed by RP-HPLC-A purification, provided the title compound (14 mg, 8%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10–7.98 (m, 2H), 7.65–7.48 (m, 3H), 7.09–7.02 (m, 2H), 6.87 (dd, <i>J</i> = 5.8, 3.2 Hz, 2H), 2.69 (d, <i>J</i> = 1.0 Hz, 3H). HRMS calcd for C<sub>18</sub>H<sub>15</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> 308.0954, found 308.0966.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-4,5-dihydrooxazol-2-amine (<b>5</b>)</h3><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Step 1: 1-(2-Chloro-4-methylnaphthalen-1-yl)-3-(2-hydroxyethyl)thiourea (<b>64</b>)</h4><div class="NLM_p last">General procedure B with <b>60</b> (150 mg, 0.783 mmol) and ethanolamine (0.142 mL, 2.35 mmol) provided the title compound (231 mg, quant) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 295.0 (M + H).</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Step 2: <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-4,5-dihydrooxazol-2-amine (<b>5</b>)</h4><div class="NLM_p last">To a solution of <b>64</b> (231 mg, 0.783 mmol) in THF (8 mL) were added 2.0 M aqueous NaOH (0.98 mL, 1.96 mmol) and TsCl (164 mg, 0.861 mmol), and the reaction was stirred at rt overnight. The mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate and then saturated aqueous brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by RP-HPLC-A to provide the title compound (63 mg, 31%). <sup>1</sup>H NMR (400 MHz, acetonitrile-<i>d</i><sub>3</sub>) δ 8.01 (ddd, <i>J</i> = 12.8, 7.6, 2.3 Hz, 2H), 7.61–7.48 (m, 2H), 7.35 (d, <i>J</i> = 1.1 Hz, 1H), 5.46 (s, 1H), 4.43 (d, <i>J</i> = 8.1 Hz, 2H), 3.57 (t, <i>J</i> = 7.3 Hz, 2H), 2.64 (s, 3H). HRMS calcd for C<sub>14</sub>H<sub>14</sub>ClN<sub>2</sub>O (M + H)<sup>+</sup> 261.0795, found 261.0852.</div></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(2-Chloro-4-methylnaphthalen-1-yl)-1,4,5,6-tetrahydropyrimidin-2-amine (<b>6</b>)</h3><div class="NLM_p last">General procedure C with <b>61</b> (100 mg, 0.378 mmol) and 1,3-diaminopropane (0.129 mL, 1.51 mmol) was followed except that potassium carbonate (104 mg, 0.755 mmol) was added during the cyclization step. RP-HPLC-A purification provided the title compound (5.3 mg, 5%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.11–8.04 (m, 1H), 7.98–7.90 (m, 1H), 7.69–7.61 (m, 2H), 7.53 (s, 1H), 3.25–3.17 (m, 4H), 2.67 (s, 3H), 1.90–1.78 (m, 2H). HRMS calcd for C<sub>15</sub>H<sub>17</sub>ClN<sub>3</sub> (M + H)<sup>+</sup> 274.1111, found 274.1136.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 5-Bromo-<i>N</i>-(4,5-dihydro-1<i>H</i>-imidazol-2-yl)-7-methyl-1<i>H</i>-indol-4-amine (<b>7</b>)</h3><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Step 1: 7-Methyl-4-nitroindoline (<b>65</b>)</h4><div class="NLM_p last">To 7-methylindoline (CAS no. 65673-86-1, 4.6 g, 34.5 mmol) was added sulfuric acid (135 mL), and the mixture was cooled to 0 °C (ice/salt bath). KNO<sub>3</sub> (3.88 g, 38.0 mmol) was added portionwise over 18 min while maintaining the internal temperature below 0 °C. The reaction was stirred in the ice/salt bath for 2.5 h, then was poured over ice. The pH of the dark purple solution was adjusted with 50% aqueous NaOH until the solution became a dark orange mixture, at which point 1 N aqueous NaOH was used to adjust the pH to neutral. The now red mixture was extracted 4× with EtOAc and the combined organic layers were dried over magnesium sulfate, filtered, and concentrated to provide the title compound as the minor component of a ∼30:70 mixture with 7-methyl-6-nitroindoline (6.6 g total) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 179.2 (M + H).</div></div><div id="sec5_1_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Step 2: 1-(7-Methyl-4-nitroindolin-1-yl)ethan-1-one (<b>66</b>)</h4><div class="NLM_p last">The mixture of isomers containing 7-methyl-6-nitroindoline and 7-methyl-4-nitroindoline (<b>65</b>) (6.6 g, 37.0 mmol) was dissolved in THF (370 mL), and Et<sub>3</sub>N (6.87 mL, 49.3 mmol) was added, and the reaction was cooled to 0 °C. Acetic anhydride (4.02 mL, 42.6 mmol) was added, and the reaction was stirred at rt for 1.5 h. The reaction was cooled again to 0 °C, and acetyl chloride (3.03 mL, 42.6 mmol) was added. The mixture was then partitioned between EtOAc and 1 N aqueous HCl. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated to provide the title compound as a mixture with 1-(7-methyl-6-nitroindolin-1-yl)ethanone (7.8 g total), which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 221.2 (M + H).</div></div><div id="sec5_1_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Step 3: 1-(4-Amino-7-methylindolin-1-yl)ethan-1-one (<b>67</b>)</h4><div class="NLM_p last">General procedure D with the mixture of isomers 1-(7-methyl-6-nitroindolin-1-yl)ethanone and 1-(7-methyl-4-nitroindolin-1-yl)ethan-1-one (<b>66</b>) (7.8 g, 35.4 mmol), followed by FCC purification (0–40% EtOAc/heptanes), provided the title compound (2 g, 31% for 3 steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.67 (d, <i>J</i> = 8.1 Hz, 1H), 6.31 (d, <i>J</i> = 8.0 Hz, 1H), 4.75 (s, 2H), 3.99 (t, <i>J</i> = 7.5 Hz, 2H), 2.72 (t, <i>J</i> = 7.5 Hz, 2H), 2.15 (s, 3H), 2.00 (s, 3H). MS (ESI+) <i>m</i>/<i>z</i> 191.3 (M + H).</div></div><div id="sec5_1_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Step 4: 1-(4-Amino-5-bromo-7-methylindolin-1-yl)ethan-1-one (<b>68</b>)</h4><div class="NLM_p last">General procedure A with <b>67</b> (500 mg, 2.63 mmol) and NBS, followed by FCC purification (0–50% EtOAc/heptane), provided the title compound (0.70 g, 98%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.01 (s, 1H), 4.93 (s, 2H), 4.03 (t, <i>J</i> = 7.6 Hz, 2H), 2.82 (t, <i>J</i> = 7.6 Hz, 2H), 2.16 (s, 3H), 2.00 (s, 3H). MS (ESI+) <i>m</i>/<i>z</i> 271.3 (M + H).</div></div><div id="sec5_1_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Step 5: 1-(1-Acetyl-5-bromo-7-methylindolin-4-yl)-3-methylthiourea (<b>69</b>)</h4><div class="NLM_p last">General procedure B with <b>68</b> (700 mg, 2.60 mmol) and methylamine (33% in ethanol, 2.59 mL, 20.8 mmol), followed by FCC purification (0–5% MeOH/DCM), provided the title compound (0.85 g, 95%). MS (ESI+) <i>m</i>/<i>z</i> 344.0 (M + H).</div></div><div id="sec5_1_8_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Step 6: 1-(5-Bromo-4-((4,5-dihydro-1<i>H</i>-imidazol-2-yl)amino)-7-methylindolin-1-yl)ethan-1-one (<b>70</b>)</h4><div class="NLM_p last">General procedure C with <b>69</b> (0.85 g, 2.48 mmol) and ethylenediamine (0.666 mL, 9.93 mmol), followed by FCC purification (0–10% MeOH/DCM, MeOH contains 10% ammonium hydroxide), provided the title compound (0.46 g, 55%). MS (ESI+) <i>m</i>/<i>z</i> 339.0 (M + H).</div></div><div id="sec5_1_8_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Step 7: 5-Bromo-<i>N</i>-(4,5-dihydro-1<i>H</i>-imidazol-2-yl)-7-methyl-1<i>H</i>-indol-4-amine (<b>7</b>)</h4><div class="NLM_p last">To a solution of <b>70</b> (100 mg, 0.297 mmol) in MeOH (3 mL) was added ∼8.4 N aqueous NaOH solution (obtained by diluting 50% NaOH solution, 0.177 mL, 1.48 mmol). The reaction was stirred at rt for 12 h, then at 50 °C for 7 h. Additional aqueous NaOH (0.177 mL, 1.48 mmol) was added, and the reaction was stirred at 50 °C for 16 h, then cooled and purified directly by FCC (0–20% MeOH/DCM, MeOH contains 10% ammonium hydroxide) to provide the title compound (14.6 mg, 17%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.38 (br s, 1 H), 7.36 (d, <i>J</i> = 2.78 Hz, 1 H), 7.12 (s, 1 H), 6.31 (d, <i>J</i> = 3.03 Hz, 1 H), 3.51 (s, 4 H), 2.45 (s, 3 H). HRMS calcd for C<sub>12</sub>H<sub>14</sub>BrN<sub>4</sub> (M + H)<sup>+</sup> 293.0402, found 293.0409.</div></div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 5-Bromo-3-chloro-<i>N</i>-(4,5-dihydro-1<i>H</i>-imidazol-2-yl)-7-methyl-1<i>H</i>-indol-4-amine (<b>8</b>)</h3><div class="NLM_p last">General procedure A with <b>7</b> (70 mg, 0.239 mmol) and NCS, followed by FCC purification (0–20% MeOH/DCM, MeOH contains 10% ammonium hydroxide), provided the title compound (16 mg, 21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.87 (d, <i>J</i> = 2.8 Hz, 1H), 10.32 (s, 1H), 8.31 (s, 1H), 7.98 (s, 1H), 7.66 (d, <i>J</i> = 2.8 Hz, 1H), 7.32 (s, 1H), 3.71 (m, 2H), 3.56 (m, 2H), 2.48 (s, 3H). HRMS calcd for C<sub>12</sub>H<sub>13</sub>BrClN<sub>4</sub> (M + H)<sup>+</sup> 327.0012, found 327.0013.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(4,5-Dihydro-1<i>H</i>-imidazol-2-yl)-5,7-dimethyl-1<i>H</i>-indol-4-amine (<b>9</b>)</h3><div id="sec5_1_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step 1: 1-(5,7-Dimethyl-1<i>H</i>-indol-4-yl)-3-methylthiourea (<b>71</b>)</h4><div class="NLM_p last">General procedure B with 5,7-dimethyl-1<i>H</i>-indol-4-amine (<b>93</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (202 mg, 1.26 mmol) and methylamine (33% in ethanol, 0.261 mL, 6.31 mmol), followed by FCC purification (0–20% EtOAc/DCM), provided the title compound (294 mg, quant). MS (ESI+) <i>m</i>/<i>z</i> 234.4 (M + H).</div></div><div id="sec5_1_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Step 2: <i>N</i>-(4,5-Dihydro-1<i>H</i>-imidazol-2-yl)-5,7-dimethyl-1<i>H</i>-indol-4-amine (<b>9</b>)</h4><div class="NLM_p last">General procedure C with <b>71</b> (100 mg, 0.429 mmol) and ethylenediamine (0.058 mL, 0.857 mmol), followed by FCC purification [0–60% (2 M NH<sub>3</sub> in MeOH)/EtOAc] and RP-HPLC-A purification, provided the title compound (40 mg, 41%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.77 (br s, 1 H), 7.14 (d, <i>J</i> = 2.53 Hz, 1 H), 6.67 (s, 1 H), 6.17 (d, <i>J</i> = 2.53 Hz, 1 H), 3.35 (br s, 2 H), 3.31 (br s, 2 H), 2.37 (s, 3 H), 2.11 (s, 3 H). HRMS calcd for C<sub>13</sub>H<sub>17</sub>N<sub>4</sub> (M + H)<sup>+</sup> 229.1453, found 229.1452.</div></div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-(4,5-Dihydro-1<i>H</i>-imidazol-2-yl)-7-methyl-1<i>H</i>-indol-4-amine (<b>11</b>)</h3><div id="sec5_1_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Step 1: 1-Methyl-3-(7-methyl-1-tosyl-1<i>H</i>-indol-4-yl)thiourea (<b>72</b>)</h4><div class="NLM_p last">General procedure B with 7-methyl-1-tosyl-1<i>H</i>-indol-4-amine (<b>95</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (300 mg, 0.999 mmol) and methylamine (33% in ethanol, 0.207 mL, 4.99 mmol), followed by FCC purification [40–100% (30% EtOAc in DCM)/heptane], provided the title compound (310 mg, 83%). MS (ESI+) <i>m</i>/<i>z</i> 374.2 (M + H).</div></div><div id="sec5_1_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 2: <i>N</i>-(4,5-Dihydro-1<i>H</i>-imidazol-2-yl)-7-methyl-1-tosyl-1<i>H</i>-indol-4-amine (<b>73</b>)</h4><div class="NLM_p last">General procedure C with <b>72</b> (310 mg, 0.830 mmol) and ethylenediamine (0.280 mL, 4.15 mmol), followed by FCC purification [EtOAc wash, then 0–70% (2 M NH<sub>3</sub> in MeOH)/DCM] and trituration with EtOH, provided the title compound (270 mg, 88%). MS (ESI+) <i>m</i>/<i>z</i> 369.1 (M + H).</div></div><div id="sec5_1_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Step 3: <i>N</i>-(4,5-Dihydro-1<i>H</i>-imidazol-2-yl)-7-methyl-1<i>H</i>-indol-4-amine (<b>11</b>)</h4><div class="NLM_p last">To a solution of <b>73</b> (70 mg, 0.190 mmol) in EtOH (2 mL) was added NaOEt (21% in EtOH, 0.074 mL, 0.950 mmol) and THF (1 mL), and this was stirred at 80 °C for 15 h. The mixture was cooled to rt, neutralized with AcOH, and directly purified by RP-HPLC-A to provide the title compound as the TFA salt (30 mg, 42%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, TFA salt) δ ppm 11.37 (br s, 1 H), 10.34 (s, 1 H), 8.04 (s, 2 H), 7.45–7.39 (m, 1 H), 6.94 (d, <i>J</i> = 8.08 Hz, 1 H), 6.83 (d, <i>J</i> = 8.08 Hz, 1 H), 6.45–6.39 (m, 1 H), 3.63 (s, 4 H), 2.48 (s, 3 H). HRMS calcd for C<sub>12</sub>H<sub>15</sub>N<sub>4</sub> (M + H)<sup>+</sup> 215.1288, found 215.1291.</div></div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-(4,5-Dihydro-1<i>H</i>-imidazol-2-yl)-5-methyl-1<i>H</i>-indol-4-amine (<b>12</b>)</h3><div class="NLM_p last">To a mixture of 5-methyl-1-tosyl-1<i>H</i>-indol-4-amine (<b>98</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (43.6 mg, 0.145 mmol) and 1-acetylimidazolidin-2-one (20.5 mg, 0.160 mmol) under nitrogen was added POCl<sub>3</sub> (0.97 mL, 10.4 mmol), and this was stirred at 50 °C overnight. The mixture was concentrated, sodium ethoxide (21% in ethanol, 110 μL, 0.29 mmol) and ethanol (0.6 mL) were added, and the reaction was stirred at rt. After 2 h additional sodium ethoxide (21% in ethanol, 542 μL, 1.45 mmol) was added and the reaction was stirred at 50 °C for 1 h, then additional sodium ethoxide (21% in ethanol, 542 μL, 1.45 mmol) was added and the reaction was stirred at 80 °C for 2 h. The reaction was filtered, rinsing with MeOH, and purified by RP-HPLC-A to provide the title compound as the TFA salt (14 mg, 45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.27 (br s, 1 H), 10.11 (s, 1 H), 7.98 (br s, 2 H), 7.43–7.31 (m, 2 H), 7.04 (d, <i>J</i> = 8.34 Hz, 1 H), 6.28 (t, <i>J</i> = 2.15 Hz, 1 H), 3.63 (s, 4 H), 2.27 (s, 3 H). HRMS calcd for C<sub>12</sub>H<sub>15</sub>N<sub>4</sub> (M + H)<sup>+</sup> 215.1290, found 215.1291.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 4-((4,5-Dihydro-1<i>H</i>-imidazol-2-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole (<b>13</b>)</h3><div id="sec5_1_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Step 1: 4-(2,2-Dibromovinyl)-5,7-dimethyl-1-tosyl-1<i>H</i>-indole (<b>44</b>)</h4><div class="NLM_p last">To a solution of <b>43</b> (100 mg, 0.305 mmol) and CBr<sub>4</sub> (152 mg, 0.458 mmol) in DCM (3 mL) at 0 °C was added PPh<sub>3</sub> (240 mg, 0.916 mmol), and the mixture was stirred at 0 °C for 3.5 h, then purified directly by FCC [0–50% (30% EtOAc in DCM)/heptane] to provide the title compound (125 mg, 85%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.85 (s, 1H), 7.83 (d, <i>J</i> = 3.79 Hz, 1H), 7.58 (d, <i>J</i> = 8.34 Hz, 2H), 7.42–7.37 (m, 2H), 6.95 (s, 1H), 6.63 (d, <i>J</i> = 3.79, 1H), 2.44 (s, 3H), 2.33 (s, 3H), 2.19 (s, 3H).</div></div><div id="sec5_1_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Step 2: 4-((4,5-Dihydro-1<i>H</i>-imidazol-2-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole (<b>13</b>)</h4><div class="NLM_p last">A solution of <b>44</b> (125 mg, 0.259 mmol) in ethylenediamine (1 mL) was stirred at rt for 9 h. The mixture was diluted with DCM, washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. This was dissolved in EtOH (2 mL), and isoamylamine (22.5 mg, 0.259 mmol) and sodium ethoxide (21% in EtOH, 0.5 mL) were added, and the reaction was heated at 85 °C overnight. The reaction was cooled to rt, neutralized with AcOH, and purified directly by RP-HPLC-A to provide the title compound as the TFA salt (45 mg, 42%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.12 (br s, 1H), 9.60 (s, 1H), 7.38–7.32 (m, 1H), 6.79 (s, 1H), 6.46 (dd, <i>J</i> = 3.03, 1.77 Hz, 1H), 4.06 (s, 2H), 3.80–3.74 (m, 4H), 2.43 (s, 3H), 2.30 (s, 3H). HRMS calcd for C<sub>14</sub>H<sub>18</sub>N<sub>3</sub> (M + H)<sup>+</sup> 228.1501, found 228.1496.</div></div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 4-((1<i>H</i>-1,2,4-Triazol-5-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole (<b>14</b>)</h3><div id="sec5_1_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Step 1: (5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)(1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-1,2,4-triazol-5-yl)methanol (<b>45</b>)</h4><div class="NLM_p last">To a solution of 1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-1,2,4-triazole (CAS no. 288-88-0, 82 mg, 0.412 mmol) in THF (2 mL) at −78 °C was added <i>n</i>-BuLi (1.6 M in hexanes, 0.241 mL, 0.385 mmol), and this was stirred for 1 h, then added to a solution of <b>43</b> (90 mg, 0.275 mmol) in THF (2 mL) at −78 °C. This was stirred at −78 °C for 1 h, then diluted with half saturated aqueous KHSO<sub>4</sub> and extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to provide the title compound (130 mg, 90%) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 527.0 (M + H).</div></div><div id="sec5_1_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Step 2: 4-((1<i>H</i>-1,2,4-Triazol-5-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole (<b>14</b>)</h4><div class="NLM_p last">To a solution of <b>45</b> (130 mg, 0.247 mmol) and triethylamine (0.103 mL, 0.740 mmol) in DCM (5 mL) at 0 °C was added MsCl (0.038 mL, 0.494 mmol), and this was stirred at 0 °C for 5 h. The mixture was diluted with EtOAc, washed with H<sub>2</sub>O and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was dissolved in THF (10 mL) and cooled to 0 °C. LiAlH<sub>4</sub> (94 mg, 2.47 mmol) was added, and the reaction was stirred at rt overnight. The mixture was cooled to 0 °C, and H<sub>2</sub>O (100 μL), 15% aqueous NaOH (100 μL), and H<sub>2</sub>O (300 μL) were added carefully. The mixture was stirred at rt for 1 h, then Celite was added and the solid was filtered off through Celite. The filtrate was concentrated and purified by FCC to provide a mixture of intermediates 5,7-dimethyl-1-tosyl-4-((1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-1,2,4-triazol-5-yl)methyl)-1<i>H</i>-indole (MS (ESI+) <i>m</i>/<i>z</i> 511.0 (M + H)) and 5,7-dimethyl-4-((1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-1,2,4-triazol-5-yl)methyl)-1<i>H</i>-indole (MS (ESI+) <i>m</i>/<i>z</i> 357.0 (M + H)). This mixture was dissolved in THF (1 mL), and TBAF trihydrate (278 mg, 0.881 mmol) was added. The reaction was stirred at rt for 1.5 h, then at 45 °C for 6 h. The reaction was cooled to rt, additional TBAF trihydrate (278 mg, 0.881 mmol) was added, and this was stirred at 45 °C for 9 h, then cooled to rt, diluted with H<sub>2</sub>O, and extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by RP-HPLC-A. Fractions containing product were basified with saturated aqueous sodium bicarbonate, extracted with DCM, partitioned by an Isolute phase separator, and concentrated to provide the title compound (13 mg, 23% for 3 steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 13.54 (br s, 1H), 10.91 (br s, 1H), 7.93 (br s, 1H), 7.28–7.15 (m, 1H), 6.69 (s, 1H), 6.48 (dd, <i>J</i> = 3.03, 2.02 Hz, 1H), 4.19 (s, 2H), 2.38 (s, 3H), 2.38 (s, 3H). HRMS calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub> (M + H)<sup>+</sup> 227.1291, found 227.1292.</div></div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 2-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-1<i>H</i>-benzo[<i>d</i>]imidazole (<b>15</b>)</h3><div id="sec5_1_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Step 1: 2-((5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)-1<i>H</i>-benzo[<i>d</i>]imidazole (<b>74</b>)</h4><div class="NLM_p last">A mixture of <b>44</b> (90 mg, 0.186 mmol), 1,2-phenylenediamine (30.2 mg, 0.279 mmol), and DABCO (46.0 mg, 0.410 mmol) in NMP (2 mL) was stirred at 100 °C for 22.5 h. The reaction was cooled to rt and purified directly by FCC (0–67% EtOAc/heptanes) to provide the title compound (65 mg, 81%). MS (ESI+) <i>m</i>/<i>z</i> 430.1 (M + H).</div></div><div id="sec5_1_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Step 2: 2-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-1<i>H</i>-benzo[<i>d</i>]imidazole (<b>15</b>)</h4><div class="NLM_p last">General procedure E was performed on <b>74</b> (65 mg, 0.151 mmol), followed by RP-HPLC-A purification. Fractions containing product were basified with saturated aqueous sodium bicarbonate, extracted with DCM, partitioned by an Isolute phase separator, and concentrated to provide the title compound (35 mg, 84%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 11.82 (br s, 1H), 10.91 (br s, 1H), 7.45 (br s, 1H), 7.34 (br s, 1H), 7.26–7.17 (m, 1H), 7.11–6.96 (m, 2H), 6.74 (s, 1H), 6.49 (dd, <i>J</i> = 3.03, 1.77 Hz, 1H), 4.35 (s, 2H), 2.41 (s, 3H), 2.38 (s, 3H). HRMS calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub> (M + H)<sup>+</sup> 276.1501, found 276.1499.</div></div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 2-(5,7-Dimethyl-1<i>H</i>-indol-4-yl)ethan-1-amine (<b>16</b>)</h3><div id="sec5_1_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Step 1: <i>tert</i>-Butyl (2-(5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)ethyl)carbamate (<b>75</b>)</h4><div class="NLM_p last">A suspension of 4-iodo-5,7-dimethyl-1-tosyl-1<i>H</i>-indole (<b>100</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (200 mg, 0.470 mmol), potassium (2-((<i>tert</i>-butoxycarbonyl)amino)ethyl)trifluoroborate (CAS no. 926280-83-3, 381 mg, 1.41 mmol), Cs<sub>2</sub>CO<sub>3</sub> (613 mg, 1.88 mmol), and PdCl<sub>2</sub>(dppf).DCM adduct (77 mg, 0.094 mmol) in toluene (3 mL) and H<sub>2</sub>O (1 mL) was stirred at 80 °C under nitrogen overnight. The reaction was cooled to rt and purified directly by FCC [0–67% (30% EtOAc in DCM)/heptane] to afford the title compound (120 mg, 58%). <sup>1</sup>H NMR (400 MHz, dichloromethane-<i>d</i><sub>2</sub>) δ ppm 7.78 (d, <i>J</i> = 3.79 Hz, 1H), 7.58 (d, <i>J</i> = 8.34 Hz, 2H), 7.29 (d, <i>J</i> = 8.34 Hz, 2H), 6.89 (s, 1H), 6.86 (d, <i>J</i> = 3.79 Hz, 1H), 3.29 (t, <i>J</i> = 7.33 Hz, 2H), 3.03 (t, <i>J</i> = 7.33 Hz, 2H), 2.51 (s, 3H), 2.41 (s, 3H), 2.36 (s, 3H), 1.47 (s, 9H).</div></div><div id="sec5_1_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Step 2: 2-(5,7-Dimethyl-1<i>H</i>-indol-4-yl)ethan-1-amine (<b>16</b>)</h4><div class="NLM_p last">General procedure G was performed on <b>75</b> (60 mg, 0.136 mmol). The resulting residue was dissolved in EtOH (2 mL), and NaOEt (21% in EtOH, 1 mL) and isoamylamine (500 μL, 4.30 mmol) were added. This was heated at 80 °C for 20 h, then cooled to rt, acidified with AcOH, and purified by RP-HPLC-A to provide the title compound (6 mg, 24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.86 (br s, 1H), 7.28–7.19 (m, 1H), 6.68 (s, 1H), 6.44 (dd, <i>J</i> = 3.03, 1.77 Hz, 1H), 4.43 (br s, 2H), 2.98–2.90 (m, 2H), 2.80–2.70 (m, 2H), 2.38 (s, 3H), 2.29 (s, 3H). HRMS calcd for C<sub>12</sub>H<sub>17</sub>N<sub>2</sub> (M + H)<sup>+</sup> 189.1392, found 189.1383.</div></div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 4-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)morpholine (<b>17</b>)</h3><div class="NLM_p last">General procedure I with <b>46</b> (50 mg, 0.144 mmol) and morpholine (0.025 mL, 0.287 mmol), followed by RP-HPLC-B purification, provided the title compound (21 mg, 60%). <sup>1</sup>H NMR (400 MHz, dichloromethane-<i>d</i><sub>2</sub>) δ ppm 8.10 (br s, 1 H), 7.20 (br s, 1 H), 6.82 (s, 1 H), 6.65 (br s, 1 H), 3.70 (s, 2 H), 3.65–3.44 (m, 4 H), 2.45 (m, 4H), 2.44 (s, 3H), 2.43 (s, 3H). HRMS calcd for C<sub>15</sub>H<sub>21</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 245.1648, found 245.1657.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 5,7-Dimethyl-4-(piperidin-1-ylmethyl)-1<i>H</i>-indole (<b>18</b>)</h3><div class="NLM_p last">To a solution of <b>43</b> (50 mg, 0.153 mmol) and AcOH (0.017 mL, 0.305 mmol) in DCM (2 mL) and MeOH (0.5 mL) was added piperidine (0.015 mL, 0.153 mmol). The mixture was stirred for 15 min, then NaBH(OAc)<sub>3</sub> (64.7 mg, 0.305 mmol) was added, and the mixture was stirred at rt for 19 h. The reaction was diluted with DCM, washed with 5% aqueous NaHCO<sub>3</sub>, H<sub>2</sub>O, and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by FCC [5–15% (2 M NH<sub>3</sub> in MeOH)/DCM] to provide intermediate 5,7-dimethyl-4-(piperidin-1-ylmethyl)-1-tosyl-1<i>H</i>-indole (MS (ESI+) <i>m</i>/<i>z</i> 397.3 (M + H)). General procedure E was then performed, followed by RP-HPLC-A purification. Fractions containing product were basified with saturated aqueous sodium bicarbonate, extracted with DCM, partitioned by an Isolute phase separator, and concentrated to provide the title compound (8 mg, 22% for 2 steps). <sup>1</sup>H NMR (400 MHz, dichloromethane-<i>d</i><sub>2</sub>) δ ppm 8.03 (br s, 1H), 7.10 (t, <i>J</i> = 2.78 Hz, 1H), 6.73 (s, 1H), 6.56 (dd, <i>J</i> = 3.16, 2.15 Hz, 1H), 3.59 (br s, 2H), 2.35 (s, 3H), 2.34 (s, 3H), 2.34 (br s, 4H), 1.45 (br s, 4H), 1.33 (br s, 2H). MS (ESI+) <i>m</i>/<i>z</i> 243.2 (M + H).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (<i>R</i>)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1<i>H</i>-indole ((<i>R</i>)<b>-19</b>) and (<i>S</i>)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1<i>H</i>-indole ((<i>S</i>)<b>-19</b>)</h3><div class="NLM_p last">General procedure I with <b>46</b> (50 mg, 0.144 mmol) and 2-phenylpiperidine (CAS no. 3466-80-6, 46.4 mg, 0.287 mmol), followed by FCC purification (0–60% EtOAc/heptane), gave 33 mg of (±)-<b>19</b>. The enantiomers were separated by chiral HPLC using a CHIRALPAK OD column (Waters prep-100, 20 mm × 250 mm, 10–40% (IPA + 0.05% diethylamine) in heptane) to provide the first eluting enantiomer (<i>R</i>)-<b>19</b> (<i>t</i><sub>r</sub> = 7.9 min, 7.1 mg, 16%) and the second eluting enantiomer (<i>S</i>)-<b>19</b> (<i>t</i><sub>r</sub> = 10.8 min, 6.9 mg, 15%). The absolute stereochemistry was determined via cocrystallization of (<i>S</i>)-<b>19</b> with the catalytic domain of FB. Data for (±)-<b>19</b>: <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ ppm 8.04 (br s, 1 H), 7.53 (d, <i>J</i> = 7.1 Hz, 2 H), 7.36 (app t, <i>J</i> = 7.3 Hz, 2 H), 7.26 (app t, <i>J</i> = 7.2 Hz, 1 H), 7.16 (br s, 1 H), 6.74 (s, 1 H), 6.68 (br s, 1 H), 3.72 (d, <i>J</i> = 12.4 Hz, 1 H), 3.15 (d, <i>J</i> = 12.4 Hz, 1 H), 3.10–3.00 (m, 1 H), 2.72 (d, <i>J</i> = 10.9 Hz, 1 H), 2.40 (s, 3 H), 2.31 (s, 3 H), 1.94 (t, <i>J</i> = 11.4 Hz, 1 H), 1.79–1.65 (m, 3 H), 1.47–1.26 (m, 3 H). HRMS calcd for C<sub>22</sub>H<sub>27</sub>N<sub>2</sub> (M + H)<sup>+</sup> 319.2174, found 319.2177.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)methanol (<b>20</b>-entA) and (<b>20</b>-entB)</h3><div class="NLM_p last">General procedure I with <b>46</b> (60 mg, 0.172 mmol) and 2-piperidin-2-ylmethanol (CAS no. 3433-37-2, 39.7 mg, 0.345 mmol), followed by FCC purification (0–100% EtOAc/heptane), gave 26 mg of (±)-<b>20</b>. The enantiomers were separated by chiral HPLC using a CHIRALPAK OD column (Waters prep-100, 20 mm × 250 mm, 20% (EtOH + 0.05% diethylamine) in heptane) to provide the first eluting enantiomer <b>20</b>-ent A (<i>t</i><sub>r</sub> = 10.7 min, 4 mg, 8%) and the second eluting enantiomer <b>20</b>-ent B (<i>t</i><sub>r</sub> = 12.1 min, 5 mg, 11%). <b>20</b>-entA: <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>) δ 8.17 (s, 1H), 7.22 (d, <i>J</i> = 3.3 Hz, 1H), 6.84 (s, 1H), 6.68 (s, 1H), 4.32 (s, 1H), 3.98–3.37 (m, 3H), 2.83 (s, 1H), 2.65–2.21 (m, 8H), 1.90–1.42 (m, 7H). HRMS calcd for C<sub>17</sub>H<sub>25</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 273.1967, found 273.1969. <b>20</b>-entB: <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>) δ 8.17 (s, 1H), 7.22 (d, <i>J</i> = 3.3 Hz, 1H), 6.84 (s, 1H), 6.68 (s, 1H), 4.32 (s, 1H), 3.98–3.37 (m, 3H), 2.83 (s, 1H), 2.65–2.21 (m, 8H), 1.90–1.42 (m, 7H). HRMS calcd for C<sub>17</sub>H<sub>25</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 273.1967, found 273.1969.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (±)-4-((4-Methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole ((±)-<b>21</b> (trans)) and (±)-4-((4-Methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole ((±)-<b>22</b> (cis))</h3><div id="sec5_1_21_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Step 1: (±)-4-((4-Methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1-tosyl-1<i>H</i>-indole ((±)-<b>76</b>, Diastereomeric Mixture)</h4><div class="NLM_p last">General procedure J with (±)-4-methoxy-2-phenylpiperidine ((±)-<b>113</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (180 mg, 0.789 mmol) and <b>46</b> (200 mg, 0.575 mmol) provided the title compound (206 mg, 71%) as a diastereomeric mixture which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 503.5 (M + H).</div></div><div id="sec5_1_21_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Step 2: (±)-4-((4-Methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole ((±)-<b>21</b> (trans)) and (±)-4-((4-Methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole ((±)-<b>22</b> (cis))</h4><div class="NLM_p last">General procedure F was performed on (±)-<b>76</b> (206 mg, 0.409 mmol). The reaction mixture was diluted with DCM, filtered through a silica plug, rinsing with 6:1 DCM/MeOH, and concentrated. Separation of the diastereomers was achieved by FCC [14% (10% MeOH in EtOAc)/DCM] with mixed fractions repurified by FCC [23% (10% MeOH in EtOAc)/heptane] and combined to provide the first eluting product (±)-<b>22</b> (cis) (50 mg, 34%) and the second eluting product (±)-<b>21</b> (trans) (35 mg, 24%). (±)-<b>22</b> (cis): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 9.09 (br s, 1H), 7.54 (d, <i>J</i> = 7.20 Hz, 2H), 7.38 (dd, <i>J</i> = 7.20, 7.80 Hz, 2H), 7.31–7.26 (m, 1H), 7.16 (dd, <i>J</i> = 2.80, 3.00 Hz, 1H), 6.71 (s, 1H), 6.57–6.54 (m, 1H), 3.62 (d, <i>J</i> = 12.13 Hz, 1H), 3.29–3.19 (m, 4H), 3.18–3.10 (m, 2H), 2.64 (td, <i>J</i> = 3.54, 11.87 Hz, 1H), 2.38 (s, 3H), 2.25 (s, 3H), 2.10–2.02 (m, 1H), 2.02–1.97 (m, 1H), 1.90–1.79 (m, 1H), 1.55 (dd, <i>J</i> = 11.40, 12.13 Hz, 1H), 1.25–1.14 (m, 1H). HRMS calcd for C<sub>23</sub>H<sub>29</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 349.2280, found 349.2278. (±)-<b>21</b> (trans): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 9.08 (br s, 1H), 7.54 (d, <i>J</i> = 7.33 Hz, 2H), 7.37 (dd, <i>J</i> = 7.33, 7.80 Hz, 2H), 7.30–7.25 (m, 1H), 7.17–7.14 (m, 1H), 6.70 (s, 1H), 6.58 (dd, <i>J</i> = 2.02, 3.03 Hz, 1H), 3.63 (d, <i>J</i> = 12.13 Hz, 1H), 3.50–3.45 (m, 1H), 3.41 (dd, <i>J</i> = 3.41, 11.24 Hz, 1H), 3.27 (s, 3H), 3.19 (d, <i>J</i> = 12.13 Hz, 1H), 2.38 (s, 3H), 2.37–2.32 (m, 1H), 2.31–2.21 (m, 4H), 1.91–1.78 (m, 2H), 1.77–1.70 (m, 1H), 1.54–1.45 (m, 1H). HRMS calcd for C<sub>23</sub>H<sub>29</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 349.2280, found 349.2276.</div></div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (+)-4-((4-Methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole ((+)-<b>21</b>) and (−)-4-((4-Methoxy-2-phenylpiperidin-1-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole ((−)-<b>21</b>)</h3><div class="NLM_p last">Resolution of the enantiomers of (±)-<b>21</b> (trans) (21 mg, 0.060 mmol) was achieved by chiral SFC using a CHIRALPAK IB column with 30% (10 mM NH<sub>4</sub>OH in <i><sup>i</sup></i>PrOH) in CO<sub>2</sub> to provide (+)-<b>21</b> (<i>t</i><sub>r</sub> = 3.1 min, 8 mg, 37%) [α]<sub>25</sub><sup>D</sup> +67.2° (<i>c</i> 0.1, MeOH) and (−)-<b>21</b> (<i>t</i><sub>r</sub> = 4.3 min, 9 mg, 42%) [α]<sub>25</sub><sup>D</sup> −67.2° (<i>c</i> 0.1, MeOH).</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> (±)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-ol ((±)-<b>23</b> (trans)) and (±)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-ol ((±)-<b>24</b> (cis))</h3><div id="sec5_1_23_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Step 1: (±)-1-((5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-ol ((±)-<b>77</b>, Diastereomeric Mixture)</h4><div class="NLM_p last">General procedure J with (±)-2-phenylpiperidin-4-ol ((±)-<b>114</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (154 mg, 0.72 mmol) and <b>46</b> (170 mg, 0.489 mmol) followed by FCC purification (25% EtOAc/heptane) provided the title compound (200 mg, 84%) as a diastereomeric mixture which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 489.4 (M + H).</div></div><div id="sec5_1_23_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Step 2: (±)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-ol ((±)-<b>23</b> (trans)) and (±)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-ol ((±)-<b>24</b> (cis))</h4><div class="NLM_p last">General procedure F was performed on (±)-<b>77</b> (200 mg, 0.409 mmol). The reaction mixture was diluted with DCM, filtered through a silica plug, rinsing with 6:1 DCM/MeOH, and concentrated. Separation of the diastereomers was achieved by FCC (7–15% MeOH/DCM) to provide the first eluting product (±)-<b>24</b> (cis) (50 mg, 36%) and the second eluting product (±)-<b>23</b> (trans) (37 mg, 26%). (±)-<b>24</b> (cis): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 9.12 (br s, 1H), 7.53 (d, <i>J</i> = 7.33 Hz, 2H), 7.38 (dd, <i>J</i> = 7.33, 7.80 Hz, 2H), 7.32–7.26 (m, 1H), 7.16 (dd, <i>J</i> = 2.80, 3.03 Hz, 1H), 6.71 (s, 1H), 6.56 (dd, <i>J</i> = 2.02, 3.03 Hz, 1H), 3.63 (d, <i>J</i> = 12.13 Hz, 1H), 3.60–3.53 (m, 1H), 3.19–3.14 (m, 1H), 3.12 (d, <i>J</i> = 12.13 Hz, 1H), 2.80 (br s, 1H), 2.65–2.59 (m, 1H), 2.38 (s, 3H), 2.25 (s, 3H), 2.05–1.96 (m, 1H), 1.91–1.87 (m, 1H), 1.75–1.68 (m, 1H), 1.67–1.56 (m, 1H), 1.34–1.21 (m, 1H). HRMS calcd for C<sub>22</sub>H<sub>27</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 335.2123, found 335.2119. (±)-<b>23</b> (trans): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 9.09 (br s, 1H), 7.54 (d, <i>J</i> = 7.30 Hz, 2H), 7.37 (dd, <i>J</i> = 7.30, 7.80 Hz, 2H), 7.32–7.23 (m, 1H), 7.21–7.12 (m, 1H), 6.71 (s, 1H), 6.63–6.55 (m, 1H), 4.00–3.91 (m, 1H), 3.66 (d, <i>J</i> = 12.13 Hz, 1H), 3.53 (br d, <i>J</i> = 8.80 Hz, 1H), 3.23 (br d, <i>J</i> = 10.90 Hz, 1H), 2.64 (br s, 1H), 2.48–2.31 (m, 5H), 2.27 (s, 3H), 1.91–1.84 (m, 1H), 1.78–1.68 (m, 1H), 1.66–1.43 (m, 2H). HRMS calcd for C<sub>22</sub>H<sub>27</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 335.2123, found 335.2123.</div></div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> (±)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-<i>N</i>-methyl-2-phenylpiperidin-4-amine ((±)-<b>25</b> (trans))</h3><div id="sec5_1_24_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Step 1: (±)-Benzyl (1-((5,7-dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-yl)carbamate ((±)-<b>78</b> (trans))</h4><div class="NLM_p last">General procedure J with (±)-benzyl (2-phenylpiperidin-4-yl)carbamate ((±)-<b>120</b> (trans); see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (178 mg, 0.512 mmol) and <b>46</b> (150 mg, 0.431 mmol) provided the title compound (260 mg, 97%) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 622.6 (M + H).</div></div><div id="sec5_1_24_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Step 2: (±)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-<i>N</i>-methyl-2-phenylpiperidin-4-amine ((±)-<b>25</b> (trans))</h4><div class="NLM_p last">Starting with (±)-<b>78</b> (trans) (100 mg, 0.161 mmol), general procedure E was followed except that the reaction was heated at 50 °C for 2.5 h. RP-HPLC-A purification followed by additional FCC purification [10% (2 M NH<sub>3</sub> in MeOH)/DCM] provided the title compound (22 mg, 37%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.53 (br d, <i>J</i> = 7.10 Hz, 2H), 7.37 (dd, <i>J</i> = 7.30, 8.10 Hz, 2H), 7.32–7.26 (m, 1H), 7.14 (d, <i>J</i> = 3.15 Hz, 1H), 6.67 (s, 1H), 6.51 (d, <i>J</i> = 3.15 Hz, 1H), 3.71 (d, <i>J</i> = 12.13 Hz, 1H), 3.20–3.11 (m, 2H), 2.85 (td, <i>J</i> = 3.35, 12.00 Hz, 1H), 2.60–2.50 (m, 1H), 2.40 (s, 3H), 2.34 (s, 3H), 2.24 (s, 3H), 2.11–2.03 (m, 1H), 2.03–1.96 (m, 1H), 1.85–1.77 (m, 1H), 1.63–1.53 (m, 1H), 1.35–1.23 (m, 1H). HRMS calcd for C<sub>23</sub>H<sub>30</sub>N<sub>3</sub> (M + H)<sup>+</sup> 348.2440, found 348.2430.</div></div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (±)-1-((5,7-Dimethyl-1<i>H-</i>indol-4-yl)methyl)-<i>N</i>-methyl-2-phenylpiperidin-4-amine ((±)-<b>26</b> (cis))</h3><div id="sec5_1_25_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Step 1: (±)-Benzyl (1-((5,7-dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-yl)carbamate ((±)-<b>79</b> (cis))</h4><div class="NLM_p last">General procedure J with (±)-benzyl (2-phenylpiperidin-4-yl)carbamate ((±)-<b>121</b> (cis); see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (101 mg, 0.29 mmol) and <b>46</b> (100 mg, 0.29 mmol) provided the title compound (100 mg, 56%) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 622.6 (M + H).</div></div><div id="sec5_1_25_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Step 2: (±)-1-((5,7-Dimethyl-1<i>H-</i>indol-4-yl)methyl)-<i>N</i>-methyl-2-phenylpiperidin-4-amine ((±)-<b>26</b> (cis))</h4><div class="NLM_p last">Starting with (±)-<b>79</b> (cis) (100 mg, 0.161 mmol), general procedure E was followed except that the reaction was heated at 50 °C for 15 h. RP-HPLC-A purification followed by FCC purification [10% (2 M NH<sub>3</sub> in MeOH)/DCM] provided the title compound (11 mg, 18%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.53 (d, <i>J</i> = 7.30 Hz, 2H), 7.36 (dd, <i>J</i> = 7.30, 7.80 Hz, 2H), 7.30–7.25 (m, 1H), 7.14 (d, <i>J</i> = 3.30 Hz, 1H), 6.68 (s, 1H), 6.54 (d, <i>J</i> = 3.28 Hz, 1H), 3.75 (d, <i>J</i> = 12.13 Hz, 1H), 3.50 (dd, <i>J</i> = 3.16, 11.49 Hz, 1H), 3.29 (br d, <i>J</i> = 12.10 Hz, 1H), 2.83–2.79 (m, 1H), 2.65–2.58 (m, 1H), 2.47–2.42 (m, 1H), 2.39 (br s, 6H), 2.25 (s, 3H), 2.06–1.96 (m, 1H), 1.90–1.83 (m, 1H), 1.77–1.68 (m, 2H). HRMS calcd for C<sub>23</sub>H<sub>30</sub>N<sub>3</sub> (M + H)<sup>+</sup> 348.2440, found 348.2426.</div></div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (±)-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol ((±)-<b>27</b> (trans))</h3><div id="sec5_1_26_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Step 1: (±)-(1-((5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-yl)methanol ((±)-<b>80</b> (trans))</h4><div class="NLM_p last">General procedure J with (±)-(2-phenylpiperidin-4-yl)methanol ((±)-<b>125</b> (trans); see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (100 mg, 0.44 mmol) and <b>46</b> (100 mg, 0.29 mmol) followed by FCC purification [55–95% (30% EtOAc in DCM)/heptane] provided the title compound (40 mg, 18%). MS (ESI+) <i>m</i>/<i>z</i> 503.5 (M + H).</div></div><div id="sec5_1_26_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Step 2: (±)-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol ((±)-<b>27</b> (trans))</h4><div class="NLM_p last">General procedure F was performed on (±)-<b>80</b> (trans) (77 mg, 0.153 mmol). The reaction mixture was diluted with DCM, filtered through a silica plug, rinsing with 6:1 DCM/MeOH, and concentrated. RP-HPLC-A purification provided the title compound as the TFA salt (13 mg, 14%). <sup>1</sup>H NMR (TFA salt, 400 MHz, D<sub>2</sub>O) δ 7.63–7.49 (m, 5H), 7.26 (d, <i>J</i> = 3.03 Hz, 1H), 6.78 (s, 1H), 6.12 (br s, 1H), 4.46 (dd, <i>J</i> = 2.65, 13.26 Hz, 1H), 4.20 (d, <i>J</i> = 13.40 Hz, 1H), 4.10 (d, <i>J</i> = 13.40 Hz, 1H), 3.77 (d, <i>J</i> = 7.83 Hz, 2H), 3.29–3.15 (m, 2H), 2.40–2.26 (m, 4H), 2.14–1.95 (m, 5H), 1.90–1.70 (m, 2H). HRMS calcd for C<sub>23</sub>H<sub>29</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 349.2280, found 349.2270.</div></div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> (±)-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol ((±)-<b>28</b> (cis))</h3><div id="sec5_1_27_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Step 1: (±)-(1-((5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)-2-phenylpiperidin-4-yl)methanol ((±)-<b>81</b> (cis))</h4><div class="NLM_p last">General procedure J with (±)-(2-phenylpiperidin-4-yl)methanol ((±)-<b>126</b> (cis); see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (155 mg, 0.68 mmol) and <b>46</b> (200 mg, 0.575 mmol) followed by FCC purification (32–43% EtOAc/heptane) provided the title compound (77 mg, 23%). MS (ESI+) <i>m</i>/<i>z</i> 503.5 (M + H).</div></div><div id="sec5_1_27_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Step 2: (±)-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-2-phenyl-piperidin-4-yl)methanol ((±)-<b>28</b> (cis))</h4><div class="NLM_p last">General procedure F was performed on (±)-<b>81</b> (cis) (77 mg, 0.153 mmol). The reaction mixture was diluted with DCM, filtered through a silica plug, rinsing with 6:1 DCM/MeOH, and concentrated. RP-HPLC-A purification provided the title compound as the TFA salt (65 mg, 75%). <sup>1</sup>H NMR (TFA salt, 400 MHz, D<sub>2</sub>O) δ 7.67–7.47 (m, 5H), 7.25 (d, <i>J</i> = 3.03 Hz, 1H), 6.78 (s, 1H), 6.12 (br s, 1H), 4.40 (br dd, <i>J</i> = 2.90, 12.30 Hz, 1H), 4.23 (d, <i>J</i> = 13.60 Hz, 1H), 4.07 (d, <i>J</i> = 13.60 Hz, 1H), 3.39 (d, <i>J</i> = 6.32 Hz, 2H), 3.38–3.33 (m, 1H), 3.29–3.18 (m, 1H), 2.32 (s, 3H), 2.13–2.05 (m, 1H), 2.03–1.91 (m, 4H), 1.89–1.77 (m, 2H), 1.38–1.24 (m, 1H). HRMS calcd for C<sub>23</sub>H<sub>29</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 349.2280, found 349.2265.</div></div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> ((2<i>S</i>,4<i>S</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol (<b>29</b>)</h3><div class="NLM_p last">General procedure I was performed with <b>46</b> (50 mg, 0.144 mmol) and ((2<i>S</i>,4<i>S</i>)-4-methoxypiperidin-2-yl)methanol hydrochloride (prepared as described in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>, 39.4 mg, 0.216 mmol), followed by RP-HPLC-A purification. Fractions containing product were basified with saturated aqueous NaHCO<sub>3</sub>, extracted with DCM, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to provide the title compound (13 mg, 30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.80 (br s, 1 H), 7.21 (t, <i>J</i> = 2.7 Hz, 1 H), 6.67 (s, 1 H), 6.44–6.57 (m, 1 H), 4.34 (t, <i>J</i> = 5.2 Hz, 1 H), 4.14 (d, <i>J</i> = 12.6 Hz, 1 H), 3.68 (ddd, <i>J</i> = 10.5, 5.2, 5.1 Hz, 1 H), 3.55 (d, <i>J</i> = 12.4 Hz, 1 H), 3.48 (ddd, <i>J</i> = 11.1, 5.9, 5.7 Hz, 1 H), 3.44–3.35 (m, 1 H), 3.20 (s, 3 H), 2.47–2.21 (m, 9 H), 1.66 (t, <i>J</i> = 5.2 Hz, 2 H), 1.52–1.32 (m, 2 H). HRMS calcd for C<sub>18</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub> (M + H)<sup>+</sup> 303.2073, found 303.2075.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> (±)-<i>N</i>-((1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)methyl)methanesulfonamide (<b>30</b>)</h3><div id="sec5_1_29_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Step 1: (±)-<i>tert</i>-Butyl ((1-((5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)methyl)carbamate (<b>82</b>)</h4><div class="NLM_p last">General procedure K with <i>tert</i>-butyl piperidin-2-ylmethylcarbamate (CAS no. 141771-61-0, 444 mg, 2.07 mmol) and <b>46</b> (600 mg, 1.73 mmol) followed by FCC purification (26–47% EtOAc/heptane) provided the title compound (840 mg, 93%). MS (ESI+) <i>m</i>/<i>z</i> 526.4 (M + H).</div></div><div id="sec5_1_29_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Step 2: (±)-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)methanamine (<b>83</b>)</h4><div class="NLM_p last">Starting with <b>82</b> (400 mg, 0.761 mmol), general procedure G was performed followed by general procedure F. The resulting mixture was concentrated to half the original volume, diluted with MeOH (∼15 mL), and neutralized with 1 N aqueous NaHSO<sub>4</sub> (pH ∼ 7). This was concentrated, diluted with 1:1 MeOH/DCM (∼20 mL), filtered, and concentrated again to provide the title compound (125 mg, 60% for 2 steps) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 272.5 (M + H).</div></div><div id="sec5_1_29_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Step 3: (±)-<i>N</i>-((1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)methyl)methanesulfonamide (<b>30</b>)</h4><div class="NLM_p last">To a solution of <b>83</b> (110 mg, 0.405 mmol) in DCM (8 mL) at 0 °C was added DIPEA (0.425 mL, 2.43 mmol) followed by MsCl (0.095 mL, 1.22 mmol). The resulting mixture was stirred for 10 min and then diluted with saturated aqueous NaHCO<sub>3</sub>, warmed to rt, and stirred for 30 more minutes. The mixture was further diluted with DCM and saturated aqueous NaHCO<sub>3</sub> and extracted 2× with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was partially purified by FCC (5–15% 2 M NH<sub>3</sub> in MeOH/DCM) and then further purified by RP-HPLC-B to provide the title compound (7 mg, 5%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ ppm 9.16 (br s, 1 H), 7.22 (t, <i>J</i> = 2.8 Hz, 1 H), 6.79 (s, 1 H), 6.62 (dd, <i>J</i> = 3.0, 2.0 Hz, 1 H), 4.77 (br s, 1 H), 4.19 (d, <i>J</i> = 12.9 Hz, 1 H), 3.70 (d, <i>J</i> = 12.9 Hz, 1 H), 3.31–3.18 (m, 1 H), 3.16–3.03 (m, 1 H), 2.86–2.70 (m, 1 H), 2.58–2.51 (m, 1 H), 2.48 (s, 3 H), 2.41 (s, 6 H), 2.38–2.30 (m, 1 H), 1.84–1.25 (m, 6 H). HRMS calcd for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub>S (M + H)<sup>+</sup> 350.1897, found 350.1897.</div></div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> (±)-5,7-Dimethyl-4-((2-(2-(methylsulfonyl)ethyl)piperidin-1-yl)methyl)-1<i>H</i>-indole (<b>31</b>)</h3><div id="sec5_1_30_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Step 1: (±)-5,7-Dimethyl-4-((2-(2-(methylsulfonyl)ethyl)piperidin-1-yl)methyl)-1-tosyl-1<i>H</i>-indole (<b>84</b>)</h4><div class="NLM_p last">To a solution of the TFA salt of (±)-2-(2-(methylsulfonyl)ethyl)piperidine (<b>129</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (200 mg, 0.65 mmol) in DCM (10 mL) was added 1 N aqueous NaOH (2 mL), and this was stirred vigorously for 10 min. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. This material was subjected to general procedure K with <b>46</b> (150 mg, 0.431 mmol) followed by FCC purification (40–57% EtOAc/heptane) to provide the title compound (230 mg, 88%). MS (ESI+) <i>m</i>/<i>z</i> 503.3 (M + H).</div></div><div id="sec5_1_30_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Step 2: (±)-5,7-Dimethyl-4-((2-(2-(methylsulfonyl)ethyl)piperidin-1-yl)methyl)-1<i>H</i>-indole (<b>31</b>)</h4><div class="NLM_p last">General procedure F was performed on <b>84</b> (230 mg, 0.458 mmol). The reaction was diluted with DCM and water and extracted with DCM. Organic layers were combined, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated, and purified by FCC (10–80% EtOAc/DCM) to provide the title compound (105 mg, 66%). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>) δ 8.10 (br s, 1 H), 7.20 (t, <i>J</i> = 2.8 Hz, 1 H), 6.81 (s, 1 H), 6.72–6.61 (m, 1 H), 4.13 (d, <i>J</i> = 12.6 Hz, 1 H), 3.65 (d, <i>J</i> = 12.6 Hz, 1 H), 3.10–2.87 (m, 2 H), 2.75–2.70 (m, 1 H), 2.68 (s, 3 H), 2.57–2.48 (m, 1 H), 2.44 (s, 3 H), 2.43 (s, 3 H), 2.23 (ddd, <i>J</i> = 11.9, 8.0, 3.3 Hz, 1 H), 2.18–1.97 (m, 2 H), 1.82–1.60 (m, 2 H), 1.57–1.54 (m 1 H), 1.47–1.26 (m, 3 H). HRMS calcd for C<sub>19</sub>H<sub>29</sub>N<sub>2</sub>O<sub>2</sub>S (M + H)<sup>+</sup> 349.1944, found 349.1949.</div></div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> (±)-1-((1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)methyl)urea (<b>32</b>)</h3><div class="NLM_p last">To a solution of <b>83</b> (125 mg, 0.46 mmol) in THF (4 mL) was added isocyanatotrimethylsilane (0.26 mL, 1.67 mmol) in three portions. After 1 h the reaction was diluted with MeOH (5 mL), concentrated, and purified by RP-HPLC-B to provide the title compound (4.5 mg, 3%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.81 (br s, 1 H), 7.21 (t, <i>J</i> = 2.7 Hz, 1 H), 6.68 (s, 1 H), 6.52 (dd, <i>J</i> = 3.0, 2.0 Hz, 1 H), 5.83 (br s, 1 H), 5.44 (s, 2 H), 4.15 (d, <i>J</i> = 12.1 Hz, 1 H), 3.45–3.35 (m, 2 H), 3.30–3.18 (m, 2 H), 2.39 (s, 3 H), 2.36 (s, 3 H), 2.32–2.24 (m, 1 H), 2.04–1.84 (m, 1 H), 1.73–1.52 (m, 2 H), 1.47–0.98 (m, 4 H). HRMS calcd for C<sub>18</sub>H<sub>27</sub>N<sub>4</sub>O (M + H)<sup>+</sup> 315.2179, found 315.2174.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> (±)-5,7-Dimethyl-4-((2-(4-(methylsulfonyl)phenyl)piperidin-1-yl)methyl)-1<i>H-</i>indole (<b>33</b>)</h3><div id="sec5_1_32_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Step 1: (±)-5,7-Dimethyl-4-((2-(4-(methylsulfonyl)phenyl)piperidin-1-yl)methyl)-1-tosyl-1<i>H</i>-indole (<b>85</b>)</h4><div class="NLM_p last">General procedure K with (±)-2-(4-(methylsulfonyl)phenyl)piperidine (<b>135</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (83 mg, 0.347 mmol) and <b>46</b> (101 mg, 0.289 mmol) followed by FCC purification (0–80% EtOAc/heptane) provided the title compound (98 mg, 62%). MS (ESI+) <i>m</i>/<i>z</i> 551.5 (M + H).</div></div><div id="sec5_1_32_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Step 2: (±)-5,7-Dimethyl-4-((2-(4-(methylsulfonyl)phenyl)piperidin-1-yl)methyl)-1<i>H-</i>indole (<b>33</b>)</h4><div class="NLM_p last">General procedure F was performed on <b>85</b> (98 mg, 0.178 mmol). The reaction was diluted with water, acidified with 2 N HCl until pH < 7, basified with sodium bicarbonate, and extracted 2× with EtOAc. Organic layers were combined, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by FCC (0–100% EtOAc/heptane) to provide the title compound (12 mg, 16%). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 8.12 (br s, 1H), 7.91 (d, <i>J</i> = 8.34 Hz, 2H), 7.78 (d, <i>J</i> = 8.08 Hz, 2H), 7.22 (dd, <i>J</i> = 2.80, 3.00 Hz, 1H), 6.78 (s, 1H), 6.70 (dd, <i>J</i> = 2.27, 3.03 Hz, 1H), 3.70 (d, <i>J</i> = 12.38 Hz, 1H), 3.27 (d, <i>J</i> = 12.38 Hz, 1H), 3.24–3.20 (m, 1H), 3.06 (s, 3H), 2.82–2.74 (m, 1H), 2.44 (s, 3H), 2.35 (s, 3H), 2.05–1.96 (m, 1H), 1.85–1.75 (m, 2H), 1.75–1.64 (m, 1H), 1.53–1.38 (m, 3H). HRMS calcd for C<sub>23</sub>H<sub>29</sub>N<sub>2</sub>O<sub>2</sub>S (M + H)<sup>+</sup> 397.1950, found 397.1936.</div></div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> (±)-4-(1-((5,7-Dimethyl-1<i>H-</i>indol-4-yl)methyl)piperidin-2-yl)benzamide ((±)-<b>34</b>) and (±)-4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid ((±)-<b>35</b>)</h3><div id="sec5_1_33_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Step 1: (±)-4-(1-((5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzonitrile (<b>86</b>)</h4><div class="NLM_p last">General procedure K with 4-(piperidin-2-yl)benzonitrile hydrochloride (CAS no. 1203685-85-1, 112 mg, 0.600 mmol) and <b>46</b> (174 mg, 0.50 mmol) followed by FCC purification (0–100% EtOAc/heptane) provided the title compound (176 mg, 71%). MS (ESI+) <i>m</i>/<i>z</i> 498.5 (M + H).</div></div><div id="sec5_1_33_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Step 2: (±)-4-(1-((5,7-Dimethyl-1<i>H-</i>indol-4-yl)methyl)piperidin-2-yl)benzamide ((±)-<b>34</b>) and (±)-4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid ((±)-<b>35</b>)</h4><div class="NLM_p last">A mixture of <b>86</b> (100 mg, 0.201 mmol) and KOH (100 mg, 1.78 mmol) in EtOH (2 mL) was stirred and heated at 100 °C via microwave irradiation for 1 h. The mixture was acidified with AcOH until pH ∼ 6, then purified directly by RP-HPLC-A to provide the first eluting product (±)-<b>34</b> (26 mg, 23%) and the second eluting product (±)-<b>35</b> (27 mg, 26%). (±)-<b>34</b>: <sup>1</sup>H NMR (TFA salt, 400 MHz, D<sub>2</sub>O) δ 8.02–7.92 (m, 2H), 7.76 (d, <i>J</i> = 7.9 Hz, 2H), 7.36 (d, <i>J</i> = 3.1 Hz, 1H), 6.86 (s, 1H), 6.24 (s, 1H), 4.56–4.47 (m, 1H), 4.32–4.17 (m, 2H), 3.44 (d, <i>J</i> = 12.4 Hz, 1H), 3.29 (t, <i>J</i> = 12.6 Hz, 1H), 2.41 (s, 3H), 2.20–2.03 (m, 5H), 2.00–1.80 (m, 2H), 1.80–1.58 (m, 2H). HRMS calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O (M + H)<sup>+</sup> 362.2232, found 362.2221. (±)-<b>35</b>: <sup>1</sup>H NMR (TFA salt, 400 MHz, methanol-<i>d</i><sub>4</sub>) δ 10.82 (s, 1H), 8.24 (d, <i>J</i> = 8.2 Hz, 2H), 7.76 (d, <i>J</i> = 8.1 Hz, 2H), 7.32 (dt, <i>J</i> = 3.0, 1.3 Hz, 1H), 6.83 (s, 1H), 6.36 (d, <i>J</i> = 3.1 Hz, 1H), 4.58 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H), 4.38–4.18 (m, 2H), 3.53 (d, <i>J</i> = 12.6 Hz, 1H), 3.44–3.34 (m, 1H), 2.45 (s, 3H), 2.24–2.07 (m, 5H), 2.01–1.72 (m, 4H). HRMS calcd for C<sub>23</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub> (M + H)<sup>+</sup> 363.2073, found 363.2070.</div></div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> (−)-4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid ((−)-<b>35</b>)</h3><div id="sec5_1_34_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Step 1: (±)-Methyl 4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoate ((±)-<b>87</b>)</h4><div class="NLM_p last">Starting with <b>86</b> (550 mg, 1.10 mmol), general procedure L followed by general procedure M was performed followed by FCC purification (24% EtOAc/heptane) to provide the title compound (300 mg, 72% for 2 steps). <sup>1</sup>H NMR (400 MHz, acetonitrile-<i>d</i><sub>3</sub>) δ 9.10 (s, 1H), 8.04–7.95 (m, 2H), 7.65 (d, <i>J</i> = 8.0 Hz, 2H), 7.17 (t, <i>J</i> = 2.9 Hz, 1H), 6.71 (s, 1H), 6.58 (dd, <i>J</i> = 3.2, 2.0 Hz, 1H), 3.86 (s, 3H), 3.61 (d, <i>J</i> = 12.1 Hz, 1H), 3.24–3.12 (m, 2H), 2.66 (ddd, <i>J</i> = 10.6, 3.4, 1.8 Hz, 1H), 2.39 (s, 3H), 2.27 (s, 3H), 1.82–1.61 (m, 4H), 1.57–1.39 (m, 3H). MS (ESI+) <i>m</i>/<i>z</i> 377.5 (M + H).</div></div><div id="sec5_1_34_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Step 2: Methyl 4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoate (<b>87a</b>) and Methyl 4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoate (<b>87b</b>)</h4><div class="NLM_p last">Resolution of the enantiomers of (±)-<b>87</b> (500 mg, 1.33 mmol) was achieved by chiral SFC using a CHIRALCEL OJ-H column with 30% (0.2% DEA in MeOH) in CO<sub>2</sub> to provide the first eluting enantiomer <b>87a</b> (<i>t</i><sub>r</sub> = 2.6 min, 230 mg, 46%) and the second eluting enantiomer <b>87b</b> (<i>t</i><sub>r</sub> = 4.1 min, 210 mg, 42%).</div></div><div id="sec5_1_34_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Step 3: (−)-4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid ((−)-<b>35</b>)</h4><div class="NLM_p last">A mixture of <b>87b</b> (150 mg, 0.398 mmol) and KOH (50 mg, 0.89 mmol) in THF (1 mL) was stirred at rt for 1 h. The mixture was then concentrated and purified by RP-HPLC-B to provide the title compound (120 mg, 83%). [α]<sub>25</sub><sup>D</sup> +5.8° (<i>c</i> 0.1, MeOH); <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.95 (d, <i>J</i> = 8.59 Hz, 2H), 7.58 (br d, <i>J</i> = 7.80 Hz, 2H), 7.20 (d, <i>J</i> = 3.00 Hz, 1H), 6.71 (s, 1H), 6.08 (br s, 1H), 4.39–4.32 (m, 1H), 4.13 (d, <i>J</i> = 13.60 Hz, 1H), 4.06 (d, <i>J</i> = 13.60 Hz, 1H), 3.27 (br d, <i>J</i> = 12.40 Hz, 1H), 3.17–3.07 (m, 1H), 2.25 (s, 3H), 2.03–1.92 (m, 5H), 1.82–1.74 (m, 1H), 1.74–1.65 (m, 1H), 1.61–1.44 (m, 2H). HRMS calcd for C<sub>23</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub> (M + H)<sup>+</sup> 363.2073, found 363.2067.</div></div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> (+)-4-(1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid ((+)-<b>35</b>)</h3><div class="NLM_p last">Starting with <b>87a</b> (150 mg, 0.398 mmol), following the same procedure used for ((−)-<b>35</b>) provided the title compound (130 mg, 88%). [α]<sub>25</sub><sup>D</sup> −26.5° (<i>c</i> 0.1, MeOH); <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.95 (d, <i>J</i> = 8.59 Hz, 2H), 7.58 (br d, <i>J</i> = 7.80 Hz, 2H), 7.20 (d, <i>J</i> = 3.00 Hz, 1H), 6.71 (s, 1H), 6.08 (br s, 1H), 4.39–4.32 (m, 1H), 4.13 (d, <i>J</i> = 13.60 Hz, 1H), 4.06 (d, <i>J</i> = 13.60 Hz, 1H), 3.27 (br d, <i>J</i> = 12.40 Hz, 1H), 3.17–3.07 (m, 1H), 2.25 (s, 3H), 2.03–1.92 (m, 5H), 1.82–1.74 (m, 1H), 1.74–1.65 (m, 1H), 1.61–1.44 (m, 2H). HRMS calcd for C<sub>23</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub> (M + H)<sup>+</sup> 363.2073, found 363.2068.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic Acid (<b>36</b>)</h3><div id="sec5_1_36_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Step 1: (±)-4-(<i>trans</i>-1-((5,7-Dimethyl-1-tosyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzonitrile (<b>88</b>)</h4><div class="NLM_p last">General procedure J with (±)-4-(<i>trans</i>-4-methoxypiperidin-2-yl)benzonitrile (<b>140</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (170 mg, 0.786 mmol) and <b>46</b> (420 mg, 1.21 mmol) was followed. The crude material was cooled to rt, diluted with DCM, filtered, and purified by passage through a cation exchange column (Biotage Isolute SCX-2 column) eluting initially with 20% MeOH/DCM followed by 7 N NH<sub>3</sub> in MeOH to provide the title compound (320 mg, 77%). MS (ESI+) <i>m</i>/<i>z</i> 528.5 (M + H).</div></div><div id="sec5_1_36_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Step 2: (±)-Methyl 4-(<i>trans</i>-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate ((±)-<b>89</b>)</h4><div class="NLM_p last">Starting with <b>88</b> (320 mg, 0.606 mmol), general procedure L was followed except that isoamylamine (0.5 mL, 4.3 mmol) was also added to the reaction mixture. General procedure M was then performed, followed by FCC purification (33% EtOAc/heptane) to provide the title compound (35 mg, 14% for 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) δ 9.09 (br s, 1H), 7.99 (d, <i>J</i> = 8.34 Hz, 2H), 7.65 (br d, <i>J</i> = 8.10 Hz, 2H), 7.17 (app t, <i>J</i> = 2.78 Hz, 1H), 6.71 (s, 1H), 6.57 (dd, <i>J</i> = 2.02, 3.03 Hz, 1H), 3.85 (s, 3H), 3.60 (d, <i>J</i> = 12.10 Hz, 1H), 3.54–3.45 (m, 2H), 3.29–3.21 (m, 4H), 2.40–2.34 (m, 4H), 2.33–2.23 (m, 4H), 1.91–1.86 (m, 1H), 1.85–1.79 (m, 1H), 1.78–1.70 (m, 1H), 1.56–1.45 (m, 1H). HRMS calcd for C<sub>25</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 407.2335, found 407.2326.</div></div><div id="sec5_1_36_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Step 3: Methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>89a</b>) and Methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>89b</b>)</h4><div class="NLM_p last">Resolution of the enantiomers of (±)-<b>89</b> (30 mg, 0.074 mmol) was achieved by chiral SFC using a CHIRALCEL OJ-H column with 30% (10 mM NH<sub>4</sub>OH in MeOH) in CO<sub>2</sub> to provide the first eluting enantiomer, methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5,7-dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>89a</b>) (<i>t</i><sub>r</sub> = 2.4 min, 12 mg, 40%) and the second eluting enantiomer, methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>89b</b>) (<i>t</i><sub>r</sub> = 3.4 min, 14 mg, 47%). The absolute stereochemistry was determined via chemical correlation to compound <b>41</b>.</div></div><div id="sec5_1_36_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> Step 4: 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic Acid (<b>36</b>)</h4><div class="NLM_p last">General procedure N was performed on <b>89b</b> (14 mg, 0.034 mmol) at 70 °C for 1 h, followed by RP-HPLC-B purification to provide the title compound (4 mg, 29%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.81 (d, <i>J</i> = 8.08 Hz, 2H), 7.47 (d, <i>J</i> = 8.10 Hz, 2H), 7.11 (d, <i>J</i> = 3.03 Hz, 1H), 6.60 (s, 1H), 6.06 (br s, 1H), 3.92 (br s, 1H), 3.70 (d, <i>J</i> = 12.63 Hz, 1H), 3.59 (br s, 1H), 3.53–3.28 (m, 1H), 3.22 (s, 3H), 2.74 (br s, 2H), 2.19 (s, 3H), 2.10–1.94 (m, 2H), 1.88 (s, 3H), 1.84–1.70 (m, 1H), 1.69–1.40 (m, 1H). HRMS calcd for C<sub>24</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 393.2178, found 393.2173.</div></div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> 4-((2<i>S</i>,4<i>S</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic Acid (<b>37</b>)</h3><div id="sec5_1_37_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Step 1: (±)-<i>tert</i>-Butyl 5-Cyclopropyl-4-(<i>trans</i>-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>90</b>)</h4><div class="NLM_p last">General procedure J with (±)-methyl 4-(<i>trans</i>-4-methoxypiperidin-2-yl)benzoate (<b>143</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (287 mg, 1.15 mmol) and <b>52</b> (350 mg, 1.09 mmol) followed by FCC purification (23% EtOAc/heptane) provided the title compound (410 mg, 70%). MS (ESI+) <i>m</i>/<i>z</i> 533.6 (M + H).</div></div><div id="sec5_1_37_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Step 2: (±)-Methyl 4-(<i>trans</i>-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate ((±)-<b>91</b>)</h4><div class="NLM_p last">General procedure H was performed on <b>90</b> (410 mg, 0.770 mmol). The reaction was cooled to rt, acidified with half saturated aqueous citric acid, extracted 3×x with DCM/TFE (9:1), dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. General procedure M was then performed, followed by FCC purification (21% EtOAc/heptane) to provide the title compound (300 mg, 90% for 2 steps). MS (ESI+) <i>m</i>/<i>z</i> 433.4 (M + H).</div></div><div id="sec5_1_37_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Step 3: Methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>91a</b>) and Methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>91b</b>)</h4><div class="NLM_p last">Resolution of the enantiomers of (±)-<b>91</b> (300 mg, 0.69 mmol) was achieved by chiral SFC using a CHIRALCEL OJ-H column with 30% (5 mM NH<sub>4</sub>OH in MeOH) in CO<sub>2</sub> to provide the first eluting enantiomer, methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5-cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>91a</b>) (<i>t</i><sub>r</sub> = 2.0 min, 100 mg, 28%), and the second eluting enantiomer, methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5-cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoate (<b>91b</b>) (<i>t</i><sub>r</sub> = 4.3 min, 100 mg, 28%). The absolute stereochemistry was determined via chemical correlation to compound <b>41</b>.</div></div><div id="sec5_1_37_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Step 4: 4-((2<i>S</i>,4<i>S</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)benzoic Acid (<b>37</b>)</h4><div class="NLM_p last">General procedure N was performed on <b>91a</b> (100 mg, 0.23 mmol) at 70 °C for 8 h, followed by RP-HPLC-B purification to provide the title compound (59 mg, 61%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.81 (br d, <i>J</i> = 8.30 Hz, 2H), 7.51 (br d, <i>J</i> = 7.80 Hz, 2H), 7.20 (d, <i>J</i> = 3.28 Hz, 1H), 6.52 (s, 1H), 6.16 (br s, 1H), 4.46–4.15 (m, 2H), 3.97 (br s, 1H), 3.66 (br s, 1H), 3.24 (s, 3H), 3.20–2.96 (m, 2H), 2.23 (s, 3H), 2.14 (br s, 2H), 1.90 (br d, <i>J</i> = 15.40 Hz, 1H), 1.70 (br s, 1H), 1.45 (br s, 1H), 0.66 (br s, 1H), 0.55 (br s, 1H), 0.14 (br s, 1H), −0.11 (br s, 1H). HRMS calcd for C<sub>26</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 419.2335, found 419.2335.</div></div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> 4-((2<i>S</i>,4<i>S</i>)-4-Methoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (<b>38</b>)</h3><div id="sec5_1_38_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> Step 1: (±)-<i>tert</i>-Butyl 5-Methoxy-4-(<i>trans</i>-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1<i>H</i>-indole-1-carboxylate ((±)-<b>92</b>)</h4><div class="NLM_p last">General procedure O with <b>57</b> (120 mg, 0.415 mmol) and (±)-methyl 4-(<i>trans</i>-4-methoxypiperidin-2-yl)benzoate (<b>143</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>) (100 mg, 0.401 mmol), followed by FCC purification on aminopropyl-functionalized silica gel (6% EtOAc/heptane), provided the title compound (110 mg, 52%). MS (ESI+) <i>m</i>/<i>z</i> 523.4 (M + H).</div></div><div id="sec5_1_38_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> Step 2: <i>tert</i>-Butyl 5-Methoxy-4-((2<i>R</i>,4<i>R</i>)-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>92a</b>) and <i>tert</i>-Butyl 5-Methoxy-4-((2<i>S</i>,4<i>S</i>)-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>92b</b>)</h4><div class="NLM_p last">Resolution of the enantiomers of (±)-<b>92</b> (110 mg, 0.21 mmol) was achieved by chiral SFC using a CHIRALPAK AD-H column with 15% (5 mM NH<sub>4</sub>OH in MeOH) in CO<sub>2</sub> to provide the first eluting enantiomer, <i>tert</i>-butyl 5-methoxy-4-((2<i>R</i>,4<i>R</i>)-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>92a</b>) (<i>t</i><sub>r</sub> = 2.8 min, 35 mg, 29%), and the second eluting enantiomer, <i>tert</i>-butyl 5-methoxy-4-((2<i>S</i>,4<i>S</i>)-(4-methoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>92b</b>) (<i>t</i><sub>r</sub> = 5.5 min, 30 mg, 25%). The absolute stereochemistry was determined via chemical correlation to compound <b>41</b>.</div></div><div id="sec5_1_38_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> Step 3: 4-((2<i>S</i>,4<i>S</i>)-4-Methoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (<b>38</b>)</h4><div class="NLM_p last">General procedure N was performed on <b>92b</b> (30 mg, 0.057 mmol) at 70 °C for 4 h, followed by RP-HPLC-B purification to provide the title compound (19 mg, 79%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.99 (d, <i>J</i> = 8.10 Hz, 2H), 7.63 (br d, <i>J</i> = 8.10 Hz, 2H), 7.34 (d, <i>J</i> = 3.03 Hz, 1H), 6.80 (s, 1H), 6.30 (d, <i>J</i> = 3.03 Hz, 1H), 4.02–3.79 (m, 2H), 3.79–3.73 (m, 1H), 3.69 (s, 3H), 3.49–3.29 (m, 4H), 2.89 (br d, <i>J</i> = 10.90 Hz, 1H), 2.83–2.63 (m, 1H), 2.45 (s, 3H), 2.20–2.07 (m, 1H), 2.06–1.88 (m, 2H), 1.87–1.61 (m, 1H). HRMS calcd for C<sub>24</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub> (M + H)<sup>+</sup> 409.2127, found 409.2119.</div></div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic Acid (<b>39</b>)</h3><div id="sec5_1_39_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> Step 1: (±)-<i>tert</i>-Butyl 4-(<i>trans</i>-(4-Ethoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5,7-dimethyl-1<i>H</i>-indole-1-carboxylate (<b>53</b>)</h4><div class="NLM_p last">General procedure K with (±)-<b>50</b> (300 mg, 1.14 mmol) and <b>51</b> (368 mg, 1.25 mmol) followed by FCC purification (0–80% EtOAc/heptane) provided the title compound (530 mg, 89%). MS (ESI+) <i>m</i>/<i>z</i> 521.6 (M + H).</div></div><div id="sec5_1_39_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Step 2: (±)-Methyl 4-(<i>trans</i>-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate ((±)-<b>55</b>)</h4><div class="NLM_p last">General procedure H was performed on <b>53</b> (530 mg, 1.02 mmol). The reaction was cooled to rt, diluted with water, and immediately neutralized with 1 N HCl until pH < 7, then basified with sodium bicarbonate, extracted 3× with EtOAc, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. General procedure M was then performed, followed by FCC purification (0–100% EtOAc/heptane) to provide the title compound (350 mg, 82% for 2 steps). MS (ESI+) <i>m</i>/<i>z</i> 421.8 (M + H).</div></div><div id="sec5_1_39_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> Step 3: Methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>55a</b>) and Methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>55b</b>)</h4><div class="NLM_p last">Resolution of the enantiomers of (±)-<b>55</b> (350 mg, 0.83 mmol) was achieved by chiral SFC using a CHIRALPAK AD-H column with 40% (5 mM NH<sub>4</sub>OH in <i><sup>i</sup></i>PrOH) in CO<sub>2</sub> to provide the first eluting enantiomer, methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>55a</b>) (<i>t</i><sub>r</sub> = 1.7 min, 164 mg, 47%), and the second eluting enantiomer, methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5,7-dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>55b</b>) (<i>t</i><sub>r</sub> = 4.4 min, 161 mg, 46%). The absolute stereochemistry was determined via chemical correlation to compound <b>41</b>.</div></div><div id="sec5_1_39_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> Step 4: 4-((2<i>S</i>,4<i>S</i>)-1-((5,7-Dimethyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic Acid (<b>39</b>)</h4><div class="NLM_p last">General procedure N was performed on <b>55a</b> (86 mg, 0.20 mmol) at rt for 16 h, followed by RP-HPLC-A purification to provide the title compound as the TFA salt (101 mg, 90%). <sup>1</sup>H NMR (TFA salt, 600 MHz, D<sub>2</sub>O) δ 8.04 (d, <i>J</i> = 7.79 Hz, 2H), 7.73 (br d, <i>J</i> = 7.40 Hz, 2H), 7.38 (d, <i>J</i> = 2.84 Hz, 1H), 6.89 (s, 1H), 6.29 (br s, 1H), 4.64 (br s, 1H), 4.28 (br s, 1H), 4.13 (br s, 1H), 3.97 (br s, 1H), 3.65 (q, <i>J</i> = 6.94 Hz, 2H), 3.40 (br s, 1H), 3.22 (br s, 1H), 2.45 (s, 3H), 2.34 (br s, 2H), 2.15 (br s, 3H), 2.11–2.03 (m, 1H), 1.90 (br s, 1H), 1.29 (t, <i>J</i> = 7.02 Hz, 3H). HRMS calcd for C<sub>25</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 407.2335, found 407.2332.</div></div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> 4-((2<i>S</i>,4<i>S</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic Acid (<b>40</b>)</h3><div id="sec5_1_40_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> Step 1: (±)-<i>tert</i>-Butyl 5-Cyclopropyl-4-(<i>trans</i>-(4-ethoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>54</b>)</h4><div class="NLM_p last">General procedure K with (±)-<b>50</b> (256 mg, 0.972 mmol) and <b>52</b> (342 mg, 1.07 mmol) followed by FCC purification (0–80% EtOAc/heptane) provided the title compound (450 mg, 85%). MS (ESI+) <i>m</i>/<i>z</i> 547.3 (M + H).</div></div><div id="sec5_1_40_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> Step 2: (±)-Methyl 4-(<i>trans</i>-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate ((±)-<b>56</b>)</h4><div class="NLM_p last">General procedure H was performed on <b>54</b> (450 mg, 0.82 mmol). The reaction was cooled to rt, diluted with water, and immediately neutralized with 1 N HCl until pH < 7, then basified with sodium bicarbonate, extracted 3× with EtOAc, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. This was purified by FCC (0–100% EtOAc/heptane) to provide the title compound (230 mg, 63%). MS (ESI+) <i>m</i>/<i>z</i> 447.5 (M + H).</div></div><div id="sec5_1_40_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> Step 3: Methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>56a</b>) and Methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>56b</b>)</h4><div class="NLM_p last">Resolution of the enantiomers of (±)-<b>56</b> (265 mg, 0.59 mmol) was achieved by chiral SFC using a CHIRALPAK AD-H column with 40% (5 mM NH<sub>4</sub>OH in <i><sup>i</sup></i>PrOH) in CO<sub>2</sub> to provide the first eluting enantiomer, methyl 4-((2<i>S</i>,4<i>S</i>)-1-((5-cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>56a</b>) (<i>t</i><sub>r</sub> = 1.3 min, 84 mg, 32%), and the second eluting enantiomer, methyl 4-((2<i>R</i>,4<i>R</i>)-1-((5-cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoate (<b>56b</b>) (<i>t</i><sub>r</sub> = 2.9 min, 69 mg, 26%). The absolute stereochemistry was determined via chemical correlation to compound <b>41</b>.</div></div><div id="sec5_1_40_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> Step 4: 4-((2<i>S</i>,4<i>S</i>)-1-((5-Cyclopropyl-7-methyl-1<i>H</i>-indol-4-yl)methyl)-4-ethoxypiperidin-2-yl)benzoic Acid (<b>40</b>)</h4><div class="NLM_p last">General procedure N was performed on <b>56a</b> (84 mg, 0.19 mmol) at rt for 16 h, followed by RP-HPLC-A purification to provide the title compound as the TFA salt (72 mg, 68%). <sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O) δ 8.03 (d, <i>J</i> = 8.25 Hz, 2H), 7.71 (br d, <i>J</i> = 7.80 Hz, 2H), 7.41 (d, <i>J</i> = 2.93 Hz, 1H), 6.71 (s, 1H), 6.32 (br s, 1H), 4.73–4.63 (m, 1H), 4.52 (d, <i>J</i> = 12.30 Hz, 1H), 4.30 (d, <i>J</i> = 12.30 Hz, 1H), 3.98 (br s, 1H), 3.65 (q, <i>J</i> = 7.00 Hz, 2H), 3.56–3.42 (m, 1H), 3.34 (br d, <i>J</i> = 11.00 Hz, 1H), 2.43 (s, 3H), 2.40–2.26 (m, 2H), 2.10 (d, <i>J</i> = 15.31 Hz, 1H), 1.92 (br s, 1H), 1.61 (br s, 1H), 1.29 (t, <i>J</i> = 7.00 Hz, 3H), 0.87 (br s, 1H), 0.76 (br s, 1H), 0.34 (br s, 1H), 0.08 (br s, 1H). HRMS calcd for C<sub>27</sub>H<sub>33</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 433.2491, found 433.2482.</div></div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> 4-((2<i>S</i>,4<i>S</i>)-(4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl))benzoic Acid (<b>41</b>, LNP023)</h3><div id="sec5_1_41_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> Step 1: <i>tert</i>-Butyl 4-(((2<i>S</i>,4<i>S</i>)-4-Ethoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>58</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-formyl-5-methoxy-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>57</b>) (1.5 g, 5.18 mmol) and methyl 4-((2<i>S</i>,4<i>S</i>)-4-ethoxypiperidin-2-yl)benzoate ((2<i>S</i>,4<i>S</i>)-<b>50</b>) (1.185 g, 4.50 mmol) in DCE (20 mL) was added NaBH(OAc)<sub>3</sub> (3 g, 14.1 mmol), and this was stirred at rt for 21.5h. Additional <i>tert</i>-butyl 4-formyl-5-methoxy-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>57</b>) (500 mg, 1.90 mmol) was added, and this was stirred for 20 h. The reaction was diluted with EtOAc, washed successively with 5% aqueous NaHCO<sub>3</sub>, H<sub>2</sub>O, and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to provide the title compound (2.415 g, quant) which was used without further purification. MS (ESI+) <i>m</i>/<i>z</i> 537.4 (M + H). The absolute stereochemistry was ultimately determined via cocrystallization of <b>41</b> with the catalytic domain of FB.</div></div><div id="sec5_1_41_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> Step 2: 4-((2<i>S</i>,4<i>S</i>)-(4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl))benzoic Acid (<b>41</b>, LNP023)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(((2<i>S</i>,4<i>S</i>)-4-ethoxy-2-(4-(methoxycarbonyl)phenyl)piperidin-1-yl)methyl)-5-methoxy-7-methyl-1<i>H</i>-indole-1-carboxylate (<b>58</b>) (2.415 g, 4.50 mmol) in THF (10 mL) and MeOH (20 mL) was added 1 M LiOH in H<sub>2</sub>O (15 mL, 15 mmol), and this was stirred at 70 °C for 8 h. The reaction was cooled to rt, diluted with H<sub>2</sub>O, half saturated aqueous KHSO<sub>4</sub> and citric acid, saturated with sodium chloride, then extracted with 9:1 DCM/TFE, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. RP-HPLC-B purification provided the title compound (730 mg, 38% for 2 steps). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 7.96 (d, <i>J</i> = 8.0 Hz, 2H), 7.58 (d, <i>J</i> = 8.1 Hz, 2H), 7.30 (d, <i>J</i> = 3.2 Hz, 1H), 6.66 (s, 1H), 6.20 (s, 1H), 4.62–4.47 (m, 1H), 4.06 (d, <i>J</i> = 13.2 Hz, 1H), 3.97–3.76 (m, 2H), 3.66–3.48 (m, 5H), 3.43–3.29 (m, 1H), 3.26–3.15 (m, 1H), 2.35 (s, 3H), 2.31–2.11 (m, 2H), 2.00 (d, <i>J</i> = 15.4 Hz, 1H), 1.93–1.74 (m, 1H), 1.25–1.07 (m, 3H). HRMS calcd for C<sub>25</sub>H<sub>31</sub>N<sub>2</sub>O<sub>4</sub> (M + H)<sup>+</sup> 423.2284, found 423.2263.</div></div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> 4-((2<i>S</i>,4<i>S</i>)-(4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl))benzoic Acid Hydrochloride (<b>41</b>·HCl)</h3><div class="NLM_p last">To a solution of <b>41</b> (620 mg, 1.47 mmol) in H<sub>2</sub>O (10 mL) and acetonitrile (3 mL) was added 5 M aqueous HCl (0.5 mL, 2.5 mmol). The mixture was then lyophilized, and the resulting solid was suspended in <sup><i>i</i></sup>PrOH and heated to 70 °C. The mixture turned into a solution after 1.5 h and was then cooled to rt with stirring. After about 5 h, the mixture turned into a suspension and the solid was collected by filtration and dried under high vacuum at 50 °C to provide the title compound as the hydrochloride salt (450 mg, 65%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 10.73 (s, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 2H), 7.74 (d, <i>J</i> = 8.3 Hz, 2H), 7.36–7.31 (m, 1H), 6.77 (s, 1H), 6.42–6.31 (m, 1H), 4.40–4.19 (m, 2H), 3.87–3.80 (m, 1H), 3.76 (s, 3H), 3.68–3.50 (m, 4H), 3.45–3.38 (m, 1H), 2.51 (s, 3H), 2.30–2.18 (m, 2H), 2.13–1.89 (m, 2H), 1.31 (t, <i>J</i> = 7.0 Hz, 3H). MS (ESI+) <i>m</i>/<i>z</i> 423.3 (M + H).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147">2.  Protein Crystallography</h3><div class="NLM_p last">Cocrystallization screening experiments were conducted with all compounds by using the catalytic domain (Asp470-Leu764) of human FB at a concentration of 25 mg/mL in 20 mM Tris, pH 7.5, containing 100 mM NaCl. Crystals were grown at 20 °C using a sitting drop vapor diffusion format. All crystals were cryocooled in liquid nitrogen without the addition of cryoprotectant, and data were collected at the PXII beamline of the Swiss Light Source (SLS) at the Paul Scherrer Institute (PSI). Crystal structures were solved by molecular replacement using the published structure of the catalytic domain (Protein Data Bank code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DLE">1DLE</a>). Atomic coordinates and structure factors for the crystal structures of FB with compounds <b>1</b>, <b>8</b>, (<i>S</i>)-<b>19</b>, <b>29</b>, <b>35</b>, and <b>41</b> are deposited in the Protein Data Bank with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSW">6QSW</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8U">6T8U</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8W">6T8W</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSX">6QSX</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8V">6T8V</a>.pdb, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RAV">6RAV</a>.pdb, respectively. Authors will release the atomic coordinates and experimental data upon article publication.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148">3.  Biological and in Vivo Experiments</h3><div class="NLM_p last">The procedures for the CVF-Bb ELISA assessments, FB-comp FRET based assay, 50% human serum MAC deposition, and 50% mouse serum C3b deposition assays, as well as SPR determinations have been reported previously and can be found in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>. The experimental protocol for the mouse LPS challenge model has previously been described in ref <a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>. In all cases protocols, handling, and care of animals were in accordance with the policy of the NIBR Cambridge Animal Care and Use Committee.</div></div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149">3.1.  Plasma Pharmacokinetic Studies in Mice</h3><div class="NLM_p last">The pharmacokinetics of compounds <b>35</b>–<b>38</b>, <b>40</b>, and <b>41</b> were determined in C57BL/6 mice. The compounds were dosed intravenously (iv, via injection into jugular vein, 1 mg/kg, <i>n</i> = 2 animals/compound) and orally (po, via oral gavage, 10 mg/kg, <i>n</i> = 3 animals/compound). The iv solution formulations were prepared at 1 mg/mL as described in the parentheses for each compound: <b>35</b>, <b>36</b>, and <b>41</b> (10% propylene glycol, 25% solution of 20% solutol, and phosphate buffered saline), <b>37</b> (1 equiv of 1 N sodium hydroxide solution, 10% propylene glycol, 25% solution of 20% solutol, and phosphate buffered saline, and 1 N hydrochloric acid for pH adjustment), <b>38</b> (1 equiv of 1 N hydrochrolic acid, 30% polyethylene glycol 300, 50% solution of 20% chremophor EL, and phosphate buffered saline), <b>40</b> (2 equiv of 1 N sodium hydroxide solution, 10% propylene glycol, 25% solution of 20% Solutol, and phosphate buffered saline and 1 N hydrochloric acid for pH adjustment). The po formulations were suspensions in 0.5% methylcellulose and 0.5% Tween 80. Approximately 50 μL of whole blood was collected from the tails at 5 min (iv dose only), 15 min (po dose only), 0.5 h, 1 h, 2 h, 4 h, and 7 h postdose and was transferred to EDTA tubes. Blood was centrifuged at 3000 rpm, and the resultant plasma was transferred to a capped PCR 96-well plate and frozen at −20 °C until subsequent analysis by high performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS). Chromatographic separation was carried out on ACE C18 column (30 mm × 2.1 mm, 50 μm) (MAC-MOD Analytical, Chadds Ford, PA), using a gradient elution method with water and acetonitrile, both containing 0.1% formic acid. Mass spectrometric measurements in positive electrospray ionization were directed at quantifying the respective [M + H]<sup>+</sup> precursor ions to the relevant fragment ions on Sciex (Sciex, Framingham, MA) or Thermo (Thermo, Waltham, MA) mass spectrometers. The relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO) or Watson LIMS (Thermo, Waltham, MA).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150">3.2.  Plasma Pharmacokinetic Studies in Rats</h3><div class="NLM_p last">The pharmacokinetics of compound <b>41</b> was determined in Wistar Han rats. The compound was dosed intravenously (iv, via injection into the jugular vein catheter; 1 mg/kg, <i>n</i> = 2 animals) and orally (po, via oral gavage; 30 mg/kg, <i>n</i> = 2 animals). The same solution formulation for both iv and po routes of administration was employed and was prepared in phosphate buffered saline containing 2 equiv of 1 N hydrochloric acid, 30% polyethylene glycol 300, and 50% of a 20% Cremophor EL solution, and phosphate buffered saline. Approximately 200 μL of whole blood was collected from the tails at 5 min (iv dose only), 15 min, 0.5 h, 1 h, 2 h, 4 h, 7 h, and 24 h postdose and was transferred to EDTA tubes. Blood was centrifuged at 3000 rpm, and the resultant plasma was transferred to a capped PCR 96-well plate and frozen at −20 °C until subsequent analysis by HPLC–MS/MS. Chromatographic separation was carried out on ACE C18 column (30 mm × 2.1 mm, 50 μm) (MAC-MOD Analytical, Chadds Ford, PA), using a gradient elution method with water and acetonitrile, both containing 0.1% formic acid. Mass spectrometric measurements in positive electrospray ionization were directed at quantifying the mass transition with [M + H]<sup>+</sup> as the precursor ion, namely, 423 → 117, and 423 → 115 on either Sciex (Sciex, Framingham, MA) or Thermo (Thermo, Waltham, MA) mass spectrometers. The relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO) or Watson LIMS (Thermo, Waltham, MA).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151">3.3.  Ocular Pharmacokinetic Studies in Rats</h3><div class="NLM_p last">Three-month-old brown Norway rats were administered <b>41</b> via oral gavage as a suspension in 0.5% hydroxypropyl methylcellulose and 0.1% Tween 80. Ocular tissues from both eyes and plasma were collected from two rats per time point at 0.25, 0.5, 1, 3, 6, and 24 h after administration. The ocular tissues collected were the retina and the posterior eye cup (RPE/choroid and posterior sclera). The tissues were diluted with phosphate buffered saline containing 10% acetonitrile and homogenized, centrifuged prior to analyses. The concentrations of the test article were measured in plasma and supernatants of ocular homogenates by HPLC–MS/MS in four individual retinas, four individual posterior eye cups, and two individual plasma samples at each time point. Chromatographic separation was carried out on ACE C18 column (30 mm × 2.1 mm, 50 μm) (MAC-MOD Analytical, Chadds Ford, PA), using a gradient elution method with water and acetonitrile, both containing 0.1% formic acid. Mass spectrometric measurements in positive electrospray ionization were directed at quantifying the mass transition with [M + H]<sup>+</sup> as the precursor ion, namely, 423 → 117 and 423 → 115 on either Sciex mass spectrometer (Sciex, Framingham, MA). The relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO) or Watson LIMS (Thermo, Waltham, MA).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152">3.4.  Plasma Pharmacokinetic Studies in Dogs</h3><div class="NLM_p last">The pharmacokinetics of compound <b>41</b> as an HCl salt was determined in male beagle dogs. The compound was dosed intravenously (0.1 mg/kg, <i>n</i> = 3 animals) and orally (10 mg/kg, <i>n</i> = 3 animals/compound) by gavage. The iv formulation was a solution consisting of 10% <i>N</i>-methyl-2-pyrrolidone and 90% polyethylene glycol 200, whereas the po formulation was a solution consisting of 0.5% methylcellulose and 0.5% Tween 80 in water. Blood was collected at 5 min (iv dose only), 15 min, 0.5 h, 1 h, 2 h, 4 h, 7 h, and 24 h postdose. The blood samples were diluted with acetonitrile and were analyzed by HPLC–MS/MS under electrospray ionization in positive mode. Chromatographic separation was carried out on Phenomenex KINETEX C18 column (50 mm × 2.1 mm, 2.6 μm) (Phenomenex, Basel, Switzerland), using a gradient elution method with water and methanol, both containing 1% formic acid. Mass spectrometric measurements in positive electrospray ionization were directed at quantifying the mass transition with [M + H]<sup>+</sup> as the precursor ion, namely, 423→ 117 and 423→ 115 on Sciex 5500 mass spectrometer (Sciex, Darmstadt, Germany). Similarly, the relevant pharmacokinetic parameters were estimated using noncompartmental methods using WinNonlin (Enterprise, version 5.2) purchased from Pharsight Corporation (St. Louis, MO) or Watson LIMS (Thermo, Waltham, MA). Other relevant calculations were performed in Microsoft Excel.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i153" class="anchor-spacer"></div><h3 class="article-section__title" id="_i153">3.5.  Ex Vivo Dog MAC Deposition Assay</h3><div class="NLM_p last">Compound <b>41</b> as an HCl salt was administered as a solution consisting of 0.5% methylcellulose and 0.5% Tween 80 in water to beagle dogs (<i>n</i> = 4). Serum samples from all animals were collected predose and at 0.1, 0.25, 0.5, 1, 2, 4, 7, 10, 12, 24, 30, and 36 h postdose and stored at −80 °C. A 384-well transfer plate was prepared with dog serum samples (15 μL per well, <i>n</i> = 3) and prediluted (1/1, v/v) in ice-cold 0.15 mM CaCl<sub>2</sub>, 141 mM NaCl, 4.5 mM MgCl<sub>2</sub>, 0.1% gelatin, 4.2 mM HEPES buffer, pH 7.4, containing purified human complement C9 (3 nM) and 20 mM EGTA (alternative pathway not blocked but classical and lectin pathways blocked) or purified human complement C9 (3 nM) and 20 mM EDTA (baseline control, all complement activation pathways blocked). A volume of 25 μL of serum plus buffer mixture was subsequently transferred to the zymosan-coated reaction plate. The plate was centrifuged (1 min, 1000 rpm), mixed (2 min), sealed with a plastic adhesive film, and placed at 37 °C for 15 min. The reaction was terminated by aspirating the samples. Wells were saturated with blocking buffer (100 μL/well, 10 min, rt) and then washed 3 times with TBS-T (100 μL/well). Detection of MAC complex deposited on the plate was achieved by ELISA using as primary antibody a mouse anti-human C9 neo-epitope monoclonal antibody (0.25 μg/mL in TBS-T, 25 μL/well, 60 min at RT) followed after washing 3 times with TBS -T (100 μL) by a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1/1000 dilution in TBS-T, 25 μL/well, 45 min at rt). After washing 3 times with TBS-T (100 μL), QuantaBlu fluorogenic peroxidase substrate (25 μL/well) was added to the plate and the HRP was allowed to develop for 10 min at rt. Plates were read at 325 nm excitation/420 nm emission in a TECAN Safire2 fluorimeter. The raw data obtained were exported into an Excel file. Excel was used to calculate averages of the triplicate wells for each sample. The baseline (EDTA-treated serum, the negative control) and the maximum (EGTA-pretreatment serum (time 0), the positive control) were used to generate a % inhibition value for each of the serum samples tested (<a class="ref internalNav" href="#eq1" aria-label="formula 1">formula 1</a>):<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_m001.gif" alt="" id="_i154" /></img><span class="labelSpan">(1)</span></span></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i155"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01870" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01870?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01870</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings with CVF-Bb or FB-comp IC<sub>50</sub> data and human and mouse 50% serum IC<sub>50</sub> data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Detailed chemistry experimentals for intermediates and details related to in vitro selectivity profiling; crystallographic structure determination information on FB with compounds <b>8</b>, (<i>S</i>)-<b>19</b>, and <b>35</b>. Crystallographic information for compounds <b>1</b>, <b>29</b>, and <b>41</b> has been reported previously.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_001.csv">jm9b01870_si_001.csv (2.71 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf">jm9b01870_si_002.pdf (934.68 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and structure factors for the crystal structures of FB with compounds <b>1</b>, <b>8</b>, (<i>S</i>)-<b>19</b>, <b>29</b>, <b>35</b>, and <b>41</b> are deposited in the Protein Data Bank with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSW">6QSW</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8U">6T8U</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8W">6T8W</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSX">6QSX</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8V">6T8V</a>.pdb, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RAV">6RAV</a>.pdb, respectively. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01870" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher M. Adams</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5246-884X" title="Orcid link">http://orcid.org/0000-0002-5246-884X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#22414a504b51564d524a47506f0c4346434f51624c4d544350564b510c414d4f"><span class="__cf_email__" data-cfemail="e6858e948f959289968e8394abc88782878b95a68889908794928f95c885898b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nello Mainolfi</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        N.M.: Kymera Therapeutics, 300 Technology Square, Cambridge, MA 02139, U.S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takeru Ehara</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        T.E.: PeptiDream Inc., 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajeshri G. Karki</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2210-5789" title="Orcid link">http://orcid.org/0000-0003-2210-5789</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Anderson</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        K.A.: Biogen, 225 Binney Street, Cambridge, MA 02142, U.S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aengus Mac Sweeney</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span>; 
    <span>Present Address:
                        A.M.S.: Drug Discovery Biology, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7250-9541" title="Orcid link">http://orcid.org/0000-0001-7250-9541</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sha-Mei Liao</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Upendra A. Argikar</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0939-0813" title="Orcid link">http://orcid.org/0000-0002-0939-0813</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith Jendza</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun Zhang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Powers</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel W. Klosowski</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        D.W.K.: Department of Chemistry, The University of Texas, 105 E 24th Street Station A5300, Austin, TX 78712-1224, U.S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maura Crowley</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Toshio Kawanami</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Ding</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Myriam April</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cornelia Forster</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Serrano-Wu</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        M.S.-W.: Sprout BioVentures, 245 Main Street, Cambridge MA 02142, U.S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Capparelli</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rrezarta Ramqaj</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine Solovay</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frederic Cumin</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas M. Smith</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luciana Ferrara</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        L.F.: Takeda Pharmaceuticals, 35 Lansdowne Street, Cambridge, MA 02139, U.S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wendy Lee</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debby Long</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa Prentiss</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea De Erkenez</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        A.D.E.: Editas Medicine, 11 Hurley Street, Cambridge, MA 02141, U.S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis Yang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fang Liu</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holger Sellner</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Finton Sirockin</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2536-7485" title="Orcid link">http://orcid.org/0000-0003-2536-7485</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Valeur</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span>; 
    <span>Present Address:
                        E.V.: Flagship Pioneering, Suite 800E, 55 Cambridge Parkway, Cambridge, MA 02142, U.S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paulus Erbel</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela Ostermeier</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Ramage</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernd Gerhartz</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span>; 
    <span>Present Address:
                        B.G.: Abcam PLC, CB4 0GZ Cambridge, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Schubart</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefanie Flohr</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathalie Gradoux</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roland Feifel</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Vogg</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Wiesmann</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jürgen Maibaum</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jörg Eder</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Sedrani</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Harrison</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland</span>; 
    <span>Present Address:
                        R.A.H.: Institute of Infection and Immunity, School of Medicine, Cardiff University, CF14 4XN Cardiff, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muneto Mogi</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce D. Jaffee</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i169">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Jay Larrow, Scott Plummer, and Carina Sanchez for their contributions to large scale preparations of <b>41</b>; Ann Brown for bioanalytical support; Andreas Boettcher for biochemical and cellular assays in support; Rene Assenberg, Claude Logel, Daniele Dietschin, and Ingrid Bechtold for support in protein production; and Christopher Towler, Lipa Shah, and Geeti Gangal for preparation of compound formulations for in vivo studies. All work described was funded by Novartis Institutes for BioMedical Research Inc.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">aHUS</td><td class="NLM_def"><p class="first last">atypical hemolytic uremic syndrome</p></td></tr><tr><td class="NLM_term">AMD</td><td class="NLM_def"><p class="first last">age-related macular degeneration</p></td></tr><tr><td class="NLM_term">AP</td><td class="NLM_def"><p class="first last">alternative complement pathway</p></td></tr><tr><td class="NLM_term">BRB</td><td class="NLM_def"><p class="first last">blood–retinal barrier</p></td></tr><tr><td class="NLM_term">C3G</td><td class="NLM_def"><p class="first last">C3 glomerulopathy</p></td></tr><tr><td class="NLM_term">CVF</td><td class="NLM_def"><p class="first last">cobra venom factor</p></td></tr><tr><td class="NLM_term">CVF-Bb</td><td class="NLM_def"><p class="first last">cobra venom factor Bb complex</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">1,2-dichloroethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMC-Cl</td><td class="NLM_def"><p class="first last">chloro-1,3-dimethylimidazolinium chloride</p></td></tr><tr><td class="NLM_term">FB</td><td class="NLM_def"><p class="first last">complement factor B</p></td></tr><tr><td class="NLM_term">FB-comp</td><td class="NLM_def"><p class="first last">TR-FRET based competition FB binding assay</p></td></tr><tr><td class="NLM_term">FCC</td><td class="NLM_def"><p class="first last">flash column chromatography</p></td></tr><tr><td class="NLM_term">FD</td><td class="NLM_def"><p class="first last">complement factor D</p></td></tr><tr><td class="NLM_term">FH</td><td class="NLM_def"><p class="first last">complement factor H</p></td></tr><tr><td class="NLM_term">FI</td><td class="NLM_def"><p class="first last">complement factor I</p></td></tr><tr><td class="NLM_term">MAC</td><td class="NLM_def"><p class="first last">membrane attack complex</p></td></tr><tr><td class="NLM_term">PNH</td><td class="NLM_def"><p class="first last">paroxysmal nocturnal hemoglobinuria</p></td></tr><tr><td class="NLM_term">RPE</td><td class="NLM_def"><p class="first last">retinal pigment epithelial</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">[2-(trimethylsilyl)ethoxy]methyl acetal</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">SPD</td><td class="NLM_def"><p class="first last">serine protease domain</p></td></tr><tr><td class="NLM_term">TBPDS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldiphenylsilyl</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i171">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 57 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaplin, H.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Review: The Burgeoning History of the Complement System 1888–2005</span>. <i>Immunohematology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=16178664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD2MrgslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2005&pages=85-93&author=H.+Chaplin&title=Review%3A+The+Burgeoning+History+of+the+Complement+System+1888%E2%80%932005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Review: the burgeoning history of the complement system 1888-2005</span></div><div class="casAuthors">Chaplin H Jr</div><div class="citationInfo"><span class="NLM_cas:title">Immunohematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">85-93</span>
        ISSN:<span class="NLM_cas:issn">0894-203X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0z-T_VbQvxEEksK8CslK8fW6udTcc2eYI4mmnZT8ty7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrgslWgug%253D%253D&md5=d23136f9514bec073cd91e955383ee7b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChaplin%26aufirst%3DH.%26atitle%3DReview%253A%2520The%2520Burgeoning%2520History%2520of%2520the%2520Complement%2520System%25201888%25E2%2580%25932005%26jtitle%3DImmunohematology%26date%3D2005%26volume%3D21%26spage%3D85%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajishengallis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span> <span> </span><span class="NLM_article-title">Complement: A Key System for Immune Surveillance and Homeostasis</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1038/ni.1923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fni.1923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=20720586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCmtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=785-797&author=D.+Ricklinauthor=G.+Hajishengallisauthor=K.+Yangauthor=J.+D.+Lambris&title=Complement%3A+A+Key+System+for+Immune+Surveillance+and+Homeostasis&doi=10.1038%2Fni.1923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Complement: a key system for immune surveillance and homeostasis</span></div><div class="casAuthors">Ricklin, Daniel; Hajishengallis, George; Yang, Kun; Lambris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">785-797</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nearly a century after the significance of the human complement system was recognized, we have come to realize that its functions extend far beyond the elimination of microbes.  Complement acts as a rapid and efficient immune surveillance system that has distinct effects on healthy and altered host cells and foreign intruders.  By eliminating cellular debris and infectious microbes, orchestrating immune responses and sending 'danger' signals, complement contributes substantially to homeostasis, but it can also take action against healthy cells if not properly controlled.  This review describes our updated view of the function, structure and dynamics of the complement network, highlights its interconnection with immunity at large and with other endogenous pathways, and illustrates its multiple roles in homeostasis and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx5zRC2bFGqLVg90H21EOLACvtfcHk0linLYCDIQ3LuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCmtbfO&md5=9fd72883ccfb6bf77b4bdebe82197d11</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fni.1923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1923%26sid%3Dliteratum%253Aachs%26aulast%3DRicklin%26aufirst%3DD.%26aulast%3DHajishengallis%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26atitle%3DComplement%253A%2520A%2520Key%2520System%2520for%2520Immune%2520Surveillance%2520and%2520Homeostasis%26jtitle%3DNat.%2520Immunol.%26date%3D2010%26volume%3D11%26spage%3D785%26epage%3D797%26doi%3D10.1038%2Fni.1923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holers, M.</span></span> <span> </span><span class="NLM_article-title">The Spectrum of Complement Alternative Pathway-Mediated Diseases</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>223</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00641.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1111%2Fj.1600-065X.2008.00641.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=18613844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=300-316&author=M.+Holers&title=The+Spectrum+of+Complement+Alternative+Pathway-Mediated+Diseases&doi=10.1111%2Fj.1600-065X.2008.00641.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The spectrum of complement alternative pathway-mediated diseases</span></div><div class="casAuthors">Holers, V. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">300-316</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The complement system has once again come into prominence in the therapeutic development arena.  The recent approval of an inhibitory monoclonal antibody, eculizumab, which is directed against complement component C5 for the disease paroxysmal nocturnal hemoglobinuria has provided the initial validation of this system as a therapeutic target.  Preclin. studies using animal models and human-derived samples demonstrate that inhibition of complement ameliorates many inflammatory and autoimmune disease manifestations.  Major efforts continue to define the most optimal means to block complement activation in a cost-effective manner.  Because the system is initiated through three pathways and generates at least six immunoregulatory and pro-inflammatory mediators, there is substantial complexity to this problem.  One pathway, designated the alternative pathway, has recently been shown to play a particularly important role in preclin. disease models.  Further evidence of the importance of the alternative pathway has been provided by studies of human diseases, where mutations or dysfunctional polymorphisms that promote activation of this pathway are highly assocd. with the diseases atypical hemolytic uremic syndrome, dense deposit disease, and age-related macular degeneration.  This article reviews evidence in support of the essential role of the alternative pathway in the generation of tissue injury and the rationale for development of therapies that modulate its activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3u8J-53XDOrVg90H21EOLACvtfcHk0ljb3xSLFTvz1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGltr4%253D&md5=41da6ad206500c88595f6d8cba76ce50</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00641.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00641.x%26sid%3Dliteratum%253Aachs%26aulast%3DHolers%26aufirst%3DM.%26atitle%3DThe%2520Spectrum%2520of%2520Complement%2520Alternative%2520Pathway-Mediated%2520Diseases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D300%26epage%3D316%26doi%3D10.1111%2Fj.1600-065X.2008.00641.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehrs, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span> <span> </span><span class="NLM_article-title">Age-Related Macular Degeneration – Emerging Pathogenetic and Therapeutic Concepts</span>. <i>Ann. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1080/07853890600946724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1080%2F07853890600946724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=17101537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD28nmsFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2006&pages=450-471&author=K.+M.+Gehrsauthor=D.+H.+Andersonauthor=L.+V.+Johnsonauthor=G.+S.+Hageman&title=Age-Related+Macular+Degeneration+%E2%80%93+Emerging+Pathogenetic+and+Therapeutic+Concepts&doi=10.1080%2F07853890600946724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Age-related macular degeneration--emerging pathogenetic and therapeutic concepts</span></div><div class="casAuthors">Gehrs Karen M; Anderson Don H; Johnson Lincoln V; Hageman Gregory S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">450-71</span>
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    </div><div class="casAbstract">Today, the average life expectancy in developed nations is over 80 years and climbing.  And yet, the quality of life during those additional years is often significantly diminished by the effects of age-related, degenerative diseases, including age-related macular degeneration (AMD), the leading cause of blindness in the elderly worldwide.  AMD is characterized by a progressive loss of central vision attributable to degenerative and neovascular changes in the macula, a highly specialized region of the ocular retina responsible for fine visual acuity.  Estimates gathered from the most recent World Health Organization (WHO) global eye disease survey conservatively indicate that 14 million persons are blind or severely visually impaired because of AMD.  The disease has a tremendous impact on the physical and mental health of the geriatric population and their families and is becoming a major public health burden.  Currently, there is neither a cure nor a means to prevent AMD.  Palliative treatment options for the less prevalent, late-stage 'wet' form of the disease include anti-neovascular agents, photodynamic therapy and thermal laser.  There are no current therapies for the more common 'dry' AMD, except for the use of antioxidants that delay progression in 20%-25% of eyes.  New discoveries, however, are beginning to provide a much clearer picture of the relevant cellular events, genetic factors, and biochemical processes associated with early AMD.  Recently, compelling evidence has emerged that the innate immune system and, more specifically, uncontrolled regulation of the complement alternative pathway plays a central role in the pathobiology of AMD.  The complement Factor H gene--which encodes the major inhibitor of the complement alternative pathway--is the first gene identified in multiple independent studies that confers a significant genetic risk for the development of AMD.  The emergence of this new paradigm of AMD pathogenesis should hasten the development of novel diagnostic and therapeutic approaches for this disease that will dramatically improve the quality of our prolonged lifespan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh0Z9BOU2wHWLFM_lbR1VmfW6udTcc2eaDbFhuSbKbUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmsFKktw%253D%253D&md5=8c8dc27435dbf65e070d0a36e49d8fbf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1080%2F07853890600946724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890600946724%26sid%3Dliteratum%253Aachs%26aulast%3DGehrs%26aufirst%3DK.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26aulast%3DHageman%26aufirst%3DG.%2BS.%26atitle%3DAge-Related%2520Macular%2520Degeneration%2520%25E2%2580%2593%2520Emerging%2520Pathogenetic%2520and%2520Therapeutic%2520Concepts%26jtitle%3DAnn.%2520Med.%26date%3D2006%26volume%3D38%26spage%3D450%26epage%3D471%26doi%3D10.1080%2F07853890600946724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triebwasser, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seddon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J. P.</span></span> <span> </span><span class="NLM_article-title">Genetic Variants in the Complement System Predisposing to Age-Related Macular Degeneration: a Review</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2014.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.molimm.2014.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=25034031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGjs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=118-125&author=E.+C.+Schrammauthor=S.+J.+Clarkauthor=M.+P.+Triebwasserauthor=S.+Raychaudhuriauthor=J.+M.+Seddonauthor=J.+P.+Atkinson&title=Genetic+Variants+in+the+Complement+System+Predisposing+to+Age-Related+Macular+Degeneration%3A+a+Review&doi=10.1016%2Fj.molimm.2014.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variants in the complement system predisposing to age-related macular degeneration</span></div><div class="casAuthors">Schramm, Elizabeth C.; Clark, Simon J.; Triebwasser, Michael P.; Raychaudhuri, Soumya; Seddon, Johanna M.; Atkinson, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-125</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Age-related macular degeneration (AMD) is a major cause of visual impairment in the western world.  It is characterized by the presence of lipoproteinaceous deposits (drusen) in the inner layers of the retina.  Immunohistochem. studies identified deposition of complement proteins in the drusen as well as in the choroid.  In the last decade, genetic studies have linked both common and rare variants in genes of the complement system to increased risk of development of AMD.  Here, we review the variants described to date and discuss the functional implications of dysregulation of the alternative pathway of complement in AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5ZQzYfD307Vg90H21EOLACvtfcHk0ljb3xSLFTvz1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGjs7vK&md5=8b8ec6496b04e1a7748b2817045d2eb1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2014.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2014.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DSchramm%26aufirst%3DE.%2BC.%26aulast%3DClark%26aufirst%3DS.%2BJ.%26aulast%3DTriebwasser%26aufirst%3DM.%2BP.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DSeddon%26aufirst%3DJ.%2BM.%26aulast%3DAtkinson%26aufirst%3DJ.%2BP.%26atitle%3DGenetic%2520Variants%2520in%2520the%2520Complement%2520System%2520Predisposing%2520to%2520Age-Related%2520Macular%2520Degeneration%253A%2520a%2520Review%26jtitle%3DMol.%2520Immunol.%26date%3D2014%26volume%3D61%26spage%3D118%26epage%3D125%26doi%3D10.1016%2Fj.molimm.2014.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, R. A.</span></span> <span> </span><span class="NLM_article-title">Paroxysmal Nocturnal Hemoglobinuria</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2811</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-02-522128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1182%2Fblood-2014-02-522128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=25237200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2804-2811&author=R.+A.+Brodsky&title=Paroxysmal+Nocturnal+Hemoglobinuria&doi=10.1182%2Fblood-2014-02-522128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxysmal nocturnal hemoglobinuria</span></div><div class="casAuthors">Brodsky, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2804-2811</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias.  The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH manifestations.  GPI anchor protein deficiency is almost always due to somatic mutations in phosphatidylinositol glycan class A (PIGA), a gene involved in the first step of GPI anchor biosynthesis; however, alternative mutations that cause PNH have recently been discovered.  In addn., hypomorphic germ-line PIGA mutations that do not cause PNH have been shown to be responsible for a condition known as multiple congenital anomalies-hypotonia-seizures syndrome 2.  Eculizumab, a first-in-class monoclonal antibody that inhibits terminal complement, is the treatment of choice for patients with severe manifestations of PNH.  Bone marrow transplantation remains the only cure for PNH but should be reserved for patients with suboptimal response to eculizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQtU772cCcqLVg90H21EOLACvtfcHk0ljTq7gHeRn8ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN&md5=b5d064494dbcbdb388bc4f2bf04be3a9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-02-522128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-02-522128%26sid%3Dliteratum%253Aachs%26aulast%3DBrodsky%26aufirst%3DR.%2BA.%26atitle%3DParoxysmal%2520Nocturnal%2520Hemoglobinuria%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2804%26epage%3D2811%26doi%3D10.1182%2Fblood-2014-02-522128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez
de Cordoba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortajada, A.</span></span> <span> </span><span class="NLM_article-title">Genetics of Atypical Hemolytic Uremic Syndrome (aHUS)</span>. <i>Semin. Thromb. Hemostasis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1055%2Fs-0034-1375296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=24799305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BC2cjgtFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=422-430&author=S.+Rodriguez%0Ade+Cordobaauthor=M.+S.+Hidalgoauthor=S.+Pintoauthor=A.+Tortajada&title=Genetics+of+Atypical+Hemolytic+Uremic+Syndrome+%28aHUS%29&doi=10.1055%2Fs-0034-1375296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of atypical hemolytic uremic syndrome (aHUS)</span></div><div class="casAuthors">Rodriguez de Cordoba Santiago; Hidalgo Marta Subias; Pinto Sheila; Tortajada Agustin</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in thrombosis and hemostasis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">422-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hemolytic uremic syndrome (HUS) is a rare, life-threatening disease characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure.  The atypical form of HUS (aHUS), representing 5 to 10% of cases, lacks the association with infection by Shiga toxin producing Escherichia coli strains that characterizes the commonest clinical presentation of HUS.  In the majority of aHUS cases, the disease results from the complement-mediated damage to the microvascular endothelium because of inherited defects in complement genes or autoantibodies against complement regulatory proteins.  Incomplete penetrance of aHUS in carriers of mutations is common to all aHUS-associated complement genes and it is now established that the overall genetic predisposition to aHUS of an individual results from the combination of different inherited factors.  Moreover, the patient's genotype influences the clinical evolution, the response to plasma therapies, and the recurrence after transplantation.  Here, we describe the genetic component of aHUS, the lessons that we have learned from the functional characterization of the aHUS-associated mutations, and the benefits of a comprehensive genetic analysis of the patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQD5i3ezOcT6-IHSmpohpd0fW6udTcc2eaEz1ubOAqHXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjgtFWmtw%253D%253D&md5=fcae4cb8162f22e694c0aa0fb7e10ae5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375296%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%2Bde%2BCordoba%26aufirst%3DS.%26aulast%3DHidalgo%26aufirst%3DM.%2BS.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DTortajada%26aufirst%3DA.%26atitle%3DGenetics%2520of%2520Atypical%2520Hemolytic%2520Uremic%2520Syndrome%2520%2528aHUS%2529%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2014%26volume%3D40%26spage%3D422%26epage%3D430%26doi%3D10.1055%2Fs-0034-1375296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Łukawska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polcyn-Adamczak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemir, Z. I.</span></span> <span> </span><span class="NLM_article-title">The Role of the Alternative Pathway of Complement Activation in Glomerular Diseases</span>. <i>Clin. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1007/s10238-018-0491-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2Fs10238-018-0491-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=29450785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlahu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=297-318&author=E.+%C5%81ukawskaauthor=M.+Polcyn-Adamczakauthor=Z.+I.+Niemir&title=The+Role+of+the+Alternative+Pathway+of+Complement+Activation+in+Glomerular+Diseases&doi=10.1007%2Fs10238-018-0491-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the alternative pathway of complement activation in glomerular diseases</span></div><div class="casAuthors">Lukawska, Emilia; Polcyn-Adamczak, Magdalena; Niemir, Zofia I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-318</span>CODEN:
                <span class="NLM_cas:coden">CEMLBA</span>;
        ISSN:<span class="NLM_cas:issn">1591-8890</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">The complement system (CS) has recently been recognized as a bridge between innate and adaptive immunity that constitutes a very complex mechanism controlling the clearance of pathogens, cellular debris, and immune complexes.  Out of three known pathways of complement activation, the alternative pathway (AP) plays a crit. role in host defense by amplifying the complement response, independently of initiation pathway and continuously maintaining low-level activity in a process called 'thick-over.'.  A key mol. of the CS is C3, in which the AP is constantly activated.  To prevent host cell destruction, a group of the AP regulators tightly controls this pathway of the CS activation.  Acquired and genetic abnormalities of the CS may alter the delicate balance between enhancing and inhibiting the AP cascade.  These can lead to the uncontrolled CS activation, inflammatory response, and subsequent tissue damage.  Since complement components are locally produced and activated in the kidney, the abnormalities targeting the AP may cause glomerular injury.  C3 glomerulopathy is a new entity, in which the AP dysregulation has been well established.  However, recent studies indicate that the AP may also contribute to a wide range of kidney pathologies, including immune-complex-mediated glomerulonephritis (GN), pauci-immune GN, and primary membranous nephropathy (PMN).  This article provides insight into current knowledge on the role of the AP in the pathogenesis of glomerular diseases, focusing mainly on various types of primary and secondary GN and PMN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkhgJKxCpuYLVg90H21EOLACvtfcHk0liiZRQuOZ_S5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlahu73O&md5=d1d4a8a9e1f9b5964d4ddfe608a8742b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs10238-018-0491-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10238-018-0491-8%26sid%3Dliteratum%253Aachs%26aulast%3D%25C5%2581ukawska%26aufirst%3DE.%26aulast%3DPolcyn-Adamczak%26aufirst%3DM.%26aulast%3DNiemir%26aufirst%3DZ.%2BI.%26atitle%3DThe%2520Role%2520of%2520the%2520Alternative%2520Pathway%2520of%2520Complement%2520Activation%2520in%2520Glomerular%2520Diseases%26jtitle%3DClin.%2520Exp.%2520Med.%26date%3D2018%26volume%3D18%26spage%3D297%26epage%3D318%26doi%3D10.1007%2Fs10238-018-0491-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fettis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussauge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Factor D Inhibitors Targeting the Alternative Complement Pathway</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fnchembio.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=27775713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslehur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1105-1110&author=J.+Maibaumauthor=S.-M.+Liaoauthor=A.+Vulpettiauthor=N.+Ostermannauthor=S.+Randlauthor=S.+Rudisserauthor=E.+Lorthioisauthor=P.+Erbelauthor=B.+Kinzelauthor=F.+A.+Kolbauthor=S.+Barbieriauthor=J.+Wagnerauthor=C.+Durandauthor=K.+Fettisauthor=S.+Dussaugeauthor=N.+Hughesauthor=O.+Delgadoauthor=U.+Hommelauthor=T.+Gouldauthor=A.+Mac+Sweeneyauthor=B.+Gerhartzauthor=F.+Cuminauthor=S.+Flohrauthor=A.+Schubartauthor=B.+Jaffeeauthor=R.+Harrisonauthor=A.+M.+Risitanoauthor=J.+Ederauthor=K.+Anderson&title=Small-Molecule+Factor+D+Inhibitors+Targeting+the+Alternative+Complement+Pathway&doi=10.1038%2Fnchembio.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule factor D inhibitors targeting the alternative complement pathway</span></div><div class="casAuthors">Maibaum, Jurgen; Liao, Sha-Mei; Vulpetti, Anna; Ostermann, Nils; Randl, Stefan; Rudisser, Simon; Lorthiois, Edwige; Erbel, Paul; Kinzel, Bernd; Kolb, Fabrice A.; Barbieri, Samuel; Wagner, Julia; Durand, Corinne; Fettis, Kamal; Dussauge, Solene; Hughes, Nicola; Delgado, Omar; Hommel, Ulrich; Gould, Ty; Mac Sweeney, Aengus; Gerhartz, Bernd; Cumin, Frederic; Flohr, Stefanie; Schubart, Anna; Jaffee, Bruce; Harrison, Richard; Risitano, Antonio Maria; Eder, Jorg; Anderson, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1105-1110</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination.  Complement component 3 (C3) is the central component of the system.  Activation of C3 can be initiated by three distinct routes-the classical, the lectin and the alternative pathways-with the alternative pathway also acting as an amplification loop for the other two pathways.  The protease factor D (FD) is essential for this amplification process, which, when dysregulated, predisposes individuals to diverse disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH).  Here the authors describe the identification of potent and selective small-mol. inhibitors of FD.  These inhibitors efficiently block alternative pathway (AP) activation and prevent both C3 deposition onto, and lysis of, PNH erythrocytes.  Their oral administration inhibited lipopolysaccharide-induced AP activation in FD-humanized mice.  These data demonstrate the feasibility of inhibiting the AP with small-mol. antagonists and support the development of FD inhibitors for the treatment of complement-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp28_wznUz9QLVg90H21EOLACvtfcHk0liiZRQuOZ_S5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslehur3P&md5=270ea1f129b3e25c22680e74f82ffc36</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2208%26sid%3Dliteratum%253Aachs%26aulast%3DMaibaum%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DRudisser%26aufirst%3DS.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DKinzel%26aufirst%3DB.%26aulast%3DKolb%26aufirst%3DF.%2BA.%26aulast%3DBarbieri%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DDurand%26aufirst%3DC.%26aulast%3DFettis%26aufirst%3DK.%26aulast%3DDussauge%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DN.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DGould%26aufirst%3DT.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DSchubart%26aufirst%3DA.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DRisitano%26aufirst%3DA.%2BM.%26aulast%3DEder%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DSmall-Molecule%2520Factor%2520D%2520Inhibitors%2520Targeting%2520the%2520Alternative%2520Complement%2520Pathway%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D1105%26epage%3D1110%26doi%3D10.1038%2Fnchembio.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1946-1958&author=A.+Vulpettiauthor=S.+Randlauthor=S.+R%C3%BCdisserauthor=N.+Ostermannauthor=P.+Erbelauthor=A.+Mac+Sweeneyauthor=T.+Zollerauthor=B.+Salemauthor=B.+Gerhartzauthor=F.+Cuminauthor=U.+Hommelauthor=C.+Dalvitauthor=E.+Lorthioisauthor=J.+Maibaum&title=Structure-Based+Library+Design+and+Fragment+Screening+for+the+Identification+of+Reversible+Complement+Factor+D+Protease+Inhibitors&doi=10.1021%2Facs.jmedchem.6b01684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span></div><div class="casAuthors">Vulpetti, Anna; Randl, Stefan; Rudisser, Simon; Ostermann, Nils; Erbel, Paul; Mac Sweeney, Aengus; Zoller, Thomas; Salem, Bahaa; Gerhartz, Bernd; Cumin, Frederic; Hommel, Ulrich; Dalvit, Claudio; Lorthiois, Edwige; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic dysregulation of alternative complement pathway activation has been assocd. with diverse clin. disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.  Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymic reaction of the amplification loop of the alternative pathway.  In this paper, the authors describe two hit finding approaches leading to the discovery of new chem. matter for this pivotal protease of the complement system: in silico active site mapping for hot spots identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries.  The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different sub-pockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPFgFvVDvCyrVg90H21EOLACvtfcHk0ljWCF70L1pPwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D&md5=179ea6dc5fb9ccb60931da60f23e6381</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01684%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DStructure-Based%2520Library%2520Design%2520and%2520Fragment%2520Screening%2520for%2520the%2520Identification%2520of%2520Reversible%2520Complement%2520Factor%2520D%2520Protease%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1946%26epage%3D1958%26doi%3D10.1021%2Facs.jmedchem.6b01684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussauge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fettis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Erkenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwieg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5717</span>– <span class="NLM_lpage">5735</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSqur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5717-5735&author=E.+Lorthioisauthor=K.+Andersonauthor=A.+Vulpettiauthor=O.+Rogelauthor=F.+Cuminauthor=N.+Ostermannauthor=S.+Steinbacherauthor=A.+Mac+Sweeneyauthor=O.+Delgadoauthor=S.+M.+Liaoauthor=S.+Randlauthor=S.+R%C3%BCdisserauthor=S.+Dussaugeauthor=K.+Fettisauthor=L.+Kiefferauthor=A.+de+Erkenezauthor=L.+Yangauthor=C.+Hartwiegauthor=U.+A.+Argikarauthor=L.+R.+La+Bonteauthor=R.+Newtonauthor=V.+Kansaraauthor=S.+Flohrauthor=U.+Hommelauthor=B.+Jaffeeauthor=J.+Maibaum&title=Discovery+of+Highly+Potent+and+Selective+Small-Molecule+Reversible+Factor+D+Inhibitors+Demonstrating+Alternative+Complement+Pathway+Inhibition+in+Vivo&doi=10.1021%2Facs.jmedchem.7b00425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo</span></div><div class="casAuthors">Lorthiois, Edwige; Anderson, Karen; Vulpetti, Anna; Rogel, Olivier; Cumin, Frederic; Ostermann, Nils; Steinbacher, Stefan; Mac Sweeney, Aengus; Delgado, Omar; Liao, Sha-Mei; Randl, Stefan; Rudisser, Simon; Dussauge, Solene; Fettis, Kamal; Kieffer, Laurence; de Erkenez, Andrea; Yang, Louis; Hartwieg, Constanze; Argikar, Upendra A.; La Bonte, Laura R.; Newton, Ronald; Kansara, Viral; Flohr, Stefanie; Hommel, Ulrich; Jaffee, Bruce; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5717-5735</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The highly specific S1 serine protease Factor D (FD) plays a central role in the amplification of the complement alternative pathway (AP) of the innate immune system.  Genetic assocns. in humans have implicated AP activation in age-related macular degeneration (AMD), and AP dysfunction predisposes individuals to disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).  The combination of structure-based hit identification and subsequent optimization of the center (S)-proline-based lead I has led to the discovery of noncovalent reversible and selective human Factor D (FD) inhibitors with drug-like properties.  The orally bioavailable compd. II exerted excellent potency in 50% human whole blood in vitro and blocked AP activity ex vivo after oral administration to monkeys as demonstrated by inhibition of membrane attack complex (MAC) formation.  Inhibitor II demonstrated sustained oral and ocular efficacy in a model of lipopolysaccharide (LPS)-induced systemic AP activation in mice expressing human FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjw5U9LMzdzLVg90H21EOLACvtfcHk0ljWCF70L1pPwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSqur%252FN&md5=06e969052e0b3ad2ca70f523eec1b63a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00425%26sid%3Dliteratum%253Aachs%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DRogel%26aufirst%3DO.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DLiao%26aufirst%3DS.%2BM.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DDussauge%26aufirst%3DS.%26aulast%3DFettis%26aufirst%3DK.%26aulast%3DKieffer%26aufirst%3DL.%26aulast%3Dde%2BErkenez%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DHartwieg%26aufirst%3DC.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DKansara%26aufirst%3DV.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Small-Molecule%2520Reversible%2520Factor%2520D%2520Inhibitors%2520Demonstrating%2520Alternative%2520Complement%2520Pathway%2520Inhibition%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5717%26epage%3D5735%26doi%3D10.1021%2Facs.jmedchem.7b00425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glazer, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugel, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lein, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosskreutz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamiri, P.</span></span> <span> </span><span class="NLM_article-title">A First in Human Study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-related Macular Degeneration (AMD)</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=2672&author=L.+C.+Glazerauthor=J.+G.+Williamsauthor=C.+M.+Gordonauthor=P.+U.+Dugelauthor=M.+Miltonauthor=T.+Valenciaauthor=U.+Leinauthor=S.+Kretzauthor=K.+Gedifauthor=C.+L.+Grosskreutzauthor=P.+Zamiri&title=A+First+in+Human+Study+of+Intravitreal+%28IVT%29+CLG561+in+Subjects+with+Advanced+Age-related+Macular+Degeneration+%28AMD%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlazer%26aufirst%3DL.%2BC.%26aulast%3DWilliams%26aufirst%3DJ.%2BG.%26aulast%3DGordon%26aufirst%3DC.%2BM.%26aulast%3DDugel%26aufirst%3DP.%2BU.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DValencia%26aufirst%3DT.%26aulast%3DLein%26aufirst%3DU.%26aulast%3DKretz%26aufirst%3DS.%26aulast%3DGedif%26aufirst%3DK.%26aulast%3DGrosskreutz%26aufirst%3DC.%2BL.%26aulast%3DZamiri%26aufirst%3DP.%26atitle%3DA%2520First%2520in%2520Human%2520Study%2520of%2520Intravitreal%2520%2528IVT%2529%2520CLG561%2520in%2520Subjects%2520with%2520Advanced%2520Age-related%2520Macular%2520Degeneration%2520%2528AMD%2529%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2016%26volume%3D57%26spage%3D2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubost, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flandre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirockin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedrani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Factor B Inhibitor for the Treatment of Complement-mediated Diseases</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7926</span>– <span class="NLM_lpage">7931</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820892116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1073%2Fpnas.1820892116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=30926668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVeksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=7926-7931&issue=16&author=A.+Schubartauthor=K.+Andersonauthor=N.+Mainolfiauthor=H.+Sellnerauthor=T.+Eharaauthor=C.+M.+Adamsauthor=A.+Mac+Sweeneyauthor=S.-M.+Liaoauthor=M.+Crowleyauthor=A.+Littlewood-Evansauthor=S.+Sarretauthor=G.+Wieczorekauthor=L.+Perrotauthor=V.+Dubostauthor=T.+Flandreauthor=Y.+Zhangauthor=R.+J.+H.+Smithauthor=A.+M.+Risitanoauthor=R.+G.+Karkiauthor=C.+Zhangauthor=E.+Valeurauthor=F.+Sirockinauthor=B.+Gerhartzauthor=P.+Erbelauthor=N.+Hughesauthor=T.+M.+Smithauthor=F.+Cuminauthor=U.+A.+Argikarauthor=B.+Haraldssonauthor=M.+Mogiauthor=R.+Sedraniauthor=C.+Wiesmannauthor=B.+Jaffeeauthor=J.+Maibaumauthor=S.+Flohrauthor=R.+Harrisonauthor=J.+Eder&title=Small-Molecule+Factor+B+Inhibitor+for+the+Treatment+of+Complement-mediated+Diseases&doi=10.1073%2Fpnas.1820892116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule factor B inhibitor for the treatment of complement-mediated diseases</span></div><div class="casAuthors">Schubart, Anna; Anderson, Karen; Mainolfi, Nello; Sellner, Holger; Ehara, Takeru; Adams, Christopher M.; MacSweeney, Aengus; Liao, Sha-Mei; Crowley, Maura; Littlewood-Evans, Amanda; Sarret, Sophie; Wieczorek, Grazyna; Perrot, Ludovic; Dubost, ValArie; Flandre, Thierry; Zhang, Yuzhou; Smith, Richard J. H.; Risitano, Antonio M.; Karki, Rajeshri G.; Zhang, Chun; Valeur, Eric; Sirockin, Finton; Gerhartz, Bernd; Erbel, Paulus; Hughes, Nicola; Smith, Thomas M.; Cumin, Frederic; Argikar, Upendra A.; Haraldsson, Boerje; Mogi, Muneto; Sedrani, Richard; Wiesmann, Christian; Jaffee, Bruce; Maibaum, Juergen; Flohr, Stefanie; Harrison, Richard; Eder, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7926-7931</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dysregulation of the alternative complement pathway (AP) predisposes individuals to a no. of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and C3 glomerulopathy.  Moreover, glomerular Ig deposits can lead to complement-driven nephropathies.  Here we describe the discovery of a highly potent, reversible, and selective small-mol. inhibitor of factor B, a serine protease that drives the central amplification loop of the AP.  Oral administration of the inhibitor prevents KRN-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an exptl. model of membranous nephropathy in rats.  In addn., inhibition of factor B prevents complement activation in sera from C3 glomerulopathy patients and the hemolysis of human PNH erythrocytes.  These data demonstrate the potential therapeutic value of using a factor B inhibitor for systemic treatment of complement-mediated diseases and provide a basis for its clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLL4lNUjAPrVg90H21EOLACvtfcHk0lglDzhfXmm04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVeksbg%253D&md5=ae1c511ce7f742f6ffb5b583d94adfae</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820892116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820892116%26sid%3Dliteratum%253Aachs%26aulast%3DSchubart%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DSellner%26aufirst%3DH.%26aulast%3DEhara%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DCrowley%26aufirst%3DM.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSarret%26aufirst%3DS.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DDubost%26aufirst%3DV.%26aulast%3DFlandre%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DR.%2BJ.%2BH.%26aulast%3DRisitano%26aufirst%3DA.%2BM.%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DValeur%26aufirst%3DE.%26aulast%3DSirockin%26aufirst%3DF.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DT.%2BM.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DHaraldsson%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26aulast%3DSedrani%26aufirst%3DR.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMaibaum%26aufirst%3DJ.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DEder%26aufirst%3DJ.%26atitle%3DSmall-Molecule%2520Factor%2520B%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Complement-mediated%2520Diseases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D16%26spage%3D7926%26epage%3D7931%26doi%3D10.1073%2Fpnas.1820892116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zierz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quentin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotze, O.</span></span> <span> </span><span class="NLM_article-title">Elevated Plasma Levels of the Immunosuppressive Complement Fragment Ba in Renal Failure</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1038/ki.1991.298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fki.1991.298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1837062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADyaK387gs1KmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1991&pages=939-947&author=M.+Oppermannauthor=C.+Kurtsauthor=R.+Zierzauthor=E.+Quentinauthor=M.+H.+Weberauthor=O.+Gotze&title=Elevated+Plasma+Levels+of+the+Immunosuppressive+Complement+Fragment+Ba+in+Renal+Failure&doi=10.1038%2Fki.1991.298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure</span></div><div class="casAuthors">Oppermann M; Kurts C; Zierz R; Quentin E; Weber M H; Gotze O</div><div class="citationInfo"><span class="NLM_cas:title">Kidney international</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">939-47</span>
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    </div><div class="casAbstract">The complement fragment Ba is a 33 kD activation product of factor B which suppresses human B-lymphocyte functions in vitro.  We report that plasma levels of Ba are highly elevated in patients with chronic renal failure (4.84 +/- 3.58 micrograms/ml) and in patients with end-stage renal disease undergoing regular hemodialysis (16.1 +/- 6.1 micrograms/ml) as compared to normals (1.01 +/- 0.30 micrograms/ml).  Ba levels were strictly correlated with the creatinine clearance.  The urinary excretion of Ba was 165-fold higher in patients with tubular proteinuria than in normals.  These results indicate that the kidney is the major catabolic site for Ba.  In addition, direct evidence was obtained for an enhanced turnover of the alternative pathway of complement in renal failure that, although it appears to be less important than the renal retention of Ba, contributes to elevated Ba plasma levels in these patients.  Ba concentrations in dialysis patients who responded to hepatitis B vaccination were significantly lower than in non-responders.  Furthermore, the in vitro IgM synthesis by purified mononuclear cells was negatively correlated with Ba concentrations determined in the plasma of these patients.  These results suggest that the accumulation of Ba contributes to the defective immune response in patients with renal failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3R8rZQlQ5zoNpW7w2tapOfW6udTcc2eYBnnkrChB2srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387gs1KmtA%253D%253D&md5=f2abfc871ce60d59fc48658e8dc505ee</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fki.1991.298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.1991.298%26sid%3Dliteratum%253Aachs%26aulast%3DOppermann%26aufirst%3DM.%26aulast%3DKurts%26aufirst%3DC.%26aulast%3DZierz%26aufirst%3DR.%26aulast%3DQuentin%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DM.%2BH.%26aulast%3DGotze%26aufirst%3DO.%26atitle%3DElevated%2520Plasma%2520Levels%2520of%2520the%2520Immunosuppressive%2520Complement%2520Fragment%2520Ba%2520in%2520Renal%2520Failure%26jtitle%3DKidney%2520Int.%26date%3D1991%26volume%3D40%26spage%3D939%26epage%3D947%26doi%3D10.1038%2Fki.1991.298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giclas, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seddon, J. M.</span></span> <span> </span><span class="NLM_article-title">Plasma Complement Components and Activation Fragments: Associations with Age-related Macular Degeneration Genotypes and Phenotypes</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5818</span>– <span class="NLM_lpage">5827</span>, <span class="refDoi"> DOI: 10.1167/iovs.09-3928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1167%2Fiovs.09-3928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=19661236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjps1CltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=5818-5827&author=R.+Reynoldsauthor=M.+E.+Hartnettauthor=J.+P.+Atkinsonauthor=P.+C.+Giclasauthor=B.+Rosnerauthor=J.+M.+Seddon&title=Plasma+Complement+Components+and+Activation+Fragments%3A+Associations+with+Age-related+Macular+Degeneration+Genotypes+and+Phenotypes&doi=10.1167%2Fiovs.09-3928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes</span></div><div class="casAuthors">Reynolds Robyn; Hartnett M Elizabeth; Atkinson John P; Giclas Patricia C; Rosner Bernard; Seddon Johanna M</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5818-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Several genes encoding complement system components and fragments are associated with age-related macular degeneration (AMD).  This study was conducted to determine whether alterations in circulating levels of these markers of complement activation and regulation are also independently associated with advanced AMD and whether they are related to AMD genotypes.  METHODS:  Plasma and DNA samples were selected from individuals in our AMD registry who had progressed to or developed the advanced stages of AMD, including 58 with geographic atrophy and 62 with neovascular disease.  Subjects of similar age and sex, but without AMD, and who did not progress were included as controls (n = 60).  Plasma complement components (C3, CFB, CFI, CFH, and factor D) and activation fragments (Bb, C3a, C5a, iC3b, and SC5b-9) were analyzed.  DNA samples were genotyped for seven single-nucleotide polymorphisms in six genes previously shown to be associated with AMD: CFB, CFH, C2, C3, and CFI and the LOC387715/ARMS2 gene region.  The association between AMD and each complement biomarker was assessed by using logistic regression, controlling for age, sex, and proinflammatory risk factors: smoking and body mass index (BMI).  Functional genomic analyses were performed to assess the relationship between the complement markers and genotypes.  Concordance, or C, statistics were calculated to assess the effect of complement components and activation fragments in an AMD gene-environment prediction model.  RESULTS:  The highest quartiles of Bb and C5a were significantly associated with advanced AMD, when compared with the lowest quartiles.  In multivariate models without genetic variants, the odds ratio (OR) for Bb was 3.3 (95% confidence interval [CI] = 1.3-8.6), and the OR for C5a was 3.6 (95% CI = 1.2-10.3).  With adjustment for genetic variants, these ORs were substantially higher.  The alternative pathway regulator CFH was inversely associated with AMD in the model without genotypes (OR = 0.3; P = 0.01).  Positive associations were found between BMI and plasma C3, CFB, CFH, iC3b, and C3a.  There were also significant associations between C5a fragment and LOC387715/ARMS2 and C3 genotypes (P for trend = 0.02, 0.04), respectively.  C statistics for models with behavioral and genetic factors increased to 0.94 +/- 0.20 with the addition of C3a, Bb, and C5a.  CONCLUSIONS:  Increased levels of activation fragments Bb and C5a are independently associated with AMD.  Higher BMI is related to increased levels of complement components.  C5a is associated with AMD genotypes.  C statistics are stronger with the addition of C3a, Bb, and C5a in predictive models.  Results implicate ongoing activation of the alternative complement pathway in AMD pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMveYtwRwaGedfST00W0BcfW6udTcc2eYBnnkrChB2srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjps1CltA%253D%253D&md5=f386cb927774c383e91fedae1e80920b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1167%2Fiovs.09-3928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.09-3928%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DHartnett%26aufirst%3DM.%2BE.%26aulast%3DAtkinson%26aufirst%3DJ.%2BP.%26aulast%3DGiclas%26aufirst%3DP.%2BC.%26aulast%3DRosner%26aufirst%3DB.%26aulast%3DSeddon%26aufirst%3DJ.%2BM.%26atitle%3DPlasma%2520Complement%2520Components%2520and%2520Activation%2520Fragments%253A%2520Associations%2520with%2520Age-related%2520Macular%2520Degeneration%2520Genotypes%2520and%2520Phenotypes%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2009%26volume%3D50%26spage%3D5818%26epage%3D5827%26doi%3D10.1167%2Fiovs.09-3928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velletri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, L.</span></span> <span> </span><span class="NLM_article-title">Plasma Levels of Complement Proteins from the Alternative Pathway in Patients with Age-Related Macular Degeneration are Independent of Complement Factor H Tyr402His polymorphism</span>. <i>Mol. Vis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=22969267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlartrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2288-2299&author=A.+S.+Silvaauthor=A.+G.+Teixeiraauthor=L.+Baviaauthor=F.+Linauthor=R.+Velletriauthor=R.+Belfortauthor=L.+Isaac&title=Plasma+Levels+of+Complement+Proteins+from+the+Alternative+Pathway+in+Patients+with+Age-Related+Macular+Degeneration+are+Independent+of+Complement+Factor+H+Tyr402His+polymorphism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr402His polymorphism</span></div><div class="casAuthors">Silva, Aldacilene Souza; Teixeira, Anderson Gustavo; Bavia, Lorena; Lin, Fabio; Velletri, Roberta; Belfort, Rubens, Jr.; Isaac, Lourdes</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Vision</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2288-2299</span>CODEN:
                <span class="NLM_cas:coden">MVEPFB</span>;
        ISSN:<span class="NLM_cas:issn">1090-0535</span>.
    
            (<span class="NLM_cas:orgname">Molecular Vision</span>)
        </div><div class="casAbstract">Purpose: To investigate the influence of the Factor H (CFH) Tyr402His polymorphism on the plasma levels of the alternative pathway proteins CFH, C3, Factor B (FB), Factor D (FD), and Factor I (FI) and the inflammatory marker C-reactive protein (CRP) in 119 patients with age-related macular degeneration (AMD) and 152 unrelated control individuals.  Methods: Patients with AMD and the control group were sepd. according to CFH polymorphism, age, and gender.  Plasma complement proteins and CRP concns. were detd. with ELISA, immunodiffusion, or nephelometry.  Results: Significant differences in the concns. of FD and FI were obsd. between the patients with AMD and the control individuals.  We obsd. significantly reduced FD plasma levels in patients with AMD.  We also identified a significant decrease in CFH plasma levels in female patients with AMD in relation to female controls.  Plasma FI levels were significantly increased in patients with AMD compared to the control group.  Regarding gender, a significant increase in FI plasma levels was obsd. in male patients.  Finally, we found no significant correlation between the CFH Tyr402His polymorphism and the CFH, C3, FB, FD, FI, and CRP plasma levels.  Conclusions: Patients with AMD present altered levels of FD and FI in a manner independent of this CFH polymorphism, and gender apparently contributes to the plasma levels of these two proteins in patients with AMD and control individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCfAvPNNrJrVg90H21EOLACvtfcHk0lifndJpy0U-3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlartrzN&md5=5bca02809c9db59208a61b325cf5d18a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DA.%2BS.%26aulast%3DTeixeira%26aufirst%3DA.%2BG.%26aulast%3DBavia%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DVelletri%26aufirst%3DR.%26aulast%3DBelfort%26aufirst%3DR.%26aulast%3DIsaac%26aufirst%3DL.%26atitle%3DPlasma%2520Levels%2520of%2520Complement%2520Proteins%2520from%2520the%2520Alternative%2520Pathway%2520in%2520Patients%2520with%2520Age-Related%2520Macular%2520Degeneration%2520are%2520Independent%2520of%2520Complement%2520Factor%2520H%2520Tyr402His%2520polymorphism%26jtitle%3DMol.%2520Vis.%26date%3D2012%26volume%3D18%26spage%3D2288%26epage%3D2299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lachmann, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes-Jones, N. C.</span></span> <span> </span><span class="NLM_article-title">Initiation of Complement Activation</span>. <i>Springer Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1007/BF01893018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2FBF01893018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=6495149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVyksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1984&pages=143-162&author=P.+J.+Lachmannauthor=N.+C.+Hughes-Jones&title=Initiation+of+Complement+Activation&doi=10.1007%2FBF01893018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Initiation of complement activation</span></div><div class="casAuthors">Lachmann, P. J.; Hughes-Jones, N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Springer Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">143-62</span>CODEN:
                <span class="NLM_cas:coden">SSIMDV</span>;
        ISSN:<span class="NLM_cas:issn">0344-4325</span>.
    </div><div class="casAbstract">A review with 53 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCpn9kpWdEqrVg90H21EOLACvtfcHk0lifndJpy0U-3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVyksLk%253D&md5=fa88ba3516acbfc8f6509eb402bfe27e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2FBF01893018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01893018%26sid%3Dliteratum%253Aachs%26aulast%3DLachmann%26aufirst%3DP.%2BJ.%26aulast%3DHughes-Jones%26aufirst%3DN.%2BC.%26atitle%3DInitiation%2520of%2520Complement%2520Activation%26jtitle%3DSpringer%2520Semin.%2520Immunopathol.%26date%3D1984%26volume%3D7%26spage%3D143%26epage%3D162%26doi%3D10.1007%2FBF01893018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holers, V. M.</span></span> <span> </span><span class="NLM_article-title">The Central Role of the Alternative Complement Pathway in Human Disease</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1310</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.176.3.1305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.4049%2Fjimmunol.176.3.1305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=16424154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=1305-1310&author=J.+M.+Thurmanauthor=V.+M.+Holers&title=The+Central+Role+of+the+Alternative+Complement+Pathway+in+Human+Disease&doi=10.4049%2Fjimmunol.176.3.1305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Central Role of the Alternative Complement Pathway in Human Disease</span></div><div class="casAuthors">Thurman, Joshua M.; Holers, V. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1305-1310</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  The complement system is increasingly recognized as important in the pathogenesis of tissue injury in vivo following immune, ischemic, or infectious insults.  Within the complement system, three pathways are capable of initiating the processes that result in C3 activation: classical, alternative, and lectin.  Although the roles that proinflammatory peptides and complexes generated during complement activation play in mediating disease processes have been studied extensively, the relative contributions of the three activating pathways is less well understood.  Herein we examine recent evidence that the alternative complement pathway plays a key and, in most instances, obligate role in generating proinflammatory complement activation products in vivo.  In addn., we discuss new concepts regarding the mechanisms by which the alternative pathway is activated in vivo, as recent clin. findings and exptl. results have provided evidence that continuous active control of this pathway is necessary to prevent unintended targeting and injury to self tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_FVfCz2QYDrVg90H21EOLACvtfcHk0lifndJpy0U-3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFyjug%253D%253D&md5=f6db4b8f56a8a99d3a74acc8de1298b0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.3.1305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.3.1305%26sid%3Dliteratum%253Aachs%26aulast%3DThurman%26aufirst%3DJ.%2BM.%26aulast%3DHolers%26aufirst%3DV.%2BM.%26atitle%3DThe%2520Central%2520Role%2520of%2520the%2520Alternative%2520Complement%2520Pathway%2520in%2520Human%2520Disease%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D1305%26epage%3D1310%26doi%3D10.4049%2Fjimmunol.176.3.1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. A.</span></span> <span> </span><span class="NLM_article-title">The Properdin Pathway: an “Alternative Activation Pathway” or a “Critical Amplification Loop” for C3 and C5 Activation?</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1007/s00281-017-0661-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2Fs00281-017-0661-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=29167939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVCmur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=15-35&author=R.+A.+Harrison&title=The+Properdin+Pathway%3A+an+%E2%80%9CAlternative+Activation+Pathway%E2%80%9D+or+a+%E2%80%9CCritical+Amplification+Loop%E2%80%9D+for+C3+and+C5+Activation%3F&doi=10.1007%2Fs00281-017-0661-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?</span></div><div class="casAuthors">Harrison, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-35</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This review is not intended to cover in detail all aspects of the discovery and evolution of our understanding of the "alternative pathway" of complement activation, there are many excellent reviews that do this (see Fearon (CRC Crit Rev Immunol 1:1-32, 1979), Pangburn and Muller-Eberhard (Springer Semin Immunopathol 7:163-192, 1984)), but instead to give sufficient background for current concepts to be put in context.  The prevailing textbook view, of components having a primary role as an alternative "pathway" for C3 activation, is challenged, with an argument developed for the primary role of the system being that of providing a surface-dependent amplification loop for both C3 and C5 activation.  Whatever the mechanism by which the initial C3b mol. is generated, deposition onto a surface has the potential to target that surface for elimination.  Elimination or escape from initial targeting is detd. by a sophisticated and highly regulated amplification loop for C3 activation.  This viewpoint of the system is then briefly developed to provide a context for therapeutic treatment of disease caused, at least in part, by dysregulated amplification of C3 activation, and to highlight some of the challenges that such therapies will face and need to address.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRbfzcgUToeLVg90H21EOLACvtfcHk0lhGf7Leb_efPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVCmur3O&md5=c62b1bb81eb95632cdaafa338d754d2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00281-017-0661-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-017-0661-x%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Properdin%2520Pathway%253A%2520an%2520%25E2%2580%259CAlternative%2520Activation%2520Pathway%25E2%2580%259D%2520or%2520a%2520%25E2%2580%259CCritical%2520Amplification%2520Loop%25E2%2580%259D%2520for%2520C3%2520and%2520C5%2520Activation%253F%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2018%26volume%3D40%26spage%3D15%26epage%3D35%26doi%3D10.1007%2Fs00281-017-0661-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckersie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Up-regulation of Complement Factor B in Retinal Pigment Epithelial Cells is Accompanied by Complement Activation in the Aged Retina</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2008.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.exer.2008.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=18926817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVaisrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2008&pages=543-550&author=M.+Chenauthor=E.+Muckersieauthor=M.+Robertsonauthor=J.+V.+Forresterauthor=H.+Xu&title=Up-regulation+of+Complement+Factor+B+in+Retinal+Pigment+Epithelial+Cells+is+Accompanied+by+Complement+Activation+in+the+Aged+Retina&doi=10.1016%2Fj.exer.2008.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Up-regulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina</span></div><div class="casAuthors">Chen, Mei; Muckersie, Elizabeth; Robertson, Marie; Forrester, John V.; Xu, Heping</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">543-550</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Complement activation is involved in the pathogenesis of age-related macular degeneration.  How complement is activated in the retina is not known.  Previously the authors have shown that complement factor H (CFH) is constitutively expressed by retinal pigment epithelial (RPE) cells and the prodn. of CFH is neg. regulated by inflammatory cytokines and oxidative insults.  Here the authors investigated the prodn. and regulation of complement factor B (CFB) in RPE cells.  Immunohistochem. showed that CFB is expressed at low levels on the apical portion of the RPE cells in normal physiol. conditions.  With age, CFB expression increases and extends to the basal part of RPE cells.  Confocal microscopy and real-time PCR of RPE cultures indicated that the prodn. of CFB by RPE cells is pos. regulated by TNF-α, IFN-γ and long-term (30 days) photoreceptor outer segments treatments.  Increased CFB expression in RPE cells in vivo is accompanied by the accumulation of complement C3 and C3a deposition at the Bruch's membrane and the basal layer of RPE cells.  These results suggest that RPE cells play important roles in regulating complement activation in the retina.  Increased complement activation in the aged retina may be important for retinal homeostasis in the context of accumulating photoreceptor waste products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSFjEFYAvZbVg90H21EOLACvtfcHk0lhGf7Leb_efPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVaisrfP&md5=0882e587f9fd95ea23cb7e44662f1f91</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2008.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2008.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DMuckersie%26aufirst%3DE.%26aulast%3DRobertson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%2BV.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DUp-regulation%2520of%2520Complement%2520Factor%2520B%2520in%2520Retinal%2520Pigment%2520Epithelial%2520Cells%2520is%2520Accompanied%2520by%2520Complement%2520Activation%2520in%2520the%2520Aged%2520Retina%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2008%26volume%3D87%26spage%3D543%26epage%3D550%26doi%3D10.1016%2Fj.exer.2008.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettrick, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaleb, M. L.</span></span> <span> </span><span class="NLM_article-title">Reduction in Ocular Complement Factor B Protein in Mice and Monkeys by Systemic Administration of Factor B Antisense Oligonucleotide</span>. <i>Mol. Vision</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=28855795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCmsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=561-571&author=T.+R.+Grossmanauthor=M.+Carrerauthor=L.+Shenauthor=R.+B.+Johnsonauthor=L.+A.+Hettrickauthor=S.+P.+Henryauthor=B.+P.+Moniaauthor=M.+L.+McCaleb&title=Reduction+in+Ocular+Complement+Factor+B+Protein+in+Mice+and+Monkeys+by+Systemic+Administration+of+Factor+B+Antisense+Oligonucleotide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction in ocular complement factor b protein in mice and monkeys by systemic administration of factor b antisense oligonucleotide</span></div><div class="casAuthors">Grossman, Tamar R.; Carrer, Michele; Shen, Lijiang; Johnson, Robert B.; Hettrick, Lisa A.; Henry, Scott P.; Monia, Brett P.; McCaleb, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Vision</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">561-571</span>CODEN:
                <span class="NLM_cas:coden">MVEPFB</span>;
        ISSN:<span class="NLM_cas:issn">1090-0535</span>.
    
            (<span class="NLM_cas:orgname">Molecular Vision</span>)
        </div><div class="casAbstract">Purpose: Age-related macular degeneration (AMD) is the leading cause of permanent vision loss among the elderly in many industrialized countries, and the complement system plays an important role in the pathogenesis of AMD.  Inhibition of complement factor B, a key regulator of the alternative pathway, is implicated as a potential therapeutic intervention for AMD.  Here we investigated the effect of liver factor B redn. on systemic and ocular factor B levels.  Methods: Second-generation antisense oligonucleotides (ASOs) targeting mouse and monkey factor B mRNA were administered by s.c. injection to healthy mice or monkeys, and the level of factor B mRNA was assessed in the liver and the eye.  In addn., the factor B protein level was detd. in plasma and whole eyes from the treated animals.  Results: Mice and monkeys treated with factor B ASOs demonstrated a robust redn. in liver factor B mRNA levels with no change in ocular factor B mRNA levels.  Plasma factor B protein levels were significantly reduced in mice and monkeys treated with factor B ASOs, leading to a dramatic redn. in ocular factor B protein, below the assay detection levels.  Conclusions: The results add to the increasing evidence that the liver is the main source of plasma and ocular factor B protein, and demonstrate that redn. of liver factor B mRNA by an ASO results in a significant redn. in plasma and ocular factor B protein levels.  The results suggest that inhibition of liver factor B mRNA by factor B ASOs would reduce systemic alternative complement pathway activation and has potential to be used as a novel therapy for AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtUd0izeq9krVg90H21EOLACvtfcHk0lhGf7Leb_efPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCmsrrN&md5=dbda9623e1c2eb90a4187e1594e04361</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrossman%26aufirst%3DT.%2BR.%26aulast%3DCarrer%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DR.%2BB.%26aulast%3DHettrick%26aufirst%3DL.%2BA.%26aulast%3DHenry%26aufirst%3DS.%2BP.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DMcCaleb%26aufirst%3DM.%2BL.%26atitle%3DReduction%2520in%2520Ocular%2520Complement%2520Factor%2520B%2520Protein%2520in%2520Mice%2520and%2520Monkeys%2520by%2520Systemic%2520Administration%2520of%2520Factor%2520B%2520Antisense%2520Oligonucleotide%26jtitle%3DMol.%2520Vision%26date%3D2017%26volume%3D23%26spage%3D561%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runkle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonetti, D. A.</span></span> <span> </span><span class="NLM_article-title">The Blood-Retinal Barrier: Structure and Functional Significance</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>686</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1007/978-1-60761-938-3_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2F978-1-60761-938-3_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=21082369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1WrsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=686&publication_year=2011&pages=133-148&author=E.+A.+Runkleauthor=D.+A.+Antonetti&title=The+Blood-Retinal+Barrier%3A+Structure+and+Functional+Significance&doi=10.1007%2F978-1-60761-938-3_5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The blood-retinal barrier: structure and functional significance</span></div><div class="casAuthors">Runkle, E. Aaron; Antonetti, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">686</span>
        (<span class="NLM_cas:issue">Blood-Brain and Other Neural Barriers</span>),
    <span class="NLM_cas:pages">133-148</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Formation and maintenance of the blood-retinal barrier is required for proper vision and loss of this barrier contributes to the pathol. of a wide no. of retinal diseases.  The retina is responsible for converting visible light into the electrochem. signal interpreted by the brain as vision.  Multiple cell types are required for this function, which are organized into eight distinct cell layers.  These neural and glial cells gain metabolic support from a unique vascular structure that provides the necessary nutrients while minimizing interference with light sensing.  In addn. to the vascular contribution, the retina also possesses an epithelial barrier, the retinal pigment epithelium, which is located at the posterior of the eye and controls exchange of nutrients with the choroidal vessels.  Together the vascular and epithelial components of the blood-retinal barrier maintain the specialized environment of the neural retina.  Both the vascular endothelium and pigment epithelium possess a well-developed junctional complex that includes both adherens and tight junctions conferring a high degree of control of solute and fluid permeability.  Understanding induction and regulation of the blood-retinal barrier will allow the development of therapies aimed at restoring the barrier when compromised in disease or allowing the specific transport of therapies across this barrier when needed.  This chapter will highlight the anatomical structure of the blood-retinal barrier and explore the mol. structure of the tight junctions that provide the unique barrier properties of the blood-retinal barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo39fRjxLfzCLVg90H21EOLACvtfcHk0lhbDznpugF1Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1WrsL3J&md5=3c4115b7a7f51aaaf2ba3b9ab71c49d2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-938-3_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-938-3_5%26sid%3Dliteratum%253Aachs%26aulast%3DRunkle%26aufirst%3DE.%2BA.%26aulast%3DAntonetti%26aufirst%3DD.%2BA.%26atitle%3DThe%2520Blood-Retinal%2520Barrier%253A%2520Structure%2520and%2520Functional%2520Significance%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D686%26spage%3D133%26epage%3D148%26doi%3D10.1007%2F978-1-60761-938-3_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inagi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, I.</span></span> <span> </span><span class="NLM_article-title">FUT-175 as a Potent Inhibitor of C5/C3 Convertase Activity for Production of C5a and C3a</span>. <i>Immunol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/0165-2478(91)90243-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2F0165-2478%2891%2990243-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=2019419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK3MXhsVWiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1991&pages=49-52&author=R.+Inagiauthor=T.+Miyataauthor=K.+Maedaauthor=S.+Sugiyamaauthor=A.+Miyamaauthor=I.+Nakashima&title=FUT-175+as+a+Potent+Inhibitor+of+C5%2FC3+Convertase+Activity+for+Production+of+C5a+and+C3a&doi=10.1016%2F0165-2478%2891%2990243-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a</span></div><div class="casAuthors">Inagi, Reiko; Miyata, Toshio; Maeda, Kenji; Sugiyama, Satoshi; Miyama, Akio; Nakashima, Izumi</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-52</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    </div><div class="casAbstract">The inhibitory effect was examd. of FUT-175 on the C3/C5 convertase activity of the cobra venom factor-derived enzyme CVF,Bb by measuring C5b6-mediated reactive lysis of unsensitized guinea pig erythrocytes and by measuring directly the released fragments C3a-des-Arg and C5a-des-Arg.  In this study, it was shown that the concn. of 4.5 × 10-6M of FUT-175 caused 50% inhibition of C5 convertase activity of CVF,Bb in reactive hemolysis assays, and that 4.0 × 10-6M FUT-175 caused 50% inhibition of the prodn. of C3a and C5a generated by the C3/C5 convertase activity of CVF,Bb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIlQO982d-U7Vg90H21EOLACvtfcHk0lhbDznpugF1Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsVWiu7k%253D&md5=a971ee4b4c73b3a865d160ba16aea04e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2F0165-2478%2891%2990243-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-2478%252891%252990243-4%26sid%3Dliteratum%253Aachs%26aulast%3DInagi%26aufirst%3DR.%26aulast%3DMiyata%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DS.%26aulast%3DMiyama%26aufirst%3DA.%26aulast%3DNakashima%26aufirst%3DI.%26atitle%3DFUT-175%2520as%2520a%2520Potent%2520Inhibitor%2520of%2520C5%252FC3%2520Convertase%2520Activity%2520for%2520Production%2520of%2520C5a%2520and%2520C3a%26jtitle%3DImmunol.%2520Lett.%26date%3D1991%26volume%3D27%26spage%3D49%26epage%3D52%26doi%3D10.1016%2F0165-2478%2891%2990243-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate (FUT-187). I:  Inhibitory Activities on various kinds of Enzymes In vitro and Anticomplement Activity In vivo</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1254/jjp.52.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1254%2Fjjp.52.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1689782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK3cXptFOnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1990&pages=23-34&author=M.+Odaauthor=Y.+Inoauthor=K.+Nakamuraauthor=S.+Kuramotoauthor=K.+Shimamuraauthor=M.+Iwakiauthor=S.+Fujii&title=Pharmacological+Studies+on+6-amidino-2-naphthyl%5B4-%284%2C5-dihydro-1H-imidazol-2-yl%29amino%5D+benzoate+dimethane+sulfonate+%28FUT-187%29.+I%3A%E2%80%89+Inhibitory+Activities+on+various+kinds+of+Enzymes+In+vitro+and+Anticomplement+Activity+In+vivo&doi=10.1254%2Fjjp.52.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino]benzoate dimethanesulfonate (FUT-187). I: Inhibitory activities on various kinds of enzymes in vitro and anticomplement activity in vivo</span></div><div class="casAuthors">Oda, Minoru; Ino, Yoshitaka; Nakamura, Kazunori; Kuramoto, Shigeru; Shimamura, Kazunori; Iwaki, Masahiro; Fujii, Setsuro</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    </div><div class="casAbstract">The protease inhibiting activity of FUT-187 (I) was compared with those of FUT-175 and FOY-305, the known serine protease inhibitors.  I, FUT-175, and FOY-305 had selective inhibitory activities on serine proteases including Cl‾r, Cl‾s, kallikrein, trypsin, plasmin, and thrombin.  The activity of I on these enzymes except Cl‾r and pancreatic kallikrein were relatively lower than those of FUT-175 and FOY-305.  In spite of its lower activities against Cl‾r and Cl‾s, inhibition by I of the complement-mediated hemolysis in vitro and in vivo was only a little weaker than or equiv. to that of FUT-175.  FOY-305 was ineffective in these tests.  Forssman shock in guinea pigs is initiated by the activation of the complement system.  The protective effect of i.v. or oral I against this shock was definitely superior to that of FUT-175.  I inhibited the changes assocd. with Forssman shock, such as increased lung wt., decreased platelet counts, and histopathol. changes.  I should be a more potent oral therapeutic agent than FUT-175 for various inflammatory diseases attributed to excessive activation of the complement system followed by platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh4va9tzczerVg90H21EOLACvtfcHk0lgCTgDJz6-1wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFOnuw%253D%253D&md5=53e57a6c717c3e171c8e8b47404f3013</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1254%2Fjjp.52.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.52.23%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DM.%26aulast%3DIno%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DKuramoto%26aufirst%3DS.%26aulast%3DShimamura%26aufirst%3DK.%26aulast%3DIwaki%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DS.%26atitle%3DPharmacological%2520Studies%2520on%25206-amidino-2-naphthyl%255B4-%25284%252C5-dihydro-1H-imidazol-2-yl%2529amino%255D%2520benzoate%2520dimethane%2520sulfonate%2520%2528FUT-187%2529.%2520I%253A%25E2%2580%2589%2520Inhibitory%2520Activities%2520on%2520various%2520kinds%2520of%2520Enzymes%2520In%2520vitro%2520and%2520Anticomplement%2520Activity%2520In%2520vivo%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D1990%26volume%3D52%26spage%3D23%26epage%3D34%26doi%3D10.1254%2Fjjp.52.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Gomez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madala, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbenante, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for Substrate-Based Inhibitors of Human Complement Factor B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6042</span>– <span class="NLM_lpage">6052</span>, <span class="refDoi"> DOI: 10.1021/jm900781m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900781m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWqu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6042-6052&author=G.+Ruiz-Gomezauthor=J.+Limauthor=M.+A.+Haliliauthor=G.+T.+Leauthor=P.+K.+Madalaauthor=G.+Abbenanteauthor=D.+P.+Fairlie&title=Structure-Activity+Relationships+for+Substrate-Based+Inhibitors+of+Human+Complement+Factor+B&doi=10.1021%2Fjm900781m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships for Substrate-Based Inhibitors of Human Complement Factor B</span></div><div class="casAuthors">Ruiz-Gomez, Gloria; Lim, Junxian; Halili, Maria A.; Le, Giang T.; Madala, Praveen K.; Abbenante, Giovanni; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6042-6052</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human complement is a cascading network of plasma proteins important in immune defense, cooperatively effecting recognition, opsonization, destruction, and removal of pathogens and infected/damaged cells.  Overstimulated or unregulated complement activation can result in immunoinflammatory diseases.  Key serine proteases in this cascade are difficult to study due to their multiprotein compn., short lifetimes, formation on membranes, or serum circulation as inactive zymogens.  Factor B is inactive at pH 7, but a catalytically active serine protease under alk. conditions, enabling structure-activity relationship studies for 63 substrate-based peptide inhibitors with 4-7 residues and a C-terminal aldehyde.  A potent factor B inhibitor was hexpeptide Ac-RLTbaLAR-H (IC50 250 nM, pH 9.5), which at pH 7 also blocked formation of membrane attack complex via the "alternative pathway" of complement activation and inhibited human complement mediated lysis of rabbit erythrocytes.  Inhibitors of factor B may be valuable probes and drug leads for complement mediated immunity and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Wqeq9DHagbVg90H21EOLACvtfcHk0lgCTgDJz6-1wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWqu7nI&md5=ff3bf3206326826d1756a88cacc4e314</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900781m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900781m%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Gomez%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DLe%26aufirst%3DG.%2BT.%26aulast%3DMadala%26aufirst%3DP.%2BK.%26aulast%3DAbbenante%26aufirst%3DG.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520Substrate-Based%2520Inhibitors%2520of%2520Human%2520Complement%2520Factor%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6042%26epage%3D6052%26doi%3D10.1021%2Fjm900781m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sedrani, R.</span></span> <span> </span><span class="NLM_article-title">Protease-Directed Drug Discovery</span>. Presented at the 15th Annual Drug Discovery Summit, Geneva, Switzerland, June 2–3, <span class="NLM_year">2014</span>; <a href="http://www.drugdiscovery-summit1.com/" class="extLink">http://www.drugdiscovery-summit1.com/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+Sedrani&title=Protease-Directed+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSedrani%26aufirst%3DR.%26atitle%3DProtease-Directed%2520Drug%2520Discovery%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1946-1958&author=V.+Vulpettiauthor=R.+Randlauthor=S.+R%C3%BCdisserauthor=N.+Ostermannauthor=P.+Erbelauthor=A.+Mac+Sweeneyauthor=T.+Zollerauthor=B.+Salemauthor=B.+Gerhartzauthor=F.+Cuminauthor=U.+Hommelauthor=C.+Dalvitauthor=E.+Lorthioisauthor=J.+Maibaum&title=Structure-Based+Library+Design+and+Fragment+Screening+for+the+Identification+of+Reversible+Complement+Factor+D+Protease+Inhibitors&doi=10.1021%2Facs.jmedchem.6b01684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span></div><div class="casAuthors">Vulpetti, Anna; Randl, Stefan; Rudisser, Simon; Ostermann, Nils; Erbel, Paul; Mac Sweeney, Aengus; Zoller, Thomas; Salem, Bahaa; Gerhartz, Bernd; Cumin, Frederic; Hommel, Ulrich; Dalvit, Claudio; Lorthiois, Edwige; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic dysregulation of alternative complement pathway activation has been assocd. with diverse clin. disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.  Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymic reaction of the amplification loop of the alternative pathway.  In this paper, the authors describe two hit finding approaches leading to the discovery of new chem. matter for this pivotal protease of the complement system: in silico active site mapping for hot spots identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries.  The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different sub-pockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPFgFvVDvCyrVg90H21EOLACvtfcHk0lgCTgDJz6-1wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D&md5=179ea6dc5fb9ccb60931da60f23e6381</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01684%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DV.%26aulast%3DRandl%26aufirst%3DR.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DStructure-Based%2520Library%2520Design%2520and%2520Fragment%2520Screening%2520for%2520the%2520Identification%2520of%2520Reversible%2520Complement%2520Factor%2520D%2520Protease%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1946%26epage%3D1958%26doi%3D10.1021%2Facs.jmedchem.6b01684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prentiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradoux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Erkenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4656</span>– <span class="NLM_lpage">4668</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4656-4668&author=R.+G.+Karkiauthor=J.+Powersauthor=N.+Mainolfiauthor=K.+Andersonauthor=D.+B.+Belangerauthor=D.+Liuauthor=N.+Jiauthor=K.+Jendzaauthor=C.+F.+Gelinauthor=A.+Mac+Sweeneyauthor=C.+Solovayauthor=O.+Delgadoauthor=M.+Crowleyauthor=S.-M.+Liaoauthor=U.+A.+Argikarauthor=S.+Flohrauthor=L.+R.+La+Bonteauthor=E.+Lorthioisauthor=A.+Vulpettiauthor=A.+Brownauthor=D.+Longauthor=M.+Prentissauthor=N.+Gradouxauthor=A.+de+Erkenezauthor=F.+Cuminauthor=C.+Adamsauthor=B.+Jaffeeauthor=M.+Mogi&title=Design%2C+Synthesis%2C+and+Preclinical+Characterization+of+Selective+Factor+D+Inhibitors+Targeting+the+Alternative+Complement+Pathway&doi=10.1021%2Facs.jmedchem.9b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway</span></div><div class="casAuthors">Karki, Rajeshri G.; Powers, James; Mainolfi, Nello; Anderson, Karen; Belanger, David B.; Liu, Donglei; Ji, Nan; Jendza, Keith; Gelin, Christine F.; Mac Sweeney, Aengus; Solovay, Catherine; Delgado, Omar; Crowley, Maura; Liao, Sha-Mei; Argikar, Upendra A.; Flohr, Stefanie; La Bonte, Laura R.; Lorthiois, Edwige L.; Vulpetti, Anna; Brown, Ann; Long, Debby; Prentiss, Melissa; Gradoux, Nathalie; de Erkenez, Andrea; Cumin, Frederic; Adams, Christopher; Jaffee, Bruce; Mogi, Muneto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4656-4668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system.  Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria.  Previously, the authors have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (I and II) binding to the open active conformation of FD.  In continuation of the authors' drug discovery program, the authors designed compds. applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases.  The authors report herein the design, synthesis, and medicinal chem. optimization of the benzylamine series culminating in the discovery of (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid, an orally bioavailable and selective FD inhibitor.  (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5uolWfBzK7Vg90H21EOLACvtfcHk0lgkyZAfAWesoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D&md5=a4a56886a758093516952737306a5d8a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00271%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DBelanger%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DN.%26aulast%3DJendza%26aufirst%3DK.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DSolovay%26aufirst%3DC.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DCrowley%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DLong%26aufirst%3DD.%26aulast%3DPrentiss%26aufirst%3DM.%26aulast%3DGradoux%26aufirst%3DN.%26aulast%3Dde%2BErkenez%26aufirst%3DA.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Preclinical%2520Characterization%2520of%2520Selective%2520Factor%2520D%2520Inhibitors%2520Targeting%2520the%2520Alternative%2520Complement%2520Pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4656%26epage%3D4668%26doi%3D10.1021%2Facs.jmedchem.9b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kam, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRae, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. C.</span></span> <span> </span><span class="NLM_article-title">Human Complement Proteins D, C2, and B</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>262</i></span>,  <span class="NLM_fpage">3444</span>– <span class="NLM_lpage">3451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=3546307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaL2sXhvFCgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1987&pages=3444-3451&author=C.-M.+Kamauthor=B.+J.+McRaeauthor=J.+W.+Harperauthor=M.+A.+Niemannauthor=J.+E.+Volanakisauthor=J.+C.+Powers&title=Human+Complement+Proteins+D%2C+C2%2C+and+B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human complement proteins D, C2, and B.  Active site mapping with peptide thioester substrates</span></div><div class="casAuthors">Kam, Chih Min; McRae, Brian J.; Harper, J. Wade; Niemann, Marilyn A.; Volanakis, John E.; Powers, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3444-51</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The specificity and reactivity of complement serine proteases D, B, Bb, C2, and C2a were detd. using a series of peptide thioester substrates.  The rates of thioester hydrolysis were measured using assay mixts. contg. the thiol reagent 4,4'-dithiodipyridine at pH 7.5.  Each substrate contained a P1 arginine residue, and the effect of various groups and amino acids in the P2, P3, and P5 positions was detd. using kcat/Km values to compare reactivities.  Among peptide thioesters corresponding to the activation site sequence in B, dipeptide thioesters contg. a P2 lysine residue were the best substrates for D.  Extending the chain to include a P3 or P4 amino acid resulted in loss of activity, and neither the tripeptide nor the tetrapeptide contg. the cleavage sequence of B was hydrolyzed.  Overall, D cleaved fewer substrates and was 2-3 orders of magnitude less reactive than ‾C1s against some thioester substrates.  C2 and fragment C2a had comparable reactivities and hydrolyzed peptides contg. Leu-Ala-Arg and Leu-Gly-Arg, which have the same sequence as the cleavage sites of C3 and C5, resp.  The best substrates for C2 and C2a were Z-Gly-Leu-Ala-Arg-SBzl and Z-Leu-Gly-Leu-Ala-Arg-SBzl, resp., where Bzl is benzyl.  B was the least reactive among these complement enzymes.  The best substrate for B was Z-Lys-Arg-SBzl with a kcat/Km value of 1370 M-1 s-1.  The catalytic fragment of B, Bb, had higher activity toward these peptide thioester substrates.  The best substrate for Bb was Z-Gly-Leu-Ala-Arg-SBzl with kcat/Km similar to C2a and 10 times higher than the value for B.  Both C2a and Bb were considerably more reactive against C3-like than C5-like substrates.  Bovine trypsin hydrolyzed thioester substrates with kcat/Km approx. 103 higher than the complement enzymes.  These thioester substrates for D, B, and C2 should be quite useful in kinetic and active site studies of the purified enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM851wsuxWNrVg90H21EOLACvtfcHk0lgkyZAfAWesoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvFCgtL0%253D&md5=5134b08c952ef4e339415f451cda2f6e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKam%26aufirst%3DC.-M.%26aulast%3DMcRae%26aufirst%3DB.%2BJ.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DNiemann%26aufirst%3DM.%2BA.%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26aulast%3DPowers%26aufirst%3DJ.%2BC.%26atitle%3DHuman%2520Complement%2520Proteins%2520D%252C%2520C2%252C%2520and%2520B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1987%26volume%3D262%26spage%3D3444%26epage%3D3451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milder, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huizinga, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romijn, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemrika, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daha, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span> <span> </span><span class="NLM_article-title">Factor B Structure Provides Insights into Activation of the Central Protease of the Complement System</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1038/nsmb1210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fnsmb1210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=17310251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVeitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=224-228&author=F.+J.+Milderauthor=L.+Gomesauthor=A.+Schoutenauthor=B.+J.+Janssenauthor=E.+G.+Huizingaauthor=R.+A.+Romijnauthor=W.+Hemrikaauthor=A.+Roosauthor=M.+R.+Dahaauthor=P.+Gros&title=Factor+B+Structure+Provides+Insights+into+Activation+of+the+Central+Protease+of+the+Complement+System&doi=10.1038%2Fnsmb1210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Factor B structure provides insights into activation of the central protease of the complement system</span></div><div class="casAuthors">Milder, Fin J.; Gomes, Lucio; Schouten, Arie; Janssen, Bert J. C.; Huizinga, Eric G.; Romijn, Roland A.; Hemrika, Wieger; Roos, Anja; Daha, Mohamed R.; Gros, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-228</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Factor B is the central protease of the complement system of immune defense.  Here, the authors present the crystal structure of human factor B at 2.3-Å resoln., which reveals how the 5-domain proenzyme is kept securely inactive.  The canonical activation helix of the Von Willebrand factor A (VWA) domain is displaced by a helix from the preceding domain linker.  The 2 helixes conformationally link the scissile-activation peptide and the metal ion-dependent adhesion site required for binding of the ligand C3b.  The data suggest that C3b binding displaces the 3 N-terminal control domains and reshuffles the 2 central helixes.  Reshuffling of the helixes releases the scissile bond for final proteolytic activation and generates a new interface between the VWA domain and the serine protease domain.  This allosteric mechanism is crucial for tight regulation of the complement-amplification step in the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzjNM3OCK6VbVg90H21EOLACvtfcHk0lgujW0IYvNg_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVeitLo%253D&md5=06616940d34117bab9bbdc2d9fbe9898</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1210%26sid%3Dliteratum%253Aachs%26aulast%3DMilder%26aufirst%3DF.%2BJ.%26aulast%3DGomes%26aufirst%3DL.%26aulast%3DSchouten%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DB.%2BJ.%26aulast%3DHuizinga%26aufirst%3DE.%2BG.%26aulast%3DRomijn%26aufirst%3DR.%2BA.%26aulast%3DHemrika%26aufirst%3DW.%26aulast%3DRoos%26aufirst%3DA.%26aulast%3DDaha%26aufirst%3DM.%2BR.%26aulast%3DGros%26aufirst%3DP.%26atitle%3DFactor%2520B%2520Structure%2520Provides%2520Insights%2520into%2520Activation%2520of%2520the%2520Central%2520Protease%2520of%2520the%2520Complement%2520System%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D224%26epage%3D228%26doi%3D10.1038%2Fnsmb1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forneris, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzekou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span> <span> </span><span class="NLM_article-title">Structures of C3b in Complex with Factors B and D give Insight into Complement Convertase Formation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1816</span>– <span class="NLM_lpage">1820</span>, <span class="refDoi"> DOI: 10.1126/science.1195821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1126%2Fscience.1195821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=21205667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1816-1820&author=F.+Fornerisauthor=D.+Ricklinauthor=J.+Wuauthor=A.+Tzekouauthor=R.+S.+Wallaceauthor=J.+D.+Lambrisauthor=P.+Gros&title=Structures+of+C3b+in+Complex+with+Factors+B+and+D+give+Insight+into+Complement+Convertase+Formation&doi=10.1126%2Fscience.1195821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation</span></div><div class="casAuthors">Forneris, Federico; Ricklin, Daniel; Wu, Jin; Tzekou, Apostolia; Wallace, Rachel S.; Lambris, John D.; Gros, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6012</span>),
    <span class="NLM_cas:pages">1816-1820</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Activation of the complement cascade induces inflammatory responses and marks cells for immune clearance.  In the central complement-amplification step, a complex consisting of surface-bound C3b and factor B is cleaved by factor D to generate active convertases on targeted surfaces.  We present crystal structures of the pro-convertase C3bB at 4 angstrom resoln. and its complex with factor D at 3.5 angstrom resoln.  Our data show how factor B binding to C3b forms an open "activation" state of C3bB.  Factor D specifically binds the open conformation of factor B through a site distant from the catalytic center and is activated by the substrate, which displaces factor D's self-inhibitory loop.  This concerted proteolytic mechanism, which is cofactor-dependent and substrate-induced, restricts complement amplification to C3b-tagged target cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0MfnHYjx4LLVg90H21EOLACvtfcHk0lgujW0IYvNg_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbvK&md5=8b9967b841de551442fa949d7ab7bab8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1126%2Fscience.1195821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1195821%26sid%3Dliteratum%253Aachs%26aulast%3DForneris%26aufirst%3DF.%26aulast%3DRicklin%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTzekou%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DR.%2BS.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DGros%26aufirst%3DP.%26atitle%3DStructures%2520of%2520C3b%2520in%2520Complex%2520with%2520Factors%2520B%2520and%2520D%2520give%2520Insight%2520into%2520Complement%2520Convertase%2520Formation%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1816%26epage%3D1820%26doi%3D10.1126%2Fscience.1195821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooijakkers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruyken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Domselaar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzekou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Strijp, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Implications of the Alternative Complement Pathway C3 Convertase Stabilized by a Staphylococcal Inhibitor</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/ni.1756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fni.1756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=19503103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVWjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=721-727&author=S.+H.+Rooijakkersauthor=J.+Wuauthor=M.+Ruykenauthor=R.+van+Domselaarauthor=K.+L.+Plankenauthor=A.+Tzekouauthor=D.+Ricklinauthor=J.+D.+Lambrisauthor=B.+J.+Janssenauthor=J.+A.+van+Strijpauthor=P.+Gros&title=Structural+and+Functional+Implications+of+the+Alternative+Complement+Pathway+C3+Convertase+Stabilized+by+a+Staphylococcal+Inhibitor&doi=10.1038%2Fni.1756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor</span></div><div class="casAuthors">Rooijakkers, Suzan H. M.; Wu, Jin; Ruyken, Maartje; van Domselaar, Robert; Planken, Karel L.; Tzekou, Apostolia; Ricklin, Daniel; Lambris, John D.; Janssen, Bert J. C.; van Strijp, Jos A. G.; Gros, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">721-727</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the complement system generates potent chemoattractants and leads to the opsonization of cells for immune clearance.  Short-lived protease complexes cleave complement component C3 into anaphylatoxin C3a and opsonin C3b.  Here the authors report the crystal structure of the C3 convertase formed by C3b and the protease fragment Bb, which was stabilized by the bacterial immune-evasion protein SCIN.  The data suggest that the proteolytic specificity and activity depend on the formation of dimers of C3 with C3b of the convertase.  SCIN blocked the formation of a productive enzyme-substrate complex.  Irreversible dissocn. of the complex of C3b and Bb is crucial to complement regulation and was detd. by slow binding kinetics of the Mg2+-adhesion site in Bb.  Understanding the mechanistic basis of the central complement-activation step and microbial immune evasion strategies targeting this step will aid in the development of complement therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_zcBU00BPg7Vg90H21EOLACvtfcHk0lgfADBknPZ8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVWjtLg%253D&md5=aaa035c7eac59df9af5e5fedaa99fc62</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fni.1756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1756%26sid%3Dliteratum%253Aachs%26aulast%3DRooijakkers%26aufirst%3DS.%2BH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRuyken%26aufirst%3DM.%26aulast%3Dvan%2BDomselaar%26aufirst%3DR.%26aulast%3DPlanken%26aufirst%3DK.%2BL.%26aulast%3DTzekou%26aufirst%3DA.%26aulast%3DRicklin%26aufirst%3DD.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DJanssen%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BStrijp%26aufirst%3DJ.%2BA.%26aulast%3DGros%26aufirst%3DP.%26atitle%3DStructural%2520and%2520Functional%2520Implications%2520of%2520the%2520Alternative%2520Complement%2520Pathway%2520C3%2520Convertase%2520Stabilized%2520by%2520a%2520Staphylococcal%2520Inhibitor%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D721%26epage%3D727%26doi%3D10.1038%2Fni.1756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M. N. G.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanism for the Conversion of Zymogen to Active Proteolytic Enzymes</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/pro.5560070401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1002%2Fpro.5560070401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=9568890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1998&pages=815-836&author=A.+R.+Khanauthor=M.+N.+G.+James&title=Molecular+Mechanism+for+the+Conversion+of+Zymogen+to+Active+Proteolytic+Enzymes&doi=10.1002%2Fpro.5560070401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes</span></div><div class="casAuthors">Khan, Amir R.; James, Michael N. G.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">815-836</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review with approx. 185 refs.  Proteolytic enzymes are synthesized as inactive precursors, or "zymogens," to prevent unwanted protein degrdn., and to enable spatial and temporal regulation of proteolytic activity.  Upon sorting or appropriate compartmentalization, zymogen conversion to the active enzyme typically involves limited proteolysis and removal of an "activation segment.".  The sizes of activation segments range from dipeptide units to independently folding domains comprising more than 100 residues.  A common form of the activation segment is an N-terminal extension of the mature enzyme, or "prosegment," that sterically blocks the active site, and thereby prevents binding of substrates.  In addn. to their inhibitory role, prosegments are frequently important for the folding, stability, and/or intracellular sorting of the zymogen.  The mechanisms of conversion to active enzymes are diverse in nature, ranging from enzymic or nonenzymic cofactors that trigger activation, to a simple change in pH that results in conversion by an autocatalytic mechanism.  Recent X-ray crystallog. studies of zymogens and comparisons with their active counterparts have identified the structural changes that accompany conversion.  This review will focus upon the structural basis for inhibition by activation segments, as well as the mol. events that lead to the conversion of zymogens to active enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkRaD6Q3GVT7Vg90H21EOLACvtfcHk0lgfADBknPZ8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSntbg%253D&md5=87af8723e541cc74915126610dca0a6b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560070401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560070401%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DA.%2BR.%26aulast%3DJames%26aufirst%3DM.%2BN.%2BG.%26atitle%3DMolecular%2520Mechanism%2520for%2520the%2520Conversion%2520of%2520Zymogen%2520to%2520Active%2520Proteolytic%2520Enzymes%26jtitle%3DProtein%2520Sci.%26date%3D1998%26volume%3D7%26spage%3D815%26epage%3D836%26doi%3D10.1002%2Fpro.5560070401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponnuraj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, V. L.</span></span> <span> </span><span class="NLM_article-title">Structural Analysis of Engineered Bb Fragment of Complement Factor B: Insights into the Activation Mechanism of the Alternative Pathway C3-Convertase</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(04)00160-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2FS1097-2765%2804%2900160-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15068800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=17-28&author=K.+Ponnurajauthor=Y.+Xuauthor=K.+Maconauthor=D.+Mooreauthor=J.+E.+Volanakisauthor=V.+L.+Narayana&title=Structural+Analysis+of+Engineered+Bb+Fragment+of+Complement+Factor+B%3A+Insights+into+the+Activation+Mechanism+of+the+Alternative+Pathway+C3-Convertase&doi=10.1016%2FS1097-2765%2804%2900160-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural analysis of engineered Bb fragment of complement factor B: Insights into the activation mechanism of the alternative pathway C3-convertase</span></div><div class="casAuthors">Ponnuraj, Karthe; Xu, Yuanyuan; Macon, Kevin; Moore, Dwight; Volanakis, John E.; Narayana, Sthanam V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The C-terminal fragment, Bb, of factor B combines with C3b to form the pivotal C3-convertase, C3bBb, of alternative complement pathway.  Bb consists of a von Willebrand factor type A (vWFA) domain that is structurally similar to the I domains of integrins and a serine protease (SP) domain that is in inactive conformation.  The structure of the C3bBb complex would be important in deciphering the activation mechanism of the SP domain.  However, C3bBb is labile and not amenable to x-ray diffraction studies.  We engineered a disulfide bond in the vWFA domain of Bb homologous to that shown to lock I domains in active conformation.  The crystal structures of BbC428-C435 and its inhibitor complexes reveal that the adoption of the "active" conformation by the vWFA domain is not sufficient to activate the C3-convertase catalytic app. and also provide insights into the possible mode of C3-convertase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC1YqIF_0QW7Vg90H21EOLACvtfcHk0lgfADBknPZ8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqsbg%253D&md5=8c2acf331c7756795be82dc2bbf66107</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2804%2900160-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252804%252900160-1%26sid%3Dliteratum%253Aachs%26aulast%3DPonnuraj%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMacon%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26aulast%3DNarayana%26aufirst%3DV.%2BL.%26atitle%3DStructural%2520Analysis%2520of%2520Engineered%2520Bb%2520Fragment%2520of%2520Complement%2520Factor%2520B%253A%2520Insights%2520into%2520the%2520Activation%2520Mechanism%2520of%2520the%2520Alternative%2520Pathway%2520C3-Convertase%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D14%26spage%3D17%26epage%3D28%26doi%3D10.1016%2FS1097-2765%2804%2900160-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Circolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, S. V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span> <span> </span><span class="NLM_article-title">Mutational Analysis of the Primary Substrate Specificity Pocket of Complement Factor B</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.1.378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1074%2Fjbc.275.1.378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10617628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=378-385&author=Y.+Xuauthor=A.+Circoloauthor=H.+Jingauthor=Y.+Wangauthor=S.+V.+L.+Narayanaauthor=J.+E.+Volanakis&title=Mutational+Analysis+of+the+Primary+Substrate+Specificity+Pocket+of+Complement+Factor+B&doi=10.1074%2Fjbc.275.1.378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational analysis of the primary substrate specificity pocket of complement factor B ASP226 is a major structural determinant for P1-ARG binding</span></div><div class="casAuthors">Xu, Yuanyuan; Circolo, Antonella; Jing, Hua; Wang, Yue; Narayana, Sthanam V. L.; Volanakis, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">378-385</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Factor B is a serine protease, which despite its trypsin-like specificity has Asn instead of the typical Asp at the bottom of the S1 pocket (position 189, chymotrypsinogen numbering).  Asp residues are present at positions 187 and 226 and either one could conceivably provide the neg. charge for binding the P1-Arg of the substrate.  Detn. of the crystal structure of the factor B serine protease domain has revealed that the side chain of Asp226 is within the S1 pocket, whereas Asp187 is located outside the pocket.  To investigate the possible role of these atypical structural features in substrate binding and catalysis, we constructed a panel of mutants of these residues.  Replacement of Asp187 caused moderate (50-60%) decrease in hemolytic activity, compared with wild type factor B, whereas replacement of Asn189 resulted in more profound redns. (71-95%).  Substitutions at these two positions did not significantly affect assembly of the alternative pathway C3 convertase.  In contrast, elimination of the neg. charge from Asp226 completely abrogated hemolytic activity and also affected formation of the C3 convertase.  Kinetic analyses of the hydrolysis of a P1-Arg contg. thioester by selected mutants confirmed that residue Asp226 is a primary structural determinant for P1-Arg binding and catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLwB2UTxHMLrVg90H21EOLACvtfcHk0lg75ZAW_BI-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvVKjtA%253D%253D&md5=e48ce8cb135ebf8f17ffb60cca4c4fd4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.1.378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.1.378%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCircolo%26aufirst%3DA.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNarayana%26aufirst%3DS.%2BV.%2BL.%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26atitle%3DMutational%2520Analysis%2520of%2520the%2520Primary%2520Substrate%2520Specificity%2520Pocket%2520of%2520Complement%2520Factor%2520B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D378%26epage%3D385%26doi%3D10.1074%2Fjbc.275.1.378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kock, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hew, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bammert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzinger, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, C.-W.</span></span> <span> </span><span class="NLM_article-title">Structure and Function of Recombinant Cobra Venom Factor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">30836</span>– <span class="NLM_lpage">30843</span>, <span class="refDoi"> DOI: 10.1074/jbc.M403196200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1074%2Fjbc.M403196200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15131128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=30836-30843&author=M.+A.+Kockauthor=B.+E.+Hewauthor=H.+Bammertauthor=D.+C.+Fritzingerauthor=C.-W.+Vogel&title=Structure+and+Function+of+Recombinant+Cobra+Venom+Factor&doi=10.1074%2Fjbc.M403196200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Function of Recombinant Cobra Venom Factor</span></div><div class="casAuthors">Kock, Michael A.; Hew, Brian E.; Bammert, Holger; Fritzinger, David C.; Vogel, Carl-Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">30836-30843</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cobra venom factor (CVF) is the complement-activating protein from cobra venom.  It is a structural and functional analog of complement component C3.  CVF functionally resembles C3b, the activated form of C3.  Like C3b, CVF binds factor B, which is subsequently cleaved by factor D to form the bimol. complex CVF,Bb.  CVF,Bb is a C3/C5 convertase that cleaves both complement components C3 and C5.  CVF is a three-chain protein that structurally resembles the C3b degrdn. product C3c, which is unable to form a C3/C5 convertase.  Both C3 and CVF are synthesized as single-chain prepro-proteins.  This study reports the recombinant expression of pro-CVF in two insect cell expression systems (baculovirus-infected Sf9 Spodoptera frugiperda cells and stably transfected S2 Drosophila melanogaster cells).  In both expression systems pro-CVF is synthesized initially as a single-chain pro-CVF mol. that is subsequently proteolytically processed into a two-chain form of pro-CVF that structurally resembles C3.  The C3-like form of pro-CVF can be further proteolytically processed into another two-chain form of pro-CVF that structurally resembles C3b.  Unexpectedly, all three forms of pro-CVF exhibit functional activity of mature, natural CVF.  Recombinant pro-CVF supports the activation of factor B in the presence of factor D and Mg2+ and depletes serum complement activity like natural CVF.  The bimol. convertase pro-CVF,Bb exhibits both C3 cleaving and C5 cleaving activity.  The activity of pro-CVF and the resulting C3/C5 convertase is indistinguishable from CVF and the CVF,Bb convertase.  The ability to produce active forms of pro-CVF recombinantly ensures the continued availability of an important research reagent for complement depletion because cobra venom as the source for natural CVF will be increasingly difficult to obtain as the Indian cobra is on the list of endangered species.  Exptl. systems to express pro-CVF recombinantly will also be invaluable for studies to delineate the structure and function relation of CVF and its differences from C3 as well as to generate human C3 derivs. with CVF-like function for therapeutic complement depletion ("humanized CVF").</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN7FHhRwulOLVg90H21EOLACvtfcHk0lg75ZAW_BI-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKhtr8%253D&md5=b6671891a60f8d439fb7e85763527d3f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403196200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403196200%26sid%3Dliteratum%253Aachs%26aulast%3DKock%26aufirst%3DM.%2BA.%26aulast%3DHew%26aufirst%3DB.%2BE.%26aulast%3DBammert%26aufirst%3DH.%26aulast%3DFritzinger%26aufirst%3DD.%2BC.%26aulast%3DVogel%26aufirst%3DC.-W.%26atitle%3DStructure%2520and%2520Function%2520of%2520Recombinant%2520Cobra%2520Venom%2520Factor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D30836%26epage%3D30843%26doi%3D10.1074%2Fjbc.M403196200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last"><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> provides a different perspective of the cocrystal structure previously reported in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klabunde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span> <span> </span><span class="NLM_article-title">GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR-Mediated Side Effects</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1002/cbic.200400369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1002%2Fcbic.200400369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15791686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFajsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=876-889&author=T.+Klabundeauthor=A.+Evers&title=GPCR+Antitarget+Modeling%3A+Pharmacophore+Models+for+Biogenic+Amine+Binding+GPCRs+to+Avoid+GPCR-Mediated+Side+Effects&doi=10.1002%2Fcbic.200400369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR antitarget modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects</span></div><div class="casAuthors">Klabunde, Thomas; Evers, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">876-889</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) form a large protein family that plays an important role in many physiol. and pathophysiol. processes.  However, the central role that the biogenic amine binding GPCRs and their ligands play in cell signaling poses a risk in new drug candidates that reveal side affinities towards these receptor sites.  These candidates have the potential to interfere with the physiol. signaling processes and to cause undersired effects in preclin. or clin. studies.  Here, we present 3D cross-chemotype pharmacophore models for three biogenic amine antitargets: the α1A adrenergic, the 5-HT2A serotonin, and the D2 dopamine receptors.  These pharmacophores describe the key chem. features present within these biogenic amine antagonists and rationalize the biogenic amine side affinities found for numerous new drug candidates.  First applications of the α1A adrenergic receptor model reveal that these in silico tools can be used to guide the chem. optimization towards development candidates with fewer α1A-mediated side effects (for example, orthostatic hypotension) and, thus, with an improved clin. safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUxTTiXyXjbVg90H21EOLACvtfcHk0lg75ZAW_BI-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFajsbo%253D&md5=3f1718c9df2842570ed2b879c59ee240</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200400369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200400369%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DGPCR%2520Antitarget%2520Modeling%253A%2520Pharmacophore%2520Models%2520for%2520Biogenic%2520Amine%2520Binding%2520GPCRs%2520to%2520Avoid%2520GPCR-Mediated%2520Side%2520Effects%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26spage%3D876%26epage%3D889%26doi%3D10.1002%2Fcbic.200400369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6917</span>– <span class="NLM_lpage">6921</span>, <span class="refDoi"> DOI: 10.1021/jm060500o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060500o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6917-6921&author=A.+M.+Aronov&title=Common+Pharmacophores+for+Uncharged+Human+Ether-a-go-go-Related+Gene+%28hERG%29+Blockers&doi=10.1021%2Fjm060500o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers</span></div><div class="casAuthors">Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6917-6921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In silico approaches are widely used to predict human ether-a-go-go-related gene (hERG) channel blockade.  Published pharmacophore models of hERG blockers typically contain a basic nitrogen center flanked by arom. or hydrophobic groups.  However, hERG blockade has been obsd. in series lacking the basic nitrogen.  By utilizing screening data for 194 potent uncharged hERG actives, we propose a pharmacophore for neutral hERG blockers, and provide guidance on eliminating hERG liability in an uncharged hERG active chem. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhdisypaGQgbVg90H21EOLACvtfcHk0lg75ZAW_BI-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ&md5=a557f6239ec176243f9823a36b3b9ec4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm060500o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060500o%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DCommon%2520Pharmacophores%2520for%2520Uncharged%2520Human%2520Ether-a-go-go-Related%2520Gene%2520%2528hERG%2529%2520Blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6917%26epage%3D6921%26doi%3D10.1021%2Fjm060500o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marankan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span> <span> </span><span class="NLM_article-title">An Oxyanion-hole Selective Serine Protease Inhibitor in Complex with Trypsin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(01)00259-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2FS0968-0896%2801%2900259-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=11738605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD3MnptV2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=41-46&author=J.+Cuiauthor=F.+Marankanauthor=W.+Fuauthor=D.+Crichauthor=A.+Mesecarauthor=M.+E.+Johnson&title=An+Oxyanion-hole+Selective+Serine+Protease+Inhibitor+in+Complex+with+Trypsin&doi=10.1016%2FS0968-0896%2801%2900259-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">An oxyanion-hole selective serine protease inhibitor in complex with trypsin</span></div><div class="casAuthors">Cui Jian; Marankan Fatima; Fu Wentao; Crich David; Mesecar Andrew; Johnson Michael E</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-6</span>
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    </div><div class="casAbstract">p-amidinophenylmethylphosphinic acid (AMPA) was designed, synthesized and crystallized in complex with trypsin to study interactions with the oxyanion hole at the S1 site.  In comparison to benzamidine, AMPA shows improved activity, which the crystal structure demonstrates to result from hydrogen bonds between the negatively charged phosphinic acid group and the catalytic residues at the oxyanion hole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIlJcC9FrU-DToTC3aBaesfW6udTcc2ebBJCyjXqb0C7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnptV2rug%253D%253D&md5=c7853de2df0e40a02692b6dae13d1d1e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2801%2900259-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252801%252900259-0%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMarankan%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DCrich%26aufirst%3DD.%26aulast%3DMesecar%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26atitle%3DAn%2520Oxyanion-hole%2520Selective%2520Serine%2520Protease%2520Inhibitor%2520in%2520Complex%2520with%2520Trypsin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D41%26epage%3D46%26doi%3D10.1016%2FS0968-0896%2801%2900259-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rumthao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhearn, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of Oxyanion-hole Selective Inhibitor Substituents for the S1 Subsite of factor Xa</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5165</span>– <span class="NLM_lpage">5170</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.07.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.bmcl.2004.07.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15380220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2cXns1Ohu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=5165-5170&author=S.+Rumthaoauthor=O.+Leeauthor=Q.+Shengauthor=W.+Fuauthor=D.+C.+Mulhearnauthor=D.+Crichauthor=A.+D.+Mesecarauthor=M.+E.+Johnson&title=Design%2C+Synthesis%2C+and+Evaluation+of+Oxyanion-hole+Selective+Inhibitor+Substituents+for+the+S1+Subsite+of+factor+Xa&doi=10.1016%2Fj.bmcl.2004.07.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa</span></div><div class="casAuthors">Rumthao, Sochanchingwung; Lee, Oukseub; Sheng, Qi; Fu, WenTao; Mulhearn, Debbie C.; Crich, David; Mesecar, Andrew D.; Johnson, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5165-5170</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">P-Amidinophenyl sulfones, amines, and alcs. intended to take advantage of the polarity and hydrogen-bonding potential of the oxyanion hole region of the S1 specificity pocket were designed, synthesized, and evaluated for their factor Xa inhibitory activities.  Placement of an anionic group within the oxyanion hole region of the catalytic site substantially enhances activity, with small flexible groups favored over bulkier ones.  Ab initio pKa calcns. suggest that the hydroxyl substituent frequently used for benzamidine moieties may be ionized to form an anionic group, consistent with the general trend.  One nonamidine based substituent also shows promising activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogczUfVJILaLVg90H21EOLACvtfcHk0lgzEPvnKcEXmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXns1Ohu7k%253D&md5=7450af5bc7e472d1496cd990aa5dcb3c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.07.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.07.054%26sid%3Dliteratum%253Aachs%26aulast%3DRumthao%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DO.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DMulhearn%26aufirst%3DD.%2BC.%26aulast%3DCrich%26aufirst%3DD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520Oxyanion-hole%2520Selective%2520Inhibitor%2520Substituents%2520for%2520the%2520S1%2520Subsite%2520of%2520factor%2520Xa%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D5165%26epage%3D5170%26doi%3D10.1016%2Fj.bmcl.2004.07.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="note"><p class="first last">A large set of compounds from a different subseries than what is disclosed in this manuscript were assessed in both the CVF-Bb and FB-comp assays, and the resulting IC<sub>50</sub> values showed good concordance enabling a direct comparison or potency between the two assay formats.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="note"><p class="first last">The cocrystal of <b>29</b> with FB illustrated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> provides a different perspective of the structure previously reported in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="note"><p class="first last">The cocrystal structure indicated that the stereochemistry of the phenylpiperidine was of the <i>S</i> configuration in line with the preferred enantiomers (<i>S</i>-)-<b>19</b> and <b>29</b>. Thus it is likely that the absolute stereochemistry of (−)-<b>35</b> is also <i>S</i>; however since the racemic <b>35</b> was used for the crystallization experiment, this cannot be concluded unambiguously.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">The absolute stereochemistry was determined via chemical correlation once the cocrystal structure was ascertained for compound <b>41</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="note"><p class="first last"><a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> provides a different perspective of the cocrystal structure previously reported in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="note"><p class="first last">A list of proteins evaluated can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="note"><p class="first last">The plasma data represented in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> have previously been disclosed in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>, while ocular complement inhibition is a new disclosure.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthert, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victor Chong, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, R. F.</span></span> <span> </span><span class="NLM_article-title">An Integrated Hypothesis that Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch’s Membrane Interface in Aging and Age-related Macular Degeneration</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1016/S1350-9462(01)00010-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2FS1350-9462%2801%2900010-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=11587915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntF2qt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=705-732&author=G.+S.+Hagemanauthor=P.+J.+Luthertauthor=N.+H.+Victor+Chongauthor=L.+V.+Johnsonauthor=D.+H.+Andersonauthor=R.+F.+Mullins&title=An+Integrated+Hypothesis+that+Considers+Drusen+as+Biomarkers+of+Immune-Mediated+Processes+at+the+RPE-Bruch%E2%80%99s+Membrane+Interface+in+Aging+and+Age-related+Macular+Degeneration&doi=10.1016%2FS1350-9462%2801%2900010-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration</span></div><div class="casAuthors">Hageman, G. S.; Luthert, P. J.; Victor Chong, N. H.; Johnson, L. V.; Anderson, D. H.; Mullins, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Retinal and Eye Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">705-732</span>CODEN:
                <span class="NLM_cas:coden">PRTRES</span>;
        ISSN:<span class="NLM_cas:issn">1350-9462</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Age-related macular degeneration (AMD) is a blinding disease that afflicts millions of adults in the Western world.  Although it has been proposed that a threshold event occurs during normal aging which leads to AMD, the sequelae of biochem., cellular, and/or mol. events leading to the development of AMD are poorly understood.  Although available data provide strong evidence that a significant proportion of AMD has a genetic basis, no gene(s) has yet been identified that causes a significant proportion of AMD.  Moreover, no major mol. pathways involved in the etiol. of this disease have been elucidated.  Drusen, pathol. deposits that form between the retinal pigmented epithelium (RPE) and Bruch's membrane, are significant risk factors for the development of AMD.  In our view, the development of testable new hypotheses of drusen origins has been hindered significantly by the absence of a comprehensive profile of their mol. compn.  In this review, we describe an integrated ultrastructural, histochem., mol. biol., and biochem. approach to identify specific mol. pathways assocd. with drusen biogenesis.  The implicit assumption underlying these recent investigations has been that a thorough understanding of the compn. of drusen and source(s) of drusen-assocd. material is likely to provide fresh insight into the pathobiol. underlying AMD.  Significantly, these studies have revealed that proteins assocd. with inflammation and immune-mediated processes are prevalent among drusen-assocd. constituents.  Transcripts that encode a no. of these mols. have been detected in retinal, RPE, and choroidal cells.  These data have also lead to the observations that dendritic cells, potent antigen-presenting cells, are intimately assocd. with drusen development and that complement activation is a key pathway that is active both within drusen and along the RPE-choroid interface.  We propose herein a unifying hypothesis of drusen biogenesis that attempts to incorporate a large body of new and previously published structural, histochem., and mol. data pertaining to drusen compn. and development.  This theory is put forth with the acknowledgment that numerous AMD genotypes may exist.  Thus, only some aspects of the proposed hypothesis may be involved in any given AMD genotype.  Importantly, this hypothesis invokes, for the first time, the potential for a direct role of cell- and immune-mediated processes in drusen biogenesis.  We acknowledge that the proposed hypothesis clearly represents a paradigm shift in our conceptualization pertaining to pathways that participate in the development of drusen and age-related macular degeneration.  It is our hope that other investigators will test, validate and/or refute various aspects of this hypothesis, and in so doing, increase our overall understanding of the biol. pathways assocd. with early AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7RgyR06dpIrVg90H21EOLACvtfcHk0lgzEPvnKcEXmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntF2qt7k%253D&md5=e01613bb1c3ac4ca247bc021d4bbafe4</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS1350-9462%2801%2900010-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1350-9462%252801%252900010-6%26sid%3Dliteratum%253Aachs%26aulast%3DHageman%26aufirst%3DG.%2BS.%26aulast%3DLuthert%26aufirst%3DP.%2BJ.%26aulast%3DVictor%2BChong%26aufirst%3DN.%2BH.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26aulast%3DMullins%26aufirst%3DR.%2BF.%26atitle%3DAn%2520Integrated%2520Hypothesis%2520that%2520Considers%2520Drusen%2520as%2520Biomarkers%2520of%2520Immune-Mediated%2520Processes%2520at%2520the%2520RPE-Bruch%25E2%2580%2599s%2520Membrane%2520Interface%2520in%2520Aging%2520and%2520Age-related%2520Macular%2520Degeneration%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2001%26volume%3D20%26spage%3D705%26epage%3D732%26doi%3D10.1016%2FS1350-9462%2801%2900010-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radeke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curletti, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebright, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span> <span> </span><span class="NLM_article-title">The Pivotal Role of the Complement System in Aging and Age-related Macular Degeneration: Hypothesis Re-visited</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/j.preteyeres.2009.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.preteyeres.2009.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=19961953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFGksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=95-112&author=D.+H.+Andersonauthor=M.+J.+Radekeauthor=N.+B.+Galloauthor=E.+A.+Chapinauthor=P.+T.+Johnsonauthor=C.+R.+Curlettiauthor=L.+S.+Hancoxauthor=J.+Huauthor=J.+N.+Ebrightauthor=G.+Malekauthor=M.+A.+Hauserauthor=C.+B.+Rickmanauthor=D.+Bokauthor=G.+S.+Hagemanauthor=L.+V.+Johnson&title=The+Pivotal+Role+of+the+Complement+System+in+Aging+and+Age-related+Macular+Degeneration%3A+Hypothesis+Re-visited&doi=10.1016%2Fj.preteyeres.2009.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited</span></div><div class="casAuthors">Anderson, Don H.; Radeke, Monte J.; Gallo, Natasha B.; Chapin, Ethan A.; Johnson, Patrick T.; Curletti, Christy R.; Hancox, Lisa S.; Hu, Jane; Ebright, Jessica N.; Malek, Goldis; Hauser, Michael A.; Bowes Rickman, Catherine; Bok, Dean; Hageman, Gregory S.; Johnson, Lincoln V.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Retinal and Eye Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-112</span>CODEN:
                <span class="NLM_cas:coden">PRTRES</span>;
        ISSN:<span class="NLM_cas:issn">1350-9462</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During the past ten years, dramatic advances have been made in unraveling the biol. bases of age-related macular degeneration (AMD), the most common cause of irreversible blindness in western populations.  In that timeframe, two distinct lines of evidence emerged which implicated chronic local inflammation and activation of the complement cascade in AMD pathogenesis.  First, a no. of complement system proteins, complement activators, and complement regulatory proteins were identified as mol. constituents of drusen, the hallmark extracellular deposits assocd. with early AMD.  Subsequently, genetic studies revealed highly significant statistical assocns. between AMD and variants of several complement pathway-assocd. genes including: Complement factor H (CFH), complement factor H-related 1 and 3 (CFHR1 and CFHR3), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3).  In this article, we revisit our original hypothesis that chronic local inflammatory and immune-mediated events at the level of Bruch's membrane play crit. roles in drusen biogenesis and, by extension, in the pathobiol. of AMD.  Secondly, we report the results of a new screening for addnl. AMD-assocd. polymorphisms in a battery of 63 complement-related genes.  Third, we identify and characterize the local complement system in the RPE-choroid complex - thus adding a new dimension of biol. complexity to the role of the complement system in ocular aging and AMD.  Finally, we evaluate the most salient, recent evidence that bears directly on the role of complement in AMD pathogenesis and progression.  Collectively, these recent findings strongly re-affirm the importance of the complement system in AMD.  They lay the groundwork for further studies that may lead to the identification of a transcriptional disease signature of AMD, and hasten the development of new therapeutic approaches that will restore the complement-modulating activity that appears to be compromised in genetically susceptible individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekkkfj3kJJbVg90H21EOLACvtfcHk0ljsPMbh_9uMWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFGksL0%253D&md5=1787c08e9671cb9c8959cca700074a26</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.preteyeres.2009.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.preteyeres.2009.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26aulast%3DRadeke%26aufirst%3DM.%2BJ.%26aulast%3DGallo%26aufirst%3DN.%2BB.%26aulast%3DChapin%26aufirst%3DE.%2BA.%26aulast%3DJohnson%26aufirst%3DP.%2BT.%26aulast%3DCurletti%26aufirst%3DC.%2BR.%26aulast%3DHancox%26aufirst%3DL.%2BS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DEbright%26aufirst%3DJ.%2BN.%26aulast%3DMalek%26aufirst%3DG.%26aulast%3DHauser%26aufirst%3DM.%2BA.%26aulast%3DRickman%26aufirst%3DC.%2BB.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DHageman%26aufirst%3DG.%2BS.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26atitle%3DThe%2520Pivotal%2520Role%2520of%2520the%2520Complement%2520System%2520in%2520Aging%2520and%2520Age-related%2520Macular%2520Degeneration%253A%2520Hypothesis%2520Re-visited%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2010%26volume%3D29%26spage%3D95%26epage%3D112%26doi%3D10.1016%2Fj.preteyeres.2009.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grebe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mughal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryden, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutty, G.</span></span> <span> </span><span class="NLM_article-title">Ultrastructural Analysis of Submacular Choriocapillaris and its Transport Systems in AMD and Aged Control Eyes</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2019.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.exer.2019.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=30807744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFaqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=252-262&author=R.+Grebeauthor=I.+Mughalauthor=W.+Brydenauthor=S.+McLeodauthor=M.+Edwardsauthor=G.+S.+Hagemanauthor=G.+Lutty&title=Ultrastructural+Analysis+of+Submacular+Choriocapillaris+and+its+Transport+Systems+in+AMD+and+Aged+Control+Eyes&doi=10.1016%2Fj.exer.2019.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrastructural analysis of submacular choriocapillaris and its transport systems in AMD and aged control eyes</span></div><div class="casAuthors">Grebe, Rhonda; Mughal, Irum; Bryden, William; McLeod, Scott; Edwards, Malia; Hageman, Gregory S.; Lutty, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">252-262</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The choriocapillaris is the source of nutrients and oxygen for photoreceptors, which consume more oxygen per g of tissue than any other cell in the body.  The purpose of this study was to evaluate and compare the ultrastructure of the choriocapillaris and its transport systems in patients with and without age-related macular degeneration (AMD).  Ultrastructural changes were also evaluated in subjects that were homozygous for polymorphisms in high risk CFH alleles (Pure 1) only or homozygous only for high risk ARMS2/HTRA1 (Pure 10) alleles.  Tissue samples were obtained from the macular region of forty male (n = 24) and female (n = 16) donor eyes and prepd. for ultrastructural studies with transmission electron microscopy (TEM).  The av. age of the aged donors was 74 ± 7.2 (n = 30) and the young donors 31.7 ± 11.25 (n = 10).  There was no significant difference in av. ages between the adult groups.  TEM images of the capillaries in the choriocapillaris (CC) were taken at 4,000X and 25,000X and used to measure the area of endothelial cell somas, the no. of fenestrations, and area of caveolae within the endothelial cells per length of Bruchs membrane (BrMb).  The Student t-test and Wilcoxon sum rank test were used to det. significant differences.  There was no significant difference between young subjects and aged controls in any of the morphol. criteria assessed.  There was a significant decrease in the no. of fenestrations/mm of BrMb in atrophic areas of GA eyes (p = 0.007) when compared with aged control eyes.  A significant increase was found in the caveolae area as a percent of the endothelial cell soma of capillaries from GA subjects as compared with the controls (p = 0.03).  Loss of capillary segments in choriocapillaris was also evident, esp. in areas of geog. atrophy and CNV.  In eyes from patients with sequence variations, the capillary endothelial cells often appeared degenerative and exhibited atypical fenestrations and pericytes covering the blood vessels.  Subjects that were homozygous for polymorphisms in high risk CFH alleles only had more fenestrations/mm of BrMb than subjects that were homozygous only for high risk ARMS2/HTRA1 alleles (p = 0.04), while the latter had greater caveolae area/endothelial cell area than the former (p = 0.007).  This study demonstrated an attenuation of CC and a significant decline in the two major transport systems in CC endothelial cells in AMD.  This may contribute to drusen deposition, nutrient transport, and vision loss in AMD subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroMM5P_LpXlrVg90H21EOLACvtfcHk0ljsPMbh_9uMWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFaqt7c%253D&md5=1a37c1a2a780eb6ebc9e1c0314da3ed3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2019.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2019.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DGrebe%26aufirst%3DR.%26aulast%3DMughal%26aufirst%3DI.%26aulast%3DBryden%26aufirst%3DW.%26aulast%3DMcLeod%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DHageman%26aufirst%3DG.%2BS.%26aulast%3DLutty%26aufirst%3DG.%26atitle%3DUltrastructural%2520Analysis%2520of%2520Submacular%2520Choriocapillaris%2520and%2520its%2520Transport%2520Systems%2520in%2520AMD%2520and%2520Aged%2520Control%2520Eyes%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2019%26volume%3D181%26spage%3D252%26epage%3D262%26doi%3D10.1016%2Fj.exer.2019.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">del Amo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimpela, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heikkinen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kari, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajunen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrizi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisalo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toropainen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteleijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antopolsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellonen, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruponen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtti, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic Aspects of Retinal Drug Delivery</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.preteyeres.2016.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.preteyeres.2016.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=28028001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvFGjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=134-185&author=E.+M.+del+Amoauthor=A.-K.+Rimpelaauthor=E.+Heikkinenauthor=O.+K.+Kariauthor=E.+Ramsayauthor=T.+Lajunenauthor=M.+Schmittauthor=L.+Pelkonenauthor=M.+Bhattacharyaauthor=D.+Richardsonauthor=A.+Subriziauthor=T.+Turunenauthor=M.+Reinisaloauthor=J.+Itkonenauthor=E.+Toropainenauthor=M.+Casteleijnauthor=H.+Kidronauthor=M.+Antopolskyauthor=K.-S.+Vellonenauthor=M.+Ruponenauthor=A.+Urtti&title=Pharmacokinetic+Aspects+of+Retinal+Drug+Delivery&doi=10.1016%2Fj.preteyeres.2016.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52aR"><div class="casContent"><span class="casTitleNuber">52a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic aspects of retinal drug delivery</span></div><div class="casAuthors">del Amo, Eva M.; Rimpela, Anna-Kaisa; Heikkinen, Emma; Kari, Otto K.; Ramsay, Eva; Lajunen, Tatu; Schmitt, Mechthild; Pelkonen, Laura; Bhattacharya, Madhushree; Richardson, Dominique; Subrizi, Astrid; Turunen, Tiina; Reinisalo, Mika; Itkonen, Jaakko; Toropainen, Elisa; Casteleijn, Marco; Kidron, Heidi; Antopolsky, Maxim; Vellonen, Kati-Sisko; Ruponen, Marika; Urtti, Arto</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Retinal and Eye Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-185</span>CODEN:
                <span class="NLM_cas:coden">PRTRES</span>;
        ISSN:<span class="NLM_cas:issn">1350-9462</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug delivery to the posterior eye segment is an important challenge in ophthalmol., because many diseases affect the retina and choroid leading to impaired vision or blindness.  Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and sol. receptors).  There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical.  Properties of the administration route, drug and delivery system det. the efficacy and safety of these approaches.  Pharmacokinetic and pharmacodynamic factors det. the required dosing rates and doses that are needed for drug action.  In addn., tolerability factors limit the use of many materials in ocular drug delivery.  This review article provides a crit. discussion of retinal drug delivery, particularly from the pharmacokinetic point of view.  This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently.  Instead, we aim to provide a systematic and quant. view on the pharmacokinetic factors in drug delivery to the posterior eye segment.  This review is based on the literature and unpublished data from the authors' lab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAiaOFhIm2JbVg90H21EOLACvtfcHk0lhiLbKopZRdoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvFGjtg%253D%253D&md5=eb5c622e81ff99739cd3d0dace43b0c8</span></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=10.1016%2Fj.preteyeres.2016.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.preteyeres.2016.12.001%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BAmo%26aufirst%3DE.%2BM.%26aulast%3DRimpela%26aufirst%3DA.-K.%26aulast%3DHeikkinen%26aufirst%3DE.%26aulast%3DKari%26aufirst%3DO.%2BK.%26aulast%3DRamsay%26aufirst%3DE.%26aulast%3DLajunen%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DPelkonen%26aufirst%3DL.%26aulast%3DBhattacharya%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DD.%26aulast%3DSubrizi%26aufirst%3DA.%26aulast%3DTurunen%26aufirst%3DT.%26aulast%3DReinisalo%26aufirst%3DM.%26aulast%3DItkonen%26aufirst%3DJ.%26aulast%3DToropainen%26aufirst%3DE.%26aulast%3DCasteleijn%26aufirst%3DM.%26aulast%3DKidron%26aufirst%3DH.%26aulast%3DAntopolsky%26aufirst%3DM.%26aulast%3DVellonen%26aufirst%3DK.-S.%26aulast%3DRuponen%26aufirst%3DM.%26aulast%3DUrtti%26aufirst%3DA.%26atitle%3DPharmacokinetic%2520Aspects%2520of%2520Retinal%2520Drug%2520Delivery%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2017%26volume%3D57%26spage%3D134%26epage%3D185%26doi%3D10.1016%2Fj.preteyeres.2016.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit52b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardegger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolfenden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassbender, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cepeda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention that are Efficacious in Models of Wet Age-Related Macular Degeneration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9273</span>– <span class="NLM_lpage">9286</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9273-9286&author=E.+L.+Meredithauthor=N.+Mainolfiauthor=S.+Poorauthor=Y.+Qiuauthor=K.+Mirandaauthor=J.+Powersauthor=D.+Liuauthor=F.+Maauthor=C.+Solovayauthor=C.+Raoauthor=L.+Johnsonauthor=N.+Jiauthor=G.+Artmanauthor=L.+Hardeggerauthor=S.+Hanksauthor=S.+Shenauthor=A.+Woolfendenauthor=E.+Fassbenderauthor=J.+Sivakauthor=Y.+Zhangauthor=D.+Longauthor=R.+Cepedaauthor=F.+Liuauthor=V.+Hosagraharaauthor=W.+Leeauthor=P.+Tarsaauthor=K.+Andersonauthor=J.+Elliottauthor=B.+Jaffee&title=Discovery+of+Oral+VEGFR-2+Inhibitors+with+Prolonged+Ocular+Retention+that+are+Efficacious+in+Models+of+Wet+Age-Related+Macular+Degeneration&doi=10.1021%2Facs.jmedchem.5b01227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52bR"><div class="casContent"><span class="casTitleNuber">52b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration</span></div><div class="casAuthors">Meredith, Erik L.; Mainolfi, Nello; Poor, Stephen; Qiu, Yubin; Miranda, Karl; Powers, James; Liu, Donglei; Ma, Fupeng; Solovay, Catherine; Rao, Chang; Johnson, Leland; Ji, Nan; Artman, Gerald; Hardegger, Leo; Hanks, Shawn; Shen, Siyuan; Woolfenden, Amber; Fassbender, Elizabeth; Sivak, Jeremy M.; Zhang, Yiqin; Long, Debby; Cepeda, Rosemarie; Liu, Fang; Hosagrahara, Vinayak P.; Lee, Wendy; Tarsa, Peter; Anderson, Karen; Elliott, Jason; Jaffee, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9273-9286</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The benefit of intravitreal anti-VEGF therapy in treating wet age-related macular degeneration (AMD) is well established.  Identification of VEGFR-2 inhibitors with optimal ADME properties for an ocular indication provides opportunities for dosing routes beyond intravitreal injection.  The authors employed a high-throughput in vivo screening strategy with rodent models of choroidal neovascularization and iterative compd. design to identify VEGFR-2 inhibitors with potential to benefit wet AMD patients.  These compds., e.g. I, demonstrate preferential ocular tissue distribution and efficacy after oral administration while minimizing systemic exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUYp1fAqKVYLVg90H21EOLACvtfcHk0lhiLbKopZRdoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7fF&md5=11ee9095e9eb62c548dec995a9c369dd</span></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01227%26sid%3Dliteratum%253Aachs%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DPoor%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DMiranda%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DF.%26aulast%3DSolovay%26aufirst%3DC.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DN.%26aulast%3DArtman%26aufirst%3DG.%26aulast%3DHardegger%26aufirst%3DL.%26aulast%3DHanks%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DWoolfenden%26aufirst%3DA.%26aulast%3DFassbender%26aufirst%3DE.%26aulast%3DSivak%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DD.%26aulast%3DCepeda%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHosagrahara%26aufirst%3DV.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DTarsa%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DElliott%26aufirst%3DJ.%26aulast%3DJaffee%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520Oral%2520VEGFR-2%2520Inhibitors%2520with%2520Prolonged%2520Ocular%2520Retention%2520that%2520are%2520Efficacious%2520in%2520Models%2520of%2520Wet%2520Age-Related%2520Macular%2520Degeneration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9273%26epage%3D9286%26doi%3D10.1021%2Facs.jmedchem.5b01227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="note"><p class="first last">Compound <b>41</b> was incubated with synthetic melanin obtained from polymerization (auto-oxidation) of <span class="smallcaps smallerCapital">l</span>-Dopa to characterize binding kinetics. Binding parameters <i>B</i><sub>max</sub> and <i>K</i><sub>d</sub> were calculated by a Langmuir type of multiple-site linear regression analysis. <i>B</i><sub>max</sub> refers to the maximal binding capacity of a particular binding site of melanin and <i>K</i><sub>d</sub> to the respective dissociation constant. These parameters are indexed 1 and 2 for low and high affinity sites, respectively. <b>41</b> affords <i>B</i><sub>max1</sub> and <i>B</i><sub>max2</sub> values of 32 and 4.9 nmol/mg, respectively, and <i>K</i><sub>d1</sub> and <i>K</i><sub>d2</sub> values of 26.0 and 2.0 μM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="note"><p class="first last">ClinicalTrials.gov identifiers: NCT03832114, NCT03439839, NCT03896152, NCT03955445, and NCT03373461.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">2-Chloro-1,3-dimethylimidazolinium Chloride. 1. A Powerful Dehydrating Equivalent to DCC</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6984</span>– <span class="NLM_lpage">6988</span>, <span class="refDoi"> DOI: 10.1021/jo990210y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo990210y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK1MXlt12rurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=6984-6988&author=T.+Isobeauthor=T.+Ishikawa&title=2-Chloro-1%2C3-dimethylimidazolinium+Chloride.+1.+A+Powerful+Dehydrating+Equivalent+to+DCC&doi=10.1021%2Fjo990210y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chloro-1,3-dimethylimidazolinium Chloride. 1. A Powerful Dehydrating Equivalent to DCC</span></div><div class="casAuthors">Isobe, Toshio; Ishikawa, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6984-6988</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Chloro-1,3-dimethylimidazolinium chloride (DMC) can act as a powerful dehydrating agent, replacing dicyclohexylcarbodiimide (DCC) under nearly neutral conditions.  Its application to acylation and dehydration is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SrU9QrhFULVg90H21EOLACvtfcHk0lhiLbKopZRdoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt12rurc%253D&md5=6650a174966038c660406240bb3029bf</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjo990210y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo990210y%26sid%3Dliteratum%253Aachs%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3D2-Chloro-1%252C3-dimethylimidazolinium%2520Chloride.%25201.%2520A%2520Powerful%2520Dehydrating%2520Equivalent%2520to%2520DCC%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D6984%26epage%3D6988%26doi%3D10.1021%2Fjo990210y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siesel, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillwell, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiftney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dyck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span> <span> </span><span class="NLM_article-title">One Pot Synthesis of Aminobenzimidazoles using 2-chloro-1,2-dimethylimidazolium chloride (DMC)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5319</span>– <span class="NLM_lpage">5321</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.07.177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.tetlet.2010.07.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaiu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=5319-5321&author=G.+Artmanauthor=C.+F.+Solovayauthor=C.+M.+Adamsauthor=B.+Diazauthor=M.+Dimitroffauthor=T.+Eharaauthor=D.+Guauthor=F.+Maauthor=D.+Liuauthor=B.+R.+Millerauthor=T.+E.+Pickauthor=D.+J.+Poonauthor=D.+Ryckmanauthor=D.+A.+Sieselauthor=B.+S.+Stillwellauthor=T.+Swiftneyauthor=J.+P.+van+Dyckauthor=C.+Zhangauthor=N.+Ji&title=One+Pot+Synthesis+of+Aminobenzimidazoles+using+2-chloro-1%2C2-dimethylimidazolium+chloride+%28DMC%29&doi=10.1016%2Fj.tetlet.2010.07.177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot synthesis of 2-aminobenzimidazoles using 2-chloro-1,3-dimethylimidazolinium chloride (DMC)</span></div><div class="casAuthors">Artman, Gerald D., III; Solovay, Catherine F.; Adams, Christopher M.; Diaz, Brian; Dimitroff, Martin; Ehara, Takeru; Gu, Danlin; Ma, Fupeng; Liu, Donglei; Miller, Bridget R.; Pick, Teresa E.; Poon, Daniel J.; Ryckman, David; Siesel, David A.; Stillwell, Brady S.; Swiftney, Tyson; van Dyck, Jonathan P.; Zhang, Chun; Ji, Nan</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">5319-5321</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">2-Chloro-1,3-dimethylimidazolinium chloride (DMC or DMC-Cl) effectively and rapidly generated 2-aminobenzimidazoles from 1,2-diaminoarenes and isothiocyanates in moderate to good yields at room temp. in a one-pot operation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTAgaMUrsdxbVg90H21EOLACvtfcHk0lgfh1NJap_sQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaiu7jM&md5=3af71ac8d9960be7fa761b93adf5ac41</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.07.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.07.177%26sid%3Dliteratum%253Aachs%26aulast%3DArtman%26aufirst%3DG.%26aulast%3DSolovay%26aufirst%3DC.%2BF.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DDiaz%26aufirst%3DB.%26aulast%3DDimitroff%26aufirst%3DM.%26aulast%3DEhara%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DPick%26aufirst%3DT.%2BE.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DRyckman%26aufirst%3DD.%26aulast%3DSiesel%26aufirst%3DD.%2BA.%26aulast%3DStillwell%26aufirst%3DB.%2BS.%26aulast%3DSwiftney%26aufirst%3DT.%26aulast%3Dvan%2BDyck%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DN.%26atitle%3DOne%2520Pot%2520Synthesis%2520of%2520Aminobenzimidazoles%2520using%25202-chloro-1%252C2-dimethylimidazolium%2520chloride%2520%2528DMC%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D5319%26epage%3D5321%26doi%3D10.1016%2Fj.tetlet.2010.07.177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, P.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Heterocyclic Amino Derivatives</span>. U.S. Patent <span class="NLM_patent">US4398028</span>, August 9, <span class="NLM_year">1983</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&author=P.+Neumann&title=Bicyclic+Heterocyclic+Amino+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DP.%26atitle%3DBicyclic%2520Heterocyclic%2520Amino%2520Derivatives%26date%3D1983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit57b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. T.</span>; <span class="NLM_string-name">Sheldon, R. J.</span>; <span class="NLM_string-name">Seibel, W.</span></span> <span> </span><span class="NLM_article-title">2-Imidazolinylaminoindole Compounds Useful as alpha-2 Adrenoceptor Agonists</span>. U.S. Patent <span class="NLM_patent">US6162818</span> December 19, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=R.+T.+Henry&author=R.+J.+Sheldon&author=W.+Seibel&title=2-Imidazolinylaminoindole+Compounds+Useful+as+alpha-2+Adrenoceptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DR.%2BT.%26atitle%3D2-Imidazolinylaminoindole%2520Compounds%2520Useful%2520as%2520alpha-2%2520Adrenoceptor%2520Agonists%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':[],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':[],'ref43':[],'ref44':[],'ref45':[],'ref46':[],'ref47':[],'ref48':[],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52a','cit52b'],'ref53':[],'ref54':[],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57a','cit57b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Jalink</span>, <span class="hlFld-ContribAuthor ">E. C. W.  de Boer</span>, <span class="hlFld-ContribAuthor ">D.  Evers</span>, <span class="hlFld-ContribAuthor ">M. Q.  Havinga</span>, <span class="hlFld-ContribAuthor ">J. M. I.  Vos</span>, <span class="hlFld-ContribAuthor ">S.  Zeerleder</span>, <span class="hlFld-ContribAuthor ">M.  de Haas</span>, <span class="hlFld-ContribAuthor ">I.  Jongerius</span>. </span><span class="cited-content_cbyCitation_article-title">Halting targeted and collateral damage to red blood cells by the complement system. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Immunopathology</span><span> <strong>2021,</strong> <em>114 </em><a href="https://doi.org/10.1007/s00281-021-00859-8" title="DOI URL">https://doi.org/10.1007/s00281-021-00859-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00281-021-00859-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00281-021-00859-8%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Immunopathology%26atitle%3DHalting%252Btargeted%252Band%252Bcollateral%252Bdamage%252Bto%252Bred%252Bblood%252Bcells%252Bby%252Bthe%252Bcomplement%252Bsystem%26aulast%3DJalink%26aufirst%3DM.%26date%3D2021%26date%3D2021%26volume%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Gu</span>, <span class="hlFld-ContribAuthor ">Hui  Xu</span>, <span class="hlFld-ContribAuthor ">Damu  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Primary Membranous Nephropathy. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (4)
                                     , 513. <a href="https://doi.org/10.3390/biom11040513" title="DOI URL">https://doi.org/10.3390/biom11040513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11040513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11040513%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DMechanisms%252Bof%252BPrimary%252BMembranous%252BNephropathy%26aulast%3DGu%26aufirst%3DYan%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D4%26spage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas L.  Li</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Birmingham</span>, <span class="hlFld-ContribAuthor ">Brad H.  Rovin</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the Role of Complement Therapies: The Case for Lupus Nephritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2021,</strong> <em>10 </em>
                                    (4)
                                     , 626. <a href="https://doi.org/10.3390/jcm10040626" title="DOI URL">https://doi.org/10.3390/jcm10040626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm10040626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm10040626%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DExpanding%252Bthe%252BRole%252Bof%252BComplement%252BTherapies%25253A%252BThe%252BCase%252Bfor%252BLupus%252BNephritis%26aulast%3DLi%26aufirst%3DNicholas%2BL.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D4%26spage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linda  Reinhard</span>, <span class="hlFld-ContribAuthor ">Rolf A.K.  Stahl</span>, <span class="hlFld-ContribAuthor ">Elion  Hoxha</span>. </span><span class="cited-content_cbyCitation_article-title">Is primary membranous nephropathy a complement mediated disease?. </span><span class="cited-content_cbyCitation_journal-name">Molecular Immunology</span><span> <strong>2020,</strong> <em>128 </em>, 195-204. <a href="https://doi.org/10.1016/j.molimm.2020.10.017" title="DOI URL">https://doi.org/10.1016/j.molimm.2020.10.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molimm.2020.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molimm.2020.10.017%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Immunology%26atitle%3DIs%252Bprimary%252Bmembranous%252Bnephropathy%252Ba%252Bcomplement%252Bmediated%252Bdisease%25253F%26aulast%3DReinhard%26aufirst%3DLinda%26date%3D2020%26volume%3D128%26spage%3D195%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susan  Yung</span>, <span class="hlFld-ContribAuthor ">Desmond YH  Yap</span>, <span class="hlFld-ContribAuthor ">Tak Mao  Chan</span>. </span><span class="cited-content_cbyCitation_article-title">A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. </span><span class="cited-content_cbyCitation_journal-name">F1000Research</span><span> <strong>2020,</strong> <em>9 </em>, 905. <a href="https://doi.org/10.12688/f1000research.22438.1" title="DOI URL">https://doi.org/10.12688/f1000research.22438.1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12688/f1000research.22438.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12688%2Ff1000research.22438.1%26sid%3Dliteratum%253Aachs%26jtitle%3DF1000Research%26atitle%3DA%252Breview%252Bof%252Badvances%252Bin%252Bthe%252Bunderstanding%252Bof%252Blupus%252Bnephritis%252Bpathogenesis%252Bas%252Ba%252Bbasis%252Bfor%252Bemerging%252Btherapies%26aulast%3DYung%26aufirst%3DSusan%26date%3D2020%26date%3D2020%26volume%3D9%26spage%3D905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of the alternative complement pathway (AP) from initiation to cell lysis, as well as representing the breakdown of C3b via the actions of factor I and factor H.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Cocrystal structure of compound <b>1</b> bound to the catalytic domain of human FB at 1.64 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSW">6QSW</a>.pdb)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and in vitro potency against CVF-Bb, hERG, and adrenergic receptors α1a and α2c. The ligand binding pocket is shown in gray, and H-bonding interaction is shown as black dotted lines. Crystallographic water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of indole <b>8</b> (yellow) with the catalytic domain of FB at 2.84 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8U">6T8U</a>.pdb) overlaid with naphthyl <b>1</b> (cyan). The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of indole (<i>S</i>)<b>-19</b> (green) with the catalytic domain of FB at 1.70 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8W">6T8W</a>.pdb). Of note the phenyl ring sits in the Pro172D and Val218 groove. The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic waters are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro potency of (2<i>S</i>,4<i>S</i>)-<b>29</b> as assessed in the CVF-Bb assay, a cocrystal structure of (2<i>S</i>,4<i>S</i>)-<b>29</b> (yellow) bound to the catalytic domain of human FB at 1.77 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSX">6QSX</a>.pdb)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> highlighting an interaction with a sulfate ion from the crystallization buffer, and an overlay with (<i>S</i>)-<b>19</b> (green) from its cocrystal structure. The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic water molecules are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal of (−)-<b>35</b> (yellow) bound to the catalytic domain of human FB at 2.29 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8V">6T8V</a>.pdb) in addition to in vitro potency, ADME, and mouse PK profile of (−)-<b>35</b>. <sup><i>a</i></sup>Determined for (±)-<b>35</b>. <sup><i>b</i></sup>Equilibrium high throughput solubility in aqueous buffer (pH 6.8). <sup><i>c</i></sup>Mouse (Ms) and human (H) liver microsomes (LM). <sup><i>d</i></sup>Plasma exposure was measured out to 7 h postdose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cocrystal of <b>41</b> within the catalytic domain of FB at 1.7 Å resolution (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RAV">6RAV</a>.pdb).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The ligand binding pocket is shown in gray, and H-bonding interactions are shown as black dotted lines. Crystallographic waters are shown as red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose–response relationship of <b>41</b> in the mouse LPS challenge model (% inhibition at 4 h ± SEM; all values have <i>p</i> values of <0.05) and time course of plasma<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and ocular AP inhibition ± SEM with a 30 mg/kg oral dose of <b>41</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Concentration versus time profile for <b>41</b> in PEC, retina, and plasma and PK parameters after a single dose (po 10 mg/kg) in brown Norway rats. <sup><i>a</i></sup>Plasma samples were taken only from two animals, and thus a standard deviation was not calculated. <sup><i>b</i></sup>AUC values were calculated as the mean of all the available concentration vs time data points for each ocular tissue. Standard deviations cannot be calculated because each time point is terminal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Ex vivo pharmacodynamic effects of <b>41</b> in beagle dogs (<i>n</i> = 4, 3 mg/kg po), evaluating percent inhibition of MAC deposition in 50% serum ± SEM and PK/PD relationship, and pharmacokinetic parameters of <b>41</b> in Wistar Han rats (<i>n</i> = 2, at 1 mg/kg iv and 30 mg/kg po) and beagle dogs (<i>n</i> = 3, 0.1 mg/kg iv and 10 mg/kg po) and represented as mean values. d.n. denotes dose normalized. Standard deviations are reported wherever applicable.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Syntheses of Aniline-Linked Inhibitors <b>1</b>–<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Routes for C-Linked Indoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaNO<sub>2</sub>, KI, HCl, H<sub>2</sub>O, EtOAc; then <i>n</i>-BuLi, DMF, CPME; (b) CBr<sub>4</sub>, PPh<sub>3</sub>, DCM; (c) ethylenediamine; (d) isoamylamine, NaOEt, EtOH; (e) 1,2-phenylenediamine, DABCO, NMP; (f) LAH, THF; (g) 1-SEM-1,2,4-triazole, <i>n</i>-BuLi, THF; (h) MsCl, Et<sub>3</sub>N, DCM; (i) TBAF, THF; (j) piperidine, NaBH(OAc)<sub>3</sub>, AcOH, DCM, MeOH; (k) NaBH<sub>4</sub>, MeOH, THF; (l) Vilsmeier reagent, DCM.</p></p></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/medium/jm9b01870_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Representative Synthesis of 2,4-Disubstituted Piperidine Intermediates and Inhibitors <b>39</b>–<b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01870/20200604/images/large/jm9b01870_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01870&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i><sup>i</sup></i>PrMgCl·LiCl, Cbz-Cl, THF; (b) Zn, AcOH; (c) LiBH<sub>4</sub>, THF; (d) TBDPS-Cl, imidazole, DMF; (e) separation of diastereomers by flash chromatography; (f) TBAF, THF; (g) NaH, EtI, DMF; (h) Ba(OH)<sub>2</sub>, <sup><i>i</i></sup>PrOH, H<sub>2</sub>O; (i) K<sub>2</sub>CO<sub>3</sub>, MeI, DMF; (j) H<sub>2</sub>, Pd/C, MeOH; (k) (±)-<b>50</b>, DIPEA, DMA; (l) K<sub>2</sub>CO<sub>3</sub>, MeOH; then TMS-diazomethane, toluene, MeOH; (m) chiral SFC; (n) LiOH, H<sub>2</sub>O, MeOH, THF; (o) (2<i>S</i>,4<i>S</i>)-<b>50</b>, NaBH(OAc)<sub>3</sub>, DCE.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i171">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68584" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68584" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 57 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaplin, H.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Review: The Burgeoning History of the Complement System 1888–2005</span>. <i>Immunohematology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=16178664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD2MrgslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2005&pages=85-93&author=H.+Chaplin&title=Review%3A+The+Burgeoning+History+of+the+Complement+System+1888%E2%80%932005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Review: the burgeoning history of the complement system 1888-2005</span></div><div class="casAuthors">Chaplin H Jr</div><div class="citationInfo"><span class="NLM_cas:title">Immunohematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">85-93</span>
        ISSN:<span class="NLM_cas:issn">0894-203X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0z-T_VbQvxEEksK8CslK8fW6udTcc2ebgr4c5i1FyQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrgslWgug%253D%253D&md5=d23136f9514bec073cd91e955383ee7b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChaplin%26aufirst%3DH.%26atitle%3DReview%253A%2520The%2520Burgeoning%2520History%2520of%2520the%2520Complement%2520System%25201888%25E2%2580%25932005%26jtitle%3DImmunohematology%26date%3D2005%26volume%3D21%26spage%3D85%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajishengallis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span> <span> </span><span class="NLM_article-title">Complement: A Key System for Immune Surveillance and Homeostasis</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1038/ni.1923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fni.1923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=20720586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCmtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=785-797&author=D.+Ricklinauthor=G.+Hajishengallisauthor=K.+Yangauthor=J.+D.+Lambris&title=Complement%3A+A+Key+System+for+Immune+Surveillance+and+Homeostasis&doi=10.1038%2Fni.1923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Complement: a key system for immune surveillance and homeostasis</span></div><div class="casAuthors">Ricklin, Daniel; Hajishengallis, George; Yang, Kun; Lambris, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">785-797</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nearly a century after the significance of the human complement system was recognized, we have come to realize that its functions extend far beyond the elimination of microbes.  Complement acts as a rapid and efficient immune surveillance system that has distinct effects on healthy and altered host cells and foreign intruders.  By eliminating cellular debris and infectious microbes, orchestrating immune responses and sending 'danger' signals, complement contributes substantially to homeostasis, but it can also take action against healthy cells if not properly controlled.  This review describes our updated view of the function, structure and dynamics of the complement network, highlights its interconnection with immunity at large and with other endogenous pathways, and illustrates its multiple roles in homeostasis and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx5zRC2bFGqLVg90H21EOLACvtfcHk0lirJ8KQF6Rzug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCmtbfO&md5=9fd72883ccfb6bf77b4bdebe82197d11</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fni.1923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1923%26sid%3Dliteratum%253Aachs%26aulast%3DRicklin%26aufirst%3DD.%26aulast%3DHajishengallis%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26atitle%3DComplement%253A%2520A%2520Key%2520System%2520for%2520Immune%2520Surveillance%2520and%2520Homeostasis%26jtitle%3DNat.%2520Immunol.%26date%3D2010%26volume%3D11%26spage%3D785%26epage%3D797%26doi%3D10.1038%2Fni.1923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holers, M.</span></span> <span> </span><span class="NLM_article-title">The Spectrum of Complement Alternative Pathway-Mediated Diseases</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>223</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00641.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1111%2Fj.1600-065X.2008.00641.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=18613844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=300-316&author=M.+Holers&title=The+Spectrum+of+Complement+Alternative+Pathway-Mediated+Diseases&doi=10.1111%2Fj.1600-065X.2008.00641.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The spectrum of complement alternative pathway-mediated diseases</span></div><div class="casAuthors">Holers, V. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">300-316</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The complement system has once again come into prominence in the therapeutic development arena.  The recent approval of an inhibitory monoclonal antibody, eculizumab, which is directed against complement component C5 for the disease paroxysmal nocturnal hemoglobinuria has provided the initial validation of this system as a therapeutic target.  Preclin. studies using animal models and human-derived samples demonstrate that inhibition of complement ameliorates many inflammatory and autoimmune disease manifestations.  Major efforts continue to define the most optimal means to block complement activation in a cost-effective manner.  Because the system is initiated through three pathways and generates at least six immunoregulatory and pro-inflammatory mediators, there is substantial complexity to this problem.  One pathway, designated the alternative pathway, has recently been shown to play a particularly important role in preclin. disease models.  Further evidence of the importance of the alternative pathway has been provided by studies of human diseases, where mutations or dysfunctional polymorphisms that promote activation of this pathway are highly assocd. with the diseases atypical hemolytic uremic syndrome, dense deposit disease, and age-related macular degeneration.  This article reviews evidence in support of the essential role of the alternative pathway in the generation of tissue injury and the rationale for development of therapies that modulate its activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3u8J-53XDOrVg90H21EOLACvtfcHk0lirJ8KQF6Rzug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGltr4%253D&md5=41da6ad206500c88595f6d8cba76ce50</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00641.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00641.x%26sid%3Dliteratum%253Aachs%26aulast%3DHolers%26aufirst%3DM.%26atitle%3DThe%2520Spectrum%2520of%2520Complement%2520Alternative%2520Pathway-Mediated%2520Diseases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D300%26epage%3D316%26doi%3D10.1111%2Fj.1600-065X.2008.00641.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehrs, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span> <span> </span><span class="NLM_article-title">Age-Related Macular Degeneration – Emerging Pathogenetic and Therapeutic Concepts</span>. <i>Ann. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1080/07853890600946724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1080%2F07853890600946724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=17101537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD28nmsFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2006&pages=450-471&author=K.+M.+Gehrsauthor=D.+H.+Andersonauthor=L.+V.+Johnsonauthor=G.+S.+Hageman&title=Age-Related+Macular+Degeneration+%E2%80%93+Emerging+Pathogenetic+and+Therapeutic+Concepts&doi=10.1080%2F07853890600946724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Age-related macular degeneration--emerging pathogenetic and therapeutic concepts</span></div><div class="casAuthors">Gehrs Karen M; Anderson Don H; Johnson Lincoln V; Hageman Gregory S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">450-71</span>
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    </div><div class="casAbstract">Today, the average life expectancy in developed nations is over 80 years and climbing.  And yet, the quality of life during those additional years is often significantly diminished by the effects of age-related, degenerative diseases, including age-related macular degeneration (AMD), the leading cause of blindness in the elderly worldwide.  AMD is characterized by a progressive loss of central vision attributable to degenerative and neovascular changes in the macula, a highly specialized region of the ocular retina responsible for fine visual acuity.  Estimates gathered from the most recent World Health Organization (WHO) global eye disease survey conservatively indicate that 14 million persons are blind or severely visually impaired because of AMD.  The disease has a tremendous impact on the physical and mental health of the geriatric population and their families and is becoming a major public health burden.  Currently, there is neither a cure nor a means to prevent AMD.  Palliative treatment options for the less prevalent, late-stage 'wet' form of the disease include anti-neovascular agents, photodynamic therapy and thermal laser.  There are no current therapies for the more common 'dry' AMD, except for the use of antioxidants that delay progression in 20%-25% of eyes.  New discoveries, however, are beginning to provide a much clearer picture of the relevant cellular events, genetic factors, and biochemical processes associated with early AMD.  Recently, compelling evidence has emerged that the innate immune system and, more specifically, uncontrolled regulation of the complement alternative pathway plays a central role in the pathobiology of AMD.  The complement Factor H gene--which encodes the major inhibitor of the complement alternative pathway--is the first gene identified in multiple independent studies that confers a significant genetic risk for the development of AMD.  The emergence of this new paradigm of AMD pathogenesis should hasten the development of novel diagnostic and therapeutic approaches for this disease that will dramatically improve the quality of our prolonged lifespan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh0Z9BOU2wHWLFM_lbR1VmfW6udTcc2eZjp8cwQ1F-rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmsFKktw%253D%253D&md5=8c8dc27435dbf65e070d0a36e49d8fbf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1080%2F07853890600946724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890600946724%26sid%3Dliteratum%253Aachs%26aulast%3DGehrs%26aufirst%3DK.%2BM.%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26aulast%3DHageman%26aufirst%3DG.%2BS.%26atitle%3DAge-Related%2520Macular%2520Degeneration%2520%25E2%2580%2593%2520Emerging%2520Pathogenetic%2520and%2520Therapeutic%2520Concepts%26jtitle%3DAnn.%2520Med.%26date%3D2006%26volume%3D38%26spage%3D450%26epage%3D471%26doi%3D10.1080%2F07853890600946724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triebwasser, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seddon, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J. P.</span></span> <span> </span><span class="NLM_article-title">Genetic Variants in the Complement System Predisposing to Age-Related Macular Degeneration: a Review</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2014.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.molimm.2014.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=25034031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGjs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=118-125&author=E.+C.+Schrammauthor=S.+J.+Clarkauthor=M.+P.+Triebwasserauthor=S.+Raychaudhuriauthor=J.+M.+Seddonauthor=J.+P.+Atkinson&title=Genetic+Variants+in+the+Complement+System+Predisposing+to+Age-Related+Macular+Degeneration%3A+a+Review&doi=10.1016%2Fj.molimm.2014.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic variants in the complement system predisposing to age-related macular degeneration</span></div><div class="casAuthors">Schramm, Elizabeth C.; Clark, Simon J.; Triebwasser, Michael P.; Raychaudhuri, Soumya; Seddon, Johanna M.; Atkinson, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-125</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Age-related macular degeneration (AMD) is a major cause of visual impairment in the western world.  It is characterized by the presence of lipoproteinaceous deposits (drusen) in the inner layers of the retina.  Immunohistochem. studies identified deposition of complement proteins in the drusen as well as in the choroid.  In the last decade, genetic studies have linked both common and rare variants in genes of the complement system to increased risk of development of AMD.  Here, we review the variants described to date and discuss the functional implications of dysregulation of the alternative pathway of complement in AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw5ZQzYfD307Vg90H21EOLACvtfcHk0lirJ8KQF6Rzug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGjs7vK&md5=8b8ec6496b04e1a7748b2817045d2eb1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2014.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2014.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DSchramm%26aufirst%3DE.%2BC.%26aulast%3DClark%26aufirst%3DS.%2BJ.%26aulast%3DTriebwasser%26aufirst%3DM.%2BP.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DSeddon%26aufirst%3DJ.%2BM.%26aulast%3DAtkinson%26aufirst%3DJ.%2BP.%26atitle%3DGenetic%2520Variants%2520in%2520the%2520Complement%2520System%2520Predisposing%2520to%2520Age-Related%2520Macular%2520Degeneration%253A%2520a%2520Review%26jtitle%3DMol.%2520Immunol.%26date%3D2014%26volume%3D61%26spage%3D118%26epage%3D125%26doi%3D10.1016%2Fj.molimm.2014.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, R. A.</span></span> <span> </span><span class="NLM_article-title">Paroxysmal Nocturnal Hemoglobinuria</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2811</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-02-522128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1182%2Fblood-2014-02-522128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=25237200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2804-2811&author=R.+A.+Brodsky&title=Paroxysmal+Nocturnal+Hemoglobinuria&doi=10.1182%2Fblood-2014-02-522128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxysmal nocturnal hemoglobinuria</span></div><div class="casAuthors">Brodsky, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2804-2811</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias.  The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH manifestations.  GPI anchor protein deficiency is almost always due to somatic mutations in phosphatidylinositol glycan class A (PIGA), a gene involved in the first step of GPI anchor biosynthesis; however, alternative mutations that cause PNH have recently been discovered.  In addn., hypomorphic germ-line PIGA mutations that do not cause PNH have been shown to be responsible for a condition known as multiple congenital anomalies-hypotonia-seizures syndrome 2.  Eculizumab, a first-in-class monoclonal antibody that inhibits terminal complement, is the treatment of choice for patients with severe manifestations of PNH.  Bone marrow transplantation remains the only cure for PNH but should be reserved for patients with suboptimal response to eculizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQtU772cCcqLVg90H21EOLACvtfcHk0lgeejnlcUMjDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWqsL%252FN&md5=b5d064494dbcbdb388bc4f2bf04be3a9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-02-522128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-02-522128%26sid%3Dliteratum%253Aachs%26aulast%3DBrodsky%26aufirst%3DR.%2BA.%26atitle%3DParoxysmal%2520Nocturnal%2520Hemoglobinuria%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2804%26epage%3D2811%26doi%3D10.1182%2Fblood-2014-02-522128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez
de Cordoba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortajada, A.</span></span> <span> </span><span class="NLM_article-title">Genetics of Atypical Hemolytic Uremic Syndrome (aHUS)</span>. <i>Semin. Thromb. Hemostasis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1055/s-0034-1375296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1055%2Fs-0034-1375296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=24799305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BC2cjgtFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=422-430&author=S.+Rodriguez%0Ade+Cordobaauthor=M.+S.+Hidalgoauthor=S.+Pintoauthor=A.+Tortajada&title=Genetics+of+Atypical+Hemolytic+Uremic+Syndrome+%28aHUS%29&doi=10.1055%2Fs-0034-1375296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics of atypical hemolytic uremic syndrome (aHUS)</span></div><div class="casAuthors">Rodriguez de Cordoba Santiago; Hidalgo Marta Subias; Pinto Sheila; Tortajada Agustin</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in thrombosis and hemostasis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">422-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hemolytic uremic syndrome (HUS) is a rare, life-threatening disease characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure.  The atypical form of HUS (aHUS), representing 5 to 10% of cases, lacks the association with infection by Shiga toxin producing Escherichia coli strains that characterizes the commonest clinical presentation of HUS.  In the majority of aHUS cases, the disease results from the complement-mediated damage to the microvascular endothelium because of inherited defects in complement genes or autoantibodies against complement regulatory proteins.  Incomplete penetrance of aHUS in carriers of mutations is common to all aHUS-associated complement genes and it is now established that the overall genetic predisposition to aHUS of an individual results from the combination of different inherited factors.  Moreover, the patient's genotype influences the clinical evolution, the response to plasma therapies, and the recurrence after transplantation.  Here, we describe the genetic component of aHUS, the lessons that we have learned from the functional characterization of the aHUS-associated mutations, and the benefits of a comprehensive genetic analysis of the patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQD5i3ezOcT6-IHSmpohpd0fW6udTcc2eY9V1KHXmuBK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjgtFWmtw%253D%253D&md5=fcae4cb8162f22e694c0aa0fb7e10ae5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1055%2Fs-0034-1375296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0034-1375296%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%2Bde%2BCordoba%26aufirst%3DS.%26aulast%3DHidalgo%26aufirst%3DM.%2BS.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DTortajada%26aufirst%3DA.%26atitle%3DGenetics%2520of%2520Atypical%2520Hemolytic%2520Uremic%2520Syndrome%2520%2528aHUS%2529%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2014%26volume%3D40%26spage%3D422%26epage%3D430%26doi%3D10.1055%2Fs-0034-1375296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Łukawska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polcyn-Adamczak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemir, Z. I.</span></span> <span> </span><span class="NLM_article-title">The Role of the Alternative Pathway of Complement Activation in Glomerular Diseases</span>. <i>Clin. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1007/s10238-018-0491-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2Fs10238-018-0491-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=29450785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlahu73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=297-318&author=E.+%C5%81ukawskaauthor=M.+Polcyn-Adamczakauthor=Z.+I.+Niemir&title=The+Role+of+the+Alternative+Pathway+of+Complement+Activation+in+Glomerular+Diseases&doi=10.1007%2Fs10238-018-0491-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the alternative pathway of complement activation in glomerular diseases</span></div><div class="casAuthors">Lukawska, Emilia; Polcyn-Adamczak, Magdalena; Niemir, Zofia I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-318</span>CODEN:
                <span class="NLM_cas:coden">CEMLBA</span>;
        ISSN:<span class="NLM_cas:issn">1591-8890</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">The complement system (CS) has recently been recognized as a bridge between innate and adaptive immunity that constitutes a very complex mechanism controlling the clearance of pathogens, cellular debris, and immune complexes.  Out of three known pathways of complement activation, the alternative pathway (AP) plays a crit. role in host defense by amplifying the complement response, independently of initiation pathway and continuously maintaining low-level activity in a process called 'thick-over.'.  A key mol. of the CS is C3, in which the AP is constantly activated.  To prevent host cell destruction, a group of the AP regulators tightly controls this pathway of the CS activation.  Acquired and genetic abnormalities of the CS may alter the delicate balance between enhancing and inhibiting the AP cascade.  These can lead to the uncontrolled CS activation, inflammatory response, and subsequent tissue damage.  Since complement components are locally produced and activated in the kidney, the abnormalities targeting the AP may cause glomerular injury.  C3 glomerulopathy is a new entity, in which the AP dysregulation has been well established.  However, recent studies indicate that the AP may also contribute to a wide range of kidney pathologies, including immune-complex-mediated glomerulonephritis (GN), pauci-immune GN, and primary membranous nephropathy (PMN).  This article provides insight into current knowledge on the role of the AP in the pathogenesis of glomerular diseases, focusing mainly on various types of primary and secondary GN and PMN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkhgJKxCpuYLVg90H21EOLACvtfcHk0liglecOo_LueA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlahu73O&md5=d1d4a8a9e1f9b5964d4ddfe608a8742b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs10238-018-0491-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10238-018-0491-8%26sid%3Dliteratum%253Aachs%26aulast%3D%25C5%2581ukawska%26aufirst%3DE.%26aulast%3DPolcyn-Adamczak%26aufirst%3DM.%26aulast%3DNiemir%26aufirst%3DZ.%2BI.%26atitle%3DThe%2520Role%2520of%2520the%2520Alternative%2520Pathway%2520of%2520Complement%2520Activation%2520in%2520Glomerular%2520Diseases%26jtitle%3DClin.%2520Exp.%2520Med.%26date%3D2018%26volume%3D18%26spage%3D297%26epage%3D318%26doi%3D10.1007%2Fs10238-018-0491-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fettis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussauge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Factor D Inhibitors Targeting the Alternative Complement Pathway</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fnchembio.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=27775713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslehur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1105-1110&author=J.+Maibaumauthor=S.-M.+Liaoauthor=A.+Vulpettiauthor=N.+Ostermannauthor=S.+Randlauthor=S.+Rudisserauthor=E.+Lorthioisauthor=P.+Erbelauthor=B.+Kinzelauthor=F.+A.+Kolbauthor=S.+Barbieriauthor=J.+Wagnerauthor=C.+Durandauthor=K.+Fettisauthor=S.+Dussaugeauthor=N.+Hughesauthor=O.+Delgadoauthor=U.+Hommelauthor=T.+Gouldauthor=A.+Mac+Sweeneyauthor=B.+Gerhartzauthor=F.+Cuminauthor=S.+Flohrauthor=A.+Schubartauthor=B.+Jaffeeauthor=R.+Harrisonauthor=A.+M.+Risitanoauthor=J.+Ederauthor=K.+Anderson&title=Small-Molecule+Factor+D+Inhibitors+Targeting+the+Alternative+Complement+Pathway&doi=10.1038%2Fnchembio.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule factor D inhibitors targeting the alternative complement pathway</span></div><div class="casAuthors">Maibaum, Jurgen; Liao, Sha-Mei; Vulpetti, Anna; Ostermann, Nils; Randl, Stefan; Rudisser, Simon; Lorthiois, Edwige; Erbel, Paul; Kinzel, Bernd; Kolb, Fabrice A.; Barbieri, Samuel; Wagner, Julia; Durand, Corinne; Fettis, Kamal; Dussauge, Solene; Hughes, Nicola; Delgado, Omar; Hommel, Ulrich; Gould, Ty; Mac Sweeney, Aengus; Gerhartz, Bernd; Cumin, Frederic; Flohr, Stefanie; Schubart, Anna; Jaffee, Bruce; Harrison, Richard; Risitano, Antonio Maria; Eder, Jorg; Anderson, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1105-1110</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination.  Complement component 3 (C3) is the central component of the system.  Activation of C3 can be initiated by three distinct routes-the classical, the lectin and the alternative pathways-with the alternative pathway also acting as an amplification loop for the other two pathways.  The protease factor D (FD) is essential for this amplification process, which, when dysregulated, predisposes individuals to diverse disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH).  Here the authors describe the identification of potent and selective small-mol. inhibitors of FD.  These inhibitors efficiently block alternative pathway (AP) activation and prevent both C3 deposition onto, and lysis of, PNH erythrocytes.  Their oral administration inhibited lipopolysaccharide-induced AP activation in FD-humanized mice.  These data demonstrate the feasibility of inhibiting the AP with small-mol. antagonists and support the development of FD inhibitors for the treatment of complement-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp28_wznUz9QLVg90H21EOLACvtfcHk0liglecOo_LueA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslehur3P&md5=270ea1f129b3e25c22680e74f82ffc36</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2208%26sid%3Dliteratum%253Aachs%26aulast%3DMaibaum%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DRudisser%26aufirst%3DS.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DKinzel%26aufirst%3DB.%26aulast%3DKolb%26aufirst%3DF.%2BA.%26aulast%3DBarbieri%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DDurand%26aufirst%3DC.%26aulast%3DFettis%26aufirst%3DK.%26aulast%3DDussauge%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DN.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DGould%26aufirst%3DT.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DSchubart%26aufirst%3DA.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DRisitano%26aufirst%3DA.%2BM.%26aulast%3DEder%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DSmall-Molecule%2520Factor%2520D%2520Inhibitors%2520Targeting%2520the%2520Alternative%2520Complement%2520Pathway%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D1105%26epage%3D1110%26doi%3D10.1038%2Fnchembio.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1946-1958&author=A.+Vulpettiauthor=S.+Randlauthor=S.+R%C3%BCdisserauthor=N.+Ostermannauthor=P.+Erbelauthor=A.+Mac+Sweeneyauthor=T.+Zollerauthor=B.+Salemauthor=B.+Gerhartzauthor=F.+Cuminauthor=U.+Hommelauthor=C.+Dalvitauthor=E.+Lorthioisauthor=J.+Maibaum&title=Structure-Based+Library+Design+and+Fragment+Screening+for+the+Identification+of+Reversible+Complement+Factor+D+Protease+Inhibitors&doi=10.1021%2Facs.jmedchem.6b01684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span></div><div class="casAuthors">Vulpetti, Anna; Randl, Stefan; Rudisser, Simon; Ostermann, Nils; Erbel, Paul; Mac Sweeney, Aengus; Zoller, Thomas; Salem, Bahaa; Gerhartz, Bernd; Cumin, Frederic; Hommel, Ulrich; Dalvit, Claudio; Lorthiois, Edwige; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic dysregulation of alternative complement pathway activation has been assocd. with diverse clin. disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.  Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymic reaction of the amplification loop of the alternative pathway.  In this paper, the authors describe two hit finding approaches leading to the discovery of new chem. matter for this pivotal protease of the complement system: in silico active site mapping for hot spots identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries.  The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different sub-pockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPFgFvVDvCyrVg90H21EOLACvtfcHk0liglecOo_LueA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D&md5=179ea6dc5fb9ccb60931da60f23e6381</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01684%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DStructure-Based%2520Library%2520Design%2520and%2520Fragment%2520Screening%2520for%2520the%2520Identification%2520of%2520Reversible%2520Complement%2520Factor%2520D%2520Protease%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1946%26epage%3D1958%26doi%3D10.1021%2Facs.jmedchem.6b01684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussauge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fettis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Erkenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwieg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5717</span>– <span class="NLM_lpage">5735</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSqur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5717-5735&author=E.+Lorthioisauthor=K.+Andersonauthor=A.+Vulpettiauthor=O.+Rogelauthor=F.+Cuminauthor=N.+Ostermannauthor=S.+Steinbacherauthor=A.+Mac+Sweeneyauthor=O.+Delgadoauthor=S.+M.+Liaoauthor=S.+Randlauthor=S.+R%C3%BCdisserauthor=S.+Dussaugeauthor=K.+Fettisauthor=L.+Kiefferauthor=A.+de+Erkenezauthor=L.+Yangauthor=C.+Hartwiegauthor=U.+A.+Argikarauthor=L.+R.+La+Bonteauthor=R.+Newtonauthor=V.+Kansaraauthor=S.+Flohrauthor=U.+Hommelauthor=B.+Jaffeeauthor=J.+Maibaum&title=Discovery+of+Highly+Potent+and+Selective+Small-Molecule+Reversible+Factor+D+Inhibitors+Demonstrating+Alternative+Complement+Pathway+Inhibition+in+Vivo&doi=10.1021%2Facs.jmedchem.7b00425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo</span></div><div class="casAuthors">Lorthiois, Edwige; Anderson, Karen; Vulpetti, Anna; Rogel, Olivier; Cumin, Frederic; Ostermann, Nils; Steinbacher, Stefan; Mac Sweeney, Aengus; Delgado, Omar; Liao, Sha-Mei; Randl, Stefan; Rudisser, Simon; Dussauge, Solene; Fettis, Kamal; Kieffer, Laurence; de Erkenez, Andrea; Yang, Louis; Hartwieg, Constanze; Argikar, Upendra A.; La Bonte, Laura R.; Newton, Ronald; Kansara, Viral; Flohr, Stefanie; Hommel, Ulrich; Jaffee, Bruce; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5717-5735</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The highly specific S1 serine protease Factor D (FD) plays a central role in the amplification of the complement alternative pathway (AP) of the innate immune system.  Genetic assocns. in humans have implicated AP activation in age-related macular degeneration (AMD), and AP dysfunction predisposes individuals to disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).  The combination of structure-based hit identification and subsequent optimization of the center (S)-proline-based lead I has led to the discovery of noncovalent reversible and selective human Factor D (FD) inhibitors with drug-like properties.  The orally bioavailable compd. II exerted excellent potency in 50% human whole blood in vitro and blocked AP activity ex vivo after oral administration to monkeys as demonstrated by inhibition of membrane attack complex (MAC) formation.  Inhibitor II demonstrated sustained oral and ocular efficacy in a model of lipopolysaccharide (LPS)-induced systemic AP activation in mice expressing human FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjw5U9LMzdzLVg90H21EOLACvtfcHk0licTkoDjYOOjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSqur%252FN&md5=06e969052e0b3ad2ca70f523eec1b63a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00425%26sid%3Dliteratum%253Aachs%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DRogel%26aufirst%3DO.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DLiao%26aufirst%3DS.%2BM.%26aulast%3DRandl%26aufirst%3DS.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DDussauge%26aufirst%3DS.%26aulast%3DFettis%26aufirst%3DK.%26aulast%3DKieffer%26aufirst%3DL.%26aulast%3Dde%2BErkenez%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DHartwieg%26aufirst%3DC.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DKansara%26aufirst%3DV.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Small-Molecule%2520Reversible%2520Factor%2520D%2520Inhibitors%2520Demonstrating%2520Alternative%2520Complement%2520Pathway%2520Inhibition%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5717%26epage%3D5735%26doi%3D10.1021%2Facs.jmedchem.7b00425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glazer, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugel, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lein, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosskreutz, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamiri, P.</span></span> <span> </span><span class="NLM_article-title">A First in Human Study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-related Macular Degeneration (AMD)</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=2672&author=L.+C.+Glazerauthor=J.+G.+Williamsauthor=C.+M.+Gordonauthor=P.+U.+Dugelauthor=M.+Miltonauthor=T.+Valenciaauthor=U.+Leinauthor=S.+Kretzauthor=K.+Gedifauthor=C.+L.+Grosskreutzauthor=P.+Zamiri&title=A+First+in+Human+Study+of+Intravitreal+%28IVT%29+CLG561+in+Subjects+with+Advanced+Age-related+Macular+Degeneration+%28AMD%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGlazer%26aufirst%3DL.%2BC.%26aulast%3DWilliams%26aufirst%3DJ.%2BG.%26aulast%3DGordon%26aufirst%3DC.%2BM.%26aulast%3DDugel%26aufirst%3DP.%2BU.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DValencia%26aufirst%3DT.%26aulast%3DLein%26aufirst%3DU.%26aulast%3DKretz%26aufirst%3DS.%26aulast%3DGedif%26aufirst%3DK.%26aulast%3DGrosskreutz%26aufirst%3DC.%2BL.%26aulast%3DZamiri%26aufirst%3DP.%26atitle%3DA%2520First%2520in%2520Human%2520Study%2520of%2520Intravitreal%2520%2528IVT%2529%2520CLG561%2520in%2520Subjects%2520with%2520Advanced%2520Age-related%2520Macular%2520Degeneration%2520%2528AMD%2529%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2016%26volume%3D57%26spage%3D2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubost, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flandre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirockin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedrani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Factor B Inhibitor for the Treatment of Complement-mediated Diseases</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7926</span>– <span class="NLM_lpage">7931</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820892116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1073%2Fpnas.1820892116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=30926668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVeksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=7926-7931&issue=16&author=A.+Schubartauthor=K.+Andersonauthor=N.+Mainolfiauthor=H.+Sellnerauthor=T.+Eharaauthor=C.+M.+Adamsauthor=A.+Mac+Sweeneyauthor=S.-M.+Liaoauthor=M.+Crowleyauthor=A.+Littlewood-Evansauthor=S.+Sarretauthor=G.+Wieczorekauthor=L.+Perrotauthor=V.+Dubostauthor=T.+Flandreauthor=Y.+Zhangauthor=R.+J.+H.+Smithauthor=A.+M.+Risitanoauthor=R.+G.+Karkiauthor=C.+Zhangauthor=E.+Valeurauthor=F.+Sirockinauthor=B.+Gerhartzauthor=P.+Erbelauthor=N.+Hughesauthor=T.+M.+Smithauthor=F.+Cuminauthor=U.+A.+Argikarauthor=B.+Haraldssonauthor=M.+Mogiauthor=R.+Sedraniauthor=C.+Wiesmannauthor=B.+Jaffeeauthor=J.+Maibaumauthor=S.+Flohrauthor=R.+Harrisonauthor=J.+Eder&title=Small-Molecule+Factor+B+Inhibitor+for+the+Treatment+of+Complement-mediated+Diseases&doi=10.1073%2Fpnas.1820892116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule factor B inhibitor for the treatment of complement-mediated diseases</span></div><div class="casAuthors">Schubart, Anna; Anderson, Karen; Mainolfi, Nello; Sellner, Holger; Ehara, Takeru; Adams, Christopher M.; MacSweeney, Aengus; Liao, Sha-Mei; Crowley, Maura; Littlewood-Evans, Amanda; Sarret, Sophie; Wieczorek, Grazyna; Perrot, Ludovic; Dubost, ValArie; Flandre, Thierry; Zhang, Yuzhou; Smith, Richard J. H.; Risitano, Antonio M.; Karki, Rajeshri G.; Zhang, Chun; Valeur, Eric; Sirockin, Finton; Gerhartz, Bernd; Erbel, Paulus; Hughes, Nicola; Smith, Thomas M.; Cumin, Frederic; Argikar, Upendra A.; Haraldsson, Boerje; Mogi, Muneto; Sedrani, Richard; Wiesmann, Christian; Jaffee, Bruce; Maibaum, Juergen; Flohr, Stefanie; Harrison, Richard; Eder, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7926-7931</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dysregulation of the alternative complement pathway (AP) predisposes individuals to a no. of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and C3 glomerulopathy.  Moreover, glomerular Ig deposits can lead to complement-driven nephropathies.  Here we describe the discovery of a highly potent, reversible, and selective small-mol. inhibitor of factor B, a serine protease that drives the central amplification loop of the AP.  Oral administration of the inhibitor prevents KRN-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an exptl. model of membranous nephropathy in rats.  In addn., inhibition of factor B prevents complement activation in sera from C3 glomerulopathy patients and the hemolysis of human PNH erythrocytes.  These data demonstrate the potential therapeutic value of using a factor B inhibitor for systemic treatment of complement-mediated diseases and provide a basis for its clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLL4lNUjAPrVg90H21EOLACvtfcHk0licTkoDjYOOjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVeksbg%253D&md5=ae1c511ce7f742f6ffb5b583d94adfae</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820892116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820892116%26sid%3Dliteratum%253Aachs%26aulast%3DSchubart%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DSellner%26aufirst%3DH.%26aulast%3DEhara%26aufirst%3DT.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DCrowley%26aufirst%3DM.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DSarret%26aufirst%3DS.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DDubost%26aufirst%3DV.%26aulast%3DFlandre%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DR.%2BJ.%2BH.%26aulast%3DRisitano%26aufirst%3DA.%2BM.%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DValeur%26aufirst%3DE.%26aulast%3DSirockin%26aufirst%3DF.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DT.%2BM.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DHaraldsson%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26aulast%3DSedrani%26aufirst%3DR.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMaibaum%26aufirst%3DJ.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DR.%26aulast%3DEder%26aufirst%3DJ.%26atitle%3DSmall-Molecule%2520Factor%2520B%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Complement-mediated%2520Diseases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D16%26spage%3D7926%26epage%3D7931%26doi%3D10.1073%2Fpnas.1820892116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zierz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quentin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotze, O.</span></span> <span> </span><span class="NLM_article-title">Elevated Plasma Levels of the Immunosuppressive Complement Fragment Ba in Renal Failure</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1038/ki.1991.298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fki.1991.298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1837062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADyaK387gs1KmtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1991&pages=939-947&author=M.+Oppermannauthor=C.+Kurtsauthor=R.+Zierzauthor=E.+Quentinauthor=M.+H.+Weberauthor=O.+Gotze&title=Elevated+Plasma+Levels+of+the+Immunosuppressive+Complement+Fragment+Ba+in+Renal+Failure&doi=10.1038%2Fki.1991.298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure</span></div><div class="casAuthors">Oppermann M; Kurts C; Zierz R; Quentin E; Weber M H; Gotze O</div><div class="citationInfo"><span class="NLM_cas:title">Kidney international</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">939-47</span>
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    </div><div class="casAbstract">The complement fragment Ba is a 33 kD activation product of factor B which suppresses human B-lymphocyte functions in vitro.  We report that plasma levels of Ba are highly elevated in patients with chronic renal failure (4.84 +/- 3.58 micrograms/ml) and in patients with end-stage renal disease undergoing regular hemodialysis (16.1 +/- 6.1 micrograms/ml) as compared to normals (1.01 +/- 0.30 micrograms/ml).  Ba levels were strictly correlated with the creatinine clearance.  The urinary excretion of Ba was 165-fold higher in patients with tubular proteinuria than in normals.  These results indicate that the kidney is the major catabolic site for Ba.  In addition, direct evidence was obtained for an enhanced turnover of the alternative pathway of complement in renal failure that, although it appears to be less important than the renal retention of Ba, contributes to elevated Ba plasma levels in these patients.  Ba concentrations in dialysis patients who responded to hepatitis B vaccination were significantly lower than in non-responders.  Furthermore, the in vitro IgM synthesis by purified mononuclear cells was negatively correlated with Ba concentrations determined in the plasma of these patients.  These results suggest that the accumulation of Ba contributes to the defective immune response in patients with renal failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3R8rZQlQ5zoNpW7w2tapOfW6udTcc2ea8QQHYHscexLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387gs1KmtA%253D%253D&md5=f2abfc871ce60d59fc48658e8dc505ee</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fki.1991.298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.1991.298%26sid%3Dliteratum%253Aachs%26aulast%3DOppermann%26aufirst%3DM.%26aulast%3DKurts%26aufirst%3DC.%26aulast%3DZierz%26aufirst%3DR.%26aulast%3DQuentin%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DM.%2BH.%26aulast%3DGotze%26aufirst%3DO.%26atitle%3DElevated%2520Plasma%2520Levels%2520of%2520the%2520Immunosuppressive%2520Complement%2520Fragment%2520Ba%2520in%2520Renal%2520Failure%26jtitle%3DKidney%2520Int.%26date%3D1991%26volume%3D40%26spage%3D939%26epage%3D947%26doi%3D10.1038%2Fki.1991.298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giclas, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seddon, J. M.</span></span> <span> </span><span class="NLM_article-title">Plasma Complement Components and Activation Fragments: Associations with Age-related Macular Degeneration Genotypes and Phenotypes</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5818</span>– <span class="NLM_lpage">5827</span>, <span class="refDoi"> DOI: 10.1167/iovs.09-3928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1167%2Fiovs.09-3928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=19661236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjps1CltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=5818-5827&author=R.+Reynoldsauthor=M.+E.+Hartnettauthor=J.+P.+Atkinsonauthor=P.+C.+Giclasauthor=B.+Rosnerauthor=J.+M.+Seddon&title=Plasma+Complement+Components+and+Activation+Fragments%3A+Associations+with+Age-related+Macular+Degeneration+Genotypes+and+Phenotypes&doi=10.1167%2Fiovs.09-3928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes</span></div><div class="casAuthors">Reynolds Robyn; Hartnett M Elizabeth; Atkinson John P; Giclas Patricia C; Rosner Bernard; Seddon Johanna M</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5818-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Several genes encoding complement system components and fragments are associated with age-related macular degeneration (AMD).  This study was conducted to determine whether alterations in circulating levels of these markers of complement activation and regulation are also independently associated with advanced AMD and whether they are related to AMD genotypes.  METHODS:  Plasma and DNA samples were selected from individuals in our AMD registry who had progressed to or developed the advanced stages of AMD, including 58 with geographic atrophy and 62 with neovascular disease.  Subjects of similar age and sex, but without AMD, and who did not progress were included as controls (n = 60).  Plasma complement components (C3, CFB, CFI, CFH, and factor D) and activation fragments (Bb, C3a, C5a, iC3b, and SC5b-9) were analyzed.  DNA samples were genotyped for seven single-nucleotide polymorphisms in six genes previously shown to be associated with AMD: CFB, CFH, C2, C3, and CFI and the LOC387715/ARMS2 gene region.  The association between AMD and each complement biomarker was assessed by using logistic regression, controlling for age, sex, and proinflammatory risk factors: smoking and body mass index (BMI).  Functional genomic analyses were performed to assess the relationship between the complement markers and genotypes.  Concordance, or C, statistics were calculated to assess the effect of complement components and activation fragments in an AMD gene-environment prediction model.  RESULTS:  The highest quartiles of Bb and C5a were significantly associated with advanced AMD, when compared with the lowest quartiles.  In multivariate models without genetic variants, the odds ratio (OR) for Bb was 3.3 (95% confidence interval [CI] = 1.3-8.6), and the OR for C5a was 3.6 (95% CI = 1.2-10.3).  With adjustment for genetic variants, these ORs were substantially higher.  The alternative pathway regulator CFH was inversely associated with AMD in the model without genotypes (OR = 0.3; P = 0.01).  Positive associations were found between BMI and plasma C3, CFB, CFH, iC3b, and C3a.  There were also significant associations between C5a fragment and LOC387715/ARMS2 and C3 genotypes (P for trend = 0.02, 0.04), respectively.  C statistics for models with behavioral and genetic factors increased to 0.94 +/- 0.20 with the addition of C3a, Bb, and C5a.  CONCLUSIONS:  Increased levels of activation fragments Bb and C5a are independently associated with AMD.  Higher BMI is related to increased levels of complement components.  C5a is associated with AMD genotypes.  C statistics are stronger with the addition of C3a, Bb, and C5a in predictive models.  Results implicate ongoing activation of the alternative complement pathway in AMD pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMveYtwRwaGedfST00W0BcfW6udTcc2ea8QQHYHscexLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjps1CltA%253D%253D&md5=f386cb927774c383e91fedae1e80920b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1167%2Fiovs.09-3928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.09-3928%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DR.%26aulast%3DHartnett%26aufirst%3DM.%2BE.%26aulast%3DAtkinson%26aufirst%3DJ.%2BP.%26aulast%3DGiclas%26aufirst%3DP.%2BC.%26aulast%3DRosner%26aufirst%3DB.%26aulast%3DSeddon%26aufirst%3DJ.%2BM.%26atitle%3DPlasma%2520Complement%2520Components%2520and%2520Activation%2520Fragments%253A%2520Associations%2520with%2520Age-related%2520Macular%2520Degeneration%2520Genotypes%2520and%2520Phenotypes%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2009%26volume%3D50%26spage%3D5818%26epage%3D5827%26doi%3D10.1167%2Fiovs.09-3928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velletri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, L.</span></span> <span> </span><span class="NLM_article-title">Plasma Levels of Complement Proteins from the Alternative Pathway in Patients with Age-Related Macular Degeneration are Independent of Complement Factor H Tyr402His polymorphism</span>. <i>Mol. Vis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=22969267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlartrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2288-2299&author=A.+S.+Silvaauthor=A.+G.+Teixeiraauthor=L.+Baviaauthor=F.+Linauthor=R.+Velletriauthor=R.+Belfortauthor=L.+Isaac&title=Plasma+Levels+of+Complement+Proteins+from+the+Alternative+Pathway+in+Patients+with+Age-Related+Macular+Degeneration+are+Independent+of+Complement+Factor+H+Tyr402His+polymorphism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr402His polymorphism</span></div><div class="casAuthors">Silva, Aldacilene Souza; Teixeira, Anderson Gustavo; Bavia, Lorena; Lin, Fabio; Velletri, Roberta; Belfort, Rubens, Jr.; Isaac, Lourdes</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Vision</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2288-2299</span>CODEN:
                <span class="NLM_cas:coden">MVEPFB</span>;
        ISSN:<span class="NLM_cas:issn">1090-0535</span>.
    
            (<span class="NLM_cas:orgname">Molecular Vision</span>)
        </div><div class="casAbstract">Purpose: To investigate the influence of the Factor H (CFH) Tyr402His polymorphism on the plasma levels of the alternative pathway proteins CFH, C3, Factor B (FB), Factor D (FD), and Factor I (FI) and the inflammatory marker C-reactive protein (CRP) in 119 patients with age-related macular degeneration (AMD) and 152 unrelated control individuals.  Methods: Patients with AMD and the control group were sepd. according to CFH polymorphism, age, and gender.  Plasma complement proteins and CRP concns. were detd. with ELISA, immunodiffusion, or nephelometry.  Results: Significant differences in the concns. of FD and FI were obsd. between the patients with AMD and the control individuals.  We obsd. significantly reduced FD plasma levels in patients with AMD.  We also identified a significant decrease in CFH plasma levels in female patients with AMD in relation to female controls.  Plasma FI levels were significantly increased in patients with AMD compared to the control group.  Regarding gender, a significant increase in FI plasma levels was obsd. in male patients.  Finally, we found no significant correlation between the CFH Tyr402His polymorphism and the CFH, C3, FB, FD, FI, and CRP plasma levels.  Conclusions: Patients with AMD present altered levels of FD and FI in a manner independent of this CFH polymorphism, and gender apparently contributes to the plasma levels of these two proteins in patients with AMD and control individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCfAvPNNrJrVg90H21EOLACvtfcHk0liaFuTXo5lckg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlartrzN&md5=5bca02809c9db59208a61b325cf5d18a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DA.%2BS.%26aulast%3DTeixeira%26aufirst%3DA.%2BG.%26aulast%3DBavia%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DVelletri%26aufirst%3DR.%26aulast%3DBelfort%26aufirst%3DR.%26aulast%3DIsaac%26aufirst%3DL.%26atitle%3DPlasma%2520Levels%2520of%2520Complement%2520Proteins%2520from%2520the%2520Alternative%2520Pathway%2520in%2520Patients%2520with%2520Age-Related%2520Macular%2520Degeneration%2520are%2520Independent%2520of%2520Complement%2520Factor%2520H%2520Tyr402His%2520polymorphism%26jtitle%3DMol.%2520Vis.%26date%3D2012%26volume%3D18%26spage%3D2288%26epage%3D2299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lachmann, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes-Jones, N. C.</span></span> <span> </span><span class="NLM_article-title">Initiation of Complement Activation</span>. <i>Springer Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1007/BF01893018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2FBF01893018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=6495149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVyksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1984&pages=143-162&author=P.+J.+Lachmannauthor=N.+C.+Hughes-Jones&title=Initiation+of+Complement+Activation&doi=10.1007%2FBF01893018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Initiation of complement activation</span></div><div class="casAuthors">Lachmann, P. J.; Hughes-Jones, N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Springer Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">143-62</span>CODEN:
                <span class="NLM_cas:coden">SSIMDV</span>;
        ISSN:<span class="NLM_cas:issn">0344-4325</span>.
    </div><div class="casAbstract">A review with 53 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCpn9kpWdEqrVg90H21EOLACvtfcHk0ljl62IxVfKbvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVyksLk%253D&md5=fa88ba3516acbfc8f6509eb402bfe27e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2FBF01893018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01893018%26sid%3Dliteratum%253Aachs%26aulast%3DLachmann%26aufirst%3DP.%2BJ.%26aulast%3DHughes-Jones%26aufirst%3DN.%2BC.%26atitle%3DInitiation%2520of%2520Complement%2520Activation%26jtitle%3DSpringer%2520Semin.%2520Immunopathol.%26date%3D1984%26volume%3D7%26spage%3D143%26epage%3D162%26doi%3D10.1007%2FBF01893018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thurman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holers, V. M.</span></span> <span> </span><span class="NLM_article-title">The Central Role of the Alternative Complement Pathway in Human Disease</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1310</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.176.3.1305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.4049%2Fjimmunol.176.3.1305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=16424154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFyjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2006&pages=1305-1310&author=J.+M.+Thurmanauthor=V.+M.+Holers&title=The+Central+Role+of+the+Alternative+Complement+Pathway+in+Human+Disease&doi=10.4049%2Fjimmunol.176.3.1305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The Central Role of the Alternative Complement Pathway in Human Disease</span></div><div class="casAuthors">Thurman, Joshua M.; Holers, V. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1305-1310</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  The complement system is increasingly recognized as important in the pathogenesis of tissue injury in vivo following immune, ischemic, or infectious insults.  Within the complement system, three pathways are capable of initiating the processes that result in C3 activation: classical, alternative, and lectin.  Although the roles that proinflammatory peptides and complexes generated during complement activation play in mediating disease processes have been studied extensively, the relative contributions of the three activating pathways is less well understood.  Herein we examine recent evidence that the alternative complement pathway plays a key and, in most instances, obligate role in generating proinflammatory complement activation products in vivo.  In addn., we discuss new concepts regarding the mechanisms by which the alternative pathway is activated in vivo, as recent clin. findings and exptl. results have provided evidence that continuous active control of this pathway is necessary to prevent unintended targeting and injury to self tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_FVfCz2QYDrVg90H21EOLACvtfcHk0ljl62IxVfKbvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFyjug%253D%253D&md5=f6db4b8f56a8a99d3a74acc8de1298b0</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.176.3.1305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.176.3.1305%26sid%3Dliteratum%253Aachs%26aulast%3DThurman%26aufirst%3DJ.%2BM.%26aulast%3DHolers%26aufirst%3DV.%2BM.%26atitle%3DThe%2520Central%2520Role%2520of%2520the%2520Alternative%2520Complement%2520Pathway%2520in%2520Human%2520Disease%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D176%26spage%3D1305%26epage%3D1310%26doi%3D10.4049%2Fjimmunol.176.3.1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, R. A.</span></span> <span> </span><span class="NLM_article-title">The Properdin Pathway: an “Alternative Activation Pathway” or a “Critical Amplification Loop” for C3 and C5 Activation?</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1007/s00281-017-0661-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2Fs00281-017-0661-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=29167939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVCmur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=15-35&author=R.+A.+Harrison&title=The+Properdin+Pathway%3A+an+%E2%80%9CAlternative+Activation+Pathway%E2%80%9D+or+a+%E2%80%9CCritical+Amplification+Loop%E2%80%9D+for+C3+and+C5+Activation%3F&doi=10.1007%2Fs00281-017-0661-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?</span></div><div class="casAuthors">Harrison, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-35</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This review is not intended to cover in detail all aspects of the discovery and evolution of our understanding of the "alternative pathway" of complement activation, there are many excellent reviews that do this (see Fearon (CRC Crit Rev Immunol 1:1-32, 1979), Pangburn and Muller-Eberhard (Springer Semin Immunopathol 7:163-192, 1984)), but instead to give sufficient background for current concepts to be put in context.  The prevailing textbook view, of components having a primary role as an alternative "pathway" for C3 activation, is challenged, with an argument developed for the primary role of the system being that of providing a surface-dependent amplification loop for both C3 and C5 activation.  Whatever the mechanism by which the initial C3b mol. is generated, deposition onto a surface has the potential to target that surface for elimination.  Elimination or escape from initial targeting is detd. by a sophisticated and highly regulated amplification loop for C3 activation.  This viewpoint of the system is then briefly developed to provide a context for therapeutic treatment of disease caused, at least in part, by dysregulated amplification of C3 activation, and to highlight some of the challenges that such therapies will face and need to address.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRbfzcgUToeLVg90H21EOLACvtfcHk0ljl62IxVfKbvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVCmur3O&md5=c62b1bb81eb95632cdaafa338d754d2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00281-017-0661-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-017-0661-x%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Properdin%2520Pathway%253A%2520an%2520%25E2%2580%259CAlternative%2520Activation%2520Pathway%25E2%2580%259D%2520or%2520a%2520%25E2%2580%259CCritical%2520Amplification%2520Loop%25E2%2580%259D%2520for%2520C3%2520and%2520C5%2520Activation%253F%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2018%26volume%3D40%26spage%3D15%26epage%3D35%26doi%3D10.1007%2Fs00281-017-0661-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckersie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span> <span> </span><span class="NLM_article-title">Up-regulation of Complement Factor B in Retinal Pigment Epithelial Cells is Accompanied by Complement Activation in the Aged Retina</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2008.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.exer.2008.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=18926817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVaisrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2008&pages=543-550&author=M.+Chenauthor=E.+Muckersieauthor=M.+Robertsonauthor=J.+V.+Forresterauthor=H.+Xu&title=Up-regulation+of+Complement+Factor+B+in+Retinal+Pigment+Epithelial+Cells+is+Accompanied+by+Complement+Activation+in+the+Aged+Retina&doi=10.1016%2Fj.exer.2008.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Up-regulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina</span></div><div class="casAuthors">Chen, Mei; Muckersie, Elizabeth; Robertson, Marie; Forrester, John V.; Xu, Heping</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">543-550</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Complement activation is involved in the pathogenesis of age-related macular degeneration.  How complement is activated in the retina is not known.  Previously the authors have shown that complement factor H (CFH) is constitutively expressed by retinal pigment epithelial (RPE) cells and the prodn. of CFH is neg. regulated by inflammatory cytokines and oxidative insults.  Here the authors investigated the prodn. and regulation of complement factor B (CFB) in RPE cells.  Immunohistochem. showed that CFB is expressed at low levels on the apical portion of the RPE cells in normal physiol. conditions.  With age, CFB expression increases and extends to the basal part of RPE cells.  Confocal microscopy and real-time PCR of RPE cultures indicated that the prodn. of CFB by RPE cells is pos. regulated by TNF-α, IFN-γ and long-term (30 days) photoreceptor outer segments treatments.  Increased CFB expression in RPE cells in vivo is accompanied by the accumulation of complement C3 and C3a deposition at the Bruch's membrane and the basal layer of RPE cells.  These results suggest that RPE cells play important roles in regulating complement activation in the retina.  Increased complement activation in the aged retina may be important for retinal homeostasis in the context of accumulating photoreceptor waste products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSFjEFYAvZbVg90H21EOLACvtfcHk0lg92CNFZOB1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVaisrfP&md5=0882e587f9fd95ea23cb7e44662f1f91</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2008.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2008.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DMuckersie%26aufirst%3DE.%26aulast%3DRobertson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%2BV.%26aulast%3DXu%26aufirst%3DH.%26atitle%3DUp-regulation%2520of%2520Complement%2520Factor%2520B%2520in%2520Retinal%2520Pigment%2520Epithelial%2520Cells%2520is%2520Accompanied%2520by%2520Complement%2520Activation%2520in%2520the%2520Aged%2520Retina%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2008%26volume%3D87%26spage%3D543%26epage%3D550%26doi%3D10.1016%2Fj.exer.2008.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettrick, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaleb, M. L.</span></span> <span> </span><span class="NLM_article-title">Reduction in Ocular Complement Factor B Protein in Mice and Monkeys by Systemic Administration of Factor B Antisense Oligonucleotide</span>. <i>Mol. Vision</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=28855795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCmsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=561-571&author=T.+R.+Grossmanauthor=M.+Carrerauthor=L.+Shenauthor=R.+B.+Johnsonauthor=L.+A.+Hettrickauthor=S.+P.+Henryauthor=B.+P.+Moniaauthor=M.+L.+McCaleb&title=Reduction+in+Ocular+Complement+Factor+B+Protein+in+Mice+and+Monkeys+by+Systemic+Administration+of+Factor+B+Antisense+Oligonucleotide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction in ocular complement factor b protein in mice and monkeys by systemic administration of factor b antisense oligonucleotide</span></div><div class="casAuthors">Grossman, Tamar R.; Carrer, Michele; Shen, Lijiang; Johnson, Robert B.; Hettrick, Lisa A.; Henry, Scott P.; Monia, Brett P.; McCaleb, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Vision</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">561-571</span>CODEN:
                <span class="NLM_cas:coden">MVEPFB</span>;
        ISSN:<span class="NLM_cas:issn">1090-0535</span>.
    
            (<span class="NLM_cas:orgname">Molecular Vision</span>)
        </div><div class="casAbstract">Purpose: Age-related macular degeneration (AMD) is the leading cause of permanent vision loss among the elderly in many industrialized countries, and the complement system plays an important role in the pathogenesis of AMD.  Inhibition of complement factor B, a key regulator of the alternative pathway, is implicated as a potential therapeutic intervention for AMD.  Here we investigated the effect of liver factor B redn. on systemic and ocular factor B levels.  Methods: Second-generation antisense oligonucleotides (ASOs) targeting mouse and monkey factor B mRNA were administered by s.c. injection to healthy mice or monkeys, and the level of factor B mRNA was assessed in the liver and the eye.  In addn., the factor B protein level was detd. in plasma and whole eyes from the treated animals.  Results: Mice and monkeys treated with factor B ASOs demonstrated a robust redn. in liver factor B mRNA levels with no change in ocular factor B mRNA levels.  Plasma factor B protein levels were significantly reduced in mice and monkeys treated with factor B ASOs, leading to a dramatic redn. in ocular factor B protein, below the assay detection levels.  Conclusions: The results add to the increasing evidence that the liver is the main source of plasma and ocular factor B protein, and demonstrate that redn. of liver factor B mRNA by an ASO results in a significant redn. in plasma and ocular factor B protein levels.  The results suggest that inhibition of liver factor B mRNA by factor B ASOs would reduce systemic alternative complement pathway activation and has potential to be used as a novel therapy for AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtUd0izeq9krVg90H21EOLACvtfcHk0lg92CNFZOB1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCmsrrN&md5=dbda9623e1c2eb90a4187e1594e04361</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrossman%26aufirst%3DT.%2BR.%26aulast%3DCarrer%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DR.%2BB.%26aulast%3DHettrick%26aufirst%3DL.%2BA.%26aulast%3DHenry%26aufirst%3DS.%2BP.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DMcCaleb%26aufirst%3DM.%2BL.%26atitle%3DReduction%2520in%2520Ocular%2520Complement%2520Factor%2520B%2520Protein%2520in%2520Mice%2520and%2520Monkeys%2520by%2520Systemic%2520Administration%2520of%2520Factor%2520B%2520Antisense%2520Oligonucleotide%26jtitle%3DMol.%2520Vision%26date%3D2017%26volume%3D23%26spage%3D561%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runkle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonetti, D. A.</span></span> <span> </span><span class="NLM_article-title">The Blood-Retinal Barrier: Structure and Functional Significance</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>686</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1007/978-1-60761-938-3_5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1007%2F978-1-60761-938-3_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=21082369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1WrsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=686&publication_year=2011&pages=133-148&author=E.+A.+Runkleauthor=D.+A.+Antonetti&title=The+Blood-Retinal+Barrier%3A+Structure+and+Functional+Significance&doi=10.1007%2F978-1-60761-938-3_5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The blood-retinal barrier: structure and functional significance</span></div><div class="casAuthors">Runkle, E. Aaron; Antonetti, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">686</span>
        (<span class="NLM_cas:issue">Blood-Brain and Other Neural Barriers</span>),
    <span class="NLM_cas:pages">133-148</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Formation and maintenance of the blood-retinal barrier is required for proper vision and loss of this barrier contributes to the pathol. of a wide no. of retinal diseases.  The retina is responsible for converting visible light into the electrochem. signal interpreted by the brain as vision.  Multiple cell types are required for this function, which are organized into eight distinct cell layers.  These neural and glial cells gain metabolic support from a unique vascular structure that provides the necessary nutrients while minimizing interference with light sensing.  In addn. to the vascular contribution, the retina also possesses an epithelial barrier, the retinal pigment epithelium, which is located at the posterior of the eye and controls exchange of nutrients with the choroidal vessels.  Together the vascular and epithelial components of the blood-retinal barrier maintain the specialized environment of the neural retina.  Both the vascular endothelium and pigment epithelium possess a well-developed junctional complex that includes both adherens and tight junctions conferring a high degree of control of solute and fluid permeability.  Understanding induction and regulation of the blood-retinal barrier will allow the development of therapies aimed at restoring the barrier when compromised in disease or allowing the specific transport of therapies across this barrier when needed.  This chapter will highlight the anatomical structure of the blood-retinal barrier and explore the mol. structure of the tight junctions that provide the unique barrier properties of the blood-retinal barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo39fRjxLfzCLVg90H21EOLACvtfcHk0lg92CNFZOB1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1WrsL3J&md5=3c4115b7a7f51aaaf2ba3b9ab71c49d2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2F978-1-60761-938-3_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60761-938-3_5%26sid%3Dliteratum%253Aachs%26aulast%3DRunkle%26aufirst%3DE.%2BA.%26aulast%3DAntonetti%26aufirst%3DD.%2BA.%26atitle%3DThe%2520Blood-Retinal%2520Barrier%253A%2520Structure%2520and%2520Functional%2520Significance%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D686%26spage%3D133%26epage%3D148%26doi%3D10.1007%2F978-1-60761-938-3_5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inagi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, I.</span></span> <span> </span><span class="NLM_article-title">FUT-175 as a Potent Inhibitor of C5/C3 Convertase Activity for Production of C5a and C3a</span>. <i>Immunol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/0165-2478(91)90243-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2F0165-2478%2891%2990243-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=2019419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK3MXhsVWiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1991&pages=49-52&author=R.+Inagiauthor=T.+Miyataauthor=K.+Maedaauthor=S.+Sugiyamaauthor=A.+Miyamaauthor=I.+Nakashima&title=FUT-175+as+a+Potent+Inhibitor+of+C5%2FC3+Convertase+Activity+for+Production+of+C5a+and+C3a&doi=10.1016%2F0165-2478%2891%2990243-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a</span></div><div class="casAuthors">Inagi, Reiko; Miyata, Toshio; Maeda, Kenji; Sugiyama, Satoshi; Miyama, Akio; Nakashima, Izumi</div><div class="citationInfo"><span class="NLM_cas:title">Immunology Letters</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-52</span>CODEN:
                <span class="NLM_cas:coden">IMLED6</span>;
        ISSN:<span class="NLM_cas:issn">0165-2478</span>.
    </div><div class="casAbstract">The inhibitory effect was examd. of FUT-175 on the C3/C5 convertase activity of the cobra venom factor-derived enzyme CVF,Bb by measuring C5b6-mediated reactive lysis of unsensitized guinea pig erythrocytes and by measuring directly the released fragments C3a-des-Arg and C5a-des-Arg.  In this study, it was shown that the concn. of 4.5 × 10-6M of FUT-175 caused 50% inhibition of C5 convertase activity of CVF,Bb in reactive hemolysis assays, and that 4.0 × 10-6M FUT-175 caused 50% inhibition of the prodn. of C3a and C5a generated by the C3/C5 convertase activity of CVF,Bb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIlQO982d-U7Vg90H21EOLACvtfcHk0lg92CNFZOB1ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsVWiu7k%253D&md5=a971ee4b4c73b3a865d160ba16aea04e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2F0165-2478%2891%2990243-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-2478%252891%252990243-4%26sid%3Dliteratum%253Aachs%26aulast%3DInagi%26aufirst%3DR.%26aulast%3DMiyata%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DS.%26aulast%3DMiyama%26aufirst%3DA.%26aulast%3DNakashima%26aufirst%3DI.%26atitle%3DFUT-175%2520as%2520a%2520Potent%2520Inhibitor%2520of%2520C5%252FC3%2520Convertase%2520Activity%2520for%2520Production%2520of%2520C5a%2520and%2520C3a%26jtitle%3DImmunol.%2520Lett.%26date%3D1991%26volume%3D27%26spage%3D49%26epage%3D52%26doi%3D10.1016%2F0165-2478%2891%2990243-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate (FUT-187). I:  Inhibitory Activities on various kinds of Enzymes In vitro and Anticomplement Activity In vivo</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1254/jjp.52.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1254%2Fjjp.52.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1689782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK3cXptFOnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1990&pages=23-34&author=M.+Odaauthor=Y.+Inoauthor=K.+Nakamuraauthor=S.+Kuramotoauthor=K.+Shimamuraauthor=M.+Iwakiauthor=S.+Fujii&title=Pharmacological+Studies+on+6-amidino-2-naphthyl%5B4-%284%2C5-dihydro-1H-imidazol-2-yl%29amino%5D+benzoate+dimethane+sulfonate+%28FUT-187%29.+I%3A%E2%80%89+Inhibitory+Activities+on+various+kinds+of+Enzymes+In+vitro+and+Anticomplement+Activity+In+vivo&doi=10.1254%2Fjjp.52.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino]benzoate dimethanesulfonate (FUT-187). I: Inhibitory activities on various kinds of enzymes in vitro and anticomplement activity in vivo</span></div><div class="casAuthors">Oda, Minoru; Ino, Yoshitaka; Nakamura, Kazunori; Kuramoto, Shigeru; Shimamura, Kazunori; Iwaki, Masahiro; Fujii, Setsuro</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    </div><div class="casAbstract">The protease inhibiting activity of FUT-187 (I) was compared with those of FUT-175 and FOY-305, the known serine protease inhibitors.  I, FUT-175, and FOY-305 had selective inhibitory activities on serine proteases including Cl‾r, Cl‾s, kallikrein, trypsin, plasmin, and thrombin.  The activity of I on these enzymes except Cl‾r and pancreatic kallikrein were relatively lower than those of FUT-175 and FOY-305.  In spite of its lower activities against Cl‾r and Cl‾s, inhibition by I of the complement-mediated hemolysis in vitro and in vivo was only a little weaker than or equiv. to that of FUT-175.  FOY-305 was ineffective in these tests.  Forssman shock in guinea pigs is initiated by the activation of the complement system.  The protective effect of i.v. or oral I against this shock was definitely superior to that of FUT-175.  I inhibited the changes assocd. with Forssman shock, such as increased lung wt., decreased platelet counts, and histopathol. changes.  I should be a more potent oral therapeutic agent than FUT-175 for various inflammatory diseases attributed to excessive activation of the complement system followed by platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh4va9tzczerVg90H21EOLACvtfcHk0lig0r9eIpV1Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFOnuw%253D%253D&md5=53e57a6c717c3e171c8e8b47404f3013</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1254%2Fjjp.52.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.52.23%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DM.%26aulast%3DIno%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DKuramoto%26aufirst%3DS.%26aulast%3DShimamura%26aufirst%3DK.%26aulast%3DIwaki%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DS.%26atitle%3DPharmacological%2520Studies%2520on%25206-amidino-2-naphthyl%255B4-%25284%252C5-dihydro-1H-imidazol-2-yl%2529amino%255D%2520benzoate%2520dimethane%2520sulfonate%2520%2528FUT-187%2529.%2520I%253A%25E2%2580%2589%2520Inhibitory%2520Activities%2520on%2520various%2520kinds%2520of%2520Enzymes%2520In%2520vitro%2520and%2520Anticomplement%2520Activity%2520In%2520vivo%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D1990%26volume%3D52%26spage%3D23%26epage%3D34%26doi%3D10.1254%2Fjjp.52.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Gomez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madala, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbenante, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for Substrate-Based Inhibitors of Human Complement Factor B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6042</span>– <span class="NLM_lpage">6052</span>, <span class="refDoi"> DOI: 10.1021/jm900781m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900781m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWqu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6042-6052&author=G.+Ruiz-Gomezauthor=J.+Limauthor=M.+A.+Haliliauthor=G.+T.+Leauthor=P.+K.+Madalaauthor=G.+Abbenanteauthor=D.+P.+Fairlie&title=Structure-Activity+Relationships+for+Substrate-Based+Inhibitors+of+Human+Complement+Factor+B&doi=10.1021%2Fjm900781m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships for Substrate-Based Inhibitors of Human Complement Factor B</span></div><div class="casAuthors">Ruiz-Gomez, Gloria; Lim, Junxian; Halili, Maria A.; Le, Giang T.; Madala, Praveen K.; Abbenante, Giovanni; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6042-6052</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human complement is a cascading network of plasma proteins important in immune defense, cooperatively effecting recognition, opsonization, destruction, and removal of pathogens and infected/damaged cells.  Overstimulated or unregulated complement activation can result in immunoinflammatory diseases.  Key serine proteases in this cascade are difficult to study due to their multiprotein compn., short lifetimes, formation on membranes, or serum circulation as inactive zymogens.  Factor B is inactive at pH 7, but a catalytically active serine protease under alk. conditions, enabling structure-activity relationship studies for 63 substrate-based peptide inhibitors with 4-7 residues and a C-terminal aldehyde.  A potent factor B inhibitor was hexpeptide Ac-RLTbaLAR-H (IC50 250 nM, pH 9.5), which at pH 7 also blocked formation of membrane attack complex via the "alternative pathway" of complement activation and inhibited human complement mediated lysis of rabbit erythrocytes.  Inhibitors of factor B may be valuable probes and drug leads for complement mediated immunity and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Wqeq9DHagbVg90H21EOLACvtfcHk0lig0r9eIpV1Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWqu7nI&md5=ff3bf3206326826d1756a88cacc4e314</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm900781m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900781m%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Gomez%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DLe%26aufirst%3DG.%2BT.%26aulast%3DMadala%26aufirst%3DP.%2BK.%26aulast%3DAbbenante%26aufirst%3DG.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520Substrate-Based%2520Inhibitors%2520of%2520Human%2520Complement%2520Factor%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6042%26epage%3D6052%26doi%3D10.1021%2Fjm900781m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sedrani, R.</span></span> <span> </span><span class="NLM_article-title">Protease-Directed Drug Discovery</span>. Presented at the 15th Annual Drug Discovery Summit, Geneva, Switzerland, June 2–3, <span class="NLM_year">2014</span>; <a href="http://www.drugdiscovery-summit1.com/" class="extLink">http://www.drugdiscovery-summit1.com/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+Sedrani&title=Protease-Directed+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSedrani%26aufirst%3DR.%26atitle%3DProtease-Directed%2520Drug%2520Discovery%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rüdisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hommel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibaum, J.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1958</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1946-1958&author=V.+Vulpettiauthor=R.+Randlauthor=S.+R%C3%BCdisserauthor=N.+Ostermannauthor=P.+Erbelauthor=A.+Mac+Sweeneyauthor=T.+Zollerauthor=B.+Salemauthor=B.+Gerhartzauthor=F.+Cuminauthor=U.+Hommelauthor=C.+Dalvitauthor=E.+Lorthioisauthor=J.+Maibaum&title=Structure-Based+Library+Design+and+Fragment+Screening+for+the+Identification+of+Reversible+Complement+Factor+D+Protease+Inhibitors&doi=10.1021%2Facs.jmedchem.6b01684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors</span></div><div class="casAuthors">Vulpetti, Anna; Randl, Stefan; Rudisser, Simon; Ostermann, Nils; Erbel, Paul; Mac Sweeney, Aengus; Zoller, Thomas; Salem, Bahaa; Gerhartz, Bernd; Cumin, Frederic; Hommel, Ulrich; Dalvit, Claudio; Lorthiois, Edwige; Maibaum, Jurgen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic dysregulation of alternative complement pathway activation has been assocd. with diverse clin. disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea.  Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymic reaction of the amplification loop of the alternative pathway.  In this paper, the authors describe two hit finding approaches leading to the discovery of new chem. matter for this pivotal protease of the complement system: in silico active site mapping for hot spots identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries.  The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different sub-pockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPFgFvVDvCyrVg90H21EOLACvtfcHk0ljBiSFRsHZ_7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFWhsL8%253D&md5=179ea6dc5fb9ccb60931da60f23e6381</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01684%26sid%3Dliteratum%253Aachs%26aulast%3DVulpetti%26aufirst%3DV.%26aulast%3DRandl%26aufirst%3DR.%26aulast%3DR%25C3%25BCdisser%26aufirst%3DS.%26aulast%3DOstermann%26aufirst%3DN.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DZoller%26aufirst%3DT.%26aulast%3DSalem%26aufirst%3DB.%26aulast%3DGerhartz%26aufirst%3DB.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DHommel%26aufirst%3DU.%26aulast%3DDalvit%26aufirst%3DC.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DMaibaum%26aufirst%3DJ.%26atitle%3DStructure-Based%2520Library%2520Design%2520and%2520Fragment%2520Screening%2520for%2520the%2520Identification%2520of%2520Reversible%2520Complement%2520Factor%2520D%2520Protease%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1946%26epage%3D1958%26doi%3D10.1021%2Facs.jmedchem.6b01684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jendza, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Sweeney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argikar, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flohr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorthiois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prentiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradoux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Erkenez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogi, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4656</span>– <span class="NLM_lpage">4668</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4656-4668&author=R.+G.+Karkiauthor=J.+Powersauthor=N.+Mainolfiauthor=K.+Andersonauthor=D.+B.+Belangerauthor=D.+Liuauthor=N.+Jiauthor=K.+Jendzaauthor=C.+F.+Gelinauthor=A.+Mac+Sweeneyauthor=C.+Solovayauthor=O.+Delgadoauthor=M.+Crowleyauthor=S.-M.+Liaoauthor=U.+A.+Argikarauthor=S.+Flohrauthor=L.+R.+La+Bonteauthor=E.+Lorthioisauthor=A.+Vulpettiauthor=A.+Brownauthor=D.+Longauthor=M.+Prentissauthor=N.+Gradouxauthor=A.+de+Erkenezauthor=F.+Cuminauthor=C.+Adamsauthor=B.+Jaffeeauthor=M.+Mogi&title=Design%2C+Synthesis%2C+and+Preclinical+Characterization+of+Selective+Factor+D+Inhibitors+Targeting+the+Alternative+Complement+Pathway&doi=10.1021%2Facs.jmedchem.9b00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway</span></div><div class="casAuthors">Karki, Rajeshri G.; Powers, James; Mainolfi, Nello; Anderson, Karen; Belanger, David B.; Liu, Donglei; Ji, Nan; Jendza, Keith; Gelin, Christine F.; Mac Sweeney, Aengus; Solovay, Catherine; Delgado, Omar; Crowley, Maura; Liao, Sha-Mei; Argikar, Upendra A.; Flohr, Stefanie; La Bonte, Laura R.; Lorthiois, Edwige L.; Vulpetti, Anna; Brown, Ann; Long, Debby; Prentiss, Melissa; Gradoux, Nathalie; de Erkenez, Andrea; Cumin, Frederic; Adams, Christopher; Jaffee, Bruce; Mogi, Muneto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4656-4668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system.  Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria.  Previously, the authors have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (I and II) binding to the open active conformation of FD.  In continuation of the authors' drug discovery program, the authors designed compds. applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases.  The authors report herein the design, synthesis, and medicinal chem. optimization of the benzylamine series culminating in the discovery of (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid, an orally bioavailable and selective FD inhibitor.  (S)-2-(2-((3'-(1-Amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov5uolWfBzK7Vg90H21EOLACvtfcHk0ljBiSFRsHZ_7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslalsbw%253D&md5=a4a56886a758093516952737306a5d8a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00271%26sid%3Dliteratum%253Aachs%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DBelanger%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJi%26aufirst%3DN.%26aulast%3DJendza%26aufirst%3DK.%26aulast%3DGelin%26aufirst%3DC.%2BF.%26aulast%3DMac%2BSweeney%26aufirst%3DA.%26aulast%3DSolovay%26aufirst%3DC.%26aulast%3DDelgado%26aufirst%3DO.%26aulast%3DCrowley%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DS.-M.%26aulast%3DArgikar%26aufirst%3DU.%2BA.%26aulast%3DFlohr%26aufirst%3DS.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DLorthiois%26aufirst%3DE.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DLong%26aufirst%3DD.%26aulast%3DPrentiss%26aufirst%3DM.%26aulast%3DGradoux%26aufirst%3DN.%26aulast%3Dde%2BErkenez%26aufirst%3DA.%26aulast%3DCumin%26aufirst%3DF.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DJaffee%26aufirst%3DB.%26aulast%3DMogi%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Preclinical%2520Characterization%2520of%2520Selective%2520Factor%2520D%2520Inhibitors%2520Targeting%2520the%2520Alternative%2520Complement%2520Pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4656%26epage%3D4668%26doi%3D10.1021%2Facs.jmedchem.9b00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kam, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRae, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J. C.</span></span> <span> </span><span class="NLM_article-title">Human Complement Proteins D, C2, and B</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>262</i></span>,  <span class="NLM_fpage">3444</span>– <span class="NLM_lpage">3451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=3546307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaL2sXhvFCgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1987&pages=3444-3451&author=C.-M.+Kamauthor=B.+J.+McRaeauthor=J.+W.+Harperauthor=M.+A.+Niemannauthor=J.+E.+Volanakisauthor=J.+C.+Powers&title=Human+Complement+Proteins+D%2C+C2%2C+and+B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human complement proteins D, C2, and B.  Active site mapping with peptide thioester substrates</span></div><div class="casAuthors">Kam, Chih Min; McRae, Brian J.; Harper, J. Wade; Niemann, Marilyn A.; Volanakis, John E.; Powers, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3444-51</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The specificity and reactivity of complement serine proteases D, B, Bb, C2, and C2a were detd. using a series of peptide thioester substrates.  The rates of thioester hydrolysis were measured using assay mixts. contg. the thiol reagent 4,4'-dithiodipyridine at pH 7.5.  Each substrate contained a P1 arginine residue, and the effect of various groups and amino acids in the P2, P3, and P5 positions was detd. using kcat/Km values to compare reactivities.  Among peptide thioesters corresponding to the activation site sequence in B, dipeptide thioesters contg. a P2 lysine residue were the best substrates for D.  Extending the chain to include a P3 or P4 amino acid resulted in loss of activity, and neither the tripeptide nor the tetrapeptide contg. the cleavage sequence of B was hydrolyzed.  Overall, D cleaved fewer substrates and was 2-3 orders of magnitude less reactive than ‾C1s against some thioester substrates.  C2 and fragment C2a had comparable reactivities and hydrolyzed peptides contg. Leu-Ala-Arg and Leu-Gly-Arg, which have the same sequence as the cleavage sites of C3 and C5, resp.  The best substrates for C2 and C2a were Z-Gly-Leu-Ala-Arg-SBzl and Z-Leu-Gly-Leu-Ala-Arg-SBzl, resp., where Bzl is benzyl.  B was the least reactive among these complement enzymes.  The best substrate for B was Z-Lys-Arg-SBzl with a kcat/Km value of 1370 M-1 s-1.  The catalytic fragment of B, Bb, had higher activity toward these peptide thioester substrates.  The best substrate for Bb was Z-Gly-Leu-Ala-Arg-SBzl with kcat/Km similar to C2a and 10 times higher than the value for B.  Both C2a and Bb were considerably more reactive against C3-like than C5-like substrates.  Bovine trypsin hydrolyzed thioester substrates with kcat/Km approx. 103 higher than the complement enzymes.  These thioester substrates for D, B, and C2 should be quite useful in kinetic and active site studies of the purified enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM851wsuxWNrVg90H21EOLACvtfcHk0ljBiSFRsHZ_7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvFCgtL0%253D&md5=5134b08c952ef4e339415f451cda2f6e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKam%26aufirst%3DC.-M.%26aulast%3DMcRae%26aufirst%3DB.%2BJ.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DNiemann%26aufirst%3DM.%2BA.%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26aulast%3DPowers%26aufirst%3DJ.%2BC.%26atitle%3DHuman%2520Complement%2520Proteins%2520D%252C%2520C2%252C%2520and%2520B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1987%26volume%3D262%26spage%3D3444%26epage%3D3451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milder, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huizinga, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romijn, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemrika, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daha, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span> <span> </span><span class="NLM_article-title">Factor B Structure Provides Insights into Activation of the Central Protease of the Complement System</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1038/nsmb1210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fnsmb1210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=17310251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVeitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=224-228&author=F.+J.+Milderauthor=L.+Gomesauthor=A.+Schoutenauthor=B.+J.+Janssenauthor=E.+G.+Huizingaauthor=R.+A.+Romijnauthor=W.+Hemrikaauthor=A.+Roosauthor=M.+R.+Dahaauthor=P.+Gros&title=Factor+B+Structure+Provides+Insights+into+Activation+of+the+Central+Protease+of+the+Complement+System&doi=10.1038%2Fnsmb1210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Factor B structure provides insights into activation of the central protease of the complement system</span></div><div class="casAuthors">Milder, Fin J.; Gomes, Lucio; Schouten, Arie; Janssen, Bert J. C.; Huizinga, Eric G.; Romijn, Roland A.; Hemrika, Wieger; Roos, Anja; Daha, Mohamed R.; Gros, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-228</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Factor B is the central protease of the complement system of immune defense.  Here, the authors present the crystal structure of human factor B at 2.3-Å resoln., which reveals how the 5-domain proenzyme is kept securely inactive.  The canonical activation helix of the Von Willebrand factor A (VWA) domain is displaced by a helix from the preceding domain linker.  The 2 helixes conformationally link the scissile-activation peptide and the metal ion-dependent adhesion site required for binding of the ligand C3b.  The data suggest that C3b binding displaces the 3 N-terminal control domains and reshuffles the 2 central helixes.  Reshuffling of the helixes releases the scissile bond for final proteolytic activation and generates a new interface between the VWA domain and the serine protease domain.  This allosteric mechanism is crucial for tight regulation of the complement-amplification step in the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzjNM3OCK6VbVg90H21EOLACvtfcHk0lhM-5qiSoZAuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVeitLo%253D&md5=06616940d34117bab9bbdc2d9fbe9898</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1210%26sid%3Dliteratum%253Aachs%26aulast%3DMilder%26aufirst%3DF.%2BJ.%26aulast%3DGomes%26aufirst%3DL.%26aulast%3DSchouten%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DB.%2BJ.%26aulast%3DHuizinga%26aufirst%3DE.%2BG.%26aulast%3DRomijn%26aufirst%3DR.%2BA.%26aulast%3DHemrika%26aufirst%3DW.%26aulast%3DRoos%26aufirst%3DA.%26aulast%3DDaha%26aufirst%3DM.%2BR.%26aulast%3DGros%26aufirst%3DP.%26atitle%3DFactor%2520B%2520Structure%2520Provides%2520Insights%2520into%2520Activation%2520of%2520the%2520Central%2520Protease%2520of%2520the%2520Complement%2520System%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D224%26epage%3D228%26doi%3D10.1038%2Fnsmb1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forneris, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzekou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span> <span> </span><span class="NLM_article-title">Structures of C3b in Complex with Factors B and D give Insight into Complement Convertase Formation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1816</span>– <span class="NLM_lpage">1820</span>, <span class="refDoi"> DOI: 10.1126/science.1195821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1126%2Fscience.1195821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=21205667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1816-1820&author=F.+Fornerisauthor=D.+Ricklinauthor=J.+Wuauthor=A.+Tzekouauthor=R.+S.+Wallaceauthor=J.+D.+Lambrisauthor=P.+Gros&title=Structures+of+C3b+in+Complex+with+Factors+B+and+D+give+Insight+into+Complement+Convertase+Formation&doi=10.1126%2Fscience.1195821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation</span></div><div class="casAuthors">Forneris, Federico; Ricklin, Daniel; Wu, Jin; Tzekou, Apostolia; Wallace, Rachel S.; Lambris, John D.; Gros, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6012</span>),
    <span class="NLM_cas:pages">1816-1820</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Activation of the complement cascade induces inflammatory responses and marks cells for immune clearance.  In the central complement-amplification step, a complex consisting of surface-bound C3b and factor B is cleaved by factor D to generate active convertases on targeted surfaces.  We present crystal structures of the pro-convertase C3bB at 4 angstrom resoln. and its complex with factor D at 3.5 angstrom resoln.  Our data show how factor B binding to C3b forms an open "activation" state of C3bB.  Factor D specifically binds the open conformation of factor B through a site distant from the catalytic center and is activated by the substrate, which displaces factor D's self-inhibitory loop.  This concerted proteolytic mechanism, which is cofactor-dependent and substrate-induced, restricts complement amplification to C3b-tagged target cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0MfnHYjx4LLVg90H21EOLACvtfcHk0lhM-5qiSoZAuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbvK&md5=8b9967b841de551442fa949d7ab7bab8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1126%2Fscience.1195821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1195821%26sid%3Dliteratum%253Aachs%26aulast%3DForneris%26aufirst%3DF.%26aulast%3DRicklin%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTzekou%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DR.%2BS.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DGros%26aufirst%3DP.%26atitle%3DStructures%2520of%2520C3b%2520in%2520Complex%2520with%2520Factors%2520B%2520and%2520D%2520give%2520Insight%2520into%2520Complement%2520Convertase%2520Formation%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1816%26epage%3D1820%26doi%3D10.1126%2Fscience.1195821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooijakkers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruyken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Domselaar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzekou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Strijp, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Implications of the Alternative Complement Pathway C3 Convertase Stabilized by a Staphylococcal Inhibitor</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/ni.1756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1038%2Fni.1756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=19503103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVWjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=721-727&author=S.+H.+Rooijakkersauthor=J.+Wuauthor=M.+Ruykenauthor=R.+van+Domselaarauthor=K.+L.+Plankenauthor=A.+Tzekouauthor=D.+Ricklinauthor=J.+D.+Lambrisauthor=B.+J.+Janssenauthor=J.+A.+van+Strijpauthor=P.+Gros&title=Structural+and+Functional+Implications+of+the+Alternative+Complement+Pathway+C3+Convertase+Stabilized+by+a+Staphylococcal+Inhibitor&doi=10.1038%2Fni.1756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor</span></div><div class="casAuthors">Rooijakkers, Suzan H. M.; Wu, Jin; Ruyken, Maartje; van Domselaar, Robert; Planken, Karel L.; Tzekou, Apostolia; Ricklin, Daniel; Lambris, John D.; Janssen, Bert J. C.; van Strijp, Jos A. G.; Gros, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">721-727</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the complement system generates potent chemoattractants and leads to the opsonization of cells for immune clearance.  Short-lived protease complexes cleave complement component C3 into anaphylatoxin C3a and opsonin C3b.  Here the authors report the crystal structure of the C3 convertase formed by C3b and the protease fragment Bb, which was stabilized by the bacterial immune-evasion protein SCIN.  The data suggest that the proteolytic specificity and activity depend on the formation of dimers of C3 with C3b of the convertase.  SCIN blocked the formation of a productive enzyme-substrate complex.  Irreversible dissocn. of the complex of C3b and Bb is crucial to complement regulation and was detd. by slow binding kinetics of the Mg2+-adhesion site in Bb.  Understanding the mechanistic basis of the central complement-activation step and microbial immune evasion strategies targeting this step will aid in the development of complement therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_zcBU00BPg7Vg90H21EOLACvtfcHk0lhM-5qiSoZAuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVWjtLg%253D&md5=aaa035c7eac59df9af5e5fedaa99fc62</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fni.1756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1756%26sid%3Dliteratum%253Aachs%26aulast%3DRooijakkers%26aufirst%3DS.%2BH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRuyken%26aufirst%3DM.%26aulast%3Dvan%2BDomselaar%26aufirst%3DR.%26aulast%3DPlanken%26aufirst%3DK.%2BL.%26aulast%3DTzekou%26aufirst%3DA.%26aulast%3DRicklin%26aufirst%3DD.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DJanssen%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BStrijp%26aufirst%3DJ.%2BA.%26aulast%3DGros%26aufirst%3DP.%26atitle%3DStructural%2520and%2520Functional%2520Implications%2520of%2520the%2520Alternative%2520Complement%2520Pathway%2520C3%2520Convertase%2520Stabilized%2520by%2520a%2520Staphylococcal%2520Inhibitor%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D721%26epage%3D727%26doi%3D10.1038%2Fni.1756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M. N. G.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanism for the Conversion of Zymogen to Active Proteolytic Enzymes</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/pro.5560070401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1002%2Fpro.5560070401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=9568890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK1cXisFSntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1998&pages=815-836&author=A.+R.+Khanauthor=M.+N.+G.+James&title=Molecular+Mechanism+for+the+Conversion+of+Zymogen+to+Active+Proteolytic+Enzymes&doi=10.1002%2Fpro.5560070401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes</span></div><div class="casAuthors">Khan, Amir R.; James, Michael N. G.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">815-836</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review with approx. 185 refs.  Proteolytic enzymes are synthesized as inactive precursors, or "zymogens," to prevent unwanted protein degrdn., and to enable spatial and temporal regulation of proteolytic activity.  Upon sorting or appropriate compartmentalization, zymogen conversion to the active enzyme typically involves limited proteolysis and removal of an "activation segment.".  The sizes of activation segments range from dipeptide units to independently folding domains comprising more than 100 residues.  A common form of the activation segment is an N-terminal extension of the mature enzyme, or "prosegment," that sterically blocks the active site, and thereby prevents binding of substrates.  In addn. to their inhibitory role, prosegments are frequently important for the folding, stability, and/or intracellular sorting of the zymogen.  The mechanisms of conversion to active enzymes are diverse in nature, ranging from enzymic or nonenzymic cofactors that trigger activation, to a simple change in pH that results in conversion by an autocatalytic mechanism.  Recent X-ray crystallog. studies of zymogens and comparisons with their active counterparts have identified the structural changes that accompany conversion.  This review will focus upon the structural basis for inhibition by activation segments, as well as the mol. events that lead to the conversion of zymogens to active enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkRaD6Q3GVT7Vg90H21EOLACvtfcHk0lic_w1P59kHkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFSntbg%253D&md5=87af8723e541cc74915126610dca0a6b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fpro.5560070401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.5560070401%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DA.%2BR.%26aulast%3DJames%26aufirst%3DM.%2BN.%2BG.%26atitle%3DMolecular%2520Mechanism%2520for%2520the%2520Conversion%2520of%2520Zymogen%2520to%2520Active%2520Proteolytic%2520Enzymes%26jtitle%3DProtein%2520Sci.%26date%3D1998%26volume%3D7%26spage%3D815%26epage%3D836%26doi%3D10.1002%2Fpro.5560070401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponnuraj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, V. L.</span></span> <span> </span><span class="NLM_article-title">Structural Analysis of Engineered Bb Fragment of Complement Factor B: Insights into the Activation Mechanism of the Alternative Pathway C3-Convertase</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(04)00160-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2FS1097-2765%2804%2900160-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15068800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVaqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=17-28&author=K.+Ponnurajauthor=Y.+Xuauthor=K.+Maconauthor=D.+Mooreauthor=J.+E.+Volanakisauthor=V.+L.+Narayana&title=Structural+Analysis+of+Engineered+Bb+Fragment+of+Complement+Factor+B%3A+Insights+into+the+Activation+Mechanism+of+the+Alternative+Pathway+C3-Convertase&doi=10.1016%2FS1097-2765%2804%2900160-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural analysis of engineered Bb fragment of complement factor B: Insights into the activation mechanism of the alternative pathway C3-convertase</span></div><div class="casAuthors">Ponnuraj, Karthe; Xu, Yuanyuan; Macon, Kevin; Moore, Dwight; Volanakis, John E.; Narayana, Sthanam V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The C-terminal fragment, Bb, of factor B combines with C3b to form the pivotal C3-convertase, C3bBb, of alternative complement pathway.  Bb consists of a von Willebrand factor type A (vWFA) domain that is structurally similar to the I domains of integrins and a serine protease (SP) domain that is in inactive conformation.  The structure of the C3bBb complex would be important in deciphering the activation mechanism of the SP domain.  However, C3bBb is labile and not amenable to x-ray diffraction studies.  We engineered a disulfide bond in the vWFA domain of Bb homologous to that shown to lock I domains in active conformation.  The crystal structures of BbC428-C435 and its inhibitor complexes reveal that the adoption of the "active" conformation by the vWFA domain is not sufficient to activate the C3-convertase catalytic app. and also provide insights into the possible mode of C3-convertase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC1YqIF_0QW7Vg90H21EOLACvtfcHk0lic_w1P59kHkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVaqsbg%253D&md5=8c2acf331c7756795be82dc2bbf66107</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2804%2900160-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252804%252900160-1%26sid%3Dliteratum%253Aachs%26aulast%3DPonnuraj%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMacon%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26aulast%3DNarayana%26aufirst%3DV.%2BL.%26atitle%3DStructural%2520Analysis%2520of%2520Engineered%2520Bb%2520Fragment%2520of%2520Complement%2520Factor%2520B%253A%2520Insights%2520into%2520the%2520Activation%2520Mechanism%2520of%2520the%2520Alternative%2520Pathway%2520C3-Convertase%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D14%26spage%3D17%26epage%3D28%26doi%3D10.1016%2FS1097-2765%2804%2900160-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Circolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana, S. V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volanakis, J. E.</span></span> <span> </span><span class="NLM_article-title">Mutational Analysis of the Primary Substrate Specificity Pocket of Complement Factor B</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.1.378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1074%2Fjbc.275.1.378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10617628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=378-385&author=Y.+Xuauthor=A.+Circoloauthor=H.+Jingauthor=Y.+Wangauthor=S.+V.+L.+Narayanaauthor=J.+E.+Volanakis&title=Mutational+Analysis+of+the+Primary+Substrate+Specificity+Pocket+of+Complement+Factor+B&doi=10.1074%2Fjbc.275.1.378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational analysis of the primary substrate specificity pocket of complement factor B ASP226 is a major structural determinant for P1-ARG binding</span></div><div class="casAuthors">Xu, Yuanyuan; Circolo, Antonella; Jing, Hua; Wang, Yue; Narayana, Sthanam V. L.; Volanakis, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">378-385</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Factor B is a serine protease, which despite its trypsin-like specificity has Asn instead of the typical Asp at the bottom of the S1 pocket (position 189, chymotrypsinogen numbering).  Asp residues are present at positions 187 and 226 and either one could conceivably provide the neg. charge for binding the P1-Arg of the substrate.  Detn. of the crystal structure of the factor B serine protease domain has revealed that the side chain of Asp226 is within the S1 pocket, whereas Asp187 is located outside the pocket.  To investigate the possible role of these atypical structural features in substrate binding and catalysis, we constructed a panel of mutants of these residues.  Replacement of Asp187 caused moderate (50-60%) decrease in hemolytic activity, compared with wild type factor B, whereas replacement of Asn189 resulted in more profound redns. (71-95%).  Substitutions at these two positions did not significantly affect assembly of the alternative pathway C3 convertase.  In contrast, elimination of the neg. charge from Asp226 completely abrogated hemolytic activity and also affected formation of the C3 convertase.  Kinetic analyses of the hydrolysis of a P1-Arg contg. thioester by selected mutants confirmed that residue Asp226 is a primary structural determinant for P1-Arg binding and catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLwB2UTxHMLrVg90H21EOLACvtfcHk0lic_w1P59kHkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvVKjtA%253D%253D&md5=e48ce8cb135ebf8f17ffb60cca4c4fd4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.1.378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.1.378%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCircolo%26aufirst%3DA.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNarayana%26aufirst%3DS.%2BV.%2BL.%26aulast%3DVolanakis%26aufirst%3DJ.%2BE.%26atitle%3DMutational%2520Analysis%2520of%2520the%2520Primary%2520Substrate%2520Specificity%2520Pocket%2520of%2520Complement%2520Factor%2520B%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D378%26epage%3D385%26doi%3D10.1074%2Fjbc.275.1.378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kock, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hew, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bammert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritzinger, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, C.-W.</span></span> <span> </span><span class="NLM_article-title">Structure and Function of Recombinant Cobra Venom Factor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">30836</span>– <span class="NLM_lpage">30843</span>, <span class="refDoi"> DOI: 10.1074/jbc.M403196200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1074%2Fjbc.M403196200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15131128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=30836-30843&author=M.+A.+Kockauthor=B.+E.+Hewauthor=H.+Bammertauthor=D.+C.+Fritzingerauthor=C.-W.+Vogel&title=Structure+and+Function+of+Recombinant+Cobra+Venom+Factor&doi=10.1074%2Fjbc.M403196200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Function of Recombinant Cobra Venom Factor</span></div><div class="casAuthors">Kock, Michael A.; Hew, Brian E.; Bammert, Holger; Fritzinger, David C.; Vogel, Carl-Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">30836-30843</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cobra venom factor (CVF) is the complement-activating protein from cobra venom.  It is a structural and functional analog of complement component C3.  CVF functionally resembles C3b, the activated form of C3.  Like C3b, CVF binds factor B, which is subsequently cleaved by factor D to form the bimol. complex CVF,Bb.  CVF,Bb is a C3/C5 convertase that cleaves both complement components C3 and C5.  CVF is a three-chain protein that structurally resembles the C3b degrdn. product C3c, which is unable to form a C3/C5 convertase.  Both C3 and CVF are synthesized as single-chain prepro-proteins.  This study reports the recombinant expression of pro-CVF in two insect cell expression systems (baculovirus-infected Sf9 Spodoptera frugiperda cells and stably transfected S2 Drosophila melanogaster cells).  In both expression systems pro-CVF is synthesized initially as a single-chain pro-CVF mol. that is subsequently proteolytically processed into a two-chain form of pro-CVF that structurally resembles C3.  The C3-like form of pro-CVF can be further proteolytically processed into another two-chain form of pro-CVF that structurally resembles C3b.  Unexpectedly, all three forms of pro-CVF exhibit functional activity of mature, natural CVF.  Recombinant pro-CVF supports the activation of factor B in the presence of factor D and Mg2+ and depletes serum complement activity like natural CVF.  The bimol. convertase pro-CVF,Bb exhibits both C3 cleaving and C5 cleaving activity.  The activity of pro-CVF and the resulting C3/C5 convertase is indistinguishable from CVF and the CVF,Bb convertase.  The ability to produce active forms of pro-CVF recombinantly ensures the continued availability of an important research reagent for complement depletion because cobra venom as the source for natural CVF will be increasingly difficult to obtain as the Indian cobra is on the list of endangered species.  Exptl. systems to express pro-CVF recombinantly will also be invaluable for studies to delineate the structure and function relation of CVF and its differences from C3 as well as to generate human C3 derivs. with CVF-like function for therapeutic complement depletion ("humanized CVF").</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN7FHhRwulOLVg90H21EOLACvtfcHk0lic_w1P59kHkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFKhtr8%253D&md5=b6671891a60f8d439fb7e85763527d3f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403196200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403196200%26sid%3Dliteratum%253Aachs%26aulast%3DKock%26aufirst%3DM.%2BA.%26aulast%3DHew%26aufirst%3DB.%2BE.%26aulast%3DBammert%26aufirst%3DH.%26aulast%3DFritzinger%26aufirst%3DD.%2BC.%26aulast%3DVogel%26aufirst%3DC.-W.%26atitle%3DStructure%2520and%2520Function%2520of%2520Recombinant%2520Cobra%2520Venom%2520Factor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D30836%26epage%3D30843%26doi%3D10.1074%2Fjbc.M403196200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last"><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> provides a different perspective of the cocrystal structure previously reported in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klabunde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span> <span> </span><span class="NLM_article-title">GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR-Mediated Side Effects</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">889</span>, <span class="refDoi"> DOI: 10.1002/cbic.200400369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1002%2Fcbic.200400369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15791686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFajsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=876-889&author=T.+Klabundeauthor=A.+Evers&title=GPCR+Antitarget+Modeling%3A+Pharmacophore+Models+for+Biogenic+Amine+Binding+GPCRs+to+Avoid+GPCR-Mediated+Side+Effects&doi=10.1002%2Fcbic.200400369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR antitarget modeling: Pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects</span></div><div class="casAuthors">Klabunde, Thomas; Evers, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">876-889</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) form a large protein family that plays an important role in many physiol. and pathophysiol. processes.  However, the central role that the biogenic amine binding GPCRs and their ligands play in cell signaling poses a risk in new drug candidates that reveal side affinities towards these receptor sites.  These candidates have the potential to interfere with the physiol. signaling processes and to cause undersired effects in preclin. or clin. studies.  Here, we present 3D cross-chemotype pharmacophore models for three biogenic amine antitargets: the α1A adrenergic, the 5-HT2A serotonin, and the D2 dopamine receptors.  These pharmacophores describe the key chem. features present within these biogenic amine antagonists and rationalize the biogenic amine side affinities found for numerous new drug candidates.  First applications of the α1A adrenergic receptor model reveal that these in silico tools can be used to guide the chem. optimization towards development candidates with fewer α1A-mediated side effects (for example, orthostatic hypotension) and, thus, with an improved clin. safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQUxTTiXyXjbVg90H21EOLACvtfcHk0lgVnhxPAEQv_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFajsbo%253D&md5=3f1718c9df2842570ed2b879c59ee240</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200400369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200400369%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DEvers%26aufirst%3DA.%26atitle%3DGPCR%2520Antitarget%2520Modeling%253A%2520Pharmacophore%2520Models%2520for%2520Biogenic%2520Amine%2520Binding%2520GPCRs%2520to%2520Avoid%2520GPCR-Mediated%2520Side%2520Effects%26jtitle%3DChemBioChem%26date%3D2005%26volume%3D6%26spage%3D876%26epage%3D889%26doi%3D10.1002%2Fcbic.200400369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6917</span>– <span class="NLM_lpage">6921</span>, <span class="refDoi"> DOI: 10.1021/jm060500o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060500o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6917-6921&author=A.+M.+Aronov&title=Common+Pharmacophores+for+Uncharged+Human+Ether-a-go-go-Related+Gene+%28hERG%29+Blockers&doi=10.1021%2Fjm060500o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers</span></div><div class="casAuthors">Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6917-6921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In silico approaches are widely used to predict human ether-a-go-go-related gene (hERG) channel blockade.  Published pharmacophore models of hERG blockers typically contain a basic nitrogen center flanked by arom. or hydrophobic groups.  However, hERG blockade has been obsd. in series lacking the basic nitrogen.  By utilizing screening data for 194 potent uncharged hERG actives, we propose a pharmacophore for neutral hERG blockers, and provide guidance on eliminating hERG liability in an uncharged hERG active chem. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhdisypaGQgbVg90H21EOLACvtfcHk0lgVnhxPAEQv_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ&md5=a557f6239ec176243f9823a36b3b9ec4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm060500o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060500o%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DCommon%2520Pharmacophores%2520for%2520Uncharged%2520Human%2520Ether-a-go-go-Related%2520Gene%2520%2528hERG%2529%2520Blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6917%26epage%3D6921%26doi%3D10.1021%2Fjm060500o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marankan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span> <span> </span><span class="NLM_article-title">An Oxyanion-hole Selective Serine Protease Inhibitor in Complex with Trypsin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(01)00259-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2FS0968-0896%2801%2900259-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=11738605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A280%3ADC%252BD3MnptV2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=41-46&author=J.+Cuiauthor=F.+Marankanauthor=W.+Fuauthor=D.+Crichauthor=A.+Mesecarauthor=M.+E.+Johnson&title=An+Oxyanion-hole+Selective+Serine+Protease+Inhibitor+in+Complex+with+Trypsin&doi=10.1016%2FS0968-0896%2801%2900259-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">An oxyanion-hole selective serine protease inhibitor in complex with trypsin</span></div><div class="casAuthors">Cui Jian; Marankan Fatima; Fu Wentao; Crich David; Mesecar Andrew; Johnson Michael E</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-6</span>
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    </div><div class="casAbstract">p-amidinophenylmethylphosphinic acid (AMPA) was designed, synthesized and crystallized in complex with trypsin to study interactions with the oxyanion hole at the S1 site.  In comparison to benzamidine, AMPA shows improved activity, which the crystal structure demonstrates to result from hydrogen bonds between the negatively charged phosphinic acid group and the catalytic residues at the oxyanion hole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIlJcC9FrU-DToTC3aBaesfW6udTcc2eY2kxWVFBFaY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnptV2rug%253D%253D&md5=c7853de2df0e40a02692b6dae13d1d1e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2801%2900259-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252801%252900259-0%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMarankan%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DCrich%26aufirst%3DD.%26aulast%3DMesecar%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26atitle%3DAn%2520Oxyanion-hole%2520Selective%2520Serine%2520Protease%2520Inhibitor%2520in%2520Complex%2520with%2520Trypsin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D41%26epage%3D46%26doi%3D10.1016%2FS0968-0896%2801%2900259-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rumthao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhearn, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of Oxyanion-hole Selective Inhibitor Substituents for the S1 Subsite of factor Xa</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5165</span>– <span class="NLM_lpage">5170</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.07.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.bmcl.2004.07.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=15380220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD2cXns1Ohu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=5165-5170&author=S.+Rumthaoauthor=O.+Leeauthor=Q.+Shengauthor=W.+Fuauthor=D.+C.+Mulhearnauthor=D.+Crichauthor=A.+D.+Mesecarauthor=M.+E.+Johnson&title=Design%2C+Synthesis%2C+and+Evaluation+of+Oxyanion-hole+Selective+Inhibitor+Substituents+for+the+S1+Subsite+of+factor+Xa&doi=10.1016%2Fj.bmcl.2004.07.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa</span></div><div class="casAuthors">Rumthao, Sochanchingwung; Lee, Oukseub; Sheng, Qi; Fu, WenTao; Mulhearn, Debbie C.; Crich, David; Mesecar, Andrew D.; Johnson, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5165-5170</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">P-Amidinophenyl sulfones, amines, and alcs. intended to take advantage of the polarity and hydrogen-bonding potential of the oxyanion hole region of the S1 specificity pocket were designed, synthesized, and evaluated for their factor Xa inhibitory activities.  Placement of an anionic group within the oxyanion hole region of the catalytic site substantially enhances activity, with small flexible groups favored over bulkier ones.  Ab initio pKa calcns. suggest that the hydroxyl substituent frequently used for benzamidine moieties may be ionized to form an anionic group, consistent with the general trend.  One nonamidine based substituent also shows promising activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogczUfVJILaLVg90H21EOLACvtfcHk0lgmS4Iyk38Zlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXns1Ohu7k%253D&md5=7450af5bc7e472d1496cd990aa5dcb3c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.07.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.07.054%26sid%3Dliteratum%253Aachs%26aulast%3DRumthao%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DO.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DMulhearn%26aufirst%3DD.%2BC.%26aulast%3DCrich%26aufirst%3DD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520Oxyanion-hole%2520Selective%2520Inhibitor%2520Substituents%2520for%2520the%2520S1%2520Subsite%2520of%2520factor%2520Xa%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D5165%26epage%3D5170%26doi%3D10.1016%2Fj.bmcl.2004.07.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="note"><p class="first last">A large set of compounds from a different subseries than what is disclosed in this manuscript were assessed in both the CVF-Bb and FB-comp assays, and the resulting IC<sub>50</sub> values showed good concordance enabling a direct comparison or potency between the two assay formats.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="note"><p class="first last">The cocrystal of <b>29</b> with FB illustrated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> provides a different perspective of the structure previously reported in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="note"><p class="first last">The cocrystal structure indicated that the stereochemistry of the phenylpiperidine was of the <i>S</i> configuration in line with the preferred enantiomers (<i>S</i>-)-<b>19</b> and <b>29</b>. Thus it is likely that the absolute stereochemistry of (−)-<b>35</b> is also <i>S</i>; however since the racemic <b>35</b> was used for the crystallization experiment, this cannot be concluded unambiguously.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">The absolute stereochemistry was determined via chemical correlation once the cocrystal structure was ascertained for compound <b>41</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="note"><p class="first last"><a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> provides a different perspective of the cocrystal structure previously reported in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="note"><p class="first last">A list of proteins evaluated can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="note"><p class="first last">The plasma data represented in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> have previously been disclosed in ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>, while ocular complement inhibition is a new disclosure.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthert, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victor Chong, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, R. F.</span></span> <span> </span><span class="NLM_article-title">An Integrated Hypothesis that Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch’s Membrane Interface in Aging and Age-related Macular Degeneration</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1016/S1350-9462(01)00010-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2FS1350-9462%2801%2900010-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=11587915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntF2qt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=705-732&author=G.+S.+Hagemanauthor=P.+J.+Luthertauthor=N.+H.+Victor+Chongauthor=L.+V.+Johnsonauthor=D.+H.+Andersonauthor=R.+F.+Mullins&title=An+Integrated+Hypothesis+that+Considers+Drusen+as+Biomarkers+of+Immune-Mediated+Processes+at+the+RPE-Bruch%E2%80%99s+Membrane+Interface+in+Aging+and+Age-related+Macular+Degeneration&doi=10.1016%2FS1350-9462%2801%2900010-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration</span></div><div class="casAuthors">Hageman, G. S.; Luthert, P. J.; Victor Chong, N. H.; Johnson, L. V.; Anderson, D. H.; Mullins, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Retinal and Eye Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">705-732</span>CODEN:
                <span class="NLM_cas:coden">PRTRES</span>;
        ISSN:<span class="NLM_cas:issn">1350-9462</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Age-related macular degeneration (AMD) is a blinding disease that afflicts millions of adults in the Western world.  Although it has been proposed that a threshold event occurs during normal aging which leads to AMD, the sequelae of biochem., cellular, and/or mol. events leading to the development of AMD are poorly understood.  Although available data provide strong evidence that a significant proportion of AMD has a genetic basis, no gene(s) has yet been identified that causes a significant proportion of AMD.  Moreover, no major mol. pathways involved in the etiol. of this disease have been elucidated.  Drusen, pathol. deposits that form between the retinal pigmented epithelium (RPE) and Bruch's membrane, are significant risk factors for the development of AMD.  In our view, the development of testable new hypotheses of drusen origins has been hindered significantly by the absence of a comprehensive profile of their mol. compn.  In this review, we describe an integrated ultrastructural, histochem., mol. biol., and biochem. approach to identify specific mol. pathways assocd. with drusen biogenesis.  The implicit assumption underlying these recent investigations has been that a thorough understanding of the compn. of drusen and source(s) of drusen-assocd. material is likely to provide fresh insight into the pathobiol. underlying AMD.  Significantly, these studies have revealed that proteins assocd. with inflammation and immune-mediated processes are prevalent among drusen-assocd. constituents.  Transcripts that encode a no. of these mols. have been detected in retinal, RPE, and choroidal cells.  These data have also lead to the observations that dendritic cells, potent antigen-presenting cells, are intimately assocd. with drusen development and that complement activation is a key pathway that is active both within drusen and along the RPE-choroid interface.  We propose herein a unifying hypothesis of drusen biogenesis that attempts to incorporate a large body of new and previously published structural, histochem., and mol. data pertaining to drusen compn. and development.  This theory is put forth with the acknowledgment that numerous AMD genotypes may exist.  Thus, only some aspects of the proposed hypothesis may be involved in any given AMD genotype.  Importantly, this hypothesis invokes, for the first time, the potential for a direct role of cell- and immune-mediated processes in drusen biogenesis.  We acknowledge that the proposed hypothesis clearly represents a paradigm shift in our conceptualization pertaining to pathways that participate in the development of drusen and age-related macular degeneration.  It is our hope that other investigators will test, validate and/or refute various aspects of this hypothesis, and in so doing, increase our overall understanding of the biol. pathways assocd. with early AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7RgyR06dpIrVg90H21EOLACvtfcHk0lgmS4Iyk38Zlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntF2qt7k%253D&md5=e01613bb1c3ac4ca247bc021d4bbafe4</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS1350-9462%2801%2900010-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1350-9462%252801%252900010-6%26sid%3Dliteratum%253Aachs%26aulast%3DHageman%26aufirst%3DG.%2BS.%26aulast%3DLuthert%26aufirst%3DP.%2BJ.%26aulast%3DVictor%2BChong%26aufirst%3DN.%2BH.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26aulast%3DMullins%26aufirst%3DR.%2BF.%26atitle%3DAn%2520Integrated%2520Hypothesis%2520that%2520Considers%2520Drusen%2520as%2520Biomarkers%2520of%2520Immune-Mediated%2520Processes%2520at%2520the%2520RPE-Bruch%25E2%2580%2599s%2520Membrane%2520Interface%2520in%2520Aging%2520and%2520Age-related%2520Macular%2520Degeneration%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2001%26volume%3D20%26spage%3D705%26epage%3D732%26doi%3D10.1016%2FS1350-9462%2801%2900010-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radeke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curletti, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebright, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. V.</span></span> <span> </span><span class="NLM_article-title">The Pivotal Role of the Complement System in Aging and Age-related Macular Degeneration: Hypothesis Re-visited</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/j.preteyeres.2009.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.preteyeres.2009.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=19961953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFGksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=95-112&author=D.+H.+Andersonauthor=M.+J.+Radekeauthor=N.+B.+Galloauthor=E.+A.+Chapinauthor=P.+T.+Johnsonauthor=C.+R.+Curlettiauthor=L.+S.+Hancoxauthor=J.+Huauthor=J.+N.+Ebrightauthor=G.+Malekauthor=M.+A.+Hauserauthor=C.+B.+Rickmanauthor=D.+Bokauthor=G.+S.+Hagemanauthor=L.+V.+Johnson&title=The+Pivotal+Role+of+the+Complement+System+in+Aging+and+Age-related+Macular+Degeneration%3A+Hypothesis+Re-visited&doi=10.1016%2Fj.preteyeres.2009.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited</span></div><div class="casAuthors">Anderson, Don H.; Radeke, Monte J.; Gallo, Natasha B.; Chapin, Ethan A.; Johnson, Patrick T.; Curletti, Christy R.; Hancox, Lisa S.; Hu, Jane; Ebright, Jessica N.; Malek, Goldis; Hauser, Michael A.; Bowes Rickman, Catherine; Bok, Dean; Hageman, Gregory S.; Johnson, Lincoln V.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Retinal and Eye Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-112</span>CODEN:
                <span class="NLM_cas:coden">PRTRES</span>;
        ISSN:<span class="NLM_cas:issn">1350-9462</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During the past ten years, dramatic advances have been made in unraveling the biol. bases of age-related macular degeneration (AMD), the most common cause of irreversible blindness in western populations.  In that timeframe, two distinct lines of evidence emerged which implicated chronic local inflammation and activation of the complement cascade in AMD pathogenesis.  First, a no. of complement system proteins, complement activators, and complement regulatory proteins were identified as mol. constituents of drusen, the hallmark extracellular deposits assocd. with early AMD.  Subsequently, genetic studies revealed highly significant statistical assocns. between AMD and variants of several complement pathway-assocd. genes including: Complement factor H (CFH), complement factor H-related 1 and 3 (CFHR1 and CFHR3), complement factor B (CFB), complement component 2 (C2), and complement component 3 (C3).  In this article, we revisit our original hypothesis that chronic local inflammatory and immune-mediated events at the level of Bruch's membrane play crit. roles in drusen biogenesis and, by extension, in the pathobiol. of AMD.  Secondly, we report the results of a new screening for addnl. AMD-assocd. polymorphisms in a battery of 63 complement-related genes.  Third, we identify and characterize the local complement system in the RPE-choroid complex - thus adding a new dimension of biol. complexity to the role of the complement system in ocular aging and AMD.  Finally, we evaluate the most salient, recent evidence that bears directly on the role of complement in AMD pathogenesis and progression.  Collectively, these recent findings strongly re-affirm the importance of the complement system in AMD.  They lay the groundwork for further studies that may lead to the identification of a transcriptional disease signature of AMD, and hasten the development of new therapeutic approaches that will restore the complement-modulating activity that appears to be compromised in genetically susceptible individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekkkfj3kJJbVg90H21EOLACvtfcHk0lisKvuAWbKu8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFGksL0%253D&md5=1787c08e9671cb9c8959cca700074a26</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.preteyeres.2009.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.preteyeres.2009.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26aulast%3DRadeke%26aufirst%3DM.%2BJ.%26aulast%3DGallo%26aufirst%3DN.%2BB.%26aulast%3DChapin%26aufirst%3DE.%2BA.%26aulast%3DJohnson%26aufirst%3DP.%2BT.%26aulast%3DCurletti%26aufirst%3DC.%2BR.%26aulast%3DHancox%26aufirst%3DL.%2BS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DEbright%26aufirst%3DJ.%2BN.%26aulast%3DMalek%26aufirst%3DG.%26aulast%3DHauser%26aufirst%3DM.%2BA.%26aulast%3DRickman%26aufirst%3DC.%2BB.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DHageman%26aufirst%3DG.%2BS.%26aulast%3DJohnson%26aufirst%3DL.%2BV.%26atitle%3DThe%2520Pivotal%2520Role%2520of%2520the%2520Complement%2520System%2520in%2520Aging%2520and%2520Age-related%2520Macular%2520Degeneration%253A%2520Hypothesis%2520Re-visited%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2010%26volume%3D29%26spage%3D95%26epage%3D112%26doi%3D10.1016%2Fj.preteyeres.2009.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grebe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mughal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryden, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutty, G.</span></span> <span> </span><span class="NLM_article-title">Ultrastructural Analysis of Submacular Choriocapillaris and its Transport Systems in AMD and Aged Control Eyes</span>. <i>Exp. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.exer.2019.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.exer.2019.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=30807744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFaqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=252-262&author=R.+Grebeauthor=I.+Mughalauthor=W.+Brydenauthor=S.+McLeodauthor=M.+Edwardsauthor=G.+S.+Hagemanauthor=G.+Lutty&title=Ultrastructural+Analysis+of+Submacular+Choriocapillaris+and+its+Transport+Systems+in+AMD+and+Aged+Control+Eyes&doi=10.1016%2Fj.exer.2019.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrastructural analysis of submacular choriocapillaris and its transport systems in AMD and aged control eyes</span></div><div class="casAuthors">Grebe, Rhonda; Mughal, Irum; Bryden, William; McLeod, Scott; Edwards, Malia; Hageman, Gregory S.; Lutty, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Eye Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">252-262</span>CODEN:
                <span class="NLM_cas:coden">EXERA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The choriocapillaris is the source of nutrients and oxygen for photoreceptors, which consume more oxygen per g of tissue than any other cell in the body.  The purpose of this study was to evaluate and compare the ultrastructure of the choriocapillaris and its transport systems in patients with and without age-related macular degeneration (AMD).  Ultrastructural changes were also evaluated in subjects that were homozygous for polymorphisms in high risk CFH alleles (Pure 1) only or homozygous only for high risk ARMS2/HTRA1 (Pure 10) alleles.  Tissue samples were obtained from the macular region of forty male (n = 24) and female (n = 16) donor eyes and prepd. for ultrastructural studies with transmission electron microscopy (TEM).  The av. age of the aged donors was 74 ± 7.2 (n = 30) and the young donors 31.7 ± 11.25 (n = 10).  There was no significant difference in av. ages between the adult groups.  TEM images of the capillaries in the choriocapillaris (CC) were taken at 4,000X and 25,000X and used to measure the area of endothelial cell somas, the no. of fenestrations, and area of caveolae within the endothelial cells per length of Bruchs membrane (BrMb).  The Student t-test and Wilcoxon sum rank test were used to det. significant differences.  There was no significant difference between young subjects and aged controls in any of the morphol. criteria assessed.  There was a significant decrease in the no. of fenestrations/mm of BrMb in atrophic areas of GA eyes (p = 0.007) when compared with aged control eyes.  A significant increase was found in the caveolae area as a percent of the endothelial cell soma of capillaries from GA subjects as compared with the controls (p = 0.03).  Loss of capillary segments in choriocapillaris was also evident, esp. in areas of geog. atrophy and CNV.  In eyes from patients with sequence variations, the capillary endothelial cells often appeared degenerative and exhibited atypical fenestrations and pericytes covering the blood vessels.  Subjects that were homozygous for polymorphisms in high risk CFH alleles only had more fenestrations/mm of BrMb than subjects that were homozygous only for high risk ARMS2/HTRA1 alleles (p = 0.04), while the latter had greater caveolae area/endothelial cell area than the former (p = 0.007).  This study demonstrated an attenuation of CC and a significant decline in the two major transport systems in CC endothelial cells in AMD.  This may contribute to drusen deposition, nutrient transport, and vision loss in AMD subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroMM5P_LpXlrVg90H21EOLACvtfcHk0lisKvuAWbKu8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFaqt7c%253D&md5=1a37c1a2a780eb6ebc9e1c0314da3ed3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.exer.2019.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exer.2019.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DGrebe%26aufirst%3DR.%26aulast%3DMughal%26aufirst%3DI.%26aulast%3DBryden%26aufirst%3DW.%26aulast%3DMcLeod%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DM.%26aulast%3DHageman%26aufirst%3DG.%2BS.%26aulast%3DLutty%26aufirst%3DG.%26atitle%3DUltrastructural%2520Analysis%2520of%2520Submacular%2520Choriocapillaris%2520and%2520its%2520Transport%2520Systems%2520in%2520AMD%2520and%2520Aged%2520Control%2520Eyes%26jtitle%3DExp.%2520Eye%2520Res.%26date%3D2019%26volume%3D181%26spage%3D252%26epage%3D262%26doi%3D10.1016%2Fj.exer.2019.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">del Amo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimpela, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heikkinen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kari, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajunen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrizi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisalo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toropainen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteleijn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antopolsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellonen, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruponen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtti, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic Aspects of Retinal Drug Delivery</span>. <i>Prog. Retinal Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.preteyeres.2016.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.preteyeres.2016.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=28028001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvFGjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=134-185&author=E.+M.+del+Amoauthor=A.-K.+Rimpelaauthor=E.+Heikkinenauthor=O.+K.+Kariauthor=E.+Ramsayauthor=T.+Lajunenauthor=M.+Schmittauthor=L.+Pelkonenauthor=M.+Bhattacharyaauthor=D.+Richardsonauthor=A.+Subriziauthor=T.+Turunenauthor=M.+Reinisaloauthor=J.+Itkonenauthor=E.+Toropainenauthor=M.+Casteleijnauthor=H.+Kidronauthor=M.+Antopolskyauthor=K.-S.+Vellonenauthor=M.+Ruponenauthor=A.+Urtti&title=Pharmacokinetic+Aspects+of+Retinal+Drug+Delivery&doi=10.1016%2Fj.preteyeres.2016.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52aR"><div class="casContent"><span class="casTitleNuber">52a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic aspects of retinal drug delivery</span></div><div class="casAuthors">del Amo, Eva M.; Rimpela, Anna-Kaisa; Heikkinen, Emma; Kari, Otto K.; Ramsay, Eva; Lajunen, Tatu; Schmitt, Mechthild; Pelkonen, Laura; Bhattacharya, Madhushree; Richardson, Dominique; Subrizi, Astrid; Turunen, Tiina; Reinisalo, Mika; Itkonen, Jaakko; Toropainen, Elisa; Casteleijn, Marco; Kidron, Heidi; Antopolsky, Maxim; Vellonen, Kati-Sisko; Ruponen, Marika; Urtti, Arto</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Retinal and Eye Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-185</span>CODEN:
                <span class="NLM_cas:coden">PRTRES</span>;
        ISSN:<span class="NLM_cas:issn">1350-9462</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drug delivery to the posterior eye segment is an important challenge in ophthalmol., because many diseases affect the retina and choroid leading to impaired vision or blindness.  Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and sol. receptors).  There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical.  Properties of the administration route, drug and delivery system det. the efficacy and safety of these approaches.  Pharmacokinetic and pharmacodynamic factors det. the required dosing rates and doses that are needed for drug action.  In addn., tolerability factors limit the use of many materials in ocular drug delivery.  This review article provides a crit. discussion of retinal drug delivery, particularly from the pharmacokinetic point of view.  This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently.  Instead, we aim to provide a systematic and quant. view on the pharmacokinetic factors in drug delivery to the posterior eye segment.  This review is based on the literature and unpublished data from the authors' lab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAiaOFhIm2JbVg90H21EOLACvtfcHk0lgnuI3Y10Xafw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvFGjtg%253D%253D&md5=eb5c622e81ff99739cd3d0dace43b0c8</span></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=10.1016%2Fj.preteyeres.2016.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.preteyeres.2016.12.001%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BAmo%26aufirst%3DE.%2BM.%26aulast%3DRimpela%26aufirst%3DA.-K.%26aulast%3DHeikkinen%26aufirst%3DE.%26aulast%3DKari%26aufirst%3DO.%2BK.%26aulast%3DRamsay%26aufirst%3DE.%26aulast%3DLajunen%26aufirst%3DT.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DPelkonen%26aufirst%3DL.%26aulast%3DBhattacharya%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DD.%26aulast%3DSubrizi%26aufirst%3DA.%26aulast%3DTurunen%26aufirst%3DT.%26aulast%3DReinisalo%26aufirst%3DM.%26aulast%3DItkonen%26aufirst%3DJ.%26aulast%3DToropainen%26aufirst%3DE.%26aulast%3DCasteleijn%26aufirst%3DM.%26aulast%3DKidron%26aufirst%3DH.%26aulast%3DAntopolsky%26aufirst%3DM.%26aulast%3DVellonen%26aufirst%3DK.-S.%26aulast%3DRuponen%26aufirst%3DM.%26aulast%3DUrtti%26aufirst%3DA.%26atitle%3DPharmacokinetic%2520Aspects%2520of%2520Retinal%2520Drug%2520Delivery%26jtitle%3DProg.%2520Retinal%2520Eye%2520Res.%26date%3D2017%26volume%3D57%26spage%3D134%26epage%3D185%26doi%3D10.1016%2Fj.preteyeres.2016.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit52b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardegger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolfenden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassbender, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cepeda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarsa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffee, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention that are Efficacious in Models of Wet Age-Related Macular Degeneration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9273</span>– <span class="NLM_lpage">9286</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9273-9286&author=E.+L.+Meredithauthor=N.+Mainolfiauthor=S.+Poorauthor=Y.+Qiuauthor=K.+Mirandaauthor=J.+Powersauthor=D.+Liuauthor=F.+Maauthor=C.+Solovayauthor=C.+Raoauthor=L.+Johnsonauthor=N.+Jiauthor=G.+Artmanauthor=L.+Hardeggerauthor=S.+Hanksauthor=S.+Shenauthor=A.+Woolfendenauthor=E.+Fassbenderauthor=J.+Sivakauthor=Y.+Zhangauthor=D.+Longauthor=R.+Cepedaauthor=F.+Liuauthor=V.+Hosagraharaauthor=W.+Leeauthor=P.+Tarsaauthor=K.+Andersonauthor=J.+Elliottauthor=B.+Jaffee&title=Discovery+of+Oral+VEGFR-2+Inhibitors+with+Prolonged+Ocular+Retention+that+are+Efficacious+in+Models+of+Wet+Age-Related+Macular+Degeneration&doi=10.1021%2Facs.jmedchem.5b01227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52bR"><div class="casContent"><span class="casTitleNuber">52b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration</span></div><div class="casAuthors">Meredith, Erik L.; Mainolfi, Nello; Poor, Stephen; Qiu, Yubin; Miranda, Karl; Powers, James; Liu, Donglei; Ma, Fupeng; Solovay, Catherine; Rao, Chang; Johnson, Leland; Ji, Nan; Artman, Gerald; Hardegger, Leo; Hanks, Shawn; Shen, Siyuan; Woolfenden, Amber; Fassbender, Elizabeth; Sivak, Jeremy M.; Zhang, Yiqin; Long, Debby; Cepeda, Rosemarie; Liu, Fang; Hosagrahara, Vinayak P.; Lee, Wendy; Tarsa, Peter; Anderson, Karen; Elliott, Jason; Jaffee, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9273-9286</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The benefit of intravitreal anti-VEGF therapy in treating wet age-related macular degeneration (AMD) is well established.  Identification of VEGFR-2 inhibitors with optimal ADME properties for an ocular indication provides opportunities for dosing routes beyond intravitreal injection.  The authors employed a high-throughput in vivo screening strategy with rodent models of choroidal neovascularization and iterative compd. design to identify VEGFR-2 inhibitors with potential to benefit wet AMD patients.  These compds., e.g. I, demonstrate preferential ocular tissue distribution and efficacy after oral administration while minimizing systemic exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUYp1fAqKVYLVg90H21EOLACvtfcHk0lhIbkyVHbP19g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7fF&md5=11ee9095e9eb62c548dec995a9c369dd</span></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01227%26sid%3Dliteratum%253Aachs%26aulast%3DMeredith%26aufirst%3DE.%2BL.%26aulast%3DMainolfi%26aufirst%3DN.%26aulast%3DPoor%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DMiranda%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DF.%26aulast%3DSolovay%26aufirst%3DC.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DN.%26aulast%3DArtman%26aufirst%3DG.%26aulast%3DHardegger%26aufirst%3DL.%26aulast%3DHanks%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DWoolfenden%26aufirst%3DA.%26aulast%3DFassbender%26aufirst%3DE.%26aulast%3DSivak%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DD.%26aulast%3DCepeda%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHosagrahara%26aufirst%3DV.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DTarsa%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DElliott%26aufirst%3DJ.%26aulast%3DJaffee%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520Oral%2520VEGFR-2%2520Inhibitors%2520with%2520Prolonged%2520Ocular%2520Retention%2520that%2520are%2520Efficacious%2520in%2520Models%2520of%2520Wet%2520Age-Related%2520Macular%2520Degeneration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9273%26epage%3D9286%26doi%3D10.1021%2Facs.jmedchem.5b01227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="note"><p class="first last">Compound <b>41</b> was incubated with synthetic melanin obtained from polymerization (auto-oxidation) of <span class="smallcaps smallerCapital">l</span>-Dopa to characterize binding kinetics. Binding parameters <i>B</i><sub>max</sub> and <i>K</i><sub>d</sub> were calculated by a Langmuir type of multiple-site linear regression analysis. <i>B</i><sub>max</sub> refers to the maximal binding capacity of a particular binding site of melanin and <i>K</i><sub>d</sub> to the respective dissociation constant. These parameters are indexed 1 and 2 for low and high affinity sites, respectively. <b>41</b> affords <i>B</i><sub>max1</sub> and <i>B</i><sub>max2</sub> values of 32 and 4.9 nmol/mg, respectively, and <i>K</i><sub>d1</sub> and <i>K</i><sub>d2</sub> values of 26.0 and 2.0 μM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="note"><p class="first last">ClinicalTrials.gov identifiers: NCT03832114, NCT03439839, NCT03896152, NCT03955445, and NCT03373461.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">2-Chloro-1,3-dimethylimidazolinium Chloride. 1. A Powerful Dehydrating Equivalent to DCC</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6984</span>– <span class="NLM_lpage">6988</span>, <span class="refDoi"> DOI: 10.1021/jo990210y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo990210y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADyaK1MXlt12rurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=6984-6988&author=T.+Isobeauthor=T.+Ishikawa&title=2-Chloro-1%2C3-dimethylimidazolinium+Chloride.+1.+A+Powerful+Dehydrating+Equivalent+to+DCC&doi=10.1021%2Fjo990210y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chloro-1,3-dimethylimidazolinium Chloride. 1. A Powerful Dehydrating Equivalent to DCC</span></div><div class="casAuthors">Isobe, Toshio; Ishikawa, Tsutomu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6984-6988</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Chloro-1,3-dimethylimidazolinium chloride (DMC) can act as a powerful dehydrating agent, replacing dicyclohexylcarbodiimide (DCC) under nearly neutral conditions.  Its application to acylation and dehydration is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SrU9QrhFULVg90H21EOLACvtfcHk0lhIbkyVHbP19g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt12rurc%253D&md5=6650a174966038c660406240bb3029bf</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjo990210y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo990210y%26sid%3Dliteratum%253Aachs%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3D2-Chloro-1%252C3-dimethylimidazolinium%2520Chloride.%25201.%2520A%2520Powerful%2520Dehydrating%2520Equivalent%2520to%2520DCC%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D6984%26epage%3D6988%26doi%3D10.1021%2Fjo990210y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solovay, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitroff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siesel, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillwell, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiftney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dyck, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, N.</span></span> <span> </span><span class="NLM_article-title">One Pot Synthesis of Aminobenzimidazoles using 2-chloro-1,2-dimethylimidazolium chloride (DMC)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5319</span>– <span class="NLM_lpage">5321</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.07.177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=10.1016%2Fj.tetlet.2010.07.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaiu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=5319-5321&author=G.+Artmanauthor=C.+F.+Solovayauthor=C.+M.+Adamsauthor=B.+Diazauthor=M.+Dimitroffauthor=T.+Eharaauthor=D.+Guauthor=F.+Maauthor=D.+Liuauthor=B.+R.+Millerauthor=T.+E.+Pickauthor=D.+J.+Poonauthor=D.+Ryckmanauthor=D.+A.+Sieselauthor=B.+S.+Stillwellauthor=T.+Swiftneyauthor=J.+P.+van+Dyckauthor=C.+Zhangauthor=N.+Ji&title=One+Pot+Synthesis+of+Aminobenzimidazoles+using+2-chloro-1%2C2-dimethylimidazolium+chloride+%28DMC%29&doi=10.1016%2Fj.tetlet.2010.07.177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot synthesis of 2-aminobenzimidazoles using 2-chloro-1,3-dimethylimidazolinium chloride (DMC)</span></div><div class="casAuthors">Artman, Gerald D., III; Solovay, Catherine F.; Adams, Christopher M.; Diaz, Brian; Dimitroff, Martin; Ehara, Takeru; Gu, Danlin; Ma, Fupeng; Liu, Donglei; Miller, Bridget R.; Pick, Teresa E.; Poon, Daniel J.; Ryckman, David; Siesel, David A.; Stillwell, Brady S.; Swiftney, Tyson; van Dyck, Jonathan P.; Zhang, Chun; Ji, Nan</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">5319-5321</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">2-Chloro-1,3-dimethylimidazolinium chloride (DMC or DMC-Cl) effectively and rapidly generated 2-aminobenzimidazoles from 1,2-diaminoarenes and isothiocyanates in moderate to good yields at room temp. in a one-pot operation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTAgaMUrsdxbVg90H21EOLACvtfcHk0lhIbkyVHbP19g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaiu7jM&md5=3af71ac8d9960be7fa761b93adf5ac41</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.07.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.07.177%26sid%3Dliteratum%253Aachs%26aulast%3DArtman%26aufirst%3DG.%26aulast%3DSolovay%26aufirst%3DC.%2BF.%26aulast%3DAdams%26aufirst%3DC.%2BM.%26aulast%3DDiaz%26aufirst%3DB.%26aulast%3DDimitroff%26aufirst%3DM.%26aulast%3DEhara%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DB.%2BR.%26aulast%3DPick%26aufirst%3DT.%2BE.%26aulast%3DPoon%26aufirst%3DD.%2BJ.%26aulast%3DRyckman%26aufirst%3DD.%26aulast%3DSiesel%26aufirst%3DD.%2BA.%26aulast%3DStillwell%26aufirst%3DB.%2BS.%26aulast%3DSwiftney%26aufirst%3DT.%26aulast%3Dvan%2BDyck%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DJi%26aufirst%3DN.%26atitle%3DOne%2520Pot%2520Synthesis%2520of%2520Aminobenzimidazoles%2520using%25202-chloro-1%252C2-dimethylimidazolium%2520chloride%2520%2528DMC%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D5319%26epage%3D5321%26doi%3D10.1016%2Fj.tetlet.2010.07.177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, P.</span></span> <span> </span><span class="NLM_article-title">Bicyclic Heterocyclic Amino Derivatives</span>. U.S. Patent <span class="NLM_patent">US4398028</span>, August 9, <span class="NLM_year">1983</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1983&author=P.+Neumann&title=Bicyclic+Heterocyclic+Amino+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DP.%26atitle%3DBicyclic%2520Heterocyclic%2520Amino%2520Derivatives%26date%3D1983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit57b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. T.</span>; <span class="NLM_string-name">Sheldon, R. J.</span>; <span class="NLM_string-name">Seibel, W.</span></span> <span> </span><span class="NLM_article-title">2-Imidazolinylaminoindole Compounds Useful as alpha-2 Adrenoceptor Agonists</span>. U.S. Patent <span class="NLM_patent">US6162818</span> December 19, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=R.+T.+Henry&author=R.+J.+Sheldon&author=W.+Seibel&title=2-Imidazolinylaminoindole+Compounds+Useful+as+alpha-2+Adrenoceptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DR.%2BT.%26atitle%3D2-Imidazolinylaminoindole%2520Compounds%2520Useful%2520as%2520alpha-2%2520Adrenoceptor%2520Agonists%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSW','PDB','6QSW'); return false;">PDB: 6QSW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8U','PDB','6T8U'); return false;">PDB: 6T8U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8W','PDB','6T8W'); return false;">PDB: 6T8W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSX','PDB','6QSX'); return false;">PDB: 6QSX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8V','PDB','6T8V'); return false;">PDB: 6T8V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RAV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RAV','PDB','6RAV'); return false;">PDB: 6RAV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DLE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1DLE','PDB','1DLE'); return false;">PDB: 1DLE</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i155"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01870">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77505"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01870?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01870</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings with CVF-Bb or FB-comp IC<sub>50</sub> data and human and mouse 50% serum IC<sub>50</sub> data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_001.csv">CSV</a>)</p></li><li><p class="inline">Detailed chemistry experimentals for intermediates and details related to in vitro selectivity profiling; crystallographic structure determination information on FB with compounds <b>8</b>, (<i>S</i>)-<b>19</b>, and <b>35</b>. Crystallographic information for compounds <b>1</b>, <b>29</b>, and <b>41</b> has been reported previously.<a class="ref ref13" href="javascript:void(0);">(13)</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_001.csv">jm9b01870_si_001.csv (2.71 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01870/suppl_file/jm9b01870_si_002.pdf">jm9b01870_si_002.pdf (934.68 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and structure factors for the crystal structures of FB with compounds <b>1</b>, <b>8</b>, (<i>S</i>)-<b>19</b>, <b>29</b>, <b>35</b>, and <b>41</b> are deposited in the Protein Data Bank with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSW">6QSW</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8U">6T8U</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8W">6T8W</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QSX">6QSX</a>.pdb, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6T8V">6T8V</a>.pdb, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RAV">6RAV</a>.pdb, respectively. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01870&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01870%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01870" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679949cf58cf3d94","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
